

EUROPEAN PHARMACOPOEIA

TENTH EDITION

Supplement 10.1

EUROPEAN PHARMACOPOEIA

TENTH EDITION

Supplement 10.1

*Published in accordance with the
Convention on the Elaboration of a European Pharmacopoeia
(European Treaty Series No. 50)*



Council of Europe

Strasbourg

The European Pharmacopoeia is published by the European Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM).

© Council of Europe, 67075 Strasbourg Cedex, France - 2019

All rights reserved. Apart from any fair dealing for the purposes of research or private study, this publication may not be reproduced or transmitted in any form or by any means without the prior permission in writing of the publisher. Extracts from the European Pharmacopoeia may nevertheless be used by the subscriber in the context of marketing authorisation procedures, on condition that their distribution is limited to competent authorities and excludes any third parties.

ISBN: 978-92-871-8915-8

CONTENTS

CONTENTS OF SUPPLEMENT 10.1	xxix
GENERAL CHAPTERS	4313
2. Methods of analysis	4313
2.2. Physical and physico-chemical methods	4313
2.2.47. Capillary electrophoresis	4315
2.4. Limit tests	4321
2.4.24. Identification and control of residual solvents	4323
4. Reagents	4329
4.1.1. Reagents	4331
4.2.1. Primary standards for volumetric solutions	4331
5. General texts	4333
5.22. Names of herbal drugs used in traditional Chinese medicine	4335
5.25. Process analytical technology	4337
MONOGRAPHS ON RADIOPHARMACEUTICAL PREPARATIONS AND STARTING MATERIALS FOR RADIOPHARMACEUTICAL PREPARATIONS	4343
MONOGRAPHS ON SUTURES FOR HUMAN USE	4347
MONOGRAPHS ON HERBAL DRUGS AND HERBAL DRUG PREPARATIONS	4351
MONOGRAPHS ON HOMOEOPATHIC PREPARATIONS	4367
MONOGRAPHS	4371
INDEX	4519

Note: on the first page of each chapter/section there is a list of contents.

CONTENTS OF SUPPLEMENT 10.1

All revised or corrected parts of a text are indicated by vertical lines in the margin and horizontal lines in the margin indicate where parts of a text have been deleted.

Individual copies of texts published in this edition will not be supplied.

Subscribers to the current version (book or electronic) of the European Pharmacopoeia have access to an online archive version of all obsolete editions and supplements of the European Pharmacopoeia in PDF format.

A list of new reagents published during the course of this edition is available under 'Useful information' in Pharmeuropa Online.

NEW TEXTS

The following texts appear for the first time in the European Pharmacopoeia. They will be implemented on 1 April 2020 at the latest.

MONOGRAPHS

Herbal drugs and herbal drug preparations

Raspberry leaf (2950)

Rehmannia root (2569)

Homoeopathic preparations

Adonis vernalis for homoeopathic preparations (2832)

Monographs

Almotriptan malate (2970)

Donepezil hydrochloride (2582)

Donepezil hydrochloride monohydrate (3067)

Rosuvastatin tablets (3008)

REVISED TEXTS

The following texts have been technically revised since their last publication. They will be implemented on 1 April 2020 at the latest.

GENERAL CHAPTERS

2.4.24. Identification and control of residual solvents

4. Reagents (*new, revised, corrected*)

5.22. Names of herbal drugs used in traditional Chinese medicine

MONOGRAPHS

Sutures for human use

Sutures for human use: introduction (90004)

Herbal drugs and herbal drug preparations

Calendula flower (1297)

Fraxinus chinensis bark (2452)

Hawthorn berries (1220)

Senna leaflet (0206)

Senna pods (0207)

Homoeopathic preparations

Magnesium fluoratum for homoeopathic preparations (2676)

Monographs

Asparagine monohydrate (2086)

Atenolol (0703)

Benzocaine (0011)

Castor oil, hydrogenated (1497)

Clobetasol propionate (2127)

Dimethyl sulfoxide (0763)

Ergometrine maleate (0223)

Exemestane (2766)

Fluocortolone pivalate (1212)

Fluphenazine decanoate (1014)

Fluphenazine enantate (1015)

Isoprenaline hydrochloride (1332)

Lisinopril dihydrate (1120)

Maize oil, refined (1342)

Mercaptopurine monohydrate (0096)

Metformin hydrochloride (0931)

Mometasone furoate (1449)

Nomegestrol acetate (1551)

Oxfendazole for veterinary use (1458)

Pentoxifylline (0851)

Perindopril *tert*-butylamine (2019)

Prazosin hydrochloride (0856)

Prednicarbate (1467)

Pyrantel embonate (1680)

Pyrimethamine (0288)

Rosuvastatin calcium (2631)

Squalane (1630)

Sulfamethizole (0637)

Testosterone (1373)

Tiaprofenic acid (1157)

Tranexamic acid (0875)

Zanamivir hydrate (2611)

Zoledronic acid monohydrate (2743)

Zolpidem tartrate (1280)

CORRECTED TEXTS

*The following texts have been corrected for Supplement 10.1 and specify 'corrected 10.1' above the title. These corrections are to be taken into account as soon as possible and not later than **30 November 2019** (the end of the month following the month of publication of Supplement 10.1).*

GENERAL CHAPTERS

2.2.47. Capillary electrophoresis

5.25. Process analytical technology

MONOGRAPHS

Radiopharmaceutical preparations and starting materials for radiopharmaceutical preparations

Technetium (^{99m}Tc) mebrofenin injection (2393)

Herbal drugs and herbal drug preparations

Dwarf lilyturf tuber (3000)

Monographs

Altizide (2185)

Amiloride hydrochloride dihydrate (0651)

Atazanavir sulfate (2898)

Chlortetracycline hydrochloride (0173)

Demeclocycline hydrochloride (0176)

Diprophylline (0486)

Escitalopram oxalate (2733)

Gammadex (2769)

Insulin preparations, injectable (0854)

Irinotecan hydrochloride trihydrate (2675)

Isosorbide dinitrate, diluted (1117)

Isosorbide mononitrate, diluted (1118)

Levocarnitine (1339)

Levonorgestrel (0926)

Nandrolone decanoate (1992)

Oxymetazoline hydrochloride (0943)

Primaquine diphosphate (0635)

Rabeprazole sodium hydrate (2331)

Sodium sulfate decahydrate (0100)

Thiocolchicoside hydrate (2814)

Xylometazoline hydrochloride (1162)

TEXTS WHOSE TITLE HAS CHANGED

The titles of the following texts have been changed in Supplement 10.1.

MONOGRAPHS

Herbal drugs and herbal drug preparations

Fraxinus chinensis bark (2452) (*previously Fraxinus rhynchophylla bark*)

Senna leaflet (0206) (*previously Senna leaf*)

Senna pods (0207) (*previously Senna pods, Alexandrian*)

Monographs

Mercaptopurine monohydrate (0096) (*previously Mercaptopurine*)

DELETED TEXTS

*The following texts are deleted as of **1 April 2020**.*

MONOGRAPHS

Herbal drugs and herbal drug preparations

Senna pods, Tinnevely (0208)

Monographs

Insulin, bovine (1637)

2.2. Physical and physico-chemical methods

2.2.47. Capillary electrophoresis..... 4315



01/2010:20247
corrected 10.1

The time (t) taken by the solute to migrate the distance (l) from the injection end of the capillary to the detection point (capillary effective length) is given by the expression:

$$t = \frac{l}{v_{ep} + v_{eo}} = \frac{l \times L}{(\mu_{ep} + \mu_{eo}) \times V}$$

2.2.47. CAPILLARY ELECTROPHORESIS⁽¹⁾

GENERAL PRINCIPLES

Capillary electrophoresis is a physical method of analysis based on the migration, inside a capillary, of charged analytes dissolved in an electrolyte solution, under the influence of a direct-current electric field.

The migration velocity of an analyte under an electric field of intensity E , is determined by the electrophoretic mobility of the analyte and the electro-osmotic mobility of the buffer inside the capillary. The electrophoretic mobility of a solute (μ_{ep}) depends on the characteristics of the solute (electric charge, molecular size and shape) and those of the buffer in which the migration takes place (type and ionic strength of the electrolyte, pH, viscosity and additives). The electrophoretic velocity (v_{ep}) of a solute, assuming a spherical shape, is given by the equation:

$$v_{ep} = \mu_{ep} \times E = \left(\frac{q}{6\pi\eta r} \right) \times \left(\frac{V}{L} \right)$$

- q = effective charge of the solute,
 η = viscosity of the electrolyte solution,
 r = Stoke's radius of the solute,
 V = applied voltage,
 L = total length of the capillary.

When an electric field is applied through the capillary filled with buffer, a flow of solvent is generated inside the capillary, called electro-osmotic flow. The velocity of the electro-osmotic flow depends on the electro-osmotic mobility (μ_{eo}) which in turn depends on the charge density on the capillary internal wall and the buffer characteristics. The electro-osmotic velocity (v_{eo}) is given by the equation:

$$v_{eo} = \mu_{eo} \times E = \left(\frac{\varepsilon\zeta}{\eta} \right) \times \left(\frac{V}{L} \right)$$

- ε = dielectric constant of the buffer,
 ζ = zeta potential of the capillary surface.

The velocity of the solute (v) is given by:

$$v = v_{ep} + v_{eo}$$

The electrophoretic mobility of the analyte and the electro-osmotic mobility may act in the same direction or in opposite directions, depending on the charge of the solute. In normal capillary electrophoresis, anions will migrate in the opposite direction to the electro-osmotic flow and their velocities will be smaller than the electro-osmotic velocity. Cations will migrate in the same direction as the electro-osmotic flow and their velocities will be greater than the electro-osmotic velocity. Under conditions in which there is a fast electro-osmotic velocity with respect to the electrophoretic velocity of the solutes, both cations and anions can be separated in the same run.

In general, uncoated fused-silica capillaries above pH 3 have negative charge due to ionised silanol groups in the inner wall. Consequently, the electro-osmotic flow is from anode to cathode. The electro-osmotic flow must remain constant from run to run if good reproducibility is to be obtained in the migration velocity of the solutes. For some applications, it may be necessary to reduce or suppress the electro-osmotic flow by modifying the inner wall of the capillary or by changing the concentration, composition and/or pH of the buffer solution.

After the introduction of the sample into the capillary, each analyte ion of the sample migrates within the background electrolyte as an independent zone, according to its electrophoretic mobility. Zone dispersion, that is the spreading of each solute band, results from different phenomena. Under ideal conditions the sole contribution to the solute-zone broadening is molecular diffusion of the solute along the capillary (longitudinal diffusion). In this ideal case the efficiency of the zone, expressed as the number of theoretical plates (N), is given by:

$$N = \frac{(\mu_{ep} + \mu_{eo}) \times V \times l}{2 \times D \times L}$$

D = molecular diffusion coefficient of the solute in the buffer.

In practice, other phenomena such as heat dissipation, sample adsorption onto the capillary wall, mismatched conductivity between sample and buffer, length of the injection plug, detector cell size and unlevelled buffer reservoirs can also significantly contribute to band dispersion.

Separation between 2 bands (expressed as the resolution, R_s) can be obtained by modifying the electrophoretic mobility of the analytes, the electro-osmotic mobility induced in the capillary and by increasing the efficiency for the band of each analyte, according to the equation:

$$R_s = \frac{\sqrt{N}(\mu_{epb} - \mu_{epa})}{4(\bar{\mu}_{ep} + \mu_{eo})}$$

- μ_{epa} and μ_{epb} = electrophoretic mobilities of the 2 analytes separated,
 $\bar{\mu}_{ep}$ = mean electrophoretic mobility of the 2 analytes $\bar{\mu}_{ep} = \frac{1}{2}(\mu_{epb} + \mu_{epa})$.

APPARATUS

An apparatus for capillary electrophoresis is composed of:

- a high-voltage, controllable direct-current power supply;
- 2 buffer reservoirs, held at the same level, containing the prescribed anodic and cathodic solutions;
- 2 electrode assemblies (the cathode and the anode), immersed in the buffer reservoirs and connected to the power supply;
- a separation capillary (usually made of fused-silica) which, when used with some specific types of detectors, has an optical viewing window aligned with the detector. The ends of the capillary are placed in the buffer reservoirs. The capillary is filled with the solution prescribed in the monograph;
- a suitable injection system;

(1) This chapter has undergone pharmacopoeial harmonisation. See chapter 5.8. *Pharmacopoeial harmonisation*.

- a detector able to monitor the amount of substances of interest passing through a segment of the separation capillary at a given time; it is usually based on absorption spectrophotometry (UV and visible) or fluorimetry, but conductimetric, amperometric or mass spectrometric detection can be useful for specific applications; indirect detection is an alternative method used to detect non-UV-absorbing and non-fluorescent compounds;
- a thermostatic system able to maintain a constant temperature inside the capillary is recommended to obtain a good separation reproducibility;
- a recorder and a suitable integrator or a computer.

The definition of the injection process and its automation are critical for precise quantitative analysis. Modes of injection include gravity, pressure or vacuum injection and electrokinetic injection. The amount of each sample component introduced electrokinetically depends on its electrophoretic mobility, leading to possible discrimination using this injection mode.

Use the capillary, the buffer solutions, the preconditioning method, the sample solution and the migration conditions prescribed in the monograph of the considered substance. The employed electrolytic solution is filtered to remove particles and degassed to avoid bubble formation that could interfere with the detection system or interrupt the electrical contact in the capillary during the separation run. A rigorous rinsing procedure should be developed for each analytical method to achieve reproducible migration times of the solutes.

CAPILLARY ZONE ELECTROPHORESIS

PRINCIPLE

In capillary zone electrophoresis, analytes are separated in a capillary containing only buffer without any anticonvective medium. With this technique, separation takes place because the different components of the sample migrate as discrete bands with different velocities. The velocity of each band depends on the electrophoretic mobility of the solute and the electro-osmotic flow in the capillary (see General Principles). Coated capillaries can be used to increase the separation capacity of those substances adsorbing on fused-silica surfaces.

Using this mode of capillary electrophoresis, the analysis of both small ($M_r < 2000$) and large molecules ($2000 < M_r < 100\,000$) can be accomplished. Due to the high efficiency achieved in capillary zone electrophoresis, separation of molecules having only minute differences in their charge-to-mass ratio can be effected. This separation mode also allows the separation of chiral compounds by addition of chiral selectors to the separation buffer.

OPTIMISATION

Optimisation of the separation is a complex process where several separation parameters can play a major role. The main factors to be considered in the development of separations are instrumental and electrolytic solution parameters.

Instrumental parameters

Voltage. A Joule heating plot is useful in optimising the applied voltage and capillary temperature. Separation time is inversely proportional to applied voltage. However, an increase in the voltage used can cause excessive heat production, giving rise to temperature and, as a result thereof, viscosity gradients in the buffer inside the capillary. This effect causes band broadening and decreases resolution.

Polarity. Electrode polarity can be normal (anode at the inlet and cathode at the outlet) and the electro-osmotic flow will move toward the cathode. If the electrode polarity is reversed, the electro-osmotic flow is away from the outlet and only charged analytes with electrophoretic mobilities greater than the electro-osmotic flow will pass to the outlet.

Temperature. The main effect of temperature is observed on buffer viscosity and electrical conductivity, and therefore on migration velocity. In some cases, an increase in capillary

temperature can cause a conformational change in proteins, modifying their migration time and the efficiency of the separation.

Capillary. The dimensions of the capillary (length and internal diameter) contribute to analysis time, efficiency of separations and load capacity. Increasing both effective length and total length can decrease the electric fields (working at constant voltage) which increases migration time. For a given buffer and electric field, heat dissipation, and hence sample band-broadening, depend on the internal diameter of the capillary. The latter also affects the detection limit, depending on the sample volume injected and the detection system employed.

Since the adsorption of the sample components on the capillary wall limits efficiency, methods to avoid these interactions should be considered in the development of a separation method. In the specific case of proteins, several strategies have been devised to avoid adsorption on the capillary wall. Some of these strategies (use of extreme pH and adsorption of positively charged buffer additives) only require modification of the buffer composition to prevent protein adsorption. In other strategies, the internal wall of the capillary is coated with a polymer, covalently bonded to the silica, that prevents interaction between the proteins and the negatively charged silica surface. For this purpose, ready-to-use capillaries with coatings consisting of neutral-hydrophilic, cationic and anionic polymers are available.

Electrolytic solution parameters

Buffer type and concentration. Suitable buffers for capillary electrophoresis have an appropriate buffer capacity in the pH range of choice and low mobility to minimise current generation.

Matching buffer-ion mobility to solute mobility, whenever possible, is important for minimising band distortion. The type of sample solvent used is also important to achieve on-column sample focusing, which increases separation efficiency and improves detection.

An increase in buffer concentration (for a given pH) decreases electro-osmotic flow and solute velocity.

Buffer pH. The pH of the buffer can affect separation by modifying the charge of the analyte or additives, and by changing the electro-osmotic flow. In protein and peptide separation, changing the pH of the buffer from above to below the isoelectric point (pI) changes the net charge of the solute from negative to positive. An increase in the buffer pH generally increases the electro-osmotic flow.

Organic solvents. Organic modifiers (methanol, acetonitrile, etc.) may be added to the aqueous buffer to increase the solubility of the solute or other additives and/or to affect the degree of ionisation of the sample components. The addition of these organic modifiers to the buffer generally causes a decrease in the electro-osmotic flow.

Additives for chiral separations. For the separation of enantiomers, a chiral selector is added to the separation buffer. The most commonly used chiral selectors are cyclodextrins, but crown ethers, polysaccharides and proteins may also be used. Since chiral recognition is governed by the different interactions between the chiral selector and each of the enantiomers, the resolution achieved for the chiral compounds depends largely on the type of chiral selector used. In this regard, for the development of a given separation it may be useful to test cyclodextrins having a different cavity size (α -, β -, or γ -cyclodextrin) or modified cyclodextrins with neutral (methyl, ethyl, hydroxyalkyl, etc.) or ionisable (aminomethyl, carboxymethyl, sulfobutyl ether, etc.) groups. When using modified cyclodextrins, batch-to-batch variations in the degree of substitution of the cyclodextrins must be taken into account since it will influence the selectivity. Other factors controlling the resolution in chiral separations are

concentration of chiral selector, composition and pH of the buffer and temperature. The use of organic additives, such as methanol or urea can also modify the resolution achieved.

CAPILLARY GEL ELECTROPHORESIS

PRINCIPLE

In capillary gel electrophoresis, separation takes place inside a capillary filled with a gel that acts as a molecular sieve. Molecules with similar charge-to-mass ratios are separated according to molecular size since smaller molecules move more freely through the network of the gel and therefore migrate faster than larger molecules. Different biological macromolecules (for example, proteins and DNA fragments), which often have similar charge-to-mass ratios, can thus be separated according to their molecular mass by capillary gel electrophoresis.

CHARACTERISTICS OF GELS

2 types of gels are used in capillary electrophoresis: permanently coated gels and dynamically coated gels. Permanently coated gels, such as cross-linked polyacrylamide, are prepared inside the capillary by polymerisation of the monomers. They are usually bonded to the fused-silica wall and cannot be removed without destroying the capillary. If the gels are used for protein analysis under reducing conditions, the separation buffer usually contains sodium dodecyl sulfate and the samples are denatured by heating in a mixture of sodium dodecyl sulfate and 2-mercaptoethanol or dithiothreitol before injection. When non-reducing conditions are used (for example, analysis of an intact antibody), 2-mercaptoethanol and dithiothreitol are not used. Separation in cross-linked gels can be optimised by modifying the separation buffer (as indicated in the capillary zone electrophoresis section) and controlling the gel porosity during the gel preparation. For cross-linked polyacrylamide gels, the porosity can be modified by changing the concentration of acrylamide and/or the proportion of cross-linker. As a rule, a decrease in the porosity of the gel leads to a decrease in the mobility of the solutes. Due to the rigidity of these gels, only electrokinetic injection can be used.

Dynamically coated gels are hydrophilic polymers, such as linear polyacrylamide, cellulose derivatives, dextran, etc., which can be dissolved in aqueous separation buffers giving rise to a separation medium that also acts as a molecular sieve. These separation media are easier to prepare than cross-linked polymers. They can be prepared in a vial and filled by pressure in a wall-coated capillary (with no electro-osmotic flow). Replacing the gel before every injection generally improves the separation reproducibility. The porosity of the gels can be increased by using polymers of higher molecular mass (at a given polymer concentration) or by decreasing the polymer concentration (for a given polymer molecular mass). A reduction in the gel porosity leads to a decrease in the mobility of the solute for the same buffer. Since the dissolution of these polymers in the buffer gives low viscosity solutions, both hydrodynamic and electrokinetic injection techniques can be used.

CAPILLARY ISOELECTRIC FOCUSING

PRINCIPLE

In isoelectric focusing, the molecules migrate under the influence of the electric field, so long as they are charged, in a pH gradient generated by ampholytes having pI values in a wide range (poly-aminocarboxylic acids), dissolved in the separation buffer.

The three basic steps of isoelectric focusing are loading, focusing and mobilisation.

Loading step. Two methods may be employed:

- loading in one step: the sample is mixed with ampholytes and introduced into the capillary either by pressure or vacuum;
- sequential loading: a leading buffer, then the ampholytes, then the sample mixed with ampholytes, again ampholytes alone and finally the terminating buffer are introduced into the capillary. The volume of the sample must be small enough not to modify the pH gradient.

Focusing step. When the voltage is applied, ampholytes migrate toward the cathode or the anode, according to their net charge, thus creating a pH gradient from anode (lower pH) to cathode (higher pH). During this step the components to be separated migrate until they reach a pH corresponding to their isoelectric point (pI) and the current drops to very low values.

Mobilisation step. If mobilisation is required for detection, use one of the following methods.

- in the first method, mobilisation is accomplished during the focusing step under the effect of the electro-osmotic flow; the electro-osmotic flow must be small enough to allow the focusing of the components;
- in the second method, mobilisation is accomplished by applying positive pressure after the focusing step;
- in the third method, mobilisation is achieved after the focusing step by adding salts to the cathode reservoir or the anode reservoir (depending on the direction chosen for mobilisation) in order to alter the pH in the capillary when the voltage is applied. As the pH is changed, the proteins and ampholytes are mobilised in the direction of the reservoir which contains the added salts and pass the detector.

The separation achieved, expressed as ΔpI , depends on the pH gradient (dpH / dx), the number of ampholytes having different pI values, the molecular diffusion coefficient (D), the intensity of the electric field (E) and the variation of the electrophoretic mobility of the analyte with the pH ($-d\mu / dpH$):

$$\Delta pI = 3 \times \sqrt{\frac{D(dpH / dx)}{E(-d\mu / dpH)}}$$

OPTIMISATION

The main parameters to be considered in the development of separations are:

Voltage. Capillary isoelectric focusing utilises very high electric fields, 300 V/cm to 1000 V/cm in the focusing step.

Capillary. The electro-osmotic flow must be reduced or suppressed depending on the mobilisation strategy (see above). Coated capillaries tend to reduce the electro-osmotic flow.

Solutions. The anode buffer reservoir is filled with a solution with a pH lower than the pI of the most acidic ampholyte and the cathode reservoir is filled with a solution with a pH higher than the pI of the most basic ampholyte. Phosphoric acid for the anode and sodium hydroxide for the cathode are frequently used.

Addition of a polymer, such as methylcellulose, in the ampholyte solution tends to suppress convective forces (if any) and electro-osmotic flow by increasing the viscosity. Commercial ampholytes are available covering many pH ranges and may be mixed if necessary to obtain an expanded pH range. Broad pH ranges are used to estimate the isoelectric point whereas narrower ranges are employed to improve accuracy. Calibration can be done by correlating migration time with isoelectric point for a series of protein markers. During the focusing step precipitation of proteins at their isoelectric point can be prevented, if necessary, using buffer additives such as glycerol, surfactants, urea or zwitterionic buffers. However, depending on the concentration, urea denatures proteins.

MICELLAR ELECTROKINETIC CHROMATOGRAPHY (MEKC)

PRINCIPLE

In micellar electrokinetic chromatography, separation takes place in an electrolyte solution which contains a surfactant at a concentration above the critical micellar concentration (*cmc*). The solute molecules are distributed between the aqueous buffer and the pseudo-stationary phase composed of micelles, according to the partition coefficient of the solute. The technique can therefore be considered as a hybrid of electrophoresis and chromatography. It is a technique that can be used for the separation of both neutral and charged solutes, maintaining the efficiency, speed and instrumental suitability of capillary electrophoresis. One of the most widely used surfactants in MEKC is the anionic surfactant sodium dodecyl sulfate, although other surfactants, for example cationic surfactants such as cetyltrimethylammonium salts, are also used.

The separation mechanism is as follows. At neutral and alkaline pH, a strong electro-osmotic flow is generated and moves the separation buffer ions in the direction of the cathode. If sodium dodecyl sulfate is employed as the surfactant, the electrophoretic migration of the anionic micelle is in the opposite direction, towards the anode. As a result, the overall micelle migration velocity is slowed down compared to the bulk flow of the electrolytic solution. In the case of neutral solutes, since the analyte can partition between the micelle and the aqueous buffer, and has no electrophoretic mobility, the analyte migration velocity will depend only on the partition coefficient between the micelle and the aqueous buffer. In the electropherogram, the peaks corresponding to each uncharged solute are always between that of the electro-osmotic flow marker and that of the micelle (the time elapsed between these two peaks is called the separation window). For electrically charged solutes, the migration velocity depends on both the partition coefficient of the solute between the micelle and the aqueous buffer, and on the electrophoretic mobility of the solute in the absence of micelle.

Since the mechanism in MEKC of neutral and weakly ionised solutes is essentially chromatographic, migration of the solute and resolution can be rationalised in terms of the retention factor of the solute (k'), also referred to as mass distribution ratio (D_m), which is the ratio of the number of moles of solute in the micelle to those in the mobile phase. For a neutral compound, k' is given by:

$$k' = \frac{t_R - t_0}{t_0 \times \left(1 - \frac{t_R}{t_{mc}}\right)} = K \times \frac{V_S}{V_M}$$

t_R = migration time of the solute,

t_0 = analysis time of an unretained solute (determined by injecting an electro-osmotic flow marker which does not enter the micelle, for instance methanol),

t_{mc} = micelle migration time (measured by injecting a micelle marker, such as Sudan III, which migrates while continuously associated in the micelle),

K = partition coefficient of the solute,

V_S = volume of the micellar phase,

V_M = volume of the mobile phase.

Likewise, the resolution between 2 closely-migrating solutes (R_s) is given by:

$$R_s = \frac{\sqrt{N}}{4} \times \frac{\alpha - 1}{\alpha} \times \frac{k'_b}{k'_b + 1} \times \frac{1 - \left(\frac{t_0}{t_{mc}}\right)}{1 + k'_a \times \left(\frac{t_0}{t_{mc}}\right)}$$

N = number of theoretical plates for one of the solutes,
 α = selectivity,
 k'_a and k'_b = retention factors for both solutes, respectively ($k'_b > k'_a$).

Similar, but not identical, equations give k' and R_s values for electrically charged solutes.

OPTIMISATION

The main parameters to be considered in the development of separations by MEKC are instrumental and electrolytic solution parameters.

Instrumental parameters

Voltage. Separation time is inversely proportional to applied voltage. However, an increase in voltage can cause excessive heat production that gives rise to temperature gradients and viscosity gradients of the buffer in the cross-section of the capillary. This effect can be significant with high conductivity buffers such as those containing micelles. Poor heat dissipation causes band broadening and decreases resolution.

Temperature. Variations in capillary temperature affect the partition coefficient of the solute between the buffer and the micelles, the critical micellar concentration and the viscosity of the buffer. These parameters contribute to the migration time of the solutes. The use of a good cooling system improves the reproducibility of the migration time for the solutes.

Capillary. As in capillary zone electrophoresis, the dimensions of the capillary (length and internal diameter) contribute to analysis time and efficiency of separations. Increasing both effective length and total length can decrease the electric fields (working at constant voltage), increase migration time and improve the separation efficiency. The internal diameter controls heat dissipation (for a given buffer and electric field) and consequently the sample band broadening.

Electrolytic solution parameters

Surfactant type and concentration. The type of surfactant, in the same way as the stationary phase in chromatography, affects the resolution since it modifies separation selectivity. Also, the log k' of a neutral compound increases linearly with the concentration of surfactant in the mobile phase. Since resolution in MEKC reaches a maximum when k' approaches the value of $\sqrt{t_{mc}/t_0}$, modifying the concentration of surfactant in the mobile phase changes the resolution obtained.

Buffer pH. Although pH does not modify the partition coefficient of non-ionised solutes, it can modify the electro-osmotic flow in uncoated capillaries. A decrease in the buffer pH decreases the electro-osmotic flow and therefore increases the resolution of the neutral solutes in MEKC, resulting in a longer analysis time.

Organic solvents. To improve MEKC separation of hydrophobic compounds, organic modifiers (methanol, propanol, acetonitrile, etc.) can be added to the electrolytic solution. The addition of these modifiers usually decreases migration time and the selectivity of the separation. Since the addition of organic modifiers affects the critical micellar concentration, a given surfactant concentration can be used only within a certain percentage of organic modifier before the micellisation is inhibited or adversely affected, resulting in the absence of micelles and, therefore, in the absence of partition. The dissociation of micelles in the presence of a high content of organic solvent does not always mean that the separation will no longer be possible; in some cases the hydrophobic interaction between the ionic surfactant monomer and the neutral solutes forms solvophobic complexes that can be separated electrophoretically.

Additives for chiral separations. For the separation of enantiomers using MEKC, a chiral selector is included in the micellar system, either covalently bound to the surfactant or added to the micellar separation electrolyte. Micelles that have a moiety with chiral discrimination properties include

salts of *N*-dodecanoyl-L-amino acids, bile salts, etc. Chiral resolution can also be achieved using chiral discriminators, such as cyclodextrins, added to the electrolytic solutions which contain micellised achiral surfactants.

Other additives. Several strategies can be carried out to modify selectivity, by adding chemicals to the buffer. The addition of several types of cyclodextrins to the buffer can also be used to reduce the interaction of hydrophobic solutes with the micelle, thus increasing the selectivity for this type of compound.

The addition of substances able to modify solute-micelle interactions by adsorption on the latter, is used to improve the selectivity of the separations in MEKC. These additives may be a second surfactant (ionic or non-ionic) which gives rise to mixed micelles or metallic cations which dissolve in the micelle and form co-ordination complexes with the solutes.

QUANTIFICATION

Peak areas must be divided by the corresponding migration time to give the corrected area in order to:

- compensate for the shift in migration time from run to run, thus reducing the variation of the response,
- compensate for the different responses of sample constituents with different migration times.

Where an internal standard is used, verify that no peak of the substance to be examined is masked by that of the internal standard.

CALCULATIONS

From the values obtained, calculate the content of the component or components being examined. When prescribed, the percentage content of one or more components of the sample to be examined is calculated by determining the corrected area(s) of the peak(s) as a percentage of the total of the corrected areas of all peaks, excluding those due to solvents or any added reagents (normalisation procedure). The use of an automatic integration system (integrator or data acquisition and processing system) is recommended.

SYSTEM SUITABILITY

In order to check the behaviour of the capillary electrophoresis system, system suitability parameters are used. The choice of these parameters depends on the mode of capillary electrophoresis used. They are: retention factor (*k'*) (only for micellar electrokinetic chromatography), apparent number of theoretical plates (*N*), symmetry factor (*A_s*) and resolution (*R_s*). In previous sections, the theoretical expressions for *N* and *R_s* have been described, but more practical equations that allow these parameters to be calculated from the electropherograms are given below.

APPARENT NUMBER OF THEORETICAL PLATES

The apparent number of theoretical plates (*N*) may be calculated using the expression:

$$N = 5.54 \times \left(\frac{t_R}{w_h} \right)^2$$

- t_R* = migration time or distance along the baseline from the point of injection to the perpendicular dropped from the maximum of the peak corresponding to the component,
- w_h* = width of the peak at half-height.

RESOLUTION

The resolution (*R_s*) between peaks of similar height of 2 components may be calculated using the expression:

$$R_s = \frac{1.18 \times (t_{R2} - t_{R1})}{w_{h1} + w_{h2}}$$

$$t_{R2} > t_{R1}$$

- t_{R1}* and *t_{R2}* = migration times or distances along the baseline from the point of injection to the perpendiculars dropped from the maxima of two adjacent peaks,
- w_{h1}* and *w_{h2}* = peak widths at half-height.

When appropriate, the resolution may be calculated by measuring the height of the valley (*H_v*) between 2 partly resolved peaks in a standard preparation and the height of the smaller peak (*H_p*) and calculating the peak-to-valley ratio:

$$\frac{p}{v} = \frac{H_p}{H_v}$$

SYMMETRY FACTOR

The symmetry factor (*A_s*) of a peak may be calculated using the expression:

$$A_s = \frac{w_{0.05}}{2d}$$

- w_{0.05}* = width of the peak at one-twentieth of the peak height,
- d* = distance between the perpendicular dropped from the peak maximum and the leading edge of the peak at one-twentieth of the peak height.

Tests for area repeatability (standard deviation of areas or of the area/migration-time ratio) and for migration time repeatability (standard deviation of migration time) are introduced as suitability parameters. Migration time repeatability provides a test for the suitability of the capillary washing procedures. An alternative practice to avoid the lack of repeatability of the migration time is to use migration time relative to an internal standard.

A test for the verification of the signal-to-noise ratio for a standard preparation (or the determination of the limit of quantification) may also be useful for the determination of related substances.

SIGNAL-TO-NOISE RATIO

The detection limit and quantification limit correspond to signal-to-noise ratios of 3 and 10 respectively. The signal-to-noise ratio (*S/N*) is calculated using the expression:

$$\frac{S}{N} = \frac{2H}{h}$$

- H* = height of the peak corresponding to the component concerned, in the electropherogram obtained with the prescribed reference solution, measured from the maximum of the peak to the extrapolated baseline of the signal observed over a distance equal to twenty times the width at half-height,
- h* = range of the background in an electropherogram obtained after injection of a blank, observed over a distance equal to twenty times the width at the half-height of the peak in the electropherogram obtained with the prescribed reference solution and, if possible, situated equally around the place where this peak would be found.

2.4. Limit tests

2.4.24. Identification and control of residual solvents..... 4323



04/2020:20424

2.4.24. IDENTIFICATION AND CONTROL OF RESIDUAL SOLVENTS

The test procedures described in this general method may be used:

- i. for the identification of the majority of Class 1 and Class 2 residual solvents in an active substance, excipient or medicinal product when the residual solvents are unknown;
- ii. as a limit test for Class 1 and Class 2 solvents when present in an active substance, excipient or medicinal product;
- iii. for the quantification of Class 2 solvents when the limits are greater than 1000 ppm (0.1 per cent) or for the quantification of Class 3 solvents when required.

Class 1, Class 2 and Class 3 residual solvents are listed in general chapter 5.4. *Residual solvents*.

Three diluents are described for sample preparation and the conditions to be applied for head-space injection of the gaseous sample onto the chromatographic system. Two chromatographic systems are prescribed but System A is preferred whilst System B is employed normally for confirmation of identity. The choice of sample preparation procedure depends on the solubility of the substance to be examined and in certain cases the residual solvents to be controlled.

The following residual solvents are not readily detected by the head-space injection conditions described: formamide, 2-ethoxyethanol, 2-methoxyethanol, ethylene glycol, *N*-methylpyrrolidone and sulfolane. Other appropriate procedures should be employed for the control of these residual solvents.

When the test procedure is applied quantitatively to control residual solvents in a substance, then it must be validated.

PROCEDURE

Examine by gas chromatography with static head-space injection (2.2.28).

Sample preparation 1. This is intended for the control of residual solvents in water-soluble substances.

Sample solution (1). Dissolve 0.200 g of the substance to be examined in *water R* and dilute to 20.0 mL with the same solvent.

Sample preparation 2. This is intended for the control of residual solvents in water-insoluble substances.

Sample solution (2). Dissolve 0.200 g of the substance to be examined in *dimethylformamide R* (DMF) and dilute to 20.0 mL with the same solvent.

Sample preparation 3. This is intended for the control of *N,N*-dimethylacetamide and/or *N,N*-dimethylformamide, when it is known or suspected that one or both of these substances are present in the substance to be examined.

Sample solution (3). Dissolve 0.200 g of the substance to be examined in *1,3-dimethyl-2-imidazolidinone R* (DMI) and dilute to 20.0 mL with the same solvent.

In some cases none of the above sample preparation procedures are appropriate, in which case the diluent to be used for the preparation of the sample solution and the static head-space conditions to be employed must be demonstrated to be suitable.

Solvent solution (a). To 1.0 mL of *Class 1 residual solvent solution CRS*, add 9 mL of *dimethyl sulfoxide R* and dilute to 100.0 mL with *water R*. Dilute 1.0 mL of this solution to 100 mL with *water R*. Dilute 1.0 mL of this solution to 10.0 mL with *water R*.

The reference solutions correspond to the following limits:

- benzene: 2 ppm;
- carbon tetrachloride: 4 ppm;
- 1,2-dichloroethane: 5 ppm;
- 1,1-dichloroethene: 8 ppm;
- 1,1,1-trichloroethane: 10 ppm.

Solvent solution (b). Dissolve appropriate quantities of the Class 2 residual solvents in *dimethyl sulfoxide R* and dilute to 100.0 mL with the same solvent. Dilute in *water R* to give a concentration of 1/20 of the limits stated in Table 2 (see 5.4. *Residual solvents*).

Solvent solution (c). Dissolve 1.00 g of the solvent or solvents present in the substance to be examined in *dimethyl sulfoxide R* or *water R*, if appropriate, and dilute to 100.0 mL with *water R*. Dilute to give a concentration of 1/20 of the limit(s) stated in Table 1 or 2 (see 5.4. *Residual solvents*).

Blank solution. Prepare as described for solvent solution (c) but without the addition of solvent(s) (used to verify the absence of interfering peaks).

Test solution. Introduce 5.0 mL of the sample solution and 1.0 mL of the blank solution into an injection vial.

Reference solution (a) (Class 1). Introduce 1.0 mL of solvent solution (a) and 5.0 mL of the appropriate diluent into an injection vial.

Reference solution (a₁) (Class 1). Introduce 5.0 mL of the sample solution and 1.0 mL of solvent solution (a) into an injection vial.

Reference solution (b) (Class 2). Introduce 1.0 mL of solvent solution (b) and 5.0 mL of the appropriate diluent into an injection vial.

Reference solution (c). Introduce 5.0 mL of the sample solution and 1.0 mL of solvent solution (c) into an injection vial.

Reference solution (d). Introduce 1.0 mL of the blank solution and 5.0 mL of the appropriate diluent into an injection vial.

Close the vials with a tight rubber membrane stopper coated with polytetrafluoroethylene and secure with an aluminium crimp cap. Shake to obtain a homogeneous solution.

The following static head-space injection conditions may be used:

Operating parameters	Sample preparation procedure		
	1	2	3
Equilibration temperature (°C)	80	105	80
Equilibration time (min)	60	45	45
Transfer-line temperature (°C)	85	110	105
Carrier gas: <i>nitrogen for chromatography R</i> or <i>helium for chromatography R</i> at an appropriate pressure			
Pressurisation time (s)	30	30	30
Injection volume (mL)	1	1	1

The chromatographic procedure may be carried out using:

SYSTEM A

- a fused-silica capillary or wide-bore column 30 m long and 0.32 mm or 0.53 mm in internal diameter coated with *cyanopropyl(3)phenyl(3)methyl(94)polysiloxane R* (film thickness 1.8 µm or 3 µm);
- *nitrogen for chromatography R* or *helium for chromatography R* as the carrier gas, split ratio 1:5 with a linear velocity of about 35 cm/s;
- a flame-ionisation detector (a mass spectrometer may also be used or an electron-capture detector for the chlorinated residual solvents of Class 1);

maintaining the temperature of the column at 40 °C for 20 min, then raising the temperature at a rate of 10 °C per min to 240 °C and maintaining it at 240 °C for 20 min and maintaining the temperature of the injection port at 140 °C and that of the detector at 250 °C; or, where there is interference from the matrix, use:

SYSTEM B

- a fused-silica capillary or wide-bore column 30 m long and 0.32 mm or 0.53 mm in internal diameter coated with *macrogol 20 000 R* (film thickness 0.25 µm);
- *nitrogen for chromatography R* or *helium for chromatography R* as the carrier gas, split ratio 1:5 with a linear velocity of about 35 cm/s;
- a flame-ionisation detector (a mass spectrophotometer may also be used or an electron-capture detector for the chlorinated residual solvents of Class 1);

maintaining the temperature of the column at 50 °C for 20 min, then raising the temperature at a rate of 6 °C per min to 165 °C and maintaining it at 165 °C for 20 min and maintaining the temperature of the injection port at 140 °C and that of the detector at 250 °C.

Inject 1 mL of the gaseous phase of reference solution (a) onto the column described in System A and record the chromatogram under such conditions that the signal-to-noise ratio for 1,1,1-trichloroethane can be measured. The signal-to-noise ratio must be at least 5. A typical chromatogram is shown in Figure 2.4.24.-1.

Inject 1 mL of the gaseous phase of reference solution (a₁) onto the column described in System A. The peaks due to the Class 1 residual solvents are still detectable.

Inject 1 mL of the gaseous phase of reference solution (b) onto the column described in System A and record the chromatogram under such conditions that the resolution between acetonitrile and dichloromethane can be determined. The system is suitable if the chromatogram obtained resembles the chromatogram shown in Figure 2.4.24.-2 and the resolution between acetonitrile and dichloromethane is at least 1.0.

Inject 1 mL of the gaseous phase of the test solution onto the column described in System A. If in the chromatogram obtained, there is no peak which corresponds to one of

the residual solvent peaks in the chromatograms obtained with reference solution (a) or (b), then the substance to be examined meets the requirements of the test. If any peak in the chromatogram obtained with the test solution corresponds to any of the residual solvent peaks obtained with reference solution (a) or (b) then System B is to be employed.

Inject 1 mL of the gaseous phase of reference solution (a) onto the column described in System B and record the chromatogram under such conditions that the signal-to-noise ratio for benzene can be measured. The signal-to-noise ratio must be at least 5. A typical chromatogram is shown in Figure 2.4.24.-3.

Inject 1 mL of the gaseous phase of reference solution (a₁) onto the column described in System B. The peaks due to the Class 1 residual solvents are still detectable.

Inject 1 mL of the gaseous phase of reference solution (b) onto the column described in System B and record the chromatogram under such conditions that the resolution between acetonitrile and 1,1,2-trichloroethene can be determined. The system is suitable if the chromatogram obtained resembles the chromatogram shown in Figure 2.4.24.-4 and the resolution between acetonitrile and 1,1,2-trichloroethene is at least 1.0.

Inject 1 mL of the gaseous phase of the test solution onto the column described in System B. If in the chromatogram obtained, there is no peak which corresponds to any of the residual solvent peaks in the chromatogram obtained with the reference solution (a) or (b), then the substance to be examined meets the requirements of the test. If any peak in the chromatogram obtained with the test solution corresponds to any of the residual solvent peaks obtained with reference solution (a) or (b) and confirms the correspondence obtained when using System A, then proceed as follows.

Inject 1 mL of the gaseous phase of reference solution (c) onto the column described for System A or System B. If necessary, adjust the sensitivity of the system so that the height of the peak corresponding to the identified residual solvent(s) is at least 50 per cent of the full scale of the recorder.

Inject 1 mL of the gaseous phase of reference solution (d) onto the column. No interfering peaks should be observed.

Inject 1 mL of the gaseous phase of the test solution and 1 mL of the gaseous phase of reference solution (c) on to the column. Repeat these injections twice more.

The mean area of the peak of the residual solvent(s) in the chromatograms obtained with the test solution is not greater than half the mean area of the peak of the corresponding residual solvent(s) in the chromatograms obtained with reference solution (c). The test is not valid unless the relative standard deviation of the differences in areas between the analyte peaks obtained from 3 replicate paired injections of reference solution (c) and the test solution, is at most 15 per cent.

A flow diagram of the procedure is shown in Figure 2.4.24.-5.

When a residual solvent (Class 2 or Class 3) is present at a level of 0.1 per cent or greater then the content may be quantitatively determined by the method of standard additions.




Figure 2.4.24.-1. – Typical chromatogram of Class 1 solvents using the conditions described for System A and Procedure 1. Flame-ionisation detector




Figure 2.4.24.-2. – Chromatogram of Class 2 solvents (solvent solution (b)) using the conditions described for System A and Procedure 1. Flame-ionisation detector




Figure 2.4.24.-3. – Chromatogram of Class 1 residual solvents using the conditions described for System B and Procedure 1. Flame-ionisation detector




Figure 2.4.24.-4. – Typical chromatogram of Class 2 residual solvents (solvent solution (b)) using the conditions described for System B and Procedure 1. Flame-ionisation detector




Figure 2.4.24.-5. – Diagram relating to the identification of residual solvents and the application of limit tests

4. Reagents

4.1.1. Reagents.. 4331 4.2.1. Primary standards for volumetric solutions..... 4331



4.1.1. REAGENTS

Calcium chloride, anhydrous. CaCl_2 . (M_r 111.0). 1014800. [10043-52-4].

Content: minimum 98.0 per cent (dried substance).

White or almost white granules, deliquescent, very soluble in water, freely soluble in ethanol (96 per cent) and in methanol.

Loss on drying (2.2.32): maximum 5.0 per cent, determined by drying in an oven at $200 \pm 10^\circ\text{C}$.

Storage: in an airtight container, protected from moisture.

Convallatoxin. $\text{C}_{29}\text{H}_{42}\text{O}_{10}$. (M_r 550.6). 1207900. [508-75-8]. 3β -[(6-Deoxy- α -L-mannopyranosyl)oxy]-5,14-dihydroxy-19-oxo-5 β -card-20(22)-enolide. 5,14-Dihydroxy-19-oxo-3 β -[(α -L-rhamnopyranosyl)oxy]-5 β -card-20(22)-enolide.

White or slightly yellow, crystalline powder, slightly soluble in water, soluble in ethanol, and in acetone, slightly soluble in ethyl acetate.

mp: 235-242 $^\circ\text{C}$.

Cymar. $\text{C}_{30}\text{H}_{44}\text{O}_9$. (M_r 548.7). 1208000. [508-77-0]. 3β -[(2,6-Dideoxy-3-*O*-methyl- β -D-ribo-hexopyranosyl)oxy]-5 β ,14-dihydroxy-19-oxocard-20(22)-enolide.

White or slightly yellow powder, slightly soluble in water, soluble in methanol.

mp: about 148 $^\circ\text{C}$.

2,4-Dihydroxybenzaldehyde. $\text{C}_7\text{H}_6\text{O}_3$. (M_r 138.1). 1208100. [95-01-2]. β -Resorcyraldehyde.

Dioxan solution. 1032002.

Dissolve 1.00 g of *dioxan R* in *water R* and dilute to 100.0 mL with the same solvent. Dilute 5.0 mL of this solution to 100.0 mL with *water R* (0.5 mg/mL of dioxan).

Isorhamnetin-3-*O*-rutinoside. $\text{C}_{28}\text{H}_{32}\text{O}_{16}$. (M_r 625). 1208200. [604-80-8]. 3-*O*-Methylquercetin-3-rutinoside. Narcissoside.

Methyl decanoate. $\text{C}_{11}\text{H}_{22}\text{O}_2$. (M_r 186.3). 1054000. [110-42-9].

Content: minimum 99.0 per cent.

Clear, colourless or yellow liquid, soluble in light petroleum.

d_{20}^{20} : 0.871 to 0.876.

n_D^{20} : 1.425 to 1.426.

Molecular sieve. 1056600. [70955-01-0].

Molecular sieve composed of sodium aluminosilicate. It is available as beads or powder with a pore size of 0.4 nm.

When reused, it is recommended that the molecular sieve be regenerated according to the manufacturer's instructions.

04/2020:40101 Raffinose. $\text{C}_{18}\text{H}_{32}\text{O}_{16}$. (M_r 504.4). 1208300. [512-69-6]. β -D-Fructofuranosyl α -D-galactopyranosyl-(1 $\rightarrow$ 6)- α -D-glucopyranoside.

Rosuvastatin ethyl ester. $\text{C}_{24}\text{H}_{32}\text{FN}_3\text{O}_6\text{S}$. (M_r 509.6). 1208400. [851443-04-4]. Ethyl (3*R*,5*S*,6*E*)-7-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate.

Content: minimum 98 per cent.

White or pale yellow powder.

Sennoside A. $\text{C}_{42}\text{H}_{38}\text{O}_{20}$. (M_r 863). 1208500. [81-27-6]. (9*R*,9'*R*)-5,5'-Bis(β -D-glucopyranosyloxy)-4,4'-dihydroxy-10,10'-dioxo-9,9',10,10'-tetrahydro[9,9'-bianthracene]-2,2'-dicarboxylic acid.

Silica gel for chromatography, octadecylsilyl R1. 1110100.

A very finely divided ultrapure silica gel, chemically modified at the surface by the bonding of octadecylsilyl groups.

Silica gel for chromatography, octadecylsilyl, with embedded polar groups, end-capped. 1177900.

A very finely divided silica gel, chemically modified at the surface by the bonding of polar-embedded octadecylsilyl groups. To minimise any interaction with basic compounds, it is carefully end-capped to cover most of the remaining silanol groups.

Silica gel for chromatography, octylsilyl, solid core, end-capped. 1208600.

Silica gel with spherical silica particles containing a non-porous solid silica core surrounded by a thin outer porous silica coating with octylsilyl groups. To minimise any interaction with basic compounds it is carefully end-capped to cover most of the remaining silanol groups.

Silica gel for chromatography, octylsilyl, with embedded polar groups, end-capped. 1152600.

A very finely divided silica gel, chemically modified at the surface by the bonding of polar-embedded octylsilyl groups. To minimise any interaction with basic compounds, it is carefully end-capped to cover most of the remaining silanol groups.

Sodium laurilsulfate R1. 1208700. [151-21-3].

Content: minimum 99.0 per cent.



04/2020:40201

4.2.1. PRIMARY STANDARDS FOR VOLUMETRIC SOLUTIONS

Potassium bromate. KBrO_3 . (M_r 167.0). 2000300. [7758-01-2].

Crystallise *potassium bromate R* from boiling *water R*. Collect the crystals and dry to constant mass in an oven at $180 \pm 10^\circ\text{C}$ (2.2.32).

5.22. Names of herbal drugs used in traditional Chinese medicine

5.22. Names of herbal drugs used in traditional Chinese
medicine.. 4335



04/2020:52200 For transparency, this general chapter provides cross-references to the Chinese names in pinyin and in sinograms for herbal drugs used in traditional Chinese medicine for which a monograph is published in the Ph. Eur.

However, the titles in English, French and Latin are the only official names; the samples of herbal drugs must be labelled with at least one official title.

5.22. NAMES OF HERBAL DRUGS USED IN TRADITIONAL CHINESE MEDICINE

This general chapter is published for information.

Monograph number	Latin title	English title	Pinyin	Sinogram
2827	Abelmoschi corolla	Abelmoschi corolla	huangshukuihua	黄蜀葵花
2432	Acanthopanax gracilistylis cortex	Acanthopanax bark	wujiapi	五加皮
2999	Achyranthis bidentatae radix	Achyranthes bidentata root	niuxi	牛膝
2472	Akebiae caulis	Akebia stem	mutong	木通
2554	Amomi fructus	Amomum fruit	sharen	砂仁
2555	Amomi fructus rotundus	Round amomum fruit	doukou	豆蔻
2712	Andrographidis herba	Andrographis herb	chuanxinlian	穿心莲
2661	Anemarrhenae asphodeloides rhizoma	Anemarrhena asphodeloides rhizome	zhimu	知母
2556	Angelicae dahuricae radix	Angelica dahurica root	baizhi	白芷
2557	Angelicae pubescentis radix	Angelica pubescens root	duhuo	独活
2558	Angelicae sinensis radix	Angelica sinensis root	danggui	当归
2435	Astragali mongholici radix	Astragalus mongholicus root	huangqi	黄芪
2559	Atractylodis lanceae rhizoma	Atractylodes lancea rhizome	cangzhu	苍术
2560	Atractylodis macrocephalae rhizoma	Atractylodes rhizome, largehead	baizhu	白术
1797	Aucklandiae radix	Aucklandia root	muxiang	木香
2561	Belamcandae chinensis rhizoma	Belamcanda chinensis rhizome	shegan	射干
2384	Bistortae rhizoma	Bistort rhizome	quanshen	拳参
2562	Bupleuri radix	Bupleurum root	chaihu	柴胡
2386	Carthami flos	Safflower flower	honghua	红花
2430	Citri reticulatae epicarpium et mesocarpium	Mandarin epicarp and mesocarp	chenpi	陈皮
2463	Clematidis armandii caulis	Clematis armandii stem	chuanmutong	川木通
2714	Codonopsis radix	Codonopsis root	dangshen	党参
2454	Coicis semen	Coix seed	yiwiren	薏苡仁
2715	Coptidis rhizoma	Chinese goldthread rhizome	huanglian	黄连
2976	Corydalis rhizoma	Corydalis rhizome	yanhusuo	延胡索
2890	Dioscoreae nipponicae rhizoma	Dioscorea nipponica rhizome	chuanshanlong	穿山龙
2473	Dioscoreae oppositifoliae rhizoma	Dioscorea oppositifolia rhizome	shanyao	山药
2563	Drynariae rhizoma	Drynaria rhizome	gusuibu	骨碎补
2564	Ecliptae herba	Eclipta herb	mohanlian	墨旱莲
2451	Ephedrae herba	Ephedra herb	ma huang	麻黄
2412	Eucommiae cortex	Eucommia bark	duzhong	杜仲
2718	Evodiae fructus	Evodia fruit	wuzhuyu	吴茱萸
2452	Fraxini chinensis cortex	Fraxinus chinensis bark	qinpi	秦皮
2565	Gardeniae fructus	Cape jasmine fruit	zhizi	栀子
2721	Gastrodiae rhizoma	Gastrodia rhizome	tianma	天麻
2722	Houttuyniae herba	Houttuynia herb	yuxingcao	鱼腥草
2566	Isatidis radix	Isatis root	banlangen	板蓝根
2634	Ligustici chuanxiong rhizoma	Szechwan lovage rhizome	chuanxiong	川芎
2431	Ligustici radix et rhizoma	Ligusticum root and rhizome	gaoben	藁本
2612	Lycii fructus	Barbary wolfberry fruit	gouqizi	枸杞子

Monograph number	Latin title	English title	Pinyin	Sinogram
2723	<i>Lycopi herba</i>	<i>Lycopus lucidus</i> herb	<i>zelan</i>	泽兰
2742	<i>Magnoliae biondii flos immaturus</i>	<i>Magnolia biondii</i> flower bud	<i>xinyi</i>	辛夷
2567	<i>Magnoliae officinalis cortex</i>	<i>Magnolia officinalis</i> bark	<i>houpo</i>	厚朴
2568	<i>Magnoliae officinalis flos</i>	<i>Magnolia officinalis</i> flower	<i>houpohua</i>	厚朴花
2474	<i>Moutan cortex</i>	<i>Moutan</i> bark	<i>mudanpi</i>	牡丹皮
2383	<i>Notoginseng radix</i>	<i>Notoginseng</i> root	<i>sanqi</i>	三七
3000	<i>Ophiopogonis radix</i>	Dwarf lilyturf tuber	<i>maidong</i>	麦冬
2424	<i>Paeoniae radix alba</i>	Peony root, white	<i>baishao</i>	白芍
2425	<i>Paeoniae radix rubra</i>	Peony root, red	<i>chishao</i>	赤芍
2727	<i>Persicariae tinctoriae folium</i>	Indigo plant leaf	<i>liaodaqingye</i>	蓼大青叶
2477	<i>Piperis fructus</i>	Pepper	<i>hujiao</i>	胡椒
2453	<i>Piperis longi fructus</i>	Long pepper	<i>bibo</i>	荜茇
2660	<i>Platycodonis radix</i>	<i>Platycodon</i> root	<i>jiegeng</i>	桔梗
2724	<i>Polygoni cuspidati rhizoma et radix</i>	<i>Polygonum cuspidatum</i> rhizome and root	<i>huzhang</i>	虎杖
2433	<i>Polygoni multiflori radix</i>	Fleeceflower root	<i>heshouwu</i>	何首乌
2726	<i>Polygoni orientalis fructus</i>	<i>Polygonum orientale</i> fruit	<i>shuihonghuazhi</i>	水红花子
2475	<i>Poria</i>	<i>Poria</i>	<i>fuling</i>	茯苓
2439	<i>Prunellae spica</i>	Common selfheal fruit-spike	<i>xiakucao</i>	夏枯草
2434	<i>Puerariae lobatae radix</i>	Kudzuvine root	<i>gegen (yege)</i>	葛根 (野葛)
2483	<i>Puerariae thomsonii radix</i>	Thomson kudzuvine root	<i>fenge</i>	粉葛
2569	<i>Rehmanniae radix</i>	<i>Rehmannia</i> root	<i>dihuang</i>	地黄
2663	<i>Salviae miltiorrhizae radix et rhizoma</i>	<i>Salvia miltiorrhiza</i> root and rhizome	<i>danshen</i>	丹参
2385	<i>Sanguisorbae radix</i>	<i>Sanguisorba</i> root	<i>diyu</i>	地榆
2428	<i>Schisandrae chinensis fructus</i>	<i>Schisandra</i> fruit	<i>wuweizi (bei wuweizi)</i>	五味子 (北五味子)
2438	<i>Scutellariae baicalensis radix</i>	Baical skullcap root	<i>huangqin</i>	黄芩
2450	<i>Sinomenii caulis</i>	Orientvine stem	<i>qingfengteng</i>	青风藤
2440	<i>Sophorae flavescens radix</i>	Lightyellow sophora root	<i>kushen</i>	苦参
2639	<i>Sophorae japonicae flos</i>	<i>Sophora</i> flower	<i>huaihua</i>	槐花
2427	<i>Sophorae japonicae flos immaturus</i>	<i>Sophora</i> flower-bud	<i>huaimi</i>	槐米
2478	<i>Stephaniae tetrandrae radix</i>	Fourstamen stephania root	<i>fenfangji (hanfangji)</i>	粉防己 (汉防己)
2937	<i>Typhae pollis</i>	<i>Typhae</i> pollen	<i>puhuang</i>	蒲黄
2729	<i>Uncariae rhynchophyllae ramulus cum uncis</i>	<i>Uncaria</i> stem with hooks	<i>gou teng</i>	钩藤
2656	<i>Zanthoxyli bungeani pericarpium</i>	<i>Zanthoxylum bungeanum</i> pericarp	<i>huajiao</i>	花椒

5.25. Process analytical technology

5.25. Process analytical technology..	4339
---	------

01/2020:52500
corrected 10.1

5.25. PROCESS ANALYTICAL TECHNOLOGY

This general chapter focuses on the interfacing of analytical techniques with the manufacturing process as a means of enhancing process control and improving process understanding. It should be noted that it is not within the scope of the chapter to give specific instructions for all possible process analytical technology sensors; instead, it offers a general approach to the integration of analytical techniques in the process environment together with aspects to be taken into consideration for the application of process analytical technology.

1. INTRODUCTION

Process analytical technology (PAT) can be defined as a system for designing, analysing and controlling manufacturing processes through timely measurements (i.e. during processing) of critical quality attributes (CQA) of raw and in-process materials and critical performance characteristics of processes in order to ensure the quality of the final product. It is important to note that the term 'analytical' in PAT is used in a broad sense to include chemical, physical and microbiological measurements conducted in an integrated manner and combined with data analysis. The goal of PAT is control of the manufacturing process and enhanced process understanding, guided by risk management. Interfacing manufacturing processes with analytical techniques is therefore essential in PAT, as it facilitates process development in accordance with quality by design (QbD) principles, enables real-time release testing (RTRT) and supports continuous manufacturing processes.

Time delays between obtaining a sample for testing, analysis of that sample and any consequent outcomes must be taken into consideration when applying PAT. When the analytical results are used on a continuous basis to monitor and control a process, it is important to minimise such delays. This can be achieved most effectively with sensor-based continuous measurement systems directly interfacing with the process stream during a specific unit operation. The sensors interfaced with the process continuously measure the process conditions and material characteristics within the process environment (*in situ*) and send the measured data (e.g. a spectrum) to an operating system where it is recorded and analysed, and where any necessary adjustments to processing conditions can be determined on a continuous basis. These *in situ* measurements can generate very large volumes of data representative of the process.

2. INTERFACING MODES

The interfacing of analytical techniques with the manufacturing process is central to the application of PAT. Results generated by analytical equipment interfaced with a process can be used for monitoring purposes and to ensure that the process is stable, for example via automated feedback or feedforward control loops.

The terms 'off-line', 'at-line', 'on-line' and 'in-line' describe interfacing modes (see Figure 5.25.-1). Measurements using on-line and in-line systems generally support rapid and automated process adjustments since they move the analytical techniques into the process stream. In contrast, off-line and at-line measurements involve transferring the samples away from the process stream to the analytical equipment.

Off-line measurements

These correspond to conventional analytical testing in which the sample is removed from the manufacturing process

environment and tested in a laboratory, typically located away from the production environment. This transfer of samples away from the process stream can result in a significant time lag and generally does not permit immediate process adjustments. However, off-line measurements can nonetheless be useful for PAT purposes if relevant analytical data can be obtained within a time frame that is compatible with process dynamics.

At-line measurements

With at-line measurements, the sample is also removed (manually or automatically) from the process stream for testing, but the testing equipment is usually located within the production environment, i.e. in close physical proximity to the process stream, and testing can therefore take place with minimal delay. This results in a shorter time frame for obtaining analytical data, and also differentiates at-line measurements from off-line measurements. It is therefore possible to make process adjustments based on the results of at-line measurements.

On-line measurements

On-line measurements typically involve sensor-based measurements made under real-time conditions by diverting a portion of the material from the process stream directly into a measuring device and the results are available after a minimal time delay.

Depending on the nature of the test, e.g. whether or not it is detrimental to the product, the diverted portion may be returned to the process stream, otherwise it is discarded.

In-line measurements

In-line measurements are taken within the process stream by placing measuring devices, typically sensors, directly in contact with or into the process stream. No portions of the material are therefore removed from the process stream.

In-line measurements must also be non-detrimental to the product.




Figure 5.25.-1. – Interfacing modes

3. COMPARISON OF INTERFACING MODES

Both off-line and at-line measurements are based on analysis of discrete samples removed from a process stream or bulk material. These samples are considered representative of the material in the process stream at the time they are removed. Frequent at-line measurements also provide data supporting the application of PAT, as they are carried out within a short time frame and in the immediate vicinity of the process stream.

Neither in-line nor on-line measurements involve sampling in the conventional sense. The tested portion might not be separated from the process stream, and is usually smaller than a conventional sample.

Scale of scrutiny must be considered and will determine the frequency and duration of measurements. Furthermore, measurements can be influenced by physical attributes interfering with the acquisition properties of the measuring system. When measuring solids or suspensions, for example using spectroscopic methods, consideration must be given to the surface and bulk scattering properties of samples, and movement of the material. Influencing factors such as particle size, surface roughness and solid density can cause significant spectral differences, which must be taken into account when a method is designed and used in order to ensure that the process and material are described adequately.

In-line and on-line modes offer the advantage of fast data acquisition, allowing high measurement frequency, and thus enabling rapid continuous monitoring as well as immediate action and control of the process.

In some cases, PAT measurements can be used qualitatively to build models such as process trajectories or process signatures which can be used to characterise process variability and highlight unusual process behaviours. These models are not necessarily directly linked to a critical in-process quality attribute or performance characteristic. It is therefore recommended to demonstrate the causal relationship between the PAT measurements, the model and the relevant quality attributes or performance characteristics when using such models for process control purposes.

General validation principles also apply to in-line or on-line measurements although some validation procedures may be different to those for conventional quality control methods.

Analytical validation procedures for at-line and off-line measurements assume homogenous and authentic samples, which are crucial for the assessment of precision. However, this requirement is rarely fulfilled for on-line or in-line methods which are often used to measure processes in which the material rapidly changes and/or moves during the measurement, for example a fast-drying process or reaction monitoring. Comparison of results from on-line/in-line measurements with results from a reference test procedure would normally be needed.

4. STATISTICAL PROCESS CONTROL

Statistical process control (SPC) comprises a set of data analysis methods applied in order to monitor and control a process based on analysis of process variability (e.g. of CQAs). For PAT purposes, the process can be monitored using, for example, real-time data collected by process analysers.

Based on this data, SPC can be used to make process adjustments, when necessary, to maintain or attain a desired state and to ensure that the process remains under control. This includes, for example, trend analysis of quality attributes or process variables. SPC can also be used to measure process variability and process capability (i.e. the ability of a process to produce a product that complies with requirements), with a view to enhancing process understanding, thereby improving lifecycle management.

Rather than using univariate SPC methods to monitor several individual variables, it is often preferable to use multivariate statistical process control (MSPC) to analyse several variables simultaneously, taking into account potential correlations.

5. EUROPEAN PHARMACOPOEIA TEXTS SUPPORTING THE APPLICATION OF PAT

Typically, the analytical techniques described in the Ph. Eur. include qualification criteria designed for off-line analytical systems. These criteria are not always relevant or practical in a PAT setting, for instance when the equipment is

specifically designed for on-line or in-line measurements. For this reason, certain general chapters (including 2.2.40. *Near-infrared spectroscopy*, 2.2.48. *Raman spectroscopy* and 2.9.47. *Demonstration of uniformity of dosage units using large sample sizes*) have been revised or specifically elaborated to support and promote the use of the techniques in conjunction with PAT.

General Notices

Section 1.1, under Demonstration of compliance with the Pharmacopoeia, states that a substance can be demonstrated to be of pharmacopoeial quality on the basis of product design, together with the control strategy applied and data derived, for example, from validation studies of the manufacturing process.

The section also states that an enhanced approach to quality control could utilise PAT and/or real-time release testing strategies (including parametric release) as alternatives to end-product testing alone.

Absorption spectrophotometry, infrared

General chapter 2.2.24 has a wide variety of applications in the manufacturing process that enable PAT, such as reaction monitoring in chemical synthesis. Wavenumber shifts and acceptable tolerances for the reference material polystyrene are described for both transmission and ATR measurement modes.

Absorption spectrophotometry, ultraviolet and visible

General chapter 2.2.25 covers the use of PAT in the UV-Vis range using modern detectors such as photodiode arrays (PDA) or charge-coupled devices (CCD). Both transmission and diffuse reflection measurement modes are possible with off-line, at-line, on-line and in-line measurements. The table with reference wavelengths for the control of wavelength accuracy includes wavelengths in the UV range down to 180 nm.

X-ray fluorescence spectrometry

General chapter 2.2.37 includes references to modern equipment and the current applications of the XRF technique. Substantial advances in miniaturisation and automation have led to the development of hand-held energy dispersive XRF (ED-XRF) spectrometers for rapid field measurements. XRF is potentially non-destructive, although it may cause sample instability. Hence, XRF lends itself to applications of PAT such as the analysis of unwanted trace catalysts in active pharmaceutical ingredients (API).

Near-infrared spectroscopy

General chapter 2.2.40 takes into account the increasing use of NIR spectroscopy for process monitoring and control, and the development of modern NIR spectrometers. NIR measurements can be performed off-line, but the technique also lends itself to at-line, on-line and in-line testing.

The 'Sample preparation/presentation' section includes moving materials or samples, and the use of fibre-optic probe systems in different measurement modes (i.e. transmission, diffuse reflection and transflection). The use of internal referencing for process analysis purposes is permitted when it is impossible to remove a probe for reference background data collection. A detailed table for the control of instrument performance depending on measurement mode and instrument used (benchtop, mobile or process instrument) is also provided. The chapter includes a section on qualitative analysis for identification and characterisation of a substance in addition to sections on limit analysis (e.g. for dryer end-point control) and trend analysis (for monitoring blend uniformity).

Raman spectroscopy

General chapter 2.2.48 includes Raman technologies that have potential uses for the application of PAT, including hand-held instruments.

Wavenumber shifts and acceptable tolerances for the reference materials cyclohexane, paracetamol and polystyrene (values derived from an inter-laboratory study) are described for both benchtop and hand-held Raman systems.

Demonstration of uniformity of dosage units using large sample sizes

General chapter 2.9.47 allows the determination of dosage unit uniformity in a PAT environment where the sample size is markedly greater than 30 units.

Compliance with the acceptance criteria of general chapter 2.9.47 is considered as evidence that the batch would also comply with general chapter 2.9.40. *Uniformity of dosage units* if tested using a small sample size (e.g. 30-unit). Therefore, general chapter 2.9.47 does not constitute stand-alone acceptance criteria.

Alternative methods for control of microbiological quality

General chapter 5.1.6 describes alternative methods that might be used for the application of PAT in order to contribute to real-time or near-real-time microbiological quality control (e.g. test for microbiological examination of non-sterile products or for sterility based on laser-induced fluorescence) of in-process samples, active substances, medicinal products

or excipients (particularly water). The chapter also provides guidance on how to validate these alternative methods.

Chemometric methods applied to analytical data

Chemometrics (general chapter 5.21) has proven to be well suited for PAT. The investigation of large data tables and treatment of intricate signals, i.e. data collections with a hidden structure, of the type accumulated during measurements in PAT setups, requires alternative analytical tools to those used in a one-variable-at-a-time approach.

Chemical imaging

Chemical imaging (CI) (general chapter 5.24) can be used to support PAT applications. CI measures spatial distribution and contributes to the understanding of the properties of materials such as finished products, pharmaceutical intermediates, excipients, APIs and starting materials.

The uses of CI include, for example, detection of defects at the sample surface such as cracks in tablet coatings and identification of foreign particles. It is a versatile tool used in process development and improvement, root cause analysis (e.g. for out-of-specification results), and may also be used to enhance process understanding.

Radiopharmaceutical preparations and starting materials for radiopharmaceutical preparations


Technetium (^{99m}Tc) mebrofenin injection..... 4345



07/2019:2393
corrected 10.1

TECHNETIUM (^{99m}Tc) MEBROFENIN INJECTION

Technetii (^{99m}Tc) mebrofenini solutio iniectionabilis



DEFINITION

Sterile solution of a complex of technetium-99m with mebrofenin. It may contain stabilisers and inert additives.

Content: 90 per cent to 110 per cent of the declared technetium-99m radioactivity at the date and time stated on the label.

PRODUCTION

It is prepared by dissolving [[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]azanediy]diacetic acid (mebrofenin) in Sodium pertechnetate (^{99m}Tc) injection (fission) (0124) or Sodium pertechnetate (^{99m}Tc) injection (non-fission) (0283) in the presence of a reducing agent such as a stannous salt.

CHARACTERS

Appearance: clear, colourless solution.

Half-life and nature of radiation of technetium-99m: see general chapter 5.7. Table of physical characteristics of radionuclides.

IDENTIFICATION

A. Gamma-ray spectrometry.

Results: the most prominent gamma photon of technetium-99m has an energy of 0.141 MeV.

B. Examine the chromatogram obtained in the test for other radiochemical impurities (see Tests).

Results: the principal peak in the chromatogram obtained with the test solution is similar in retention time to the peak due to technetium-99m mebrofenin in the chromatogram obtained with the reference solution.

TESTS

pH (2.2.3): 4.0 to 7.5.

Sterility. It complies with the test for sterility prescribed in the monograph on Radiopharmaceutical preparations (0125). The injection may be released for use before completion of the test.

Bacterial endotoxins (2.6.14): less than 175/V IU/mL, V being the maximum recommended dose in millilitres.

RADIOCHEMICAL PURITY

Technetium-99m mebrofenin: minimum 90 per cent of the total radioactivity.

Impurity A. Thin-layer chromatography (2.2.27).

Test solution. The preparation to be examined.

Reference solution (a). To 1 mL of a 1 g/L solution of stannous chloride R in 0.05 M hydrochloric acid in a closed vial, add 2 mL of sodium pertechnetate (^{99m}Tc) injection (fission or non-fission). Use within 30 min after preparation.

Reference solution (b). Dissolve 40 mg of mebrofenin CRS in 2 mL of a 4 g/L solution of sodium hydroxide R and adjust to pH 6.5 with 1 M hydrochloric acid or a 40 g/L solution of sodium hydroxide R. To this solution add 25 µL of a 20 mg/mL solution of stannous chloride R in 0.05 M hydrochloric acid and 400 MBq of sodium pertechnetate (^{99m}Tc) injection (fission or non-fission) in a volume of 2 mL. Allow to stand for 30-60 min.

Plate: TLC silica gel plate R; use a glass-fibre plate.

Mobile phase: water R, acetonitrile R (40:60 V/V).

Application: about 5 µL.

Development: immediately, over 4/5 of the plate.

Drying: in air.

Detection: determine the distribution of radioactivity using a suitable detector.

Retardation factor: impurity A = 0.0 to 0.1.

System suitability: the retardation factor of the principal peak in the chromatogram obtained with reference solution (a) is not more than 0.1; the retardation factor of the principal peak in the chromatogram obtained with reference solution (b) is more than 0.7.

Limit:

– **impurity A:** maximum 5 per cent of the total radioactivity.

Other radiochemical impurities. Liquid chromatography (2.2.29).

Test solution. The preparation to be examined.

Reference solution. Use reference solution (b) of the test for impurity A.

Column:

– **size:** $l = 0.25$ m, $\varnothing = 4.0$ mm;

– **stationary phase:** end-capped polar-embedded octadecylsilyl amorphous organosilica polymer R (5 µm).

Mobile phase:

– **mobile phase A:** 3.85 g/L solution of ammonium acetate R;

– **mobile phase B:** acetonitrile R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 20	70	30
20 - 25	70 → 0	30 → 100
25 - 30	0	100

Flow rate: 1.0 mL/min.

Detection: radioactivity detector.

Injection: 20 µL.

Relative retention with reference to technetium-99m mebrofenin (retention time = about 20 min): impurity B = about 0.17.

Limits:

– **sum of the areas of the peaks eluted before the principal peak (corresponding to hydrophilic impurities, including impurity B):** maximum 6 per cent of the total area of the peaks in the chromatogram obtained with the test solution.

RADIOACTIVITY

Determine the radioactivity using a calibrated instrument.

IMPURITIES

A. technetium-99m in colloidal form,

B. [^{99m}Tc]pertechnetate ion.

Sutures for human use

Sutures for human use: introduction..... 4349





04/2020:90004

SUTURES FOR HUMAN USE: INTRODUCTION

Sutures for human use are medical devices as defined in Regulation (EU) 2017/745 and any subsequent amendments. Monographs can be applied to show compliance with certain requirements therein.

Herbal drugs and herbal drug preparations

Calendula flower.....	4353	Raspberry leaf.....	4359
Dwarf lilyturf tuber.....	4354	Rehmannia root.....	4360
Fraxinus chinensis bark.....	4356	Senna leaflet.....	4361
Hawthorn berries.....	4357	Senna pods.....	4363



- 04/2020:1297 B. Microscopic examination (2.8.23). The powder is yellowish-brown. Examine under a microscope using *chloral hydrate solution R*. The powder shows the following diagnostic characters (Figure 1297.-1): fragments of epidermises of the corolla [C, F, K] containing light yellow oil droplets, some with fairly large anomocytic stomata (2.8.3) [Fa, Ka]; covering trichomes biseriate, multicellular and conical [G], usually fragmented, and glandular trichomes with a multicellular stalk [E], very abundant on the base of the corolla [D]; fragments of parenchyma of the corolla [B] containing prisms and very small cluster crystals of calcium oxalate [Ba, Da] and small vessels [Bb]; spherical pollen grains up to about 40 µm in diameter with a sharply spiny exine and 3 germinal pores [A, J]; occasional fragments of the stigmas with short, bulbous papillae [H].

CALENDULA FLOWER

Calendulae flos

DEFINITION

Whole or cut, dried, and fully opened flowers that have been detached from the receptacle of the cultivated, double-flowered varieties of *Calendula officinalis* L.

Content: minimum 0.4 per cent of flavonoids, expressed as hyperoside ($C_{21}H_{20}O_{12}$; M_r 464.4) (dried drug).

IDENTIFICATION

- A. The ligulate florets consist of a yellow or orange-yellow ligule, about 3-5 mm wide and about 7 mm in the middle part, with a 3-toothed apex and a hairy, partly sickle-shaped, yellowish-brown or orange-brown tube with a projecting style and a bifid stigma occasionally with a partly bent yellowish-brown or orange-brown ovary. The tubular florets, about 5 mm long, are present and consist of the yellow, orange-red or reddish-violet 5-lobed corolla and the yellowish-brown or orange-brown tube, hairy in its lower part, mostly with a partly bent yellowish-brown or orange-brown ovary.




Figure 1297.-1. – Illustration for identification test B of powdered herbal drug of calendula flower

- C. High-performance thin-layer chromatography (2.8.25).

Test solution. To 0.5 g of the powdered herbal drug (355) (2.9.12) add 5.0 mL of *methanol R*. Sonicate for 15 min, filter or centrifuge and use the filtrate or supernatant.

Reference solution (a). Dissolve 3.0 mg of *chlorogenic acid R* and 4.0 mg of *isorhamnetin-3-O-rutinoside R* in *methanol R* and dilute to 10.0 mL with the same solvent.

Reference solution (b). Dilute 2.5 mL of reference solution (a) to 10.0 mL with *methanol R*.

Reference solution (c). Dissolve 2.5 mg of *hyperoside R* and 3 mg of *chlorogenic acid R* in *methanol R* and dilute to 10 mL with the same solvent.

Intensity marker: isorhamnetin-3-O-rutinoside.

Plate: TLC silica gel F_{254} plate R (2-10 µm).

Mobile phase: anhydrous formic acid R, water R, ethyl acetate R (10:10:80 V/V/V).

Application: 4 µL as bands of 8 mm.

Development: 70 mm from the lower edge of the plate.

Drying: in a current of air at room temperature for 5 min.

Detection: heat at 100-105 °C for 5 min; spray the warm plate with a 10 g/L solution of *diphenylboric acid aminoethyl ester R* in *methanol R*, then with a 50 g/L solution of *macrogol 400 R* in *methanol R* or, alternatively, dip the warm plate in a 5 g/L solution of *diphenylboric acid aminoethyl ester R* in *ethyl acetate R* and then in a 50 g/L solution of *macrogol 400 R* in *methylene chloride R*; allow to dry in air for about 1 min and examine in ultraviolet light at 366 nm.

System suitability: reference solution (c):

- the chromatogram shows in the middle third 2 distinct zones, which may be touching; the lower zone (chlorogenic acid) shows a light blue fluorescence and the upper zone (hyperoside) shows a yellow or orange fluorescence.

Results: see below the sequence of fluorescent zones present in the chromatograms obtained with reference solution (a) and the test solution. Furthermore, in the chromatogram obtained with the test solution, other faint to very faint blue, brown or orange fluorescent zones may be present.

Top of the plate	
	2 blue zones, faint to equivalent
Chlorogenic acid: a light blue zone	A greenish-yellow zone, faint
	A light blue zone, faint to equivalent
Isorhamnetin-3-O-rutinoside: a greenish-yellow zone	A greenish-yellow zone (isorhamnetin-3-O-rutinoside)
	A brown or orange zone, faint to equivalent
	A greenish-yellow zone
	A brownish-orange zone, very faint to faint
Reference solution (a)	Test solution

Compensation liquid. Dilute 10.0 mL of the stock solution to 25.0 mL with a 5 per cent V/V solution of *glacial acetic acid R* in *methanol R*.

Measure the absorbance (2.2.25) of the test solution after 30 min, by comparison with the compensation liquid at 425 nm.

Calculate the percentage content of flavonoids, expressed as hyperoside, using the following expression:

$$\frac{A \times 1.25}{m}$$

i.e. taking the specific absorbance of hyperoside to be 500.

A = absorbance at 425 nm;

m = mass of the herbal drug to be examined, in grams.

07/2019:3000
corrected 10.1



DWARF LILYTURF TUBER

Ophiopogonis radix

TESTS

Foreign matter (2.8.2): maximum 5 per cent of bracts and maximum 2 per cent of other foreign matter.

Loss on drying (2.2.32): maximum 12.0 per cent, determined on 1.000 g of the powdered herbal drug (500) (2.9.12) by drying in an oven at 105 °C for 2 h.

Total ash (2.4.16): maximum 10.0 per cent.

ASSAY

Stock solution. Into a 100 mL round-bottomed flask introduce 0.800 g of the powdered herbal drug (500) (2.9.12), 1 mL of a 5 g/L solution of *hexamethylenetetramine R*, 7 mL of *hydrochloric acid R1* and 20 mL of *acetone R*. Boil the mixture under a reflux condenser for 30 min. Filter the liquid through a plug of absorbent cotton into a 100 mL volumetric flask. Add the absorbent cotton to the residue in the round-bottomed flask and extract with 2 quantities, each of 20 mL, of *acetone R*, each time boiling under a reflux condenser for 10 min. Allow to cool to room temperature, filter the liquid through a plug of absorbent cotton, then filter the combined acetone solution through a filter-paper into the volumetric flask, and dilute to 100.0 mL with *acetone R* by rinsing the flask and filter. Introduce 20.0 mL of this solution into a separating funnel, add 20 mL of *water R* and extract the mixture with 1 quantity of 15 mL and then with 3 quantities, each of 10 mL, of *ethyl acetate R*. Combine the ethyl acetate extracts in a separating funnel, rinse with 2 quantities, each of 50 mL, of *water R*, filter the extract over 10 g of *anhydrous sodium sulfate R* into a 50 mL volumetric flask and dilute to 50.0 mL with *ethyl acetate R*.

Test solution. To 10.0 mL of the stock solution add 1 mL of *aluminium chloride reagent R* and dilute to 25.0 mL with a 5 per cent V/V solution of *glacial acetic acid R* in *methanol R*.

DEFINITION

Dried root tuber of *Ophiopogon japonicus* (Thunb.) Ker Gawl., with the spindly roots removed.

Content: minimum 0.12 per cent of total saponins, expressed as ruscogenin (C₂₇H₄₂O₄; *M_r* 430.6) (dried drug).

IDENTIFICATION

- A. It is fusiform with both ends slightly tapered, 1.5-3 cm long and 3-6 mm in diameter. The outer surface is whitish-yellow, fine and longitudinally wrinkled. The texture is hard, the fracture is yellowish-white and translucent, and the vascular system appears as a small ring in the centre.
- B. Microscopic examination (2.8.23). The powder is yellowish-white. Examine under a microscope using *chloral hydrate solution R*. The powder shows the following diagnostic characters (Figure 3000.-1): numerous fragments of parenchyma consisting of suborbicular or elliptical cells [A]; different sized raphides of calcium oxalate, free [F] or included in parenchymatous cells [Aa], either fine, 12-65 µm long [Aa], or thicker, up to 130 µm long [F]; sclereids, usually in groups (surface view [E]), subsquare, rectangular or polygonal (20-57 µm in diameter) with distinct, dense channels; fragments of the endodermis with rectangular or elongated cells, with channelled and pitted walls (surface view [C]); fragments (transverse section [B]) showing the endodermis [Ba], sclereids with unevenly thickened walls [Bb] and parenchymatous cells [Bc]; thin xylem fibres [G], with oblique or square ends, slightly thickened walls, and oblique, cross-shaped or V-shaped pits; fragments of xylem [D] consisting of spiral or reticulate vessels [Da] and fibres [Db, Dc].




Figure 3000.-1. – Illustration for identification test B of powdered herbal drug of dwarf lilyturf tuber

C. High-performance thin-layer chromatography (2.8.25).

Test solution. To 2.0 g of the powdered herbal drug (355) (2.9.12) add 20 mL of *anhydrous ethanol R*. Sonicate for 30 min, filter and evaporate to dryness. Dissolve the residue in 0.5 mL of *anhydrous ethanol R*, centrifuge and use the supernatant.

Reference solution (a). Dissolve 1 mg of β -sitosterol *R* and 1 mg of methylphopogonanone *A R* in 2.0 mL of *anhydrous ethanol R*.

Reference solution (b). Mix 1.0 mL of reference solution (a) and 3.0 mL of *anhydrous ethanol R*.

Reference solution (c). Dilute 3 μ L of *isoeugenol R* and 6 μ L of *methyleugenol R* in 20 mL of *toluene R*.

Intensity markers: β -sitosterol and methylphopogonanone *A*.

Plate: TLC silica gel F_{254} plate *R* (2-10 μ m).

Mobile phase: *ethyl acetate R*, *toluene R* (10:90 V/V).

Application: 5 μ L as bands of 8 mm.

Development: 70 mm from the lower edge of the plate.

Drying: in a current of cold air for 5 min.

Detection: dip the plate in a 10 per cent V/V solution of *sulfuric acid R* in *anhydrous ethanol R*; heat the plate at 105 °C for 10 min and examine under white light.

System suitability: reference solution (c):

- the chromatogram shows 2 distinct zones in the middle third; the lower zone (*isoeugenol*) and the upper zone (*methyleugenol*) show a violet-red fluorescence.

Results: see below the sequence of zones present in the chromatograms obtained with reference solution (a) and the test solution. Furthermore, in the chromatogram obtained with the test solution, other faint fluorescent zones may be present.

Top of the plate	
	2 violet-red zones
Methylphopogonanone <i>A</i> : a brownish-yellow zone	A brownish-yellow zone, faint to equivalent
β -sitosterol: a violet-red zone	1 or 2 violet-red or reddish zones, faint to equivalent (possibly overlapping) A violet-red zone A broad, intense violet-red zone
Reference solution (a)	Test solution

TESTS

Loss on drying (2.2.32): maximum 15.0 per cent, determined on 1.000 g of the powdered herbal drug (355) (2.9.12) by drying in an oven at 105 °C for 2 h.

Total ash (2.4.16): maximum 2.5 per cent.

Ash insoluble in hydrochloric acid (2.8.1): maximum 0.5 per cent.

ASSAY

Test solution. Introduce 1.20 g of the powdered herbal drug (355) (2.9.12) into a 50 mL round-bottomed flask, add 20.0 mL of *methanol R* and weigh. Boil under a reflux condenser for 2 h. Allow to cool to room temperature, weigh again and adjust to the original mass with *methanol R*. Mix thoroughly and filter through a membrane filter (nominal pore size 0.22 μ m). Evaporate 12.5 mL of the filtrate to dryness under a current of *nitrogen R*. Dissolve the residue in 5 mL of *water R* and extract with 5 quantities, each of 5 mL, of *butanol R* saturated with *water R* using a separating funnel. Combine the butanol extracts in a separating funnel and wash with 2 quantities, each of 2.5 mL, of *dilute ammonia R1*. Evaporate to dryness under a current of *nitrogen R*. Dissolve the residue in a mixture of 20 volumes of *water R* and 80 volumes of *methanol R* and dilute to 25.0 mL with the same mixture of solvents. Evaporate 2.5 mL of the solution to dryness under a current of *nitrogen R*. Dissolve the residue in *perchloric acid R* and dilute to 10.0 mL with the same solvent. Transfer the solution to a test tube, stopper and heat at 80 °C in a water-bath for 15 min. Cool to room temperature.

Measure the absorbance (2.2.25) of the test solution at 397 nm using *perchloric acid R* as the compensation liquid.

Calculate the percentage content of total saponins, expressed as ruscogenin, using the following expression:

$$\frac{A \times 160}{m \times 196}$$

i.e. taking the specific absorbance of ruscogenin to be 196.

A = absorbance at 397 nm;

m = mass of the herbal drug to be examined used to prepare the test solution, in grams.



04/2020:2452

FRAXINUS CHINENSIS BARK

Fraxini chinensis cortex

DEFINITION

Whole or fragmented, dried branch or trunk bark of *Fraxinus chinensis* subsp. *rhynchophylla* (Hance) A.E.Murray (syn. *Fraxinus rhynchophylla* Hance), collected in spring or autumn.

Content: minimum 1.0 per cent for the sum of esculetin ($C_9H_6O_4$; M_r 178.1) and esculin ($C_{15}H_{16}O_9$; M_r 340.3) (dried drug).

IDENTIFICATION

A. The branch bark occurs as flexible, curved or channelled, rolled or folded pieces up to 60 cm long and 3 mm thick; the outer surface is whitish-grey to dark brownish-grey, sometimes in patches, and is smooth or slightly rough, dotted with whitish-grey, rounded lenticels; the inner surface is smooth, soft to the touch, yellowish-white or brown. The fracture is fibrous.

The trunk bark occurs as compact, rigid, flat-shaped pieces, up to 6 mm thick; the outer surface is brownish-grey, with fine longitudinal furrows and many reddish-brown lenticels, rounded or slightly split transversally; the inner surface is smooth, orange-brown. The fracture is fibrous.




Figure 2452.-1. – Illustration for identification B of powdered herbal drug of *fraxinus chinensis* bark

B. Microscopic examination (2.8.23). The powder is brownish. Examine under a microscope using *chloral hydrate* solution R. The powder shows the following diagnostic characters (Figure 2452.-1): large sclereids up to 300 µm in diameter, single [J] or in groups [E], with a very narrow lumen and channelled walls with concentric striations; fragments of brownish cork consisting of polygonal cells with slightly thickened and pitted walls (surface view [A])

and of superimposed layers of cells with slightly thickened and channelled walls (transverse section [D]), sometimes associated with one or more layers of collenchyma [Da]; long fibres, usually fragmented, with very thick walls and a greatly reduced lumen, slightly channelled, isolated [B, G] or in groups [C, F, H], sometimes accompanied by sclereids [Ca, Ha] or medullary rays with rectangular cells containing tiny acicular crystals of calcium oxalate [Fa]; groups of parenchymatous cells [K], some containing tiny crystals of calcium oxalate [Ka].

C. To 0.1 g of the powdered herbal drug (355) (2.9.12) add 10 mL of *water R* previously heated to 60 °C. Allow to stand for 2 min and filter. Examined in ultraviolet light at 365 nm, the solution shows an intense blue fluorescence that fades considerably after the addition of 2 mL of *hydrochloric acid R*.

D. Thin-layer chromatography (2.2.27).

Test solution. To 0.25 g of the powdered herbal drug (355) (2.9.12) add 5 mL of *methanol R*. Heat in a water-bath at 60 °C for 1 min. Centrifuge and use the supernatant; filter, if necessary.

Reference solution. Dissolve 1 mg of *esculetin R* and 1 mg of *esculin R* in 2 mL of *methanol R*.

Plate: TLC silica gel F_{254} plate R (5–40 µm) [or TLC silica gel F_{254} plate R (2–10 µm)].

Mobile phase: *anhydrous formic acid R*, *water R*, *ethyl acetate R* (10:10:80 V/V/V).

Application: 10 µL as bands of 15 mm [or 8 mm].

Development: over a path of 10 cm [or 6 cm].

Drying: in air.

Detection: treat with a solution containing 10 g/L of *diphenylboric acid aminoethyl ester R* and 50 g/L of *macrogol 400 R* in *methanol R*; examine in ultraviolet light at 365 nm.

Results: see below the sequence of zones present in the chromatograms obtained with the reference solution and the test solution. Furthermore, other fluorescent zones may be present in the chromatogram obtained with the test solution.

Top of the plate	
Esculetin: a greenish-yellow fluorescent zone	A greenish-yellow fluorescent zone (esculetin)
	A green fluorescent zone may be present
	A blue fluorescent zone may be present
Esculin: an intense blue fluorescent zone	An intense blue fluorescent zone (esculin)
	A whitish-blue fluorescent zone
Reference solution	Test solution

TESTS

Loss on drying (2.2.32): maximum 12.0 per cent, determined on 1.000 g of the powdered herbal drug (355) (2.9.12) by drying in an oven at 105 °C.

Total ash (2.4.16): maximum 5.0 per cent.

Ash insoluble in hydrochloric acid (2.8.1): maximum 2.0 per cent.

ASSAY

Liquid chromatography (2.2.29).

Test solution. To 0.500 g of the powdered herbal drug (355) (2.9.12) add 50.0 mL of *methanol R* and weigh. Heat on a water-bath under a reflux condenser for 1 h. Cool and weigh

again. Compensate for the loss of solvent with *methanol R* and mix. Filter through a membrane filter (nominal pore size 0.45 µm).

Reference solution (a). Dissolve 10.0 mg of *esculin CRS* in the mobile phase and dilute to 50.0 mL with the mobile phase.

Reference solution (b). Dissolve 10.0 mg of *esculetin CRS* in 10 mL of *acetonitrile R* and dilute to 50.0 mL with the mobile phase.

Reference solution (c). Mix 3.0 mL of reference solution (b) and 5.0 mL of reference solution (a) and dilute to 10.0 mL with the mobile phase.

Column:

- size: $l = 0.15$ m, $\varnothing = 4.0$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography *R* (5 µm).

Mobile phase: *acetonitrile R*, 0.1 per cent V/V solution of *phosphoric acid R* (12:88 V/V).

Flow rate: 0.75 mL/min.

Detection: spectrophotometer at 334 nm.

Injection: 10 µL.

Run time: 1.5 times the retention time of *esculetin*.

Retention time: *esculin* = about 4.5 min; *esculetin* = about 8.5 min.

Identification of peaks: use the chromatogram obtained with reference solution (a) to identify the peak due to *esculin* and the chromatogram obtained with reference solution (b) to identify the peak due to *esculetin*.

System suitability: reference solution (c):

- resolution: minimum 5.0 between the peaks due to *esculin* and *esculetin*.

Calculate the percentage content of the sum of *esculetin* and *esculin* using the following expression:

$$\frac{A_1 \times m_2 \times p_1 \times 0.5}{A_2 \times m_1} + \frac{A_3 \times m_3 \times p_2 \times 0.3}{A_4 \times m_1}$$

- A_1 = area of the peak due to *esculin* in the chromatogram obtained with the test solution;
- A_2 = area of the peak due to *esculin* in the chromatogram obtained with reference solution (c);
- A_3 = area of the peak due to *esculetin* in the chromatogram obtained with the test solution;
- A_4 = area of the peak due to *esculetin* in the chromatogram obtained with reference solution (c);
- m_1 = mass of the herbal drug to be examined used to prepare the test solution, in grams;
- m_2 = mass of *esculin CRS* used to prepare reference solution (a), in grams;
- m_3 = mass of *esculetin CRS* used to prepare reference solution (b), in grams;
- p_1 = percentage content of *esculin* in *esculin CRS*;
- p_2 = percentage content of *esculetin* in *esculetin CRS*.



04/2020:1220

HAWTHORN BERRIES

Crataegi fructus

DEFINITION

Dried false fruits of *Crataegus monogyna* Jacq. or *C. laevigata* (Poir.) DC. (syn. *C. oxyacantha* L.) or their hybrids or a mixture of these false fruits.

Content: minimum 0.06 per cent of procyanidins, expressed as cyanidin chloride ($C_{15}H_{11}ClO_6$; M_r 322.7) (dried drug).

IDENTIFICATION

A. The false fruit of *C. monogyna* is obovate or globular, generally 6-10 mm long and 4-8 mm wide, reddish-brown or dark red. The surface is pitted or, more rarely, reticulated. The upper end of the fruit is crowned by the remains of 5 reflexed sepals surrounding a small, sunken disc with a shallow, raised rim. The remains of the style occur in the centre of the disc with tufts of stiff, colourless hairs at the base. At the lower end of the fruit is a short length of pedicel or, more frequently, a small, pale, circular scar where the pedicel was attached. The receptacle is fleshy and encloses a yellowish-brown, ovoid fruit with a hard, thick wall containing a single, elongated, pale brown, smooth and shiny seed.

The false fruit of *C. laevigata* is up to 13 mm long. It contains 2-3 stony fruits, ventrally flattened, with short hairs at the top. The centre of the disc of the false fruit frequently bears the remains of the 2 styles.

B. Microscopic examination (2.8.23). The powder is greyish-red. Examine under a microscope using *chloral hydrate solution R*. The powder shows the following diagnostic characters (Figure 1220.-1): covering trichomes [F] from inside the disc that are long, unicellular, frequently bent, tapering to a point, with heavily thickened and lignified walls; fragments of the red outer layer of the receptacle (surface view [G]); fragments of the inner layers of the receptacle [A], some cells containing cluster crystals [Aa] or prisms [Ab] of calcium oxalate; occasional fragments [J, K] including groups of sclereids [Ka] and vascular bundles [Ja, Kb] associated with rows of cells containing prisms of calcium oxalate [Jb, Kc]; fragments of the pericarp [B] consisting of parenchyma including some cells containing cluster crystals of calcium oxalate [Ba] and groups of sclereids of various sizes with numerous pits [Bb]; thick-walled sclereids [E, H], channelled [E], some with conspicuously branched channels [H]; a few fragments of the testa [C] having an outer layer composed of hexagonal, mucilaginous cells [Ca] beneath which is a yellowish-brown pigment layer containing numerous prisms of calcium oxalate [Cb]; parenchyma of the endosperm and cotyledons consisting of cells containing aleurone grains and globules of fixed oil [D].




Figure 1220.-1. – Illustration for identification test B of powdered herbal drug of hawthorn berries

C. High-performance thin-layer chromatography (2.8.25).

Test solution. To 0.5 g of the powdered herbal drug (355) (2.9.12) add 5.0 mL of *methanol R*. Sonicate for 15 min, filter or centrifuge and use the filtrate or supernatant.

Reference solution (a). Dissolve 2.5 mg of *hyperoside R* and 3.5 mg of *rutoside trihydrate R* in *methanol R* and dilute to 10.0 mL with the same solvent.

Reference solution (b). Dilute 2.5 mL of reference solution (a) to 10.0 mL with *methanol R*.

Reference solution (c). Dissolve 2.5 mg of *hyperoside R* and 3 mg of *chlorogenic acid R* in *methanol R* and dilute to 10 mL with the same solvent.

Intensity marker: hyperoside.

Plate: TLC silica gel F_{254} plate *R* (2–10 µm).

Mobile phase: anhydrous formic acid *R*, water *R*, ethyl acetate *R* (10:10:80 V/V/V).

Application: 4 µL as bands of 8 mm.

Development: 70 mm from the lower edge of the plate.

Drying: in a current of air at room temperature for 5 min.

Detection: heat at 100–105 °C for 5 min; spray the warm plate with a 10 g/L solution of *diphenylboric acid aminoethyl ester R* in *methanol R*, then with a 50 g/L solution of *macrogol 400 R* in *methanol R* or, alternatively, dip the warm plate in a 5 g/L solution of *diphenylboric acid aminoethyl ester R* in *ethyl acetate R*, then in a 50 g/L solution of *macrogol 400 R* in *methylene chloride R*; allow to dry in air for about 1 min and examine in ultraviolet light at 366 nm.

System suitability: reference solution (c):

- the chromatogram shows in the middle third 2 distinct zones, which may be touching; the lower zone (chlorogenic acid) shows a light blue fluorescence and the upper zone (hyperoside) shows a yellow or orange fluorescence.

Results: see below the sequence of fluorescent zones present in the chromatograms obtained with reference solution (a) and the test solution. Furthermore, in the chromatogram obtained with the test solution, other faint blue, greenish and orange or yellow fluorescent zones may be present.

Top of the plate	
	1–2 blue zones, very faint to faint
Hyperoside: a yellow or orange zone	A yellow or orange zone, very faint to faint A yellow or orange zone, faint to equivalent (hyperoside) A light blue zone, faint (chlorogenic acid)
Rutoside: a yellow or orange zone	A yellow or orange zone, very faint (rutoside)
Reference solution (a)	Test solution

TESTS

Foreign matter (2.8.2): maximum 5 per cent of deteriorated false fruit and maximum 2 per cent of other foreign matter. It does not contain false fruits of other *Crataegus* species (*C. nigra* Waldst. et Kit., *C. pentagyna* Waldst. et Kit. ex Willd. and *C. azarolus* L.), which are characterised by the presence of more than 3 hard stones.

Loss on drying (2.2.32): maximum 12.0 per cent, determined on 1.000 g of the powdered herbal drug (355) (2.9.12) by drying in an oven at 105 °C for 2 h.

Total ash (2.4.16): maximum 5.0 per cent.

ASSAY

To 2.50 g of the powdered herbal drug (355) (2.9.12) add 30 mL of *ethanol* (70 per cent V/V) *R*. Heat under a reflux condenser for 30 min and filter. Wash the residue with 10.0 mL of *ethanol* (70 per cent V/V) *R*. Add to the filtrate 15.0 mL of *hydrochloric acid R1* and 10.0 mL of *water R*. Heat under a reflux condenser for 80 min. Allow to cool, filter and wash the residue with *ethanol* (70 per cent V/V) *R* until the filtrate is colourless. Dilute the filtrate to 250.0 mL with *ethanol* (70 per cent V/V) *R*. Evaporate 50.0 mL of this solution in a round-bottomed flask to about 3 mL and transfer to a separating funnel. Rinse the round-bottomed flask sequentially with 10 mL and 5 mL of *water R* and transfer to the separating funnel. Shake the combined solution with 3 quantities, each of 15 mL, of *butanol R*. Combine the organic layers and dilute to 100.0 mL with *butanol R*.

Measure the absorbance (2.2.25) of the solution at 555 nm.

Calculate the percentage content of procyanidins, expressed as cyanidin chloride, using the following expression:

$$\frac{A \times 500}{1200 \times m}$$

i.e. taking the specific absorbance of cyanidin chloride to be 1200.

A = absorbance at 555 nm;

m = mass of the substance to be examined, in grams.



04/2020:2950

RASPBERRY LEAF

Rubi idaei folium

DEFINITION

Whole or fragmented, dried leaves of *Rubus idaeus* L. harvested in spring or early summer.

Content: minimum 3.0 per cent of tannins, expressed as pyrogallol ($C_6H_6O_3$; M_r 126.1) (dried drug).

IDENTIFICATION

A. Whole drug. The leaf is imparipinnate, with 3, 5 or rarely 7 ovate to lanceolate leaflets with sharply serrate or doubly-serrate margins. The upper surface is dark green to brownish-green and weakly pubescent; the lower surface is silvery grey and densely tomentose with a prominent pinnate venation. The petiole is about 1-2 mm thick, green or occasionally reddish, slightly channelled on the upper surface, and sometimes shows small, straight prickles. The stipules are long and thin. The leaves of the short shoots are often simple, more or less 3-lobed, or they are trifoliate.

Fragmented drug. It is characterised by clumped fragments of leaves and petioles.

B. Microscopic examination (2.8.23). Reduce to a powder (710) (2.9.12). The powder is greyish-green and flocculent. Examine under a microscope using *chloral hydrate solution R*. The powder shows the following diagnostic characters (Figure 2950.-1): very numerous broken unicellular covering trichomes, either rigid with thickened walls [G], or twisted with slightly thickened walls [F]; fragments of the upper epidermis of the leaflet lamina (surface view [D]) with polygonal cells [Da] and rare, rigid, unicellular covering trichomes with thickened walls, measuring from 20 µm to more than 500 µm in length [Db], or their scars, often accompanied by palisade parenchyma [Dc] including some hypertrophied cells containing a cluster crystal of calcium oxalate [Dd]; fragments of the lower epidermis of the leaflet lamina [A] containing cells with thin, slightly lobed walls [Aa] and anomocytic stomata (2.8.3) (5-7 subsidiary cells) [Ab], with an abundant indumentum composed of unicellular, fine, twisted covering trichomes [Ac] up to 500 µm long; annular or spiral vessels from the petioles, rachis or principal veins [J], sometimes accompanied by cells of the pith with slightly thickened, pitted walls [Ja]; fragments of pericyclic fibres [C], frequently with a crystal sheath containing small cluster crystals of calcium oxalate [Ca]; fragments of the lamina (transverse section [H]) consisting of the upper epidermis [Ha], 1 or 2 layers of palisade parenchyma [Hb], including hypertrophied cells containing a cluster crystal of calcium oxalate [Hc], spongy parenchyma [Hd] and the lower epidermis with twisted unicellular covering trichomes [He]; free cluster crystals of calcium oxalate [E]; exceptionally, secretory trichomes with a biseriate, multicellular stalk and a globular, multicellular head, located on the upper epidermis of the leaflet veins [B].




Figure 2950.-1. – Illustration for identification test B of powdered herbal drug of raspberry leaf

C. High-performance thin-layer chromatography (2.8.25).

Test solution. To 0.5 g of the powdered herbal drug (710) (2.9.12) add 10.0 mL of *methanol R*. Sonicate for 15 min, filter or centrifuge and use the filtrate or supernatant.

Reference solution (a). Dissolve 2.5 mg of *hyperoside R* and 3.5 mg of *rutoside trihydrate R* in *methanol R* and dilute to 10.0 mL with the same solvent.

Reference solution (b). Dilute 2.5 mL of reference solution (a) to 10.0 mL with *methanol R*.

Reference solution (c). Dissolve 3 mg of *hyperoside R* and 2.5 mg of *chlorogenic acid R* in *methanol R* and dilute to 10 mL with the same solvent.

Intensity marker: hyperoside.

Plate: TLC silica gel F_{254} plate R (2-10 µm).

Mobile phase: *anhydrous formic acid R*, *water R*, *ethyl acetate R* (10:10:80 V/V/V).

Application: 10 µL of the test solution and 4 µL of reference solutions (a), (b) and (c), as bands of 8 mm.

Development: 70 mm from the lower edge of the plate.

Drying: in a current of air at room temperature for 5 min.

Detection: heat at 100-105 °C for 5 min; spray the warm plate with a 10 g/L solution of *diphenylboric acid aminoethyl ester R* in *methanol R*, then with a 50 g/L solution of *macrogol 400 R* in *methanol R* or, alternatively, dip the warm plate in a 5 g/L solution of *diphenylboric acid aminoethyl ester R* in *ethyl acetate R*, then in a 50 g/L solution of *macrogol 400 R* in *methylene chloride R*; allow to dry in air for about 1 min and examine in ultraviolet light at 366 nm.

System suitability: reference solution (c):

- the chromatogram shows in the middle third 2 distinct zones, which may be touching; the lower zone (chlorogenic acid) shows a light blue fluorescence and the upper zone (hyperoside) shows a yellow or orange fluorescence.

Results: see below the sequence of fluorescent zones present in the chromatograms obtained with reference solution (a) and the test solution. Furthermore, in the chromatogram obtained with the test solution, other faint fluorescent zones, mainly light blue, greenish and yellow or orange, may be present, especially in the upper and lower thirds.

Top of the plate	
	A red zone
	A red zone, faint
	A light blue zone, faint to equivalent
	A greenish zone, faint (possibly overlapping with an orange zone)
Hyperoside: a yellow or orange zone	A yellow or orange zone, very faint to faint (possibly overlapping with a blue zone)
	A yellow or orange zone
Rutoside: a yellow or orange zone	A yellow or orange zone, faint to equivalent
Reference solution (a)	Test solution

TESTS

***Rubus fruticosus* L.** Microscopic examination (2.8.23). Examine the powdered herbal drug (710) (2.9.12) using *chloral hydrate solution R*. The presence of fasciculate-stellate covering trichomes indicates adulteration by *Rubus fruticosus* L.

Loss on drying (2.2.32): maximum 10.0 per cent, determined on 1.000 g of the powdered herbal drug (710) (2.9.12) by drying in an oven at 105 °C for 2 h.

Total ash (2.4.16): maximum 8.0 per cent.

ASSAY

Tannins (2.8.14). Use 1.000 g of the powdered herbal drug (710) (2.9.12).

Content: minimum 0.2 per cent of catalpol ($C_{15}H_{22}O_{10}$; M_r 362.3) (dried drug).

IDENTIFICATION

- A. The whole drug usually occurs as irregular or oblong masses, swollen in the centre, slightly tapering at both ends and bearing lenticular rootlet scars, 6-12 cm long and 3-6 cm thick. The fragmented drug occurs as slightly compressed or twisted slices. The outer surface is blackish-brown or blackish-grey, and is heavily shrunk with irregular transverse wavy lines. Fracture is difficult, with the cut surface being lustrous, blackish-brown or jet black and viscous.
- B. Microscopic examination (2.8.23). The blackish-brown powder consists of rather sticky particles. Examine under a microscope using *chloral hydrate solution R*. The powder shows the following diagnostic characters (Figure 2569.-1): blackish-brown cork fragments consisting of polygonal cells (surface view [A]) or composed of superimposed layers (transverse section [B]); fragments of parenchyma [D], brown, consisting of polygonal or rectangular cells with thin, wavy or wrinkled walls, some containing orange-yellow oil droplets [Da]; vessels about 100-200 µm long and 40-60 µm in diameter, with reticulate or pitted walls [B, C], with the junction between vessels of similar diameter being clearly visible.




Figure 2569.-1. – Illustration for identification test B of powdered herbal drug of rehmannia root

- C. High performance thin-layer chromatography (2.8.25).

Test solution. To 0.2 g of the powdered herbal drug (355) (2.9.12) add 5.0 mL of *methanol R*. Sonicate for 10 min, then filter or centrifuge the solution. Use the filtrate or supernatant.

Reference solution (a). Dissolve 10.0 mg of *sucrose R* and 10.0 mg of *raffinose R* in the minimum volume of *water R* and dilute to 2.0 mL with *methanol R*.

Reference solution (b). Mix 1.0 mL of reference solution (a) and 3.0 mL of *methanol R*.

04/2020:2569



REHMANNIA ROOT

Rehmanniae radix

DEFINITION

Dried root tuber of *Rehmannia glutinosa* (Gaertn.) DC. (syn. *Rehmannia glutinosa* (Gaertn.) Libosch. ex Fisch. & C.A. Mey.) with the crown and rootlets removed.

Reference solution (c). Dissolve 10 mg of fructose R and 10 mg of sucrose R in the minimum amount of water R and dilute to 2 mL with methanol R.

Intensity marker: sucrose.

Plate: TLC silica gel F_{254} plate R (2–10 μm).

Mobile phase: glacial acetic acid R, anhydrous formic acid R, water R, ethyl acetate R (4.5:6:12 V/V/V/V).

Application: 2 μL as bands of 8 mm.

Development: 70 mm from the lower edge of the plate.

Drying: in a current of cold air for 5 min.

Detection: treat with a 10 per cent V/V solution of sulfuric acid R in ethanol (96 per cent) R, heat at 120 °C for 3 min and examine in ultraviolet light at 366 nm.

System suitability: reference solution (c):

- the chromatogram shows in the middle third 2 distinct zones, which may be touching; both the lower zone (sucrose) and the upper zone (fructose) show a brown colour.

Results: see below the sequence of zones present in the chromatograms obtained with reference solution (a) and the test solution. Furthermore, in the chromatogram obtained with the test solution, other faint blue fluorescent zones and faint brown zones may be present.

Top of the plate	
	A blue fluorescent zone, faint to intense
	A brown zone, faint
	A blue fluorescent zone, faint
Sucrose: a brown zone	A brown zone, faint to equivalent (sucrose)
Raffinose: a brown zone	A brown zone, faint to equivalent (raffinose)
	A brown zone, intense
	A brown zone, very faint
Reference solution (a)	Test solution

TESTS

Loss on drying (2.2.32): maximum 15.0 per cent, determined on 2.000 g of the powdered herbal drug (355) (2.9.12) by drying in an oven at 105 °C for 5 h.

Total ash (2.4.16): maximum 8.0 per cent.

Ash insoluble in hydrochloric acid (2.8.1): maximum 3.0 per cent.

ASSAY

Liquid chromatography (2.2.29).

Test solution. To 1.500 g of the powdered herbal drug (355) (2.9.12) add 50.0 mL of water R. Weigh and sonicate for 30 min at a temperature below 25 °C. Weigh again and compensate for the loss of solvent with water R. Shake well, then centrifuge for 10 min and filter the supernatant through a membrane filter (nominal pore size 0.45 μm).

Reference solution. Dissolve 5.0 mg of catalpol CRS in water R and dilute to 25.0 mL with the same solvent.

Column:

- size: $l = 0.15 \text{ m}$, $\varnothing = 4.6 \text{ mm}$;

- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (3 μm);

- temperature: 25 °C.

Mobile phase:

- mobile phase A: water for chromatography R;

- mobile phase B: acetonitrile R1, water for chromatography R (5:95 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 – 3	90	10
3 – 20	90 $\rightarrow$ 70	10 $\rightarrow$ 30

Flow rate: 0.5 mL/min.

Detection: spectrophotometer at 210 nm.

Injection: 10 μL .

Retention time: catalpol = about 13 min.

System suitability: reference solution:

- repeatability: maximum relative standard deviation of 2.0 per cent determined on 6 injections.

Calculate the percentage content of catalpol using the following expression:

$$\frac{A_1 \times m_2 \times p \times 2}{A_2 \times m_1}$$

A_1 = area of the peak due to catalpol in the chromatogram obtained with the test solution;

A_2 = area of the peak due to catalpol in the chromatogram obtained with the reference solution;

m_1 = mass of the herbal drug to be examined used to prepare the test solution, in grams;

m_2 = mass of catalpol CRS used to prepare the reference solution, in grams;

p = percentage content of catalpol in catalpol CRS.



04/2020:0206

SENNA LEAFLET

Sennae foliolum

DEFINITION

Dried leaflets of *Senna alexandrina* Mill. (syn. *Cassia acutifolia* Delile and *Cassia angustifolia* Vahl).

Content: minimum 2.0 per cent of total hydroxyanthracene glycosides, expressed as sennoside B ($\text{C}_{42}\text{H}_{38}\text{O}_{20}$; M_r 863) (dried drug).

IDENTIFICATION

A. The green to brownish-green leaflets are thin, elongated, lanceolate, more or less asymmetrical at the base and mucronate at the apex, 15–50 mm long and 5–20 mm wide. Both surfaces of the lamina are covered with varying numbers of fine, short trichomes and may be marked with transverse or oblique lines. Pinnate venation is visible mainly on the abaxial surface and usually shows lateral veins anastomosing at the leaf margins.

B. Microscopic examination (2.8.23). The powder is light green or greenish-yellow. Examine under a microscope using chloral hydrate solution R. The powder shows the following diagnostic characters (Figure 0206.-1): fragments of epidermis [A, B, J, K] with polygonal cells [Aa, Ka], paracytic stomata (2.8.3) [Ab, Ac, Ba, Ja, Kb] and unicellular covering trichomes, conical in shape,

with warty walls (surface view [Ad], side view [G]), or their scars [Bb, Jb], frequently accompanied by palisade parenchyma [Ae, Jc]; isolated, fragmented covering trichomes [E]; fibres [F] accompanied by crystal sheaths containing prisms of calcium oxalate [Fa]; isolated prisms of calcium oxalate [D]; isolated cluster crystals of calcium oxalate [H]; fragments of median parenchyma from the lamina [C] with some cells containing cluster crystals of calcium oxalate [Ca], often accompanied by palisade parenchyma [Cb] and annular vessels [Cc].




Figure 0206.-1. – *Illustration for identification test B of powdered herbal drug of senna leaflet*

C. High-performance thin-layer chromatography (2.8.25).

Solvent mixture: ethanol (96 per cent) R, water R (50:50 V/V).

Test solution. To 0.5 g of the powdered herbal drug (355) (2.9.12) add 5.0 mL of the solvent mixture. Sonicate for 10 min, then filter or centrifuge the solution. Use the filtrate or supernatant.

Reference solution (a). Dissolve 3 mg of *sennoside A R* and 3 mg of *sennoside B R* in a mixture of equal volumes of *ethanol (96 per cent) R* and a 1 g/L solution of *sodium hydrogen carbonate R* and dilute to 20.0 mL with the same mixture of solvents.

Reference solution (b). Dilute 2.5 mL of reference solution (a) to 10.0 mL with the solvent mixture.

Reference solution (c). Dissolve 10 mg of *senna extract HRS* in 1 mL of the solvent mixture (a slight residue may remain).

Intensity marker: sennoside A.

Plate: TLC silica gel F_{254} plate R (2-10 μm).

Mobile phase: water R, ethyl acetate R, propanol R (30:40:40 V/V/V).

Application: 1 μL of the test solution and 2 μL of reference solutions (a), (b) and (c), as bands of 8 mm.

Development: 70 mm from the lower edge of the plate.

Drying: in a current of air at room temperature for 5 min.

Detection: heat at 110 °C for 10 min; treat the warm plate with a 50 g/L solution of *potassium hydroxide R* in the solvent mixture and heat at 110 °C for 10 min; examine immediately in ultraviolet light at 366 nm.

System suitability: reference solution (c):

- the chromatogram shows 2 distinct zones, which may be touching, near the border between the lower and middle thirds; the lower zone (sennoside A) shows a light yellow fluorescence and the upper zone (sennoside D) shows a faint brownish-yellow fluorescence.

Results: see below the sequence of fluorescent zones present in the chromatograms obtained with reference solution (a) and the test solution. Furthermore, in the chromatogram obtained with the test solution, other blue and/or reddish fluorescent zones may be present, mainly above the zone due to sennoside A. For sennosides, R_F values vary slightly and the zones may be curved depending on the concentration.

Top of the plate	
_____ Sennoside A: a light yellow zone _____ Sennoside B: a brownish-yellow zone	_____ A light yellow zone, very faint to faint (sennoside C) A brownish-yellow zone, faint (sennoside D) A light yellow zone, equivalent (sennoside A) _____ A brownish-yellow zone, equivalent (sennoside B)
Reference solution (a)	Test solution

TESTS

Total anthraquinones (aloe emodin and rhein). Liquid chromatography (2.2.29). Carry out the test protected from bright light.

Solvent mixture: 1.0 g/L solution of sodium hydrogen carbonate R, methanol R (30:70 V/V).

Test solution. Introduce 1.00 g of the powdered herbal drug (355) (2.9.12) into a 250 mL screw-cap bottle and add 100.0 mL of the solvent mixture. Sonicate for 30 min and shake for 2 h. Filter through a membrane filter (nominal pore size 0.45 μm).

Reference solution (a). Dissolve 10 mg of *aloe emodin R* and 10.0 mg of *rhein CRS* in *tetrahydrofuran R* and dilute to 50.0 mL with the same solvent. Dilute 1.0 mL of the solution to 20.0 mL with the solvent mixture.

Reference solution (b). Dissolve 10 mg of *senna extract HRS* in 8 mL of the solvent mixture using sonication for 5 min and dilute to 10 mL with the solvent mixture (a slight residue may remain). Filter through a membrane filter (nominal pore size 0.45 µm).

Reference solution (c). Dissolve 5.0 mg of *sennoside B CRS* in 25 mL of *methanol R* using sonication and dilute to 50.0 mL with *water R*.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped propoxybenzene silica gel for chromatography R (4 µm);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: 1.275 per cent V/V solution of *anhydrous formic acid R*;
- mobile phase B: *acetonitrile R*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 3	87	13
3 - 40	87 → 37	13 → 63

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 270 nm.

Injection: 10 µL of the test solution and reference solutions (a) and (b).

Identification of peaks: use the chromatogram supplied with *senna extract HRS* and the chromatogram obtained with reference solution (b) to identify the peaks due to isorhamnetin diglucoside and hydroxyanthracene glycosides (peaks 2-9); any shoulder appearing on the ascending part of the peak due to sennoside B (peak 3) is included in its area; peaks 4 and 5 may be co-eluted; peaks 7 and 8 may be co-eluted; use the chromatogram obtained with reference solution (a) to identify the peaks due to aloe emodin and rhein.

Relative retention with reference to sennoside B (peak 3, retention time = about 14.2 min): isorhamnetin diglucoside = about 0.93; hydroxyanthracene glycoside (peak 2) = about 0.98; hydroxyanthracene glycoside (peak 4) = about 1.01; hydroxyanthracene glycoside (peak 5) = about 1.02; hydroxyanthracene glycoside (peak 6) = about 1.07; hydroxyanthracene glycoside (peak 7) = about 1.09; hydroxyanthracene glycoside (peak 8) = about 1.11; hydroxyanthracene glycoside (peak 9) = about 1.13; aloe emodin = about 2.2; rhein = about 2.3.

System suitability: reference solution (b):

- resolution: minimum 3.0 between the peaks due to isorhamnetin diglucoside and hydroxyanthracene glycoside (peak 2).

Calculate the percentage content of total anthraquinones (aloe emodin and rhein) (*TA*), expressed as rhein, using the following expression:

$$\frac{A_1 \times m_2 \times p}{A_2 \times m_1 \times 10}$$

- A_1 = sum of the areas of the peaks due to aloe emodin and rhein in the chromatogram obtained with the test solution;
- A_2 = area of the peak due to rhein in the chromatogram obtained with reference solution (a);
- m_1 = mass of the herbal drug to be examined used to prepare the test solution, in grams;
- m_2 = mass of *rhein CRS* used to prepare reference solution (a), in grams;
- p = percentage content of rhein in *rhein CRS*.

Calculate the percentage content of total anthraquinones with reference to the sum of total hydroxyanthracene glycosides (*THG*, see Assay) and total anthraquinones, using the following expression:

$$\frac{TA}{THG + TA} \times 100$$

Limit:

- total anthraquinones (aloe emodin and rhein) expressed as rhein ($C_{15}H_8O_6$; M_r 284.2): maximum 7.0 per cent, calculated with reference to the sum of total hydroxyanthracene glycosides and total anthraquinones (dried drug).

Foreign matter (2.8.2): maximum 4 per cent.

Loss on drying (2.2.32): maximum 12.0 per cent, determined on 1.000 g of the powdered herbal drug (355) (2.9.12) by drying in an oven at 105 °C for 2 h.

Total ash (2.4.16): maximum 12.0 per cent.

Ash insoluble in hydrochloric acid (2.8.1): maximum 2.5 per cent.

ASSAY

Liquid chromatography (2.2.29) as described in the test for total anthraquinones (aloe emodin and rhein) with the following modification.

Injection: test solution and reference solution (c).

Calculate the percentage content of total hydroxyanthracene glycosides (peaks 2-9) (*THG*), expressed as sennoside B, using the following expression:

$$\frac{A_1 \times m_2 \times 2 \times p}{A_2 \times m_1}$$

A_1 = sum of the areas of the peaks due to hydroxyanthracene glycosides (peaks 2-9) in the chromatogram obtained with the test solution;

A_2 = area of the peak due to sennoside B in the chromatogram obtained with reference solution (c);

m_1 = mass of the herbal drug to be examined used to prepare the test solution, in grams;

m_2 = mass of *sennoside B CRS* used to prepare reference solution (c), in grams;

p = percentage content of sennoside B in *sennoside B CRS*.

STORAGE

Protected from moisture.



04/2020:0207

SENNA PODS

Sennae fructus

DEFINITION

Dried fruit of *Senna alexandrina* Mill. (syn. *Cassia acutifolia* Delile and *Cassia angustifolia* Vahl).

Content: minimum 2.0 per cent of total hydroxyanthracene glycosides, expressed as sennoside B ($C_{42}H_{38}O_{20}$; M_r 863) (dried drug).

IDENTIFICATION

A. Flattened, more or less reniform pods, yellowish-brown to greenish-brown with brown patches at the positions corresponding to the seeds, usually 35-60 mm long and

14-20 mm wide. At one end is a styler point and at the other a short stalk. The pods contain 5-8 flattened, obovate seeds, green or pale brown, with a more or less prominent network of transverse, wavy ridges on the testa.

B. Microscopic examination (2.8.23). The powder is brown. Examine under a microscope using *chloral hydrate solution R*. The powder shows the following diagnostic characters (Figure 0207.-1): fragments of the epicarp (surface view [B, K]) with polygonal cells, anomocytic [Ba] or paracytic [Bb, Ka] stomata (2.8.3) and covering trichomes [Kb] or their scars [Bc]; isolated conical warty covering trichomes, usually bent [C]; fragments of the mesocarp (surface view [D]) with fibres [Da] in 2 crossed layers accompanied by a layer of cells containing calcium oxalate prisms [Db] and sometimes cells of the underlying endocarp [Dc]; fragments of the outer layers of the testa (transverse section [J]) covered by a thick cuticle [Ja] with palisade cells about 50 µm long, with thick walls and a reduced lumen [Jb], accompanied by the hypodermis with pillar-like cells [Jc]; palisade cells of the testa (surface view [N]) and fragments of the hypodermis of the seed forming rings (surface view [A]); fragments of cotyledons (surface view [F], transverse section [E]) consisting of small cells of the epidermis [Ea, Fa] and of the palisade tissue [Eb, Fb]; prisms and cluster crystals of calcium oxalate, free [De, Ga] or included in parenchyma [G]; fragments of vascular bundles [L] with spiral vessels [La] and fibres with moderately thickened and pitted walls [Lb]; sclereids [M, O] and fibres [H] accompanied by crystal sheaths of calcium oxalate [Ha] from fruit stalks.




Figure 0207.-1. – Illustration for identification test B of powdered herbal drug of senna pods

C. High-performance thin-layer chromatography (2.8.25).

Solvent mixture: ethanol (96 per cent) R, water R (50:50 V/V).

Test solution. To 0.5 g of the powdered herbal drug (355) (2.9.12) add 5.0 mL of the solvent mixture. Sonicate for 10 min, then filter or centrifuge the solution. Use the filtrate or supernatant.

Reference solution (a). Dissolve 3 mg of *sennoside A R* and 3 mg of *sennoside B R* in a mixture of equal volumes of ethanol (96 per cent) R and a 1 g/L solution of sodium hydrogen carbonate R and dilute to 20.0 mL with the same mixture of solvents.

Reference solution (b). Dilute 2.5 mL of reference solution (a) to 10.0 mL with the solvent mixture.

Reference solution (c). Dissolve 10 mg of *senna extract HRS* in 1 mL of the solvent mixture (a slight residue may remain).

Intensity marker: sennoside A.

Plate: TLC silica gel F_{254} plate R (2-10 µm).

Mobile phase: water R, ethyl acetate R, propanol R (30:40:40 V/V/V).

Application: 1 µL of the test solution and 2 µL of reference solutions (a), (b) and (c), as bands of 8 mm.

Development: 70 mm from the lower edge of the plate.

Drying: in a current of air at room temperature for 5 min.

Detection: heat at 110 °C for 10 min; treat the warm plate with a 50 g/L solution of *potassium hydroxide R* in the solvent mixture and heat at 110 °C for 10 min; examine immediately in ultraviolet light at 366 nm.

System suitability: reference solution (c):

- the chromatogram shows 2 distinct zones, which may be touching, near the border between the lower and middle thirds; the lower zone (sennoside A) shows a light yellow fluorescence and the upper zone (sennoside D) shows a faint brownish-yellow fluorescence.

Results: see below the sequence of fluorescent zones present in the chromatograms obtained with reference solution (a) and the test solution. Furthermore, in the chromatogram obtained with the test solution, other blue and/or reddish fluorescent zones may be present, mainly above the zone due to sennoside A. For sennosides, R_f values vary slightly and the zones may be curved depending on the concentration.

Top of the plate	
	A light yellow zone, very faint to faint (sennoside C)
	A brownish-yellow zone, faint (sennoside D)
Sennoside A: a light yellow zone	A light yellow zone, equivalent to intense (sennoside A)
Sennoside B: a brownish-yellow zone	A brownish-yellow zone, intense (sennoside B)
Reference solution (a)	Test solution

TESTS

Total anthraquinones (aloe emodin and rhein). Liquid chromatography (2.2.29). Carry out the test protected from bright light.

Solvent mixture: 1.0 g/L solution of sodium hydrogen carbonate R, methanol R (30:70 V/V).

Test solution. Introduce 0.500 g of the powdered herbal drug (355) (2.9.12) into a 250 mL screw-cap bottle and add 100.0 mL of the solvent mixture. Sonicate for 30 min and shake for 2 h. Filter through a membrane filter (nominal pore size 0.45 µm).

Reference solution (a). Dissolve 10 mg of aloe emodin R and 10.0 mg of rhein CRS in tetrahydrofuran R and dilute to 50.0 mL with the same solvent. Dilute 1.0 mL of the solution to 20.0 mL with the solvent mixture.

Reference solution (b). Dissolve 10 mg of senna extract HRS in 8 mL of the solvent mixture using sonication for 5 min and dilute to 10 mL with the solvent mixture (a slight residue may remain). Filter through a membrane filter (nominal pore size 0.45 µm).

Reference solution (c). Dissolve 5.0 mg of sennoside B CRS in 25 mL of methanol R using sonication and dilute to 50.0 mL with water R.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped propoxybenzene silica gel for chromatography R (4 µm);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: 1.275 per cent V/V solution of anhydrous formic acid R;
- mobile phase B: acetonitrile R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 3	87	13
3 - 40	87 → 37	13 → 63

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 270 nm.

Injection: 10 µL of the test solution and reference solutions (a) and (b).

Identification of peaks: use the chromatogram supplied with senna extract HRS and the chromatogram obtained with reference solution (b) to identify the peaks due to isorhamnetin diglucoside and hydroxyanthracene glycosides (peaks 2-9); any shoulder appearing on the ascending part of the peak due to sennoside B (peak 3) is included in its area; peaks 4 and 5 may be co-eluted; peaks 7 and 8 may be co-eluted; use the chromatogram obtained with reference solution (a) to identify the peaks due to aloe emodin and rhein.

Relative retention with reference to sennoside B (peak 3, retention time = about 14.2 min): isorhamnetin diglucoside = about 0.93; hydroxyanthracene glycoside (peak 2) = about 0.98; hydroxyanthracene glycoside (peak 4) = about 1.01; hydroxyanthracene glycoside (peak 5) = about 1.02; hydroxyanthracene glycoside (peak 6) = about 1.07; hydroxyanthracene glycoside (peak 7) = about 1.09; hydroxyanthracene glycoside (peak 8) = about 1.11; hydroxyanthracene glycoside (peak 9) = about 1.13; aloe emodin = about 2.2; rhein = about 2.3.

System suitability: reference solution (b):

- resolution: minimum 3.0 between the peaks due to isorhamnetin diglucoside and hydroxyanthracene glycoside (peak 2).

Calculate the percentage content of total anthraquinones (aloe emodin and rhein) (TA), expressed as rhein, using the following expression:

$$\frac{A_1 \times m_2 \times p}{A_2 \times m_1 \times 10}$$

- A_1 = sum of the areas of the peaks due to aloe emodin and rhein in the chromatogram obtained with the test solution;
- A_2 = area of the peak due to rhein in the chromatogram obtained with reference solution (a);
- m_1 = mass of the herbal drug to be examined used to prepare the test solution, in grams;
- m_2 = mass of rhein CRS used to prepare reference solution (a), in grams;
- p = percentage content of rhein in rhein CRS.

Calculate the percentage content of total anthraquinones with reference to the sum of total hydroxyanthracene glycosides (THG, see Assay) and total anthraquinones, using the following expression:

$$\frac{TA}{THG + TA} \times 100$$

Limit:

- total anthraquinones (aloe emodin and rhein) expressed as rhein ($C_{15}H_8O_6$; M_r 284.2): maximum 7.0 per cent, calculated with reference to the sum of total hydroxyanthracene glycosides and total anthraquinones (dried drug).

Foreign matter (2.8.2): maximum 1 per cent.

Loss on drying (2.2.32): maximum 12.0 per cent, determined on 1.000 g of the powdered herbal drug (355) (2.9.12) by drying in an oven at 105 °C for 2 h.

Total ash (2.4.16): maximum 9.0 per cent.

Ash insoluble in hydrochloric acid (2.8.1): maximum 2.0 per cent.

ASSAY

Liquid chromatography (2.2.29) as described in the test for total anthraquinones (aloe emodin and rhein) with the following modification.

Injection: test solution and reference solution (c).

Calculate the percentage content of total hydroxyanthracene glycosides (peaks 2-9) (THG), expressed as sennoside B, using the following expression:

$$\frac{A_1 \times m_2 \times 2 \times p}{A_2 \times m_1}$$

- A_1 = sum of the areas of the peaks due to hydroxyanthracene glycosides (peaks 2-9) in the chromatogram obtained with the test solution;
- A_2 = area of the peak due to sennoside B in the chromatogram obtained with reference solution (c);
- m_1 = mass of the herbal drug to be examined used to prepare the test solution, in grams;
- m_2 = mass of sennoside B CRS used to prepare reference solution (c), in grams;
- p = percentage content of sennoside B in sennoside B CRS.

STORAGE

Protected from moisture.

Homoeopathic preparations

Adonis vernalis for homoeopathic preparations.. 4369 Magnesium fluoratum for homoeopathic preparations..... 4370



04/2020:2832 CHARACTERS

ADONIS VERNALIS FOR
HOMOEOPATHIC PREPARATIONS⁽¹⁾

Adonis vernalis ad praeparationes
homoeopathicas

DEFINITION

Fresh aerial parts of *Adonis vernalis* L., collected during flowering.

IDENTIFICATION

The pithy, light green stem grows to a height of 10-40 cm, very occasionally up to 60 cm, and is up to 5 mm in diameter, erect, usually unbranched, round, often flattened towards the top, with longitudinal furrows. Younger shoots are slightly hairy but soon become completely glabrous.

The alternate and sessile leaves sheath the stem and are closer together in the upper part of the stem. They are glabrous or sparsely haired, 2- to 4-pinnate, and narrowly linear to filiform with entire margins, with downward-turned tips that are approximately 1 mm across. Brownish-black scale-like leaves are present at the base of the stem.

The single, erect or slightly overhanging, terminal flowers are normally 40-70 mm in size. The calyx has 5 greenish sepals with a covering of fine hairs on the outside. The sepals are broadly oval, half as long as the petals and pressed to the latter. The corolla consists of 10-20, normally 12, distinctly lustrous, deep yellow petals that are 20-40 mm in length, 6-10 mm wide with entire margins, elongated and tapering to a finely toothed point, and glabrous with clearly visible venation. The numerous stamens are an intense yellow. The numerous, rounded, apocarpous ovaries are covered all over with hairs; they are attached to a conical, convex receptacle and have a short, hooked style.

TESTS

Foreign matter (2.8.2): maximum 5 per cent.

Loss on drying (2.2.32): minimum 60.0 per cent, determined on 5.0 g of the comminuted herbal drug by drying in an oven at 105 °C for 2 h.

Mother tincture

The mother tincture complies with the requirements of the general monograph *Mother tinctures for homoeopathic preparations* (2029).

DEFINITION

The mother tincture is prepared from the fresh aerial parts of *Adonis vernalis* L., collected during flowering.

Content: 0.01 per cent *m/m* to 0.05 per cent *m/m* of total cardenolic glycosides, expressed as cymarin (C₃₀H₄₄O₉; M_r 548.7).

PRODUCTION

The mother tincture is prepared from the fresh flowering aerial parts of *Adonis vernalis* L. according to the following methods as prescribed in the monograph *Methods of preparation of homoeopathic stocks and potentisation* (2371):

- method 1.1.3;
- method 1.1.10, using ethanol (45 per cent V/V) and a maceration time of about 3 weeks.

Appearance: brown liquid.

IDENTIFICATION

Thin-layer chromatography (2.2.27).

Solvent mixture: ethyl acetate R, methanol R (50:50 V/V).

Test solution. To 10 mL of the mother tincture to be examined add 10 mL of ethanol (50 per cent V/V) R and 10 mL of lead acetate solution R. Boil for 2 min, then cool and centrifuge. Collect the supernatant and shake with 2 quantities, each of 15 mL of ethyl acetate R, centrifuging if an emulsion forms. Dry the combined organic phases over anhydrous sodium sulfate R and filter. Evaporate the filtrate to dryness and dissolve the residue in 0.5 mL of the solvent mixture.

Reference solution. Dissolve 10 mg of convallatoxin R and 10 mg of cymarin R in the solvent mixture and dilute to 10 mL with the solvent mixture.

Plate: TLC silica gel plate R (5-40 µm) [or TLC silica gel plate R (2-10 µm)].

Mobile phase: water R, methanol R, ethyl acetate R (8:11:81 V/V/V).



Application: 25 µL [or 20 µL] as bands of 20 mm [or 10 mm].

Development: over a path of 10 cm [or 6 cm].

Drying: in air until the solvents have evaporated.

Detection: treat with a mixture of equal volumes of dilute sodium hydroxide solution R and dinitrobenzoic acid solution R; examine in daylight.

Results: see below the sequence of the zones present in the chromatograms obtained with the reference solution and the test solution. Furthermore, other faint zones may be present in the chromatogram obtained with the test solution.

Top of the plate	
	
Reference solution	Test solution

TESTS

Relative density (2.2.5): 0.930 to 0.956, where method 1.1.3 is used.

Ethanol (2.9.10): 40 per cent V/V to 50 per cent V/V, where method 1.1.10 is used.

Dry residue (2.8.16): minimum 3.6 per cent (where method 1.1.3 is used), minimum 1.0 per cent (where method 1.1.10 is used).

(1) FRENCH TITLE: Adonis vernalis pour préparations homéopathiques

ASSAY

Test solution. To 20.00 g of the mother tincture to be examined, add 12 mL of *lead subacetate solution R*. Shake and centrifuge. Collect the supernatant. Repeat the centrifugation twice using 5 mL of *water R* each time and collect the supernatant, then dilute to 50.0 mL with *water R*. To 10.0 mL of this solution add 10.0 mL of a 100 g/L solution of *anhydrous sodium sulfate R*. Filter. To 10.0 mL of the filtrate add 2.0 mL of *dinitrobenzoic acid solution R* and 1.0 mL of 1 M *sodium hydroxide*.

Reference solution. Dissolve 10.0 mg of *cymarín R* in 20 mL of *ethanol (96 per cent) R* and dilute to 100.0 mL with *water R*. Dilute 5.0 mL of the solution to 20.0 mL with *water R*. To 10.0 mL of this solution, add 2.0 mL of *dinitrobenzoic acid solution R* and 1.0 mL of 1 M *sodium hydroxide*.

Measure the absorbance (2.2.25) of the test solution and the reference solution at 540 nm several times during the first 12 min following the end of solution preparation until the maximum absorbance is reached, using a mixture of 10.0 mL of *water R*, 2.0 mL of *dinitrobenzoic acid solution R* and 1.0 mL of 1 M *sodium hydroxide* as the compensation liquid.

Calculate the percentage content *m/m* of total cardenolic glycosides, expressed as *cymarín*, using the following expression:

$$\frac{A_1 \times m_2 \times p \times 0.25}{A_2 \times m_1}$$

- A_1 = maximum absorbance of the test solution;
 A_2 = maximum absorbance of the reference solution;
 m_1 = mass of the mother tincture to be examined used to prepare the test solution, in grams;
 m_2 = mass of *cymarín R* used to prepare the reference solution, in grams;
 p = percentage content of *cymarín* in *cymarín R*.



04/2020:2676

MAGNESIUM FLUORATUM FOR HOMOEOPATHIC PREPARATIONS⁽²⁾

Magnesium fluoratum ad praeparationes homoeopathicas

MgF₂
[7783-40-6]

M_r 62.3

DEFINITION

Content: 98.5 per cent to 100.5 per cent of MgF₂.

CHARACTERS

Appearance: white or almost white powder or crystals.

Solubility: practically insoluble in water, very slightly soluble in dilute nitric acid and in concentrated sulfuric acid, practically insoluble in anhydrous acetic acid.

IDENTIFICATION

- A. Mix 0.2 g with 2 g of *potassium hydrogen sulfate R* in a platinum crucible and melt at 800 °C. Cool, carefully take up the melt in 20 mL of *water R* and boil briefly. Cool and filter. Dilute 0.5 mL of the filtrate to 2 mL with *water R*. The solution gives the reaction of magnesium (2.3.1).
- B. Mix 0.2 g with 1 g of *anhydrous sodium carbonate R* in a platinum crucible and melt at 850 °C. Cool, take up the melt in 10 mL of *dilute acetic acid R* and boil briefly. Cool, filter and dilute the filtrate to 20 mL with *water R*. To 0.4 mL of this solution add dropwise a mixture of 0.1 mL of *alizarin S solution R* and 0.1 mL of *zirconyl nitrate solution R*. The colour changes from red to yellow.

TESTS

Solution S. Boil 5.0 g with 100.0 mL of *distilled water R* under a reflux condenser for about 5 min. Allow to cool, then filter through an ashless filter paper (nominal pore size not greater than 2 µm).

Appearance of solution. Solution S is colourless (2.2.2, *Method II*).

Carbonates. Suspend 0.5 g in 5 mL of *carbon dioxide-free water R* and add 5 mL of *dilute acetic acid R*. Quickly stopper the test tube with a stopper fitted with a glass tube bent twice through 90° and which dips at the other end in *barium hydroxide solution R*. Warm the mixture. The barium hydroxide solution remains clear.

Chlorides (2.4.4): maximum 100 ppm.

Dilute 10 mL of solution S to 15 mL with *water R*.

Sulfates (2.4.13): maximum 200 ppm, determined on solution S.

Water-soluble matter: maximum 0.5 per cent.

Boil 2.00 g with 100 mL of *water R* for 5 min. Filter the hot solution, then cool the filtrate and dilute to 100 mL with *water R*. Evaporate 50 mL of this solution to dryness in an evaporating dish and dry at 100-105 °C. The residue weighs a maximum of 5 mg.

ASSAY

Thoroughly mix 0.100 g with 2 g of *potassium hydrogen sulfate R* in a platinum crucible and melt at 800 °C. Allow to cool, carefully take up the melt in 10 mL of *dilute hydrochloric acid R* and heat to dissolve. Dilute the solution to 100.0 mL with *water R*. Transfer 50.0 mL of this solution to a 500 mL conical flask and dilute to 300 mL with *water R*. Carry out the complexometric titration of magnesium (2.5.11).

1 mL of 0.1 M *sodium edetate* is equivalent to 6.23 mg of MgF₂.

(2) FRENCH TITLE: Magnesia fluorata pour préparations homéopathiques

A

Almotriptan malate..	4373	Asparagine monohydrate.....	4376
Altizide.....	4374	Atazanavir sulfate..	4378
Amiloride hydrochloride dihydrate..	4375	Atenolol.....	4380




04/2020:2970 – stationary phase: end-capped octylsilyl silica gel for chromatography R (5 µm).

Mobile phase:

- mobile phase A: acetonitrile for chromatography R, buffer solution (10:90 V/V);
- mobile phase B: buffer solution, acetonitrile for chromatography R (30:70 V/V);

ALMOTRIPTAN MALATE

Almotriptani malas



$C_{21}H_{31}N_3O_7S$
[181183-52-8]

M_r 469.6

DEFINITION

N,N-Dimethyl-2-[5-[(pyrrolidine-1-sulfonyl)methyl]-1*H*-indol-3-yl]ethan-1-amine (RS)-2-hydroxybutanedioate.

Content: 98.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or slightly yellow, crystalline powder.

Solubility: soluble in water, slightly soluble in methanol, practically insoluble in anhydrous ethanol and in heptane.

IDENTIFICATION

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: almotriptan malate CRS.

B. Examine the chromatograms obtained in the assay.

Results: the principal peak in the chromatogram obtained with test solution (b) is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (b).

TESTS

Related substances. Liquid chromatography (2.2.29). Carry out the test protected from light.

Solvent mixture: acetonitrile R, water R (20:80 V/V).

Buffer solution. Dissolve 0.5 g of sodium octanesulfonate monohydrate R in about 900 mL of water for chromatography R. Add 5 mL of phosphoric acid R, adjust to pH 3.0 with sodium hydroxide solution R and dilute to 1000 mL with water for chromatography R.

Test solution (a). Dissolve 10.0 mg of the substance to be examined in the solvent mixture and dilute to 10.0 mL with the solvent mixture.

Test solution (b). Dissolve 25.0 mg of the substance to be examined in the solvent mixture and dilute to 50.0 mL with the solvent mixture. Dilute 5.0 mL of the solution to 50.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b). Dissolve 25.0 mg of almotriptan malate CRS in the solvent mixture and dilute to 50.0 mL with the solvent mixture. Dilute 5.0 mL of the solution to 50.0 mL with the solvent mixture.

Reference solution (c). Dissolve 5 mg of almotriptan for system suitability CRS (containing impurity A) in the solvent mixture and dilute to 5 mL with the solvent mixture.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	85	15
5 - 20	85 → 78	15 → 22
20 - 30	78 → 70	22 → 30
30 - 40	70	30

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 228 nm.

Injection: 5 µL of test solution (a) and reference solutions (a) and (c).

Identification of impurities: use the chromatogram supplied with almotriptan for system suitability CRS and the chromatogram obtained with reference solution (c) to identify the peak due to impurity A.

Relative retention with reference to almotriptan (retention time = about 27 min): malic acid = about 0.1; impurity A = about 0.96.

System suitability: reference solution (c):

- resolution: minimum 1.5 between the peaks due to impurity A and almotriptan.

Calculation of percentage contents:

- for each impurity, use the concentration of almotriptan malate in reference solution (a).

Limits:

- impurity A: maximum 0.5 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.7 per cent;
- reporting threshold: 0.05 per cent; disregard the peak due to malic acid.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.

Mobile phase: acetonitrile for chromatography R, buffer solution (27:73 V/V).

Injection: 10 µL of test solution (b) and reference solution (b).

Run time: twice the retention time of almotriptan.







Retention time: almotriptan = about 9 min.

Calculate the percentage content of $C_{21}H_{31}N_3O_7S$ taking into account the assigned content of almotriptan malate CRS.

IMPURITIES


Specified impurities: A.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, C, D, E, F.

07/2008:2185
corrected 10.1A. *N*-methyl-2-[5-[(pyrrolidine-1-sulfonyl)methyl]-1*H*-indol-3-yl]ethan-1-amine,B. 2-[2-[[3-[2-(dimethylamino)ethyl]-1*H*-indol-5-yl]methyl]-5-[(pyrrolidine-1-sulfonyl)methyl]-1*H*-indol-3-yl]-*N,N*-dimethylethan-1-amine,C. [3-[2-(dimethylamino)ethyl]-5-[(pyrrolidine-1-sulfonyl)methyl]-1*H*-indol-1-yl]methanol,D. 2-[5-[(pyrrolidine-1-sulfonyl)methyl]-1*H*-indol-3-yl]ethan-1-amine,E. *N,N*-dimethyl-2-[5-[(pyrrolidine-1-sulfonyl)methyl]-1*H*-indol-3-yl]ethan-1-amine *N*-oxide,F. *N*-methyl-*N*-[2-[5-[(pyrrolidine-1-sulfonyl)methyl]-1*H*-indol-3-yl]ethyl]propan-2-amine.

ALTIZIDE

Altizidum

C₁₁H₁₄ClN₃O₄S₃
[5588-16-9]*M*_r 383.9

DEFINITION

(3*RS*)-6-Chloro-3-[(prop-2-enylsulfanyl)methyl]-3,4-dihydro-2*H*-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.*Content*: 97.5 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white powder.*Solubility*: practically insoluble in water, soluble in methanol, practically insoluble in methylene chloride.

It shows polymorphism (5.9).

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: altizide CRS.

If the spectra obtained show differences, dissolve 50 mg of the substance to be examined and 50 mg of the reference substance separately in 2 mL of *acetone R* and evaporate the solvent. Precipitate by adding 1 mL of *methylene chloride R*. Evaporate to dryness and record new spectra using the residues.

TESTS

Impurity B. Thin-layer chromatography (2.2.27).*Test solution.* Dissolve 0.200 g of the substance to be examined in *acetone R* and dilute to 2.0 mL with the same solvent.*Reference solution (a).* Dissolve 10.0 mg of altizide impurity B CRS in *acetone R* and dilute to 25.0 mL with the same solvent.*Reference solution (b).* To 1.0 mL of reference solution (a) add 1.0 mL of the test solution.*Reference solution (c).* Dilute 5.0 mL of reference solution (a) to 10.0 mL with *acetone R*.*Plate*: TLC silica gel F₂₅₄ plate R.*Mobile phase*: *acetone R*, *methylene chloride R* (25:75 V/V).*Application*: 10 µL of the test solution and reference solutions (b) and (c).*Development*: over 2/3 of the plate.*Drying*: in air.

Detection: spray with a mixture of equal volumes of a 10 g/L solution of *potassium permanganate R* and a 50 g/L solution of *sodium carbonate R*, prepared immediately before use. Allow to stand for 30 min and examine in daylight.

System suitability: reference solution (b):

– the chromatogram shows 2 clearly separated spots.

Limit: any spot due to impurity B is not more intense than the principal spot in the chromatogram obtained with reference solution (c) (0.2 per cent).

Related substances. Liquid chromatography (2.2.29).

Prepare the solutions immediately before use, except reference solution (b).

Test solution. Dissolve 50 mg of the substance to be examined in 5 mL of *acetonitrile R* and dilute to 25 mL with the mobile phase.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (b). In order to produce impurity A *in situ*, dissolve 50 mg of the substance to be examined in 5 mL of *acetonitrile R* and dilute to 25 mL with *water R*. Allow to stand for 30 min.

Reference solution (c). Dissolve 4 mg of *furosemide CRS* in 2 mL of *acetonitrile R*, add 2 mL of the test solution and dilute to 100 mL with the mobile phase.

Column:

- size: $l = 0.15$ m, $\varnothing = 3.9$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography with embedded polar groups R (5 μ m);
- temperature: 30 °C.

Mobile phase: *acetonitrile R*, *water for chromatography R* previously adjusted to pH 2.0 with *perchloric acid R* (25:75 V/V).

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 270 nm.

Injection: 5 μ L.

Run time: twice the retention time of *altizide*.

Relative retention with reference to *altizide* (retention time = about 25 min): impurity A = about 0.15; *furosemide* = about 1.05.

System suitability: reference solution (c):

- resolution: minimum 1.0 between the peaks due to *altizide* and *furosemide*.

Limits:

- impurity A: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent);
- unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- total: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);
- disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Water (2.5.32): maximum 0.5 per cent, determined on 50.0 mg.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances, with the following modifications.


Test solution. Dissolve 25.0 mg of the substance to be examined in 2 mL of *acetonitrile R* and dilute to 25.0 mL with the mobile phase.

Reference solution. Dissolve 25.0 mg of *altizide CRS* in 2 mL of *acetonitrile R* and dilute to 25.0 mL with the mobile phase.


Calculate the percentage content of $C_{11}H_{14}ClN_3O_4S_3$ from the declared content of *altizide CRS*.

IMPURITIES

Specified impurities: A, B.



A. 4-amino-6-chlorobenzene-1,3-disulfonamide,




B. 3-[(2,2-dimethoxyethyl)sulfanyl]prop-1-ene.



04/2019:0651
corrected 10.1

AMILORIDE HYDROCHLORIDE DIHYDRATE

Amiloridi hydrochloridum dihydricum



$C_6H_9Cl_2N_7O_2 \cdot 2H_2O$
[17440-83-4]

M_r 302.1

DEFINITION

3,5-Diamino-6-chloro-*N*-(diaminomethylidene)pyrazine-2-carboxamide hydrochloride dihydrate.

Content: 98.0 per cent to 101.0 per cent (anhydrous substance).

CHARACTERS

Appearance: pale yellow or greenish-yellow powder.

Solubility: slightly soluble in water and in anhydrous ethanol, practically insoluble in heptane.

IDENTIFICATION

First identification: A, C, D.

Second identification: B, C, D.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: *amiloride hydrochloride CRS*.

B. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 5 mg of the substance to be examined in *methanol R* and dilute to 10 mL with the same solvent.

Reference solution. Dissolve 5 mg of *amiloride hydrochloride CRS* in *methanol R* and dilute to 10 mL with the same solvent.

Plate: TLC silica gel F_{254} plate R.

Mobile phase: concentrated ammonia R, *propanol R* (30:70 V/V).

Application: 5 μ L; the volume may be adapted according to the type of plate used.

Development: over 2/3 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with the reference solution.

C. Dissolve 25 mg of the substance to be examined in *water R* and dilute to 10 mL with the same solvent. 2 mL of the solution gives reaction (a) of chlorides (2.3.1); acidify with 0.5 mL of *dilute acetic acid R*, instead of *dilute nitric acid R*.

D. Water (see Tests).

TESTS

Free acid. Dissolve 1.0 g in a mixture of 50 mL of *methanol R* and 50 mL of *water R* and titrate with 0.1 M *sodium hydroxide*, determining the end-point potentiometrically (2.2.20). Not more than 0.3 mL of 0.1 M *sodium hydroxide* is required to reach the end-point.

Related substances. Liquid chromatography (2.2.29).

Solution A. Dissolve 2.76 g of *sodium dihydrogen phosphate monohydrate R* in 850 mL of *water for chromatography R*, adjust to pH 3.0 with *phosphoric acid R* and dilute to 1.0 L with *water for chromatography R*.

Test solution. Dissolve 20 mg of the substance to be examined in 1 mL of *methanol R1* and dilute to 10.0 mL with solution A.

Reference solution (a). Dissolve 2 mg of *amiloride impurity A CRS* in 0.5 mL of *methanol R1*, add 0.5 mL of the test solution and dilute to 10.0 mL with solution A.

Reference solution (b). Dissolve 4 mg of *amiloride for peak identification CRS* (containing impurity C) in 0.5 mL of *methanol R1* and dilute to 2.0 mL with solution A.

Reference solution (c). Dilute 1.0 mL of the test solution to 100.0 mL with solution A. Dilute 1.0 mL of this solution to 10.0 mL with solution A.

Column:

- size: $l = 0.125$ m, $\varnothing = 4.0$ mm;
- stationary phase: base-deactivated end-capped octylsilyl silica gel for chromatography R (5 μ m);
- temperature: 30 °C.

Mobile phase: dissolve 0.8 g of *sodium hexanesulfonate monohydrate R* in a mixture of 80 mL of *acetonitrile R1* and 920 mL of solution A.

Flow rate: 1.5 mL/min.

Detection: spectrophotometer at 210 nm.

Injection: 20 μ L.

Run time: twice the retention time of *amiloride*.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peak due to impurity A; use the chromatogram supplied with *amiloride for peak identification CRS* and the chromatogram obtained with reference solution (b) to identify the peak due to impurity C.

Relative retention with reference to *amiloride* (retention time = about 10 min): impurity C = about 0.5; impurity A = about 0.8.

System suitability: reference solution (a):

- resolution: minimum 3.0 between the peaks due to impurity A and *amiloride*.

Calculation of percentage contents:

- for each impurity, use the concentration of *amiloride hydrochloride dihydrate* in reference solution (c).

Limits:

- impurity C: maximum 0.2 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.4 per cent;
- reporting threshold: 0.05 per cent.

Water (2.5.12): 11.0 per cent to 13.0 per cent, determined on 0.200 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.200 g in a mixture of 5.0 mL of 0.01 M *hydrochloric acid* and 50 mL of *ethanol* (96 per cent) R. Carry out a potentiometric titration (2.2.20), using 0.1 M *sodium hydroxide*. Read the volume added between the 2 points of inflexion.

1 mL of 0.1 M *sodium hydroxide* is equivalent to 26.61 mg of $C_6H_9Cl_2N_7O$.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: C.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B.



A. methyl 3,5-diamino-6-chloropyrazine-2-carboxylate,



B. 3,5-diamino-6-chloropyrazine-2-carboxylic acid,




C. 3-amino-6-chloro-*N*-(diaminomethylidene)-5-hydroxypyrazine-2-carboxamide.

04/2020:2086



ASPARAGINE MONOHYDRATE

Asparaginum monohydricum



$C_4H_8N_2O_3 \cdot H_2O$
[5794-13-8]

M_r 150.1

DEFINITION

(2S)-2,4-Diamino-4-oxobutanoic acid monohydrate.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder or colourless crystals.

Solubility: slightly soluble in water, practically insoluble in ethanol (96 per cent) and in methylene chloride.

IDENTIFICATION

First identification: A, B, D.

Second identification: A, C, D.

A. Specific optical rotation (see Tests).

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: *asparagine monohydrate CRS*.

C. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 10 mg of the substance to be examined in *water R* and dilute to 10 mL with the same solvent.

Reference solution. Dissolve 10 mg of *asparagine monohydrate CRS* in *water R* and dilute to 10 mL with the same solvent.

Plate: TLC silica gel plate *R*.

Mobile phase: *glacial acetic acid R*, *water R*, *butanol R* (25:25:50 V/V/V).

Application: 5 µL.

Development: over 2/3 of the plate.

Drying: at 110 °C for 15 min.

Detection: spray with *ninhydrin solution R* and heat at 105 °C for 10 min.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

D. Loss on drying (see Tests).

TESTS

Solution S. Dissolve with heating 2.0 g in *carbon dioxide-free water R* and dilute to 100 mL with the same solvent.

Appearance of solution. Solution S is clear (2.2.1) and colourless (2.2.2, *Method II*).

pH (2.2.3): 4.0 to 6.0 for solution S.

Specific optical rotation (2.2.7): + 33.7 to + 36.0 (dried substance).

Dissolve 2.50 g in a 309.0 g/L solution of *hydrochloric acid R* and dilute to 25.0 mL with the same acid.

Related substances. Liquid chromatography (2.2.29). Prepare the solutions immediately before use.

Test solution. Dissolve 0.100 g of the substance to be examined in *water R* and dilute to 10.0 mL with the same solvent.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with *water R*.

Reference solution (b). Dilute 1.0 mL of reference solution (a) to 10.0 mL with *water R*.

Reference solution (c). Dissolve 5.0 mg of *aspartic acid R* (impurity A) in *water R* and dilute to 10.0 mL with the same solvent. Dilute 1.0 mL of the solution to 10.0 mL with *water R*.

Reference solution (d). Dissolve 3.0 mg of *asparagine impurity C CRS* in 40 mL of the mobile phase using sonication and dilute to 50.0 mL with the mobile phase. Dilute 1.0 mL of the solution to 10.0 mL with *water R*.

Reference solution (e). Mix 5 mL of reference solution (c) with 2.5 mL of reference solution (a) and dilute to 10 mL with *water R*.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography *R* (5 µm);
- temperature: 25 °C.

Mobile phase: dissolve 13.6 g of *potassium dihydrogen phosphate R* and 2.16 g of *sodium octanesulfonate R* in about 900 mL of *water for chromatography R*. Adjust to pH 2.2 with *phosphoric acid R* and dilute to 1000 mL with *water for chromatography R*. Add 5 mL of *acetonitrile R1*.

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 210 nm.

Injection: 20 µL.

Run time: twice the retention time of asparagine.

Identification of impurities: use the chromatogram obtained with reference solution (c) to identify the peak due to impurity A; use the chromatogram obtained with reference solution (d) to identify the peak due to impurity C.

Relative retention with reference to asparagine (retention time = about 6.6 min): impurity C = about 0.6; impurity A = about 1.2.

System suitability: reference solution (e):

- resolution: minimum 5.0 between the peaks due to asparagine and impurity A.

Calculation of percentage contents:

- for impurity A, use the concentration of impurity A in reference solution (c);
- for impurity C, use the concentration of impurity C in reference solution (d);
- for impurities other than A and C, use the concentration of asparagine monohydrate in reference solution (b).

Limits:

- impurity A: maximum 0.5 per cent;
- impurity C: maximum 0.1 per cent;
- unspecified impurities: for each impurity, maximum 0.05 per cent;
- total: maximum 0.8 per cent;
- reporting threshold: 0.03 per cent.

Chlorides (2.4.4): maximum 200 ppm.

Dilute 12.5 mL of solution S to 15 mL with *water R*.

Sulfates (2.4.13): maximum 200 ppm.

To 0.75 g add 2.5 mL of *dilute hydrochloric acid R* and dilute to 15 mL with *distilled water R*. Examine after 30 min.

Ammonium (2.4.1, *Method B*): maximum 0.1 per cent, determined on 10 mg.

Prepare the standard using 0.1 mL of *ammonium standard solution* (100 ppm NH_4) *R*.

Iron (2.4.9): maximum 10 ppm.

Dissolve 1.0 g in *dilute hydrochloric acid R* and dilute to 10 mL with the same acid. Shake 3 times with 10 mL of *methyl isobutyl ketone R1* for 3 min. Wash the combined organic phases with 10 mL of *water R* for 3 min. The aqueous phase complies with the limit test for iron.

Loss on drying (2.2.32): 10.5 per cent to 12.5 per cent, determined on 1.000 g by drying in an oven at 130 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY


Dissolve 0.110 g in 5 mL of *anhydrous formic acid R*. Add 50 mL of *anhydrous acetic acid R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 13.21 mg of $\text{C}_4\text{H}_8\text{N}_2\text{O}_3$.


IMPURITIES

Specified impurities: A, C.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, D, E, F, G, H.



A. (2S)-2-aminobutanedioic acid (aspartic acid),




B. (2S)-2-aminopentanedioic acid (glutamic acid),




C. 2,2'-[(2E,5E)-3,6-dioxopiperazine-2,5-diyl]diacetamide,




D. (2E)-but-2-enedioic acid (fumaric acid),




E. (2S)-2,5-diamino-5-oxopentanoic acid (glutamine),



F. (2S)-2-[[[(2S)-2,4-diamino-4-oxobutanoyl]amino]butane-1,3-dioic acid (asparaginylaspartic acid),



G. (2S)-4-amino-2-[[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-oxobutanoic acid (α-aspartylasparagine),




H. (2S)-4-amino-2-[[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-4-oxobutanoic acid (asparaginylasparagine).

04/2019:2898
corrected 10.1



ATAZANAVIR SULFATE

Atazanaviri sulfas



C₃₈H₅₄N₆O₁₁S
[229975-97-7]

M_r 803

DEFINITION

Methyl [(5S,10S,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[[4-(pyridin-2-yl)phenyl]methyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]carbamate sulfate.

Content: 98.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or pale yellow, slightly hygroscopic, crystalline powder that may contain agglomerates.

Solubility: slightly soluble in water, freely soluble in ethanol (96 per cent), practically insoluble in heptane.

IDENTIFICATION

A. Specific optical rotation (see Tests).

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: atazanavir sulfate CRS.

C. It gives reaction (a) of sulfates (2.3.1).

TESTS

Specific optical rotation (2.2.7): – 44 to – 40 (anhydrous substance), measured at 25 °C.

Dissolve 0.100 g in 8 mL of *methanol R*, using sonication if necessary, and dilute to 10.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Solvent mixture. Mix equal volumes of *acetonitrile R1* and a freshly prepared 2.73 g/L solution of *potassium dihydrogen phosphate R* in *water for chromatography R* previously adjusted to pH 3.5 with *dilute phosphoric acid R*.

Test solution (a). Dissolve 20.0 mg of the substance to be examined in 40 mL of the solvent mixture, sonicate for 3 min and dilute to 50.0 mL with the solvent mixture.

Test solution (b). Dissolve 50.0 mg of the substance to be examined in 40 mL of the solvent mixture, sonicate for 3 min and dilute to 50.0 mL with the solvent mixture.

Reference solution (a). Dissolve 20.0 mg of *atazanavir sulfate CRS* in 40 mL of the solvent mixture, sonicate for 3 min and dilute to 50.0 mL with the solvent mixture.

Reference solution (b). Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (c). Dissolve 4 mg of *atazanavir for system suitability CRS* (containing impurity F) in 8 mL of the solvent mixture, sonicate for 3 min and dilute to 10 mL with the solvent mixture.

Reference solution (d). Dissolve 2.0 mg of *atazanavir impurity K CRS* in 9 mL of the solvent mixture, sonicate for 3 min and dilute to 10.0 mL with the solvent mixture. Dilute 5.0 mL of the solution to 100.0 mL with the solvent mixture. Dilute 3.0 mL of this solution to 20.0 mL with the solvent mixture.

Column:

- size: *l* = 0.15 m, Ø = 4.6 mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (3.0 µm);
- temperature: 25 °C.

Mobile phase:

- mobile phase A: mix 25 volumes of *acetonitrile R1* and 75 volumes of a freshly prepared 2.73 g/L solution of *potassium dihydrogen phosphate R* previously adjusted to pH 3.5 with *dilute phosphoric acid R*;
- mobile phase B: mix 25 volumes of a freshly prepared 2.73 g/L solution of *potassium dihydrogen phosphate R* previously adjusted to pH 3.5 with *dilute phosphoric acid R*, and 75 volumes of *acetonitrile R1*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	100	0
5 - 45	100 → 0	0 → 100

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 215 nm.

Injection: 10 µL of test solution (a) and reference solutions (b) and (c).

Identification of impurities: use the chromatogram supplied with *atazanavir for system suitability CRS* and the chromatogram obtained with reference solution (c) to identify the peak due to impurity F.

Relative retention with reference to atazanavir (retention time = about 30 min): impurity F = about 0.99.

System suitability: reference solution (c):

- **resolution:** minimum 1.5 between the peaks due to impurity F and atazanavir.

Calculation of percentage contents:

- for each impurity, use the concentration of atazanavir sulfate in reference solution (b).

Limits:

- **unspecified impurities:** for each impurity, maximum 0.10 per cent;
- **total:** maximum 0.5 per cent;
- **reporting threshold:** 0.05 per cent; disregard any peak with a relative retention with reference to atazanavir of less than 0.2.

Impurity K. Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.

Mobile phase:

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	95	5
5 - 8	95 → 0	5 → 100
8 - 14	0	100

Injection: 20 µL of test solution (b) and reference solution (d).

Identification of impurities: use the chromatogram obtained with reference solution (d) to identify the peak due to impurity K.

Relative retention with reference to atazanavir (retention time = about 10 min): impurity K = about 0.4.

Calculation of percentage content:

- for impurity K, use the concentration of impurity K in reference solution (d).

Limit:

- **impurity K:** maximum 0.15 per cent.

Water (2.5.32): maximum 2.5 per cent, determined on 0.100 g by direct sample introduction.

Sulfated ash (2.4.14): maximum 0.2 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.

Mobile phase: solvent mixture.

Injection: test solution (a) and reference solutions (a) and (c).

Run time: 1.6 times the retention time of atazanavir.

Relative retention with reference to atazanavir (retention time = about 9.5 min): impurity F = about 0.94.

System suitability: reference solution (c):

- **resolution:** minimum 1.5 between the peaks due to impurity F and atazanavir.

Calculate the percentage content of $C_{38}H_{54}N_6O_{11}S$ using the chromatogram obtained with reference solution (a) and taking into account the assigned content of *atazanavir sulfate CRS*.


STORAGE

In an airtight container.


IMPURITIES

Specified impurities: K.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. **Control of impurities in substances for pharmaceutical use**): A, B, C, D, E, F, G, H, I, J.




A. 4-(pyridin-2-yl)benzoic acid,




B. 4-(pyridin-2-yl)benzaldehyde,




C. methyl [(5S,10S,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]carbamate,




D. (2S,3S)-3-amino-4-phenyl-1-[(E)-1-[[4-(pyridin-2-yl)phenyl]methyl]-2-[[4-(pyridin-2-yl)phenyl]methylen]hydrazin-1-yl]butan-2-ol,




E. methyl [(5S,10R,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[[4-(pyridin-2-yl)phenyl]methyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]carbamate,




F. methyl [(5*R*,10*S*,11*S*,14*S*)-11-benzyl-5-*tert*-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[[4-(pyridin-2-yl)phenyl]methyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]carbamate,




J. *tert*-butyl 2-[(2*S*,3*S*)-3-(*tert*-butoxyformamido)-2-hydroxy-4-phenylbutyl]-2-[[4-(pyridin-2-yl)phenyl]methyl]hydrazine-1-carboxylate,




K. (2*S*)-2-(methoxyformamido)-3,3-dimethylbutanoic acid.



G. methyl [(5*S*,10*S*,11*S*,14*R*)-11-benzyl-5-*tert*-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[[4-(pyridin-2-yl)phenyl]methyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]carbamate,



H. methyl [(5*S*,10*R*,11*R*,14*S*)-11-benzyl-5-*tert*-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[[4-(pyridin-2-yl)phenyl]methyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]carbamate,




I. methyl [(2*S*)-1-[[[(2*S*,3*S*)-3-hydroxy-1-phenyl-4-[(*E*)-1-[[4-(pyridin-2-yl)phenyl]methyl]-2-[[4-(pyridin-2-yl)phenyl]methylidene]hydrazin-1-yl]butan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]carbamate,

04/2020:0703



ATENOLOL

Atenololum



$C_{14}H_{22}N_2O_3$
[29122-68-7]

M_r 266.3

DEFINITION

2-[4-[(2*R,S*)-2-Hydroxy-3-[(propan-2-yl)amino]propoxy]-phenyl]acetamide.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white powder.

Solubility: sparingly soluble in water, soluble in anhydrous ethanol, slightly soluble in methylene chloride.

IDENTIFICATION

First identification: B.

Second identification: A, C.

A. Melting point (2.2.14): 152 °C to 155 °C.

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: atenolol CRS.

C. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 10 mg of the substance to be examined in 1.0 mL of methanol R.

Reference solution. Dissolve 10 mg of atenolol CRS in 1.0 mL of methanol R.

Plate: TLC silanised silica gel F_{254} plate R.

Mobile phase: concentrated ammonia R1, methanol R (1:99 V/V).

Application: 10 µL.

Development: over 3/4 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with the reference solution.

TESTS

Solution S. Dissolve 0.10 g in *water R* and dilute to 10.0 mL with the same solvent.

Appearance of solution. Solution S is clear (2.2.1) and not more intensely coloured than intensity 6 of the range of reference solutions of the most appropriate colour (2.2.2, *Method II*).

Optical rotation (2.2.7): -0.10° to $+0.10^\circ$, determined on solution S.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 50 mg of the substance to be examined in 20 mL of the mobile phase and dilute to 25.0 mL with the mobile phase.

Reference solution (a). Dissolve 2 mg of *atenolol for system suitability CRS* (containing impurities B, F, G, I and J) in 1 mL of the mobile phase.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Column:

- size: $l = 0.125$ m, $\varnothing = 4.0$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase: dissolve 1.0 g of *sodium octanesulfonate R* and 0.4 g of *tetrabutylammonium hydrogen sulfate R* in 1000 mL of a mixture of 20 volumes of *tetrahydrofuran R*, 180 volumes of *methanol R2* and 800 volumes of a 3.4 g/L solution of *potassium dihydrogen phosphate R*; adjust the apparent pH to 3.0 with *phosphoric acid R*.

Flow rate: 0.6 mL/min.

Detection: spectrophotometer at 226 nm.

Injection: 10 μ L.

Run time: 5 times the retention time of *atenolol*.

Identification of impurities: use the chromatogram supplied with *atenolol for system suitability CRS* and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities B, F, G, I and J.

Relative retention with reference to *atenolol* (retention time = about 8 min): impurity B = about 0.3; impurity J = about 0.7; impurity I = about 0.8; impurity F = about 2.0 (pair of peaks); impurity G = about 3.5.

System suitability: reference solution (a):

- resolution: minimum 1.4 between the peaks due to impurities J and I.

Limits:

- impurity B: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent);
- impurities F, G, I, J: for each impurity, not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.15 per cent);
- unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);
- total: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);
- disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

Chlorides (2.4.4): maximum 0.1 per cent.

Dissolve 50 mg in a mixture of 1 mL of *dilute nitric acid R* and 15 mL of *water R*. The solution, without further addition of *dilute nitric acid R*, complies with the test.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 $^\circ$ C.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY


Dissolve 0.200 g in 80 mL of *anhydrous acetic acid R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 26.63 mg of $C_{14}H_{22}N_2O_3$.


IMPURITIES

Specified impurities: B, F, G, I, J.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, D, E, H.




A. 2-(4-hydroxyphenyl)acetamide,




B. 2-[4-[(2RS)-2,3-dihydroxypropoxy]phenyl]acetamide,




D. 2-[4-[(2RS)-3-chloro-2-hydroxypropoxy]phenyl]acetamide,




E. 2,2'-[(2-hydroxypropane-1,3-diyl)bis(oxy-4,1-phenylene)]diacetamide,




F. 2,2'-[[[(propan-2-yl)azanediyl]bis[(2-hydroxypropane-3,1-diyl)oxy-4,1-phenylene]]diacetamide,




G. 4-[(2RS)-2-hydroxy-3-[(propan-2-yl)amino]propoxy]phenylacetic acid,



H. [4-[(2*RS*)-2-hydroxy-3-[(propan-2-yl)amino]propoxy]phenyl]acetonitrile,



I. 2-[4-[(2*RS*)-3-(ethylamino)-2-hydroxypropoxy]phenyl]acetamide,



J. 2-[4-[(2*RS*)-3-amino-2-hydroxypropoxy]phenyl]acetamide.

B

Benzocaine..... 4385




04/2020:0011 – temperature: 35 °C.

Mobile phase:

- mobile phase A: dilute 1 mL of perchloric acid R to 100 mL with water for chromatography R; dilute 1 mL of this solution to 100 mL with water for chromatography R; mix 9 volumes of this solution and 1 volume of acetonitrile R1;
- mobile phase B: acetonitrile R1;

BENZOCAINE

Benzocainum



$C_9H_{11}NO_2$
[94-09-7]

 M_r 165.2

DEFINITION

Ethyl 4-aminobenzoate.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder or colourless crystals.

Solubility: very slightly soluble in water, freely soluble in ethanol (96 per cent).

It shows polymorphism (5.9).

IDENTIFICATION

First identification: A.

Second identification: B.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: benzocaine CRS.

If the spectra obtained show differences, dissolve the substance to be examined and the reference substance separately in anhydrous ethanol R, evaporate to dryness and record new spectra using the residues.

B. Melting point (2.2.14).

Determination A: determine the melting point of the substance to be examined.

Result A: 89 °C to 92 °C.

Determination B: mix equal parts of the substance to be examined and benzocaine CRS and determine the melting point of the mixture.

Result B: the absolute difference between the melting point of the mixture and the value obtained in determination A is not greater than 2 °C.

TESTS

Related substances. Liquid chromatography (2.2.29).

Solvent mixture: acetonitrile R1, water for chromatography R (50:50 V/V).

Test solution. Dissolve 25.0 mg of the substance to be examined in 5 mL of acetonitrile R and dilute to 50.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b). Dissolve 5 mg of the substance to be examined and 5 mg of 4-nitrobenzoic acid R (impurity E) in 10 mL of the solvent mixture. Dilute 1 mL of the solution to 50 mL with the solvent mixture.

Column:

- size: $l = 0.10$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography compatible with 100 per cent aqueous mobile phases R (3 μ m);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 2	100	0
2 - 15	100 → 38.5	0 → 61.5

Flow rate: 1.5 mL/min.

Detection: spectrophotometer at 215 nm.

Injection: 10 μ L.

Identification of impurities: use the chromatogram obtained with reference solution (b) to identify the peak due to impurity E.

Relative retention with reference to benzocaine (retention time = about 10 min): impurity E = about 0.9.

System suitability: reference solution (b):

- resolution: minimum 5.0 between the peaks due to impurity E and benzocaine.

Calculation of percentage contents:

- for each impurity, use the concentration of benzocaine in reference solution (a).

Limits:

- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.2 per cent;
- reporting threshold: 0.05 per cent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in vacuo.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Carry out the determination of primary aromatic amino-nitrogen (2.5.8), using 0.400 g dissolved in a mixture of 25 mL of hydrochloric acid R and 50 mL of water R.


1 mL of 0.1 M sodium nitrite is equivalent to 16.52 mg of $C_9H_{11}NO_2$.

STORAGE


Protected from light.

IMPURITIES


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use): A, B, C, D, E, F, G, H.




A. (4-aminophenyl)methanol,




B. (2-aminophenyl)methanol,




C. ethyl 3-aminobenzoate,




D. ethyl 2-aminobenzoate,




E. 4-nitrobenzoic acid,



F. (3-aminophenyl)methanol,



G. 4-aminobenzoic acid,



H. methyl 4-aminobenzoate.

C

Castor oil, hydrogenated.....	4389	Clobetasol propionate.. ..	4392
Chlortetracycline hydrochloride.....	4390		



04/2020:1497 Temperature:

CASTOR OIL, HYDROGENATED

Ricini oleum hydrogenatum

DEFINITION

Fatty oil obtained by hydrogenation of *Virgin castor oil* (0051) or *Refined castor oil* (2367) or a mixture of both. It consists mainly of the triglyceride of 12-hydroxystearic ((12*E*)-12-hydroxyoctadecanoic) acid.

CHARACTERS

Appearance: fine, almost white or pale yellow powder or almost white or pale yellow masses or flakes.

Solubility: practically insoluble in water, slightly soluble in methylene chloride, very slightly soluble in anhydrous ethanol, practically insoluble in light petroleum.

IDENTIFICATION

A. Melting point (2.2.14): 83 °C to 88 °C.

B. Hydroxyl value (see Tests).

C. Composition of fatty acids (see Tests).

TESTS

Acid value (2.5.1): maximum 4.0, determined on 10.0 g dissolved in 75 mL of hot *ethanol* (96 per cent) R.

Hydroxyl value (2.5.3, *Method A*): 145 to 165, determined on a warm solution.

Iodine value (2.5.4, *Method A*): maximum 5.0.

Alkaline impurities. Dissolve 1.0 g with gentle heating in a mixture of 1.5 mL of *ethanol* (96 per cent) R and 3 mL of *toluene* R. Add 0.05 mL of a 0.4 g/L solution of *bromophenol blue* R in *ethanol* (96 per cent) R. Not more than 0.2 mL of 0.01 M *hydrochloric acid* is required to change the colour of the indicator to yellow.

Composition of fatty acids. Gas chromatography (2.4.22, *Method A*) with the following modifications. Use the mixture of calibrating substances in Table 2.4.22.-3.

Test solution. Introduce 75 mg of the substance to be examined into a 10 mL centrifuge tube with a screw cap. Dissolve in 2 mL of 1,1-dimethylethyl methyl ether R1 by shaking and heat gently (50-60 °C). Add, when still warm, 1 mL of a 12 g/L solution of *sodium R* in *anhydrous methanol R*, prepared with the necessary precautions, and mix vigorously for at least 5 min. Add 5 mL of *distilled water R* and mix vigorously for about 30 s. Centrifuge for 15 min at 1500 g. Use the upper layer.

Reference solution. Dissolve 50 mg of *methyl 12-hydroxystearate CRS* and 50 mg of *methyl stearate CRS* in 10.0 mL of 1,1-dimethylethyl methyl ether R1.

Column:

- **material:** fused silica;
- **size:** $l = 30$ m; $\varnothing = 0.25$ mm;
- **stationary phase:** *macrogol 20 000 R* (film thickness 0.25 μ m).

Carrier gas: *helium for chromatography R*.

Flow rate: 0.9 mL/min.

Split ratio: 1:100.

	Time (min)	Temperature (°C)
Column	0 - 55	215
Injection port		250
Detector		250

Detection: flame ionisation.

Injection: 1 μ L.

System suitability:

- **symmetry factor:** 0.7 to 1.5 for the peak due to methyl stearate in the chromatogram obtained with the test solution.

Calculate the fraction of each fatty acid using the following expression:

$$A_{x,s,c} / \sum A_{x,s,c} \times 100 \text{ per cent } m / m$$

$A_{x,s,c}$ = corrected peak area of the fatty acid in the test solution:

$$A_{x,s,c} = A_{x,s} \times R_c$$

$A_{x,s}$ = area of the peaks due to any specified or unspecified fatty acid methyl esters;

R_c = relative correction factor for the peak due to methyl 12-hydroxystearate:

$$R_c = \frac{m_{1,r} \times A_{2,r}}{A_{1,r} \times m_{2,r}}$$

R_c = 1 for peaks corresponding to each of the other specified fatty acids or any unspecified fatty acid;

$m_{1,r}$ = mass of methyl 12-hydroxystearate in the reference solution;

$m_{2,r}$ = mass of methyl stearate in the reference solution;

$A_{1,r}$ = area of the peak due to methyl 12-hydroxystearate in the chromatogram obtained with the reference solution;

$A_{2,r}$ = area of the peak due to methyl stearate in the chromatogram obtained with the reference solution.

Composition of the fatty-acid fraction of the oil:

- **palmitic acid:** maximum 2.0 per cent;
- **stearic acid:** 7.0 per cent to 14.0 per cent;
- **arachidic acid:** maximum 1.0 per cent;
- **12-oxostearic acid:** maximum 5.0 per cent;
- **12-hydroxystearic acid:** 78.0 per cent to 91.0 per cent;
- **any other fatty acid:** for each fatty acid, maximum 3.0 per cent.

STORAGE

In a well-filled container.

IMPURITIES




A. 12-oxooctadecanoic acid (12-oxostearic acid).



01/2017:0173
corrected 10.1

CHLORTETRACYCLINE HYDROCHLORIDE

Chlortetracyclini hydrochloridum



Compound	R	Molecular formula	M_r
Chlortetracycline hydrochloride	Cl	$C_{22}H_{24}Cl_2N_2O_8$	515.3
Tetracycline hydrochloride	H	$C_{22}H_{25}ClN_2O_8$	480.9

Chlortetracycline hydrochloride: [64-72-2]

Tetracycline hydrochloride: [64-75-5]

DEFINITION

Mixture of antibiotics, the main component being the hydrochloride of (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide (chlortetracycline hydrochloride), a substance produced by the growth of certain strains of *Streptomyces aureofaciens* or obtained by any other means.

Content:

- chlortetracycline hydrochloride ($C_{22}H_{24}Cl_2N_2O_8$): minimum 89.5 per cent (anhydrous substance);
- tetracycline hydrochloride ($C_{22}H_{25}ClN_2O_8$): maximum 6.0 per cent (anhydrous substance);
- sum of the contents of chlortetracycline hydrochloride and tetracycline hydrochloride: 94.5 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: yellow powder.

Solubility: slightly soluble in water and in ethanol (96 per cent). It dissolves in solutions of alkali hydroxides and carbonates.

IDENTIFICATION

First identification: C, D.

Second identification: A, B, C.

A. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 5 mg of the substance to be examined in *methanol R* and dilute to 10 mL with the same solvent.

Reference solution (a). Dissolve 5 mg of chlortetracycline hydrochloride CRS in *methanol R* and dilute to 10 mL with the same solvent.

Reference solution (b). Dissolve 5 mg of chlortetracycline hydrochloride CRS, 5 mg of demeclocycline hydrochloride R and 5 mg of doxycycline R in *methanol R* and dilute to 10 mL with the same solvent.

Plate: TLC octadecylsilyl silica gel F_{254} plate R.

Mobile phase: mix 20 volumes of acetonitrile R, 20 volumes of *methanol R* and 60 volumes of a 63 g/L solution of oxalic acid R previously adjusted to pH 2 with concentrated ammonia R.

Application: 1 μ L.

Development: over 3/4 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

System suitability: the chromatogram obtained with reference solution (b) shows 3 clearly separated spots.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).

B. To about 2 mg add 5 mL of *sulfuric acid R*. A deep blue colour develops and becomes bluish-green. Add the solution to 2.5 mL of *water R*. The colour becomes brownish.

C. It gives reaction (a) of chlorides (2.3.1).

D. Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution and reference solution (a).

Results: the principal peak in the chromatogram obtained with the test solution is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (a).

TESTS

pH (2.2.3): 2.3 to 3.3.

Dissolve 0.1 g in 10 mL of *carbon dioxide-free water R*, heating slightly.

Specific optical rotation (2.2.7): – 250 to – 235 (anhydrous substance).

Dissolve 0.125 g in *water R* and dilute to 50.0 mL with the same solvent.

Absorbance (2.2.25): maximum 0.40 at 460 nm.

Dissolve 0.125 g in *water R* and dilute to 25.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29). Prepare the solutions immediately before use.

Test solution. Dissolve 25.0 mg of the substance to be examined in mobile phase B and dilute to 25.0 mL with mobile phase B.

Reference solution (a). Dissolve 25.0 mg of chlortetracycline hydrochloride CRS in mobile phase B and dilute to 25.0 mL with mobile phase B.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with mobile phase B.

Reference solution (c). Dilute 1.0 mL of reference solution (b) to 10.0 mL with mobile phase B.

Reference solution (d). Dissolve 5 mg of chlortetracycline for system suitability CRS (containing impurities A, B, D, E, G, H, J, K and L) in mobile phase B and dilute to 5 mL with mobile phase B.

Reference solution (e). Dissolve 25.0 mg of tetracycline hydrochloride CRS in mobile phase B and dilute to 25.0 mL with mobile phase B. Dilute 5.0 mL of this solution to 100.0 mL with mobile phase B.

Column:

- size: $l = 0.075$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octylsilyl silica gel for chromatography with embedded polar groups R (3.5 μ m);
- temperature: 45 °C.

Mobile phase:

- mobile phase A: to 725 mL of *water R* for chromatography R add 50 mL of *perchloric acid solution R*, shake and add 225 mL of *dimethyl sulfoxide R*;
- mobile phase B: to 250 mL of *water R* for chromatography R add 50 mL of *perchloric acid solution R*, shake and add 700 mL of *dimethyl sulfoxide R*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 46	100 → 0	0 → 100

Flow rate: 0.4 mL/min.

Detection: spectrophotometer at 280 nm.

Injection: 20 µL of the test solution and reference solutions (b), (c) and (d).

Identification of impurities: use the chromatogram supplied with chlortetracycline for system suitability CRS and the chromatogram obtained with reference solution (d) to identify the peaks due to impurities A, B, D, E, G, H, J, K and L.

Relative retention with reference to chlortetracycline (retention time = about 26 min): impurity D = about 0.5; tetracycline = about 0.6; impurity E = about 0.7; impurity B = about 0.8; impurity A = about 0.86; impurity G = about 0.9; impurity H = about 1.1; impurity J = about 1.4; impurity K = about 1.67; impurity L = about 1.71.

System suitability: reference solution (d):

- resolution: minimum 1.5 between the peaks due to tetracycline and impurity E; minimum 1.5 between the peaks due to impurities A and G; minimum 1.5 between the peaks due to impurities K and L; if necessary, adjust the concentration of dimethyl sulfoxide in mobile phase A.

Limits:

- correction factors: for the calculation of content, multiply the peak areas of the following impurities by the corresponding correction factor: impurity G = 1.4; impurity J = 0.3; impurity K = 0.4; impurity L = 0.4;
- impurity A: not more than 4 times the area of the principal peak in the chromatogram obtained with reference solution (b) (4.0 per cent);
- impurities B, E: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent);
- impurity J: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.3 per cent);
- impurities D, G, H, L: for each impurity, not more than twice the area of the principal peak in the chromatogram obtained with reference solution (c) (0.2 per cent);
- impurity K: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.15 per cent);
- unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.10 per cent);
- sum of impurities other than A: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (2.0 per cent);
- disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.05 per cent).

Water (2.5.12): maximum 2.0 per cent, determined on 0.300 g.

Sulfated ash (2.4.14): maximum 0.5 per cent, determined on 1.0 g.

Bacterial endotoxins (2.6.14): less than 1 IU/mg, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: 10 µL of the test solution and reference solutions (a) and (e).

Calculate the percentage content of $C_{22}H_{24}Cl_2N_2O_8$ using the chromatogram obtained with reference solution (a) and taking into account the assigned content of chlortetracycline hydrochloride CRS. Calculate the percentage content of $C_{22}H_{25}ClN_2O_8$ using the chromatogram obtained with reference solution (e) and taking into account the assigned content of tetracycline hydrochloride CRS.


STORAGE

Protected from light. If the substance is sterile, store in a sterile, airtight, tamper-evident container.


IMPURITIES

Specified impurities: A, B, D, E, G, H, J, K, L.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): C, F, I.




A. (4R,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide (4-epichlortetracycline),




B. (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide (demeclocycline),




C. (4R,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide (4-epidemethyltetracycline),




D. (4R,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide (4-epitetracycline),




- E. (4*R*,4*aS*,5*aS*,6*S*,12*aS*)-7-chloro-4-(dimethylamino)-3,6,10,12,12*a*-pentahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotetracene-2-carboxamide (4-epidemethylchlortetracycline),




- F. (4*R*,4*aS*,6*S*,8*aS*)-6-[(1*R*)-7-chloro-4-hydroxy-1-methyl-3-oxo-1,3-dihydro-2-benzofuran-1-yl]-4-(dimethylamino)-3,8*a*-dihydroxy-1,8-dioxo-1,4,4*a*,5,6,7,8,8*a*-octahydronaphthalene-2-carboxamide (4-epiisochlortetracycline),




- G. (4*S*,4*aS*,6*S*,8*aS*)-6-[(1*R*)-7-chloro-4-hydroxy-1-methyl-3-oxo-1,3-dihydro-2-benzofuran-1-yl]-4-(dimethylamino)-3,8*a*-dihydroxy-1,8-dioxo-1,4,4*a*,5,6,7,8,8*a*-octahydronaphthalene-2-carboxamide (isochlortetracycline),




- H. (4*S*,4*aS*,5*aS*,6*S*,12*aS*)-2-acetyl-7-chloro-4-(dimethylamino)-3,6,10,12,12*a*-pentahydroxy-6-methyl-4*a*,5*a*,6,12*a*-tetrahydrotetracene-1,11(4*H*,5*H*)-dione (2-acetyl-2-decarboxamidochlortetracycline),




- I. (4*R*,4*aS*,12*aS*)-4-(dimethylamino)-3,10,12,12*a*-tetrahydroxy-6-methyl-1,11-dioxo-1,4,4*a*,5,11,12*a*-hexahydrotetracene-2-carboxamide (4-epianhydrotetracycline),



- J. (4*S*,4*aS*,12*aS*)-4-(dimethylamino)-3,10,12,12*a*-tetrahydroxy-6-methyl-1,11-dioxo-1,4,4*a*,5,11,12*a*-hexahydrotetracene-2-carboxamide (anhydrotetracycline),



- K. (4*R*,4*aS*,12*aS*)-7-chloro-4-(dimethylamino)-3,10,12,12*a*-tetrahydroxy-6-methyl-1,11-dioxo-1,4,4*a*,5,11,12*a*-hexahydrotetracene-2-carboxamide (4-epianhydrochlortetracycline),




- L. (4*S*,4*aS*,12*aS*)-7-chloro-4-(dimethylamino)-3,10,12,12*a*-tetrahydroxy-6-methyl-1,11-dioxo-1,4,4*a*,5,11,12*a*-hexahydrotetracene-2-carboxamide (anhydrochlortetracycline).

04/2020:2127



CLOBETASOL PROPIONATE

Clobetasoli propionas



$C_{25}H_{32}ClFO_5$
[25122-46-7]

M_r 467.0

DEFINITION

21-Chloro-9-fluoro-11 β -hydroxy-16 β -methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate.

Content: 97.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: practically insoluble in water, freely soluble in acetone, sparingly soluble in ethanol (96 per cent).

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: clobetasol propionate CRS.

TESTS

Specific optical rotation (2.2.7): + 112 to + 118 (dried substance).

Dissolve 0.250 g in *acetone R* and dilute to 25.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Test solution (a). Dissolve 20.0 mg of the substance to be examined in the mobile phase and dilute to 20.0 mL with the mobile phase.

Test solution (b). Dissolve 20.0 mg of the substance to be examined in the mobile phase and dilute to 100.0 mL with the mobile phase.

Reference solution (a). Dissolve 20.0 mg of clobetasol propionate CRS in the mobile phase and dilute to 100.0 mL with the mobile phase.

Reference solution (b). Dissolve the contents of a vial of clobetasol impurity J CRS in 2 mL of the mobile phase. To 0.5 mL of the solution add 0.5 mL of test solution (b) and dilute to 20 mL with the mobile phase.

Reference solution (c). Dissolve the contents of a vial of clobetasol propionate for peak identification CRS (containing impurities A, B, D and E) in 2 mL of the mobile phase.

Reference solution (d). Dilute 1.0 mL of test solution (a) to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Column:

- size: $l = 0.15$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m);
- temperature: 30 °C.

Mobile phase: mix 10 volumes of methanol R1, 42.5 volumes of a 7.85 g/L solution of sodium dihydrogen phosphate monohydrate R adjusted to pH 5.5 with a 100 g/L solution of sodium hydroxide R and 47.5 volumes of acetonitrile for chromatography R.

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 240 nm.

Injection: 10 μ L of test solution (a) and reference solutions (b), (c) and (d).

Run time: 3 times the retention time of clobetasol propionate.

Identification of impurities: use the chromatogram obtained with reference solution (b) to identify the peak due to impurity J; use the chromatogram supplied with clobetasol propionate for peak identification CRS and the chromatogram obtained with reference solution (c) to identify the peaks due to impurities A, B, D and E.

Relative retention with reference to clobetasol propionate (retention time = about 11 min): impurity A = about 0.4; impurity B = about 0.6; impurity J = about 1.1; impurity D = about 1.2; impurity E = about 2.1.

System suitability: reference solution (b):

- resolution: minimum 2.0 between the peaks due to clobetasol propionate and impurity J.

Calculation of percentage contents:

- correction factor: multiply the peak area of impurity B by 0.6;
- for each impurity, use the concentration of clobetasol propionate in reference solution (d).

Limits:

- impurities B, E: for each impurity, maximum 0.3 per cent;
- impurities A, D: for each impurity, maximum 0.2 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 1.0 per cent;
- reporting threshold: 0.05 per cent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution (b) and reference solution (a).

Calculate the percentage content of $C_{25}H_{32}ClFO_5$ taking into account the assigned content of clobetasol propionate CRS.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: A, B, D, E.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): C, F, G, H, I, J, K.




A. 9-fluoro-11 β ,21-dihydroxy-16 β -methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate (betamethasone 17-propionate),




B. 21-chloro-9-fluoro-11 β -hydroxy-16-methylpregna-1,4,16-triene-3,20-dione,




C. 21-chloro-9-fluoro-11 β -hydroxy-16 α -methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate,




D. 21-chloro-9-fluoro-11 β -hydroxy-16 β -methyl-3,20-dioxopregn-4-en-17-yl propanoate (1,2-dihydroclobetasol 17-propionate),




E. 21-chloro-16 β -methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate,




F. 9-fluoro-11 β -hydroxy-16 β -methyl-3-oxopregna-1,4,17(20)-trien-21-oic acid,




G. 21-chloro-9-fluoro-11 β ,17-dihydroxy-16 β -methylpregna-1,4-diene-3,20-dione (clobetasol),




H. 9-fluoro-11 β -hydroxy-16 β -methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate,



I. 9-fluoro-11 β -hydroxy-16 β -methyl-21-[(methanesulfonyl)oxy]-3,20-dioxopregna-1,4-dien-17-yl propanoate,



J. (17R)-4'-chloro-5'-ethyl-9-fluoro-11 β -hydroxy-16 β -methylspiro[androsta-1,4-diene-17,2'-furan]-3,3'-dione (17 α -spiro compound),



K. 9-fluoro-11 β ,17-dihydroxy-16 β -methyl-3,20-dioxopregna-1,4-dien-21-yl propanoate (betamethasone 21-propionate).

D


Demeclocycline hydrochloride.. ..	4397	Donepezil hydrochloride.. ..	4400
Dimethyl sulfoxide.. ..	4398	Donepezil hydrochloride monohydrate.....	4401
Diprophylline.. ..	4399		



01/2017:0176 TESTS
corrected 10.1

DEMECLOCYCLINE HYDROCHLORIDE

Demeclocyclini hydrochloridum



$C_{21}H_{22}Cl_2N_2O_8$
[64-73-3]

M_r 501.3

DEFINITION

(4S,4aS,5aS,6S,12aS)-7-Chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride.

Substance produced by certain strains of *Streptomyces aureofaciens*.

Content: 89.5 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: yellow powder.

Solubility: soluble or sparingly soluble in water, slightly soluble in alcohol, very slightly soluble in acetone. It dissolves in solutions of alkali hydroxides and carbonates.

IDENTIFICATION

A. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 5 mg of the substance to be examined in *methanol* R and dilute to 10 mL with the same solvent.

Reference solution (a). Dissolve 5 mg of demeclocycline hydrochloride CRS in *methanol* R and dilute to 10 mL with the same solvent.

Reference solution (b). Dissolve 5 mg of demeclocycline hydrochloride CRS, 5 mg of chlortetracycline hydrochloride R and 5 mg of tetracycline hydrochloride R in *methanol* R and dilute to 10 mL with the same solvent.

Plate: TLC octadecylsilyl silica gel F_{254} plate R.

Mobile phase: mix 20 volumes of acetonitrile R, 20 volumes of *methanol* R and 60 volumes of a 63 g/L solution of oxalic acid R previously adjusted to pH 2 with concentrated ammonia R.

Application: 1 μ L.

Development: over 3/4 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

System suitability: the chromatogram obtained with reference solution (b) shows 3 clearly separated spots.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).

B. To about 2 mg add 5 mL of sulfuric acid R. A violet colour develops. Add the solution to 2.5 mL of water R. The colour becomes yellow.

C. It gives reaction (a) of chlorides (2.3.1).

pH (2.2.3): 2.0 to 3.0.

Dissolve 0.1 g in carbon dioxide-free water R and dilute to 10 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29). Prepare the solutions immediately before use.

Buffer 1: 22.2 g/L solution of sodium edetate R adjusted to pH 7.5 with a 40 g/L solution of sodium hydroxide R.

Buffer 2: 17.0 g/L solution of tetrapropylammonium hydrogen sulfate R adjusted to pH 7.5 with a 40 g/L solution of sodium hydroxide R.

Test solution. Dissolve 25.0 mg of the substance to be examined in a 1.0 g/L solution of hydrochloric acid R and dilute to 50.0 mL with the same solution.

Reference solution (a). Dissolve 25.0 mg of demeclocycline hydrochloride CRS in a 1.0 g/L solution of hydrochloric acid R and dilute to 50.0 mL with the same solution.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with a 1.0 g/L solution of hydrochloric acid R.

Reference solution (c). Dissolve 5 mg of demeclocycline for system suitability CRS (containing impurities A, B, C, E and G) in a 1.0 g/L solution of hydrochloric acid R and dilute to 10 mL with the same solution.

Column:

- size: $l = 0.075$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octylsilyl silica gel for chromatography with embedded polar groups R (3.5 μ m);
- temperature: 40 °C.

Mobile phase:

- mobile phase A: acetonitrile R, water for chromatography R, buffer 1, buffer 2 (2:28:35:35 V/V/V/V);
- mobile phase B: acetonitrile R, buffer 1, buffer 2 (30:35:35 V/V/V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	83	17
5 - 15	83 $\rightarrow$ 30	17 $\rightarrow$ 70
15 - 25	30	70

Flow rate: 1 mL/min.

Detection: spectrophotometer at 280 nm.

Injection: 10 μ L of the test solution and reference solutions (b) and (c).

Identification of impurities: use the chromatogram supplied with demeclocycline for system suitability CRS and the chromatogram obtained with reference solution (c) to identify the peaks due to impurities A, B, C, E and G.

Relative retention with reference to demeclocycline (retention time = about 14 min): impurity C = about 0.3; impurity B = about 0.7; impurity A = about 0.8; impurity E = about 1.2; impurity G = about 1.6.

System suitability: reference solution (c):

- resolution: minimum 2.5 between the peaks due to impurities A and B.

Calculation of percentage contents:

- for each impurity, use the concentration of demeclocycline hydrochloride in reference solution (b).

Limits:

- impurities A, B: for each impurity, maximum 5.0 per cent;
- impurities C, G: for each impurity, maximum 0.3 per cent;
- impurity E: maximum 0.2 per cent;
- any other impurity: for each impurity, maximum 0.15 per cent;
- total: maximum 10.0 per cent;
- reporting threshold: 0.05 per cent.

Water (2.5.12): maximum 3.0 per cent, determined on 1.000 g.

Sulfated ash (2.4.14): maximum 0.5 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: 10 µL of the test solution and reference solution (a).

Calculate the percentage content of $C_{21}H_{22}Cl_2N_2O_8$ using the chromatogram obtained with reference solution (a) and taking into account the assigned content of *demeclocycline hydrochloride CRS*.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: A, B, C, E, G.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): D, F.




A. (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-tetracene-2-carboxamide (demethyltetraacycline),




B. (4R,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-tetracene-2-carboxamide (4-epidemeclocycline),




C. (4R,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-tetracene-2-carboxamide (4-epidemethyltetraacycline),




D. (4R,4aS,12aS)-4-(dimethylamino)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydro-tetracene-2-carboxamide (4-epianhydromethyltetraacycline),



E. (4S,4aS,12aS)-4-(dimethylamino)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydro-tetracene-2-carboxamide (anhydromethyltetraacycline),



F. (4R,4aS,12aS)-7-chloro-4-(dimethylamino)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydro-tetracene-2-carboxamide (4-epianhydromeclocycline),




G. (4S,4aS,12aS)-7-chloro-4-(dimethylamino)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydro-tetracene-2-carboxamide (anhydromeclocycline).

04/2020:0763



DIMETHYL SULFOXIDE

Dimethylis sulfoxidum



C_2H_6OS
[67-68-5]

M_r 78.1

DEFINITION

(Methanesulfinyl)methane.

CHARACTERS

Appearance: colourless liquid or colourless crystals, hygroscopic.

Solubility: miscible with water and with ethanol (96 per cent).

IDENTIFICATION

First identification: C.

Second identification: A, B, D.

A. Relative density (see Tests).

B. Refractive index (see Tests).

C. Infrared absorption spectrophotometry (2.2.24).

Comparison: dimethyl sulfoxide CRS.

D. Dissolve 50 mg of *nickel chloride R* in 5 mL of the substance to be examined. The solution is greenish-yellow. Heat in a water-bath at 50 °C. The colour changes to green or bluish-green. Cool. The colour changes to greenish-yellow.

TESTS

Acidity. Dissolve 50.0 g in 100 mL of *carbon dioxide-free water R*. Add 0.1 mL of *phenolphthalein solution R1*. Not more than 5.0 mL of 0.01 M *sodium hydroxide* is required to produce a pink colour.

Relative density (2.2.5): 1.100 to 1.104.

Refractive index (2.2.6): 1.478 to 1.480.

Freezing point (2.2.18): minimum 18.3 °C.

Absorbance (2.2.25). Purge with *nitrogen R* for 15 min. The absorbance, measured using *water R* as the compensation liquid, is not more than 0.30 at 275 nm and not more than 0.20 at both 285 nm and 295 nm. The substance to be examined shows no absorption maximum between 270 nm and 350 nm.

Related substances. Gas chromatography (2.2.28): use the normalisation procedure.

Test solution. The substance to be examined.

Reference solution (a). Dissolve 50 mg of the substance to be examined and 50 mg of *dimethyl sulfone R* (impurity A) in *methylene chloride R* and dilute to 100 mL with the same solvent.

Reference solution (b). Dilute 1.0 mL of the test solution to 10.0 mL with *methylene chloride R*. Dilute 0.5 mL of this solution to 100.0 mL with *methylene chloride R*.

Column:

- **material:** fused silica;
- **size:** $l = 30$ m, $\varnothing = 0.25$ mm;
- **stationary phase:** *methylpolysiloxane R* (5 μ m).

Carrier gas: *helium for chromatography R*.

Flow rate: 1.5 mL/min.

Split ratio: 1:100.

Temperature:

	Time (min)	Temperature (°C)
Column	0 - 6	70
	6 - 24	70 $\rightarrow$ 250
Injection port		280
Detector		280

Detection: flame ionisation.

Injection: 0.4 μ L.

Relative retention with reference to dimethyl sulfoxide (retention time = about 5.4 min): impurity A = about 1.2.

System suitability: reference solution (a):

- **resolution:** minimum 5.0 between the peaks due to dimethyl sulfoxide and impurity A.

Limits:

- **unspecified impurities:** for each impurity, maximum 0.10 per cent;
- **total:** maximum 0.15 per cent;
- **reporting threshold:** 0.05 per cent (reference solution (b)).


Water (2.5.32): maximum 0.2 per cent, determined on 1.00 g.

STORAGE

In an airtight, glass container, protected from light.

IMPURITIES

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A.




A. (methanesulfonyl)methane (dimethyl sulfone).



DIPROPHYLLINE

Diprophyllinum



$C_{10}H_{14}N_4O_4$
[479-18-5]

M_r 254.2

DEFINITION

7-[(2*RS*)-2,3-Dihydroxypropyl]-1,3-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione.

Content: 98.5 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: freely soluble in water, slightly soluble in ethanol (96 per cent).

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: *diprophylline CRS*.

TESTS

Solution S. Dissolve 2.5 g in *carbon dioxide-free water R* and dilute to 50 mL with the same solvent.

Appearance of solution. Solution S is clear (2.2.1) and colourless (2.2.2, *Method II*).

Acidity or alkalinity. To 10 mL of solution S add 0.25 mL of *bromothymol blue solution R1*. The solution is yellow or green. Not more than 0.4 mL of 0.01 *M sodium hydroxide* is required to change the colour of the indicator to blue.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 50 mg of the substance to be examined in *water R* and dilute to 50.0 mL with the same solvent.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with *water R*. Dilute 1.0 mL of this solution to 10.0 mL with *water R*.

Reference solution (b). Dissolve 5 mg of *etofylline CRS* (impurity C) in *water R* and dilute to 50 mL with the same solvent. Dilute 0.5 mL of the solution to 20 mL with the test solution.

Column:

- **size:** $l = 0.15$ m, $\varnothing = 4.6$ mm;
- **stationary phase:** *end-capped octadecylsilyl silica gel for chromatography with embedded polar groups R* (3 μ m);
- **temperature:** 30 °C.

Mobile phase: *methanol R, water for chromatography R* (10:90 V/V).

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 272 nm.

Injection: 10 μ L.

Run time: 3 times the retention time of diprophylline.

Relative retention with reference to diprophylline (retention time = about 18 min): impurity C = about 1.1.

System suitability: reference solution (b):

- **peak-to-valley ratio:** minimum 5, where H_p = height above the baseline of the peak due to impurity C and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to diprophylline.

Limits:

- **unspecified impurities:** for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- **total:** not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent);
- **disregard limit:** 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Chlorides (2.4.4): maximum 400 ppm.

Dilute 2.5 mL of solution S to 15 mL with water R.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

In order to avoid overheating in the reaction medium, mix thoroughly throughout and stop the titration immediately after the end-point has been reached.

Dissolve 0.200 g in 3.0 mL of anhydrous formic acid R and add 50.0 mL of acetic anhydride R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).


1 mL of 0.1 M perchloric acid is equivalent to 25.42 mg of $C_{10}H_{14}N_4O_4$.

STORAGE


Protected from light.

IMPURITIES


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, C, D.




- A. N-methyl-5-(methylamino)-1H-imidazole-4-carboxamide (theophyllidine),



- B. 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione (theophylline),



- C. 7-(2-hydroxyethyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione (etofylline),




- D. 7-[(2RS)-2-hydroxypropyl]-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione (proxiphylline).



04/2020:2582

DONEPEZIL HYDROCHLORIDE

Donepezili hydrochloridum



$C_{24}H_{30}ClNO_3$
[120011-70-3]

M_r 416.0

DEFINITION

(2RS)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one hydrochloride.

Content: 98.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: very slightly soluble in water, very soluble in methylene chloride, very slightly soluble in ethanol (96 per cent).

IDENTIFICATION

- A. Infrared absorption spectrophotometry (2.2.24).

Comparison: donepezil hydrochloride CRS.

- B. Water (see Tests).

- C. It gives reaction (a) of chlorides (2.3.1).

TESTS

Related substances. Liquid chromatography (2.2.29).

Solvent mixture: mobile phase B, mobile phase A (20:80 V/V).

Test solution (a). Dissolve 25.0 mg of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.

Test solution (b). Dilute 5.0 mL of test solution (a) to 10.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b). Dissolve 15.0 mg of donepezil hydrochloride CRS in the solvent mixture and dilute to 30.0 mL with the solvent mixture.

Reference solution (c). Dissolve 5 mg of donepezil for system suitability CRS (containing impurities C, D and E) in the solvent mixture and dilute to 5 mL with the solvent mixture.

Column:

- **size:** $l = 0.15$ m, $\varnothing = 4.6$ mm;

- **stationary phase:** end-capped phenylhexylsilyl silica gel for chromatography R (3 μ m).

Mobile phase:

- **mobile phase A:** add 15 mL of triethylamine *R* to about 900 mL of water for chromatography *R*, adjust to pH 6.8 with phosphoric acid *R* and dilute to 1000 mL with water for chromatography *R*;
- **mobile phase B:** acetonitrile *R*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 – 5	80	20
5 – 10	80 → 60	20 → 40
10 – 35	60	40

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 270 nm.

Injection: 100 µL of test solution (a) and reference solutions (a) and (c).

Identification of impurities: use the chromatogram supplied with donepezil for system suitability CRS and the chromatogram obtained with reference solution (c) to identify the peaks due to impurities C + E, and impurity D.

Relative retention with reference to donepezil (retention time = about 15 min): impurities C and E = about 0.78; impurity D = about 0.83.

System suitability:

- **resolution:** minimum 2.0 between the peaks due to impurities C + E, and impurity D in the chromatogram obtained with reference solution (c);
- **signal-to-noise ratio:** minimum 30 for the principal peak in the chromatogram obtained with reference solution (a).

Calculation of percentage contents:

- for each impurity, use the concentration of donepezil hydrochloride in reference solution (a).

Limits:

- **unspecified impurities:** for each impurity, maximum 0.10 per cent;
- **total:** maximum 0.3 per cent;
- **reporting threshold:** 0.05 per cent.

Water (2.5.12): maximum 0.4 per cent, determined on 1.00 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY


Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: 20 µL of test solution (b) and reference solution (b).


Calculate the percentage content of $C_{24}H_{30}ClNO_3$ taking into account the assigned content of donepezil hydrochloride CRS.

IMPURITIES


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, C, D, E, F, G.




A. (2*RS*)-5,6-dimethoxy-2-[(piperidin-4-yl)methyl]-2,3-dihydro-1*H*-inden-1-one,




B. 5,6-dimethoxy-2,3-dihydro-1*H*-inden-1-one,




C. (2*R*)-2-[(*S*)-(1-benzylpiperidin-4-yl)(hydroxy)methyl]-5,6-dimethoxy-2,3-dihydro-1*H*-inden-1-one,




D. (2*RS*)-5,6-dimethoxy-2-[(pyridin-4-yl)methyl]-2,3-dihydro-1*H*-inden-1-one,



E. 1-benzyl-4-[[[(2*RS*)-5,6-dimethoxy-1-oxo-2,3-dihydro-1*H*-inden-2-yl)methyl]pyridin-1-ium,



F. (2*E*)-2-[(1-benzylpiperidin-4-yl)methylidene]-5,6-dimethoxy-2,3-dihydro-1*H*-inden-1-one,




G. (2*RS*)-2-[(1-benzyl-1,2,3,4-tetrahydropyridin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1*H*-inden-1-one.

04/2020:3067



DONEPEZIL HYDROCHLORIDE MONOHYDRATE

Donepezili hydrochloridum monohydricum



$C_{24}H_{30}ClNO_3 \cdot H_2O$
[884740-09-4]

M_r 434.0

DEFINITION

(2*RS*)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1*H*-inden-1-one hydrochloride monohydrate.

Content: 98.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: soluble in water, freely soluble in methylene chloride, slightly soluble in ethanol (96 per cent).

IDENTIFICATION

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: donepezil hydrochloride monohydrate CRS.

B. Water (see Tests).

C. It gives the reaction (a) of chlorides (2.3.1).

TESTS

Related substances. Liquid chromatography (2.2.29).

Solvent mixture: mobile phase B, mobile phase A (20:80 V/V).

Test solution (a). Dissolve 25.0 mg of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.

Test solution (b). Dilute 5.0 mL of test solution (a) to 10.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b). Dissolve 15.0 mg of donepezil hydrochloride CRS in the solvent mixture and dilute to 30.0 mL with the solvent mixture.

Reference solution (c). Dissolve 5 mg of donepezil for system suitability CRS (containing impurities C, D and E) in the solvent mixture and dilute to 5 mL with the solvent mixture.

Column:

- size: $l = 0.15$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped phenylhexylsilyl silica gel for chromatography R (3 μ m).

Mobile phase:

- mobile phase A: add 15 mL of triethylamine R to about 900 mL of water for chromatography R, adjust to pH 6.8 with phosphoric acid R and dilute to 1000 mL with water for chromatography R;
- mobile phase B: acetonitrile R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	80	20
5 - 10	80 $\rightarrow$ 60	20 $\rightarrow$ 40
10 - 35	60	40

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 270 nm.

Injection: 100 μ L of test solution (a) and reference solutions (a) and (c).

Identification of impurities: use the chromatogram supplied with donepezil for system suitability CRS and the chromatogram obtained with reference solution (c) to identify the peaks due to impurities C + E, and impurity D.

Relative retention with reference to donepezil (retention time = about 15 min): impurities C and E = about 0.78; impurity D = about 0.83.

System suitability:

- resolution: minimum 2.0 between the peaks due to impurities C + E, and impurity D in the chromatogram obtained with reference solution (c);
- signal-to-noise ratio: minimum 30 for the principal peak in the chromatogram obtained with reference solution (a).

Calculation of percentage contents:

- for each impurity, use the concentration of donepezil hydrochloride monohydrate in reference solution (a).

Limits:

- unspecified impurities: for each impurity, maximum 0.10 per cent;

- total: maximum 0.3 per cent;
- reporting threshold: 0.05 per cent.

Water (2.5.12): 4.0 per cent to 6.0 per cent, determined on 0.200 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY


Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: 20 μ L of test solution (b) and reference solution (b).


Calculate the percentage content of $C_{24}H_{30}ClNO_3$ taking into account the assigned content of donepezil hydrochloride CRS.

IMPURITIES


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, C, D, E, F, G.




A. (2RS)-5,6-dimethoxy-2-[(piperidin-4-yl)methyl]-2,3-dihydro-1H-inden-1-one,




B. 5,6-dimethoxy-2,3-dihydro-1H-inden-1-one,




C. (2R)-2-[(S)-(1-benzylpiperidin-4-yl)(hydroxy)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one,




D. (2RS)-5,6-dimethoxy-2-[(pyridin-4-yl)methyl]-2,3-dihydro-1H-inden-1-one,



E. 1-benzyl-4-[[[(2RS)-5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl]methyl]pyridin-1-ium,



F. (2E)-2-[(1-benzylpiperidin-4-yl)methylidene]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one,



G. (2*RS*)-2-[(1-benzyl-1,2,3,4-tetrahydropyridin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1*H*-inden-1-one.

E

Ergometrine maleate.....	4407	Exemestane.....	4410
Escitalopram oxalate.....	4408		



04/2020:0223 **Related substances.** Liquid chromatography (2.2.29). Carry out the test protected from light.

Solvent mixture: acetonitrile R, water R (15:85 V/V).

Test solution. Dissolve 10.0 mg of the substance to be examined in 10 mL of the solvent mixture and dilute to 50.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with water R. Dilute 1.0 mL of this solution to 10.0 mL with water R.

Reference solution (b). Dissolve the contents of a vial of ergometrine impurity mixture CRS (impurities D, E, F and I) in 1 mL of a mixture of 30 volumes of mobile phase B and 70 volumes of water R.

Column:

- size: $l = 0.10$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography with extended pH range R (3.5 μ m);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: 2 g/L solution of ammonium carbamate R;
- mobile phase B: acetonitrile R, water for chromatography R (50:50 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	85	15
5 - 10	85 $\rightarrow$ 65	15 $\rightarrow$ 35
10 - 15	65	35
15 - 20	65 $\rightarrow$ 20	35 $\rightarrow$ 80
20 - 25	20	80

Flow rate: 2.0 mL/min.

Detection: spectrophotometer at 310 nm.

Injection: 20 μ L.

Identification of impurities: use the chromatogram supplied with ergometrine impurity mixture CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities D, E, F and I.

Relative retention with reference to ergometrine (retention time = about 11.8 min): impurity D = about 1.3; impurity I = about 1.35; impurity E = about 1.43; impurity F = about 1.55.

System suitability: reference solution (b):

- resolution: minimum 2.0 between the peaks due to impurities D and I; minimum 1.5 between the peaks due to impurities I and E.

Calculation of percentage contents:

- for each impurity, use the concentration of ergometrine maleate in reference solution (a).

Limits:

- impurity F: maximum 0.15 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.3 per cent;
- reporting threshold: maximum 0.05 per cent.

Loss on drying (2.2.32): maximum 2.0 per cent, determined on 0.200 g by drying *in vacuo* at 80 °C for 2 h.


ASSAY

Dissolve 0.150 g in 40 mL of anhydrous acetic acid R. Titrate with 0.05 M perchloric acid, determining the end-point potentiometrically (2.2.20).

1 mL of 0.05 M perchloric acid is equivalent to 22.07 mg of $C_{23}H_{27}N_3O_6$.

ERGOMETRINE MALEATE

Ergometrini maleas



$C_{23}H_{27}N_3O_6$
[129-51-1]

M_r 441.5

DEFINITION

(8 β)-N-[(2S)-1-Hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8-carboxamide (2Z)-but-2-enedioate.

Content: 98.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white or slightly coloured, crystalline powder.

Solubility: sparingly soluble in water, slightly soluble in ethanol (96 per cent).

IDENTIFICATION

First identification: A.

Second identification: B.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: ergometrine maleate CRS.

B. Thin-layer chromatography (2.2.27). Prepare the solutions immediately before use.

Solvent mixture: concentrated ammonia R, ethanol (80 per cent V/V) R (10:90 V/V).

Test solution. Dissolve 10 mg of the substance to be examined in the solvent mixture and dilute to 10 mL with the solvent mixture.

Reference solution. Dissolve 10 mg of ergometrine maleate CRS in the solvent mixture and dilute to 10 mL with the solvent mixture.

Plate: TLC silica gel G plate R.

Mobile phase: water R, methanol R, methylene chloride R (3:25:75 V/V/V).

Application: 5 μ L.

Development: over 2/3 of the plate.

Drying: in a current of cold air.

Detection: spray with dimethylaminobenzaldehyde solution R7 and dry in a current of warm air for about 2 min.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

TESTS

Solution S. Dissolve 0.100 g, without heating and protected from light, in 9 mL of carbon dioxide-free water R and dilute to 10.0 mL with the same solvent.

Appearance of solution. Solution S is clear (2.2.1) and not more intensely coloured than reference solution Y₅ or BY₅ (2.2.2, Method II).

pH (2.2.3): 3.6 to 4.4 for solution S.

Specific optical rotation (2.2.7): + 50 to + 56 (dried substance), determined on solution S.


STORAGE

In an airtight, glass container, protected from light, at a temperature of 2 °C to 8 °C.


IMPURITIES

Specified impurities: F.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, C, D, E, G, H, I.




A. (8β)-6-methyl-9,10-didehydroergoline-8-carboxylic acid (lysergic acid),




B. (8α)-6-methyl-9,10-didehydroergoline-8-carboxylic acid (isolysergic acid),




C. (8β)-6-methyl-9,10-didehydroergoline-8-carboxamide (ergine),




D. (8β)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-9,10-didehydroergoline-8-carboxamide (methylethylergometrine),




E. (8α)-6-methyl-9,10-didehydroergoline-8-carboxamide (erginine),




F. (8α)-N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8-carboxamide (ergometrine),



G. (8β)-N-[(2S)-1-hydroxybutan-2-yl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide (methysergide),



H. (8α)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-9,10-didehydroergoline-8-carboxamide (methylethylergometrine),




I. (8β)-N-[(2R)-1-hydroxybutan-2-yl]-6-methyl-9,10-didehydroergoline-8-carboxamide (2'-epi-methylethylergometrine).

07/2016:2733
corrected 10.1



ESCITALOPRAM OXALATE

Escitaloprami oxalas



C₂₂H₂₃FN₂O₅
[219861-08-2]

M_r 414.4

DEFINITION

(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile hydrogen oxalate.

Content: 99.0 per cent to 101.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: sparingly soluble in water, freely soluble in methanol, slightly soluble in methylene chloride.

IDENTIFICATION

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: escitalopram oxalate CRS.

B. Enantiomeric purity (see Tests).

TESTS

Related substances. Liquid chromatography (2.2.29).

Buffer solution. Dissolve 3.4 g of *potassium dihydrogen phosphate R* in 900 mL of *water for chromatography R*, adjust to pH 3.0 with *phosphoric acid R* and dilute to 1000 mL with *water for chromatography R*.

Test solution. Dissolve 25 mg of the substance to be examined in mobile phase A and dilute to 50.0 mL with mobile phase A.

Reference solution (a). Dissolve 5 mg of escitalopram for system suitability CRS (containing impurity D) in mobile phase A and dilute to 10.0 mL with mobile phase A.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with mobile phase A. Dilute 1.0 mL of this solution to 10.0 mL with mobile phase A.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m);
- temperature: 45 °C.

Mobile phase:

- mobile phase A: acetonitrile R, buffer solution (10:90 V/V);
- mobile phase B: buffer solution, acetonitrile R (35:65 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)	Flow rate (mL/min)
0 - 2	95	5	1.0
2 - 37	95 $\rightarrow$ 65	5 $\rightarrow$ 35	1.0
37 - 47	65 $\rightarrow$ 0	35 $\rightarrow$ 100	1.0
47 - 62	0	100	2.0

Detection: spectrophotometer at 237 nm and at 254 nm.

Injection: 20 μ L.

Identification of impurities: use the chromatogram supplied with escitalopram for system suitability CRS and the chromatogram obtained with reference solution (a) to identify the peak due to impurity D.

Relative retention with reference to escitalopram (retention time = about 38 min): impurity D = about 0.98.

System suitability: reference solution (a) at 237 nm:

- peak-to-valley ratio: minimum 5.0, where H_p = height above the baseline of the peak due to impurity D and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to escitalopram.

Calculation of percentage contents:

- for each impurity, use the concentration of escitalopram oxalate in reference solution (b) at 237 nm.

Limits:

- unspecified impurities at 237 nm and at 254 nm: for each impurity, maximum 0.10 per cent;
- total at 237 nm: maximum 0.5 per cent;
- reporting threshold at 237 nm: 0.05 per cent.

Enantiomeric purity. Liquid chromatography (2.2.29): use the normalisation procedure.

Test solution. Dissolve 25.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 20.0 mL with the mobile phase.

Reference solution (a). Dissolve 5.0 mg of citalopram hydrobromide CRS (containing equal amounts of impurity K and escitalopram) in the mobile phase and dilute to 10.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 20.0 mL with the mobile phase.

Reference solution (b). Dilute 1.0 mL of reference solution (a) to 50.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Column:

- size: $l = 0.15$ m, $\varnothing = 4.6$ mm;
- stationary phase: protein derivative of silica gel for chiral separation R (5 μ m);

- temperature: 30 °C.

Mobile phase: acetonitrile R, 0.05 M phosphate buffer solution pH 7.0 R (15:85 V/V).

Flow rate: 0.6 mL/min.

Detection: spectrophotometer at 240 nm.

Injection: 15 μ L.

Run time: twice the retention time of escitalopram.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peak due to impurity K.

Relative retention with reference to escitalopram (retention time = about 11 min): impurity K = about 1.2.

System suitability: reference solution (a):

- resolution: minimum 1.3 between the peaks due to escitalopram and impurity K;
- symmetry factor: maximum 4.0 for the peak due to escitalopram; maximum 4.0 for the peak due to impurity K.

Limits:

- impurity K: maximum 2.0 per cent;
- reporting threshold: 0.10 per cent (reference solution (b)).

Water (2.5.12): maximum 1.0 per cent, determined on 0.250 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g in a platinum crucible.

ASSAY


Dissolve 0.300 g in a mixture of 5.0 mL of acetic anhydride R and 75 mL of glacial acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M perchloric acid is equivalent to 41.44 mg of $C_{22}H_{23}FN_2O_5$.


IMPURITIES

Specified impurities: K.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, C, D, E, F, G, H, I, J, L, M.




A. (1R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carboxamide,




B. mixture of (1R,3R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile and (1R,3S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile,




- C. (1R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-oxo-1,3-dihydro-2-benzofuran-5-carbonitrile,



- D. (1R)-1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-1,3-dihydro-2-benzofuran-5-carbonitrile,




- E. (4R)-4-[4-cyano-2-(hydroxymethyl)phenyl]-4-(4-fluorophenyl)-4-hydroxy-N,N-dimethylbutan-1-aminium,




- F. (1R)-1-[3-(dimethylamino)propyl]-1-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile,




- G. 4-(dimethylamino)-1-[(1R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-yl]-butan-1-one,




- H. 3-[(1R)-5-cyano-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-1-yl]-N,N-dimethylpropan-1-amine N-oxide,




- I. 4-[(1Z)-4-(dimethylamino)-1-(4-fluorophenyl)but-1-en-1-yl]-3-(hydroxymethyl)benzonitrile,




- J. 4-methylbenzenesulfonic acid (*p*-toluenesulfonic acid),



- K. (1R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile,



- L. (1R)-1-[3-(dimethylamino)propyl]-1-phenyl-1,3-dihydro-2-benzofuran-5-carbonitrile,




- M. (1R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carboxylic acid.

04/2020:2766



EXEMESTANE

Exemestanum



$C_{20}H_{24}O_2$
[107868-30-4]

M_r 296.4

DEFINITION

6-Methylideneandrosta-1,4-diene-3,17-dione.

Content: 98.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or slightly yellow powder.

Solubility: practically insoluble in water, freely soluble in methylene chloride, soluble in methanol.

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: exemestane CRS.

TESTS

Specific optical rotation (2.2.7): + 290 to + 298 (dried substance).

Dissolve 0.250 g in *methanol R* and dilute to 25.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29). *Store the solutions protected from light.*

Solvent mixture: water R, acetonitrile R (25:75 V/V).

Test solution. Dissolve 25.0 mg of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.

Reference solution (a). Dissolve 5 mg of *exemestane for system suitability* CRS (containing impurity G) in the solvent mixture and dilute to 5 mL with the solvent mixture.

Reference solution (b). Dissolve 5 mg of *exemestane for peak identification* CRS (containing impurity I) in the solvent mixture and dilute to 5 mL with the solvent mixture.

Reference solution (c). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (d). Dissolve 25.0 mg of *exemestane CRS* in the solvent mixture and dilute to 25.0 mL with the solvent mixture.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped polar-embedded octadecylsilyl amorphous organosilica polymer R (3.5 μ m);
- temperature: 40 °C.

Mobile phase:

- mobile phase A: water for chromatography R;
- mobile phase B: acetonitrile for chromatography R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	75	25
5 - 35	75 $\rightarrow$ 55	25 $\rightarrow$ 45
35 - 45	55 $\rightarrow$ 5	45 $\rightarrow$ 95
45 - 50	5	95

Flow rate: 1.2 mL/min.

Detection: spectrophotometer at 247 nm.

Injection: 10 μ L of the test solution and reference solutions (a), (b) and (c).

Identification of impurities: use the chromatogram supplied with *exemestane for system suitability* CRS and the chromatogram obtained with reference solution (a) to identify the peak due to impurity G; use the chromatogram supplied with *exemestane for peak identification* CRS and the chromatogram obtained with reference solution (b) to identify the peak due to impurity I.

Relative retention with reference to exemestane (retention time = about 28 min): impurity G = about 1.03; impurity I = about 1.4.

System suitability: reference solution (a):

- peak-to-valley ratio: minimum 1.5, where H_p = height above the baseline of the peak due to impurity G and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to exemestane.

Calculation of percentage contents:

- for each impurity, use the concentration of exemestane in reference solution (c).

Limits:

- impurity I: maximum 0.15 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.5 per cent;
- reporting threshold: 0.05 per cent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution and reference solution (d).

Calculate the percentage content of $C_{20}H_{24}O_2$ taking into account the assigned content of *exemestane CRS*.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: I.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, C, D, E, F, G, H, J.




B. 6ξ-(hydroxymethyl)androsta-1,4-diene-3,17-dione,




C. 6,16-dimethylideneandrosta-1,4-diene-3,17-dione,



D. androsta-1,4-diene-3,17-dione,




E. 6-methylideneandrosta-4-ene-3,17-dione,




F. androsta-1,4-diene-3,6,17-trione,


G. unknown structure,



H. 17β-hydroxy-6-methylideneandrosta-1,4-dien-3-one,



I. 6-methylidene-3-oxoandrosta-1,4-dien-17β-yl formate,



J. 6-methylidene-3-oxoandrosta-1,4-dien-17β-yl acetate.

F


Fluocortolone pivalate.....	4415	Fluphenazine enantate.. ..	4418
Fluphenazine decanoate.....	4416		



04/2020:1212

FLUOCORTOLONE PIVALATE

Fluocortoloni pivalas



$C_{27}H_{37}FO_5$
[29205-06-9]

M_r 460.6

DEFINITION

6 α -Fluoro-11 β -hydroxy-16 α -methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate.

Content: 96.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in ethanol (96 per cent).

IDENTIFICATION

First identification: A, B.

Second identification: C, D.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: fluocortolone pivalate for ID and assay CRS.

B. Examine the chromatograms obtained in the assay.

Results: the principal peak in the chromatogram obtained with test solution (b) is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (c).

C. Thin-layer chromatography (2.2.27).

Solvent mixture: methanol R, methylene chloride R (10:90 V/V).

Test solution. Dissolve 10 mg of the substance to be examined in the solvent mixture and dilute to 10 mL with the solvent mixture.

Reference solution (a). Dissolve 20 mg of fluocortolone pivalate for ID and assay CRS in the solvent mixture and dilute to 20 mL with the solvent mixture.

Reference solution (b). Dissolve 10 mg of norethisterone CRS in reference solution (a) and dilute to 10 mL with reference solution (a).

Plate: TLC silica gel F_{254} plate R.

Mobile phase: add a mixture of 1.2 volumes of water R and 8 volumes of methanol R to a mixture of 15 volumes of ether R and 77 volumes of methylene chloride R.

Application: 5 μ L.

Development: over 3/4 of the plate.

Drying: in air.

Detection A: examine in ultraviolet light at 254 nm.

Results A: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).

Detection B: spray with alcoholic solution of sulfuric acid R, heat at 120 °C for 10 min or until the spots appear, then allow to cool; examine in daylight and in ultraviolet light at 365 nm.

Results B: the principal spot in the chromatogram obtained with the test solution is similar in position, colour in daylight, fluorescence in ultraviolet light at 365 nm and size to the principal spot in the chromatogram obtained with reference solution (a).

System suitability: reference solution (b):

– the chromatogram shows 2 clearly separated spots.

D. Mix about 5 mg with 45 mg of heavy magnesium oxide R and ignite in a crucible until an almost white residue is obtained (usually less than 5 min). Allow to cool, add 1 mL of water R, 0.05 mL of phenolphthalein solution R1 and about 1 mL of dilute hydrochloric acid R to render the solution colourless. Filter and add to the filtrate a freshly prepared mixture of 0.1 mL of alizarin S solution R and 0.1 mL of zirconyl nitrate solution R. Mix, allow to stand for 5 min and compare the colour of the solution with that of a blank prepared in the same manner. The test solution is yellow and the blank is red.

TESTS

Specific optical rotation (2.2.7): + 105 to + 110 (dried substance).

Dissolve 0.25 g in methylene chloride R and dilute to 25.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Test solution (a). Dissolve 25.0 mg of the substance to be examined in acetonitrile R and dilute to 25.0 mL with the same solvent.

Test solution (b). Dissolve 25.0 mg of the substance to be examined in a mixture of 50.0 mL of acetonitrile R and 50.0 mL of water R.

Reference solution (a). Dilute 1.0 mL of test solution (a) to 100.0 mL with acetonitrile R. Dilute 1.0 mL of this solution to 10.0 mL with acetonitrile R.

Reference solution (b). Dissolve 2 mg of fluocortolone pivalate for system suitability CRS (containing impurities C, D, E and F) in 2 mL of acetonitrile R.

Reference solution (c). Dissolve 25.0 mg of fluocortolone pivalate for ID and assay CRS in a mixture of 50.0 mL of acetonitrile R and 50.0 mL of water R.

Column:

– size: l = 0.25 m, $\varnothing$ = 4.6 mm;

– stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase: methanol R1, acetonitrile for chromatography R, water for chromatography R (25:30:32 V/V/V).

Flow rate: 1.5 mL/min.

Detection: spectrophotometer at 243 nm.

Injection: 20 μ L of test solution (a) and reference solutions (a) and (b).

Run time: twice the retention time of fluocortolone pivalate.

Identification of impurities: use the chromatogram supplied with fluocortolone pivalate for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities C, D, E and F.

Relative retention with reference to fluocortolone pivalate (retention time = about 21 min): impurity C = about 0.9; impurity D = about 1.1; impurity E = about 1.4; impurity F = about 1.6.

System suitability: reference solution (b):

– resolution: minimum 1.5 between the peaks due to fluocortolone pivalate and impurity D.

Calculation of percentage contents:

– correction factors: multiply the peak areas of the following impurities by the corresponding correction factor: impurity E = 1.4; impurity F = 1.3;

- for each impurity, use the concentration of fluocortolone pivalate in reference solution (a).

Limits:

- *impurities C, D*: for each impurity, maximum 1.0 per cent;
- *impurity E*: maximum 0.2 per cent;
- *impurity F*: maximum 0.15 per cent;
- *unspecified impurities*: for each impurity, maximum 0.10 per cent;
- *total*: maximum 2.0 per cent;
- *reporting threshold*: 0.05 per cent.

Loss on drying (2.2.32): maximum 1.0 per cent, determined on 1.000 g by drying in an oven at 105 °C.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.

Mobile phase: methanol R1, acetonitrile for chromatography R, water for chromatography R (25:40:32 V/V/V).

Injection: 10 µL of test solution (b) and reference solutions (b) and (c).

Run time: 1.5 times the retention time of fluocortolone pivalate.

Relative retention with reference to fluocortolone pivalate (retention time = about 11 min): impurity D = about 1.1.

System suitability: reference solution (b):

- *resolution*: minimum 1.5 between the peaks due to fluocortolone pivalate and impurity D.

Calculate the percentage content of $C_{27}H_{37}FO_5$ taking into account the assigned content of *fluocortolone pivalate* for ID and assay CRS.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: C, D, E, F.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B.




A. 6α-fluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione (fluocortolone),




B. 6αβ-hydroperoxy-11β-hydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate,




C. 6α-fluoro-16α-methyl-3,11,20-trioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate,



D. 6α-fluoro-11β-hydroxy-16α-methyl-3,20-dioxopregna-4-en-21-yl 2,2-dimethylpropanoate,



E. 4-fluoro-11β-hydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate,




F. 6α-fluoro-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate.

04/2020:1014

**FLUPHENAZINE DECANOATE**

Fluphenazini decanoas



$C_{32}H_{44}F_3N_3O_2S$
[5002-47-1]

M_r 591.8

DEFINITION

2-[4-[3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate.

Content: 98.5 per cent to 101.5 per cent (dried substance).

CHARACTERS

Appearance: pale yellow, viscous liquid or yellow solid.

Solubility: practically insoluble in water, very soluble in anhydrous ethanol and in methylene chloride, freely soluble in methanol.

IDENTIFICATION

First identification: B, C.

Second identification: A, C.

A. Ultraviolet and visible absorption spectrophotometry (2.2.25).

Test solution. Dissolve 50.0 mg in *methanol R* and dilute to 100.0 mL with the same solvent. Dilute 1.0 mL of the solution to 50.0 mL with *methanol R*.

Spectral range: 230–350 nm.

Absorption maximum: 260 nm.

Shoulder: about 310 nm.

Specific absorbance at the absorption maximum: 570 to 630.

B. Infrared absorption spectrophotometry (2.2.24).

Preparation: apply 50 µL of a 25 g/L solution in *methylene chloride R* to a disc of *potassium bromide R*. Dry the discs at 60 °C for 1 h before use.

Comparison: *fluphenazine decanoate CRS*.

C. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 10 mg of the substance to be examined in *methanol R* and dilute to 10 mL with the same solvent.

Reference solution (a). Dissolve 10 mg of *fluphenazine decanoate CRS* in *methanol R* and dilute to 10 mL with the same solvent.

Reference solution (b). Dissolve 5 mg of *fluphenazine enantate CRS* (impurity C) in reference solution (a) and dilute to 5 mL with the same solution.

Plate: TLC octadecylsilyl silica gel F_{254} plate *R*.

Mobile phase: concentrated ammonia *R1*, water *R*, *methanol R* (1:4:95 V/V/V).

Application: 2 µL.

Development: over 2/3 of the plate.

Detection: examine in ultraviolet light at 254 nm.

Retardation factors: *fluphenazine decanoate* = about 0.17; impurity C = about 0.26.

System suitability: reference solution (b):

- the chromatogram shows 2 clearly separated spots.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).

TESTS

Related substances. Liquid chromatography (2.2.29). Carry out the test protected from light and prepare the solutions immediately before use.

Solvent mixture A: mobile phase A, mobile phase B (5:95 V/V).

Solvent mixture B: water *R*, *acetonitrile R* (5:95 V/V).

Test solution. Dissolve 10.0 mg of the substance to be examined in *acetonitrile R* and dilute to 50.0 mL with the same solvent.

Reference solution (a). Dissolve 5 mg of *fluphenazine enantate CRS* (impurity C) and 5 mg of *fluphenazine octanoate CRS* (impurity D) in *acetonitrile R* and dilute to 50 mL with the same solvent.

Reference solution (b). Dilute 5.0 mL of the test solution to 100.0 mL with solvent mixture A. Dilute 1.0 mL of this solution to 10.0 mL with solvent mixture A.

Reference solution (c). Dissolve 5.0 mg of *fluphenazine sulfoxide CRS* (impurity A) and 11.7 mg of *fluphenazine dihydrochloride CRS* (corresponding to about 10.0 mg of impurity B) in solvent mixture B and dilute to 100.0 mL with solvent mixture B. Dilute 1.0 mL of the solution to 50.0 mL with solvent mixture B.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;

- stationary phase: end-capped octadecylsilyl silica gel for chromatography *R* (5 µm).

Mobile phase:

- mobile phase A: 10 g/L solution of ammonium carbonate *R* adjusted to pH 7.5 with dilute hydrochloric acid *R*;
- mobile phase B: mobile phase A, *acetonitrile R*, *methanol R* (7.5:45:45 V/V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 – 7	20	80
7 – 17	20 → 0	80 → 100
17 – 80	0	100

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 260 nm.

Injection: 10 µL.

Relative retention with reference to *fluphenazine decanoate* (retention time = about 34 min): impurity A = about 0.13; impurity B = about 0.33; impurity C = about 0.76; impurity D = about 0.82.

System suitability: reference solution (a):

- resolution: minimum 6.0 between the peaks due to impurities C and D.

Limits:

- impurity A: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (c) (0.5 per cent);
- impurity B: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (c) (1.0 per cent);
- any other impurity: not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);
- total: not more than 4 times the area of the principal peak in the chromatogram obtained with reference solution (b) (2.0 per cent);
- disregard limit: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

Loss on drying (2.2.32): maximum 1.0 per cent, determined on 1.000 g by drying *in vacuo* at 60 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g in a platinum crucible.

ASSAY


Dissolve 0.250 g in 30 mL of *glacial acetic acid R*. Using 0.05 mL of *crystal violet solution R* as indicator, titrate with 0.1 M *perchloric acid* until the colour changes from violet to green.

1 mL of 0.1 M *perchloric acid* is equivalent to 29.59 mg of $C_{32}H_{44}F_3N_3O_2S$.


STORAGE

Protected from light.


IMPURITIES




A. fluphenazine S-oxide (fluphenazine sulfoxide),




B. fluphenazine,




C. fluphenazine enantate,




D. fluphenazine octanoate,



E. fluphenazine nonanoate,



F. fluphenazine undecanoate,




G. fluphenazine dodecanoate.



04/2020:1015

FLUPHENAZINE ENANTATE

Fluphenazini enantas



C₂₉H₃₈F₃N₃O₂S
[2746-81-8]

M_r 549.7

DEFINITION

2-[4-[3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl heptanoate.

Content: 98.5 per cent to 101.5 per cent (dried substance).

CHARACTERS

Appearance: pale yellow, viscous liquid or yellow solid.

Solubility: practically insoluble in water, very soluble in anhydrous ethanol and in methylene chloride, freely soluble in methanol.

IDENTIFICATION

First identification: B, C.

Second identification: A, C.

A. Ultraviolet and visible absorption spectrophotometry (2.2.25).

Test solution. Dissolve 50.0 mg in *methanol R* and dilute to 100.0 mL with the same solvent. Dilute 1.0 mL of the solution to 50.0 mL with *methanol R*.

Spectral range: 230–350 nm.

Absorption maximum: 260 nm.

Shoulder: about 310 nm.

Specific absorbance at the absorption maximum: 610 to 670.

B. Infrared absorption spectrophotometry (2.2.24).

Preparation: apply 50 µL of a 25 g/L solution in *methylene chloride R* to a disc of *potassium bromide R*. Dry the discs at 60 °C for 1 h before use.

Comparison: *fluphenazine enantate CRS*.

C. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 10 mg of the substance to be examined in *methanol R* and dilute to 10 mL with the same solvent.

Reference solution (a). Dissolve 10 mg of *fluphenazine enantate CRS* in *methanol R* and dilute to 10 mL with the same solvent.

Reference solution (b). Dissolve 5 mg of *fluphenazine decanoate CRS* (impurity C) in reference solution (a) and dilute to 5 mL with the same solution.

Plate: TLC octadecylsilyl silica gel F₂₅₄ plate R.

Mobile phase: concentrated ammonia R1, water R, *methanol R* (1:4:95 V/V/V).

Application: 2 µL.

Development: over 2/3 of the plate.

Detection: examine in ultraviolet light at 254 nm.

Retardation factors: impurity C = about 0.17; *fluphenazine enantate* = about 0.26.

System suitability: reference solution (b):

– the chromatogram shows 2 clearly separated spots.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).

TESTS

Related substances. Liquid chromatography (2.2.29). Carry out the test protected from light and prepare the solutions immediately before use.

Solvent mixture: mobile phase A, mobile phase B (5:95 V/V).

Test solution. Dissolve 10.0 mg of the substance to be examined in *acetonitrile R* and dilute to 50.0 mL with the same solvent.

Reference solution (a). Dissolve 5 mg of *fluphenazine enantate CRS* and 5 mg of *fluphenazine octanoate CRS* (impurity D) in *acetonitrile R* and dilute to 50 mL with the same solvent.

Reference solution (b). Dilute 5.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (c). Dissolve 5.0 mg of fluphenazine sulfoxide CRS (impurity A) in acetonitrile R and dilute to 100.0 mL with the same solvent. Dilute 1.0 mL of the solution to 50.0 mL with acetonitrile R.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase:

- mobile phase A: 10 g/L solution of ammonium carbonate R adjusted to pH 7.5 with dilute hydrochloric acid R;
- mobile phase B: mobile phase A, acetonitrile R, methanol R (7.5:45:45 V/V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 7	20	80
7 - 17	20 $\rightarrow$ 0	80 $\rightarrow$ 100
17 - 80	0	100

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 260 nm.

Injection: 10 μ L.

Relative retention with reference to fluphenazine enantate (retention time = about 25 min): impurity A = about 0.2; impurity D = about 1.1.

System suitability: reference solution (a):

- resolution: minimum 6.0 between the peaks due to fluphenazine enantate and impurity D.

Limits:

- impurity A: not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.5 per cent);
- any other impurity: not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);
- total: not more than 3.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (1.6 per cent);
- disregard limit: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

Loss on drying (2.2.32): maximum 1.0 per cent, determined on 1.000 g by drying *in vacuo* at 60 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g in a platinum crucible.

ASSAY


Dissolve 0.250 g in 30 mL of glacial acetic acid R. Using 0.05 mL of crystal violet solution R as indicator, titrate with 0.1 M perchloric acid until the colour changes from violet to green.

1 mL of 0.1 M perchloric acid is equivalent to 27.49 mg of $C_{29}H_{38}F_3N_3O_2S$.


STORAGE

Protected from light.


IMPURITIES




A. fluphenazine S-oxide (fluphenazine sulfoxide),




B. fluphenazine,




C. fluphenazine decanoate,




D. fluphenazine octanoate,



E. fluphenazine nonanoate,



F. fluphenazine undecanoate,



G. fluphenazine dodecanoate.

G


Gammadex.. 4423



04/2018:2769
corrected 10.1

GAMMADEX

Gammadexum



$[C_6H_{10}O_5]_8$
[17465-86-0]

M_r 1297

DEFINITION

Cyclooctakis-(1→4)-(α -D-glucopyranosyl) (cyclomaltooctaose or γ -cyclodextrin).

Content: 97.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, amorphous or crystalline, hygroscopic powder.

Solubility: freely soluble in water, very slightly soluble in propylene glycol, practically insoluble in anhydrous ethanol and in methylene chloride. When dissolved in water, it forms a colloidal dispersion over time.

IDENTIFICATION

A. Specific optical rotation (see Tests).

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: gammacyclodextrin CRS.

TESTS

Solution S. Dissolve 1.000 g in carbon dioxide-free water R and dilute to 100.0 mL with the same solvent.

pH (2.2.3): 5.0 to 8.0.

Mix 1 mL of a 223.6 g/L solution of potassium chloride R and 30 mL of solution S.

Specific optical rotation (2.2.7): + 174 to + 180 (dried substance), determined on solution S after filtration through a membrane filter (nominal pore size 0.45 μ m).

Reducing sugars: maximum 0.2 per cent.

Test solution. To 1 mL of solution S add 1 mL of cupri-tartaric solution R4. Heat on a water-bath for 10 min and allow to cool to room temperature. Add 10 mL of ammonium molybdate reagent R1 and allow to stand for 15 min.

Reference solution. Prepare at the same time and in the same manner as for the test solution, using 1 mL of a 0.02 g/L solution of glucose R.

Measure the absorbances (2.2.25) of the 2 solutions at the absorption maximum at 740 nm using water R as the compensation liquid. The absorbance of the test solution is not greater than that of the reference solution.

Light-absorbing impurities. Examine solution S after filtration through a membrane filter (nominal pore size 0.45 μ m). The absorbance (2.2.25) is not greater than 0.10 between 230 nm and 350 nm and not greater than 0.05 between 350 nm and 750 nm.

Related substances. Liquid chromatography (2.2.29).

Test solution (a). Dissolve 0.250 g of the substance to be examined in water R with heating, cool and dilute to 25.0 mL with the same solvent.

Test solution (b). Dissolve 25.0 mg of the substance to be examined in water R and dilute to 25.0 mL with the same solvent.

Reference solution (a). Dissolve 25.0 mg of alfadex CRS (impurity A), 25.0 mg of betadex CRS (impurity B) and 25.0 mg of gammacyclodextrin CRS (gammadex) in water R and dilute to 50.0 mL with the same solvent.

Reference solution (b). Dilute 5.0 mL of reference solution (a) to 50.0 mL with water R.

Reference solution (c). Dissolve 25.0 mg of gammacyclodextrin CRS in water R and dilute to 25.0 mL with the same solvent.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m);
- temperature: 30 °C.

Mobile phase: methanol R, water for chromatography R (5:95 V/V).

Flow rate: 1.5 mL/min.

Detection: differential refractometer maintained at a constant temperature (e.g. 35 °C).

Equilibration: with the mobile phase for about 3 h.

Injection: 50 μ L of test solution (a) and reference solutions (a) and (b).

Run time: 4 times the retention time of gammadex.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peaks due to impurities A and B.

Relative retention with reference to gammadex (retention time = about 7 min): impurity A = about 1.5; impurity B = about 3.2.

System suitability: reference solution (a):

- resolution: minimum 2.5 between the peaks due to gammadex and impurity A;
- symmetry factor: 0.8 to 1.8 for the peak due to gammadex.

Calculation of percentage contents:

- for impurities A and B, use the concentration of the corresponding impurity in reference solution (b);
- for impurities other than A and B, use the concentration of gammadex in reference solution (b).

Limits:

- impurities A, B: for each impurity, maximum 0.5 per cent;
- sum of impurities other than A and B: maximum 0.5 per cent;
- reporting threshold: 0.15 per cent.

Loss on drying (2.2.32): maximum 11.0 per cent, determined on 1.000 g by drying in an oven at 120 °C for 2 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.

Injection: test solution (b) and reference solution (c).

System suitability: reference solution (c):

- symmetry factor: 0.8 to 1.8 for the peak due to gammadex;

- *repeatability*: maximum relative standard deviation of 2.0 per cent determined on 5 injections.


Calculate the percentage content of $[\text{C}_6\text{H}_{10}\text{O}_5]_8$ taking into account the assigned content of *gammacyclodextrin CRS*.

STORAGE


In an airtight container.

IMPURITIES

Specified impurities: A, B.



A. cyclohexakis-(1→4)-(α-D-glucopyranosyl) (alfadex or cyclomaltohexaose or α-cyclodextrin),



B. cycloheptakis-(1→4)-(α-D-glucopyranosyl) (betadex or cyclomaltoheptaose or β-cyclodextrin).

I

Insulin preparations, injectable.....	4427	Isosorbide dinitrate, diluted ..	4432
Irinotecan hydrochloride trihydrate.....	4429	Isosorbide mononitrate, diluted ..	4434
Isoprenaline hydrochloride..	4431		



01/2008:0854
corrected 10.1

Impurities with molecular masses greater than that of insulin. Examine by size-exclusion chromatography (2.2.30).

INSULIN PREPARATIONS, INJECTABLE

Praeparationes insulini iniectionabiles

Injectable insulin preparations comply with the requirements for Injections prescribed in the monograph on Parenteral preparations (0520).

DEFINITION

Injectable insulin preparations are sterile preparations of *Insulin, human* (0838), *Insulin, porcine* (1638) or bovine insulin. They contain not less than 90.0 per cent and not more than the equivalent of 110.0 per cent of the amount of insulin stated on the label. They are either solutions or suspensions or they are prepared by combining solutions and suspensions.

PRODUCTION

The methods of preparation are designed to confer suitable properties with respect to the onset and duration of therapeutic action.

The following procedures are carried out in a suitable sequence, depending on the method of preparation:

- addition of suitable antimicrobial preservatives;
- addition of a suitable substance or substances to render the preparation isotonic with blood;
- addition of a suitable substance or substances to adjust the pH to the appropriate value;
- determination of the strength of the insulin-containing component or components followed, where necessary, by adjustment so that the final preparation contains the requisite number of International Units per millilitre;
- sterilisation by filtration of the insulin-containing component or components; once this procedure has been carried out all subsequent procedures are carried out aseptically using materials that have been sterilised by a suitable method.

In addition, where appropriate, suitable excipients are added and suitable procedures carried out to confer the appropriate physical form on the insulin-containing component or components. The final preparation is distributed aseptically into sterile containers which are closed so as to exclude microbial contamination.

TESTS

pH (2.2.3). The pH of the solution or suspension is 6.9 to 7.8, unless otherwise prescribed in the specific monograph.

Insulin in the supernatant. For injectable insulin preparations that are suspensions, not more than 2.5 per cent of the total insulin content, unless otherwise stated. Centrifuge 10 mL of the suspension at 1500 g for 10 min and carefully separate the supernatant and the residue. Determine the insulin content of the supernatant (S) by a suitable method, for example using the chromatographic conditions described under Assay. Calculate the percentage of insulin in solution using the following expression:

$$\frac{100S}{T}$$

where *T* is the total insulin content determined as described under the Assay.

Test solution. Add 4 µL of 6 M hydrochloric acid *R* per millilitre of the preparation to be examined, whether a suspension or a solution, to obtain a clear acid insulin solution. When sampling a suspension, agitate the material prior to sampling in order to obtain a homogeneous sample. If a suspension does not turn clear within 5 min of the initial addition of hydrochloric acid, add small aliquots of acid (less than 4 µL per millilitre) until a solution is obtained. Preparations with concentrations higher than 100 IU/mL need to be diluted with 0.01 M hydrochloric acid to avoid overloading the column with insulin monomer.

Resolution solution. Use a solution of insulin (approximately 4 mg/mL), containing more than 0.4 per cent of high molecular mass proteins. An injectable insulin preparation, whether a solution or a suspension, that has been clarified with a sufficient amount of 6 M hydrochloric acid *R*, containing the indicated percentage of high molecular mass proteins, or a solution prepared from insulin, dissolved in 0.01 M hydrochloric acid, may be used. Insulin containing the indicated percentage of high molecular mass proteins may be prepared by allowing insulin powder to stand at room temperature for about ten days.

Maintain the solutions at 2 °C to 10 °C and use within 30 h (soluble insulin injection) or 7 days (other insulin preparations). If an automatic injector is used, maintain the temperature at 2 °C to 10 °C.

The chromatographic procedure may be carried out using:

- a column 0.3 m long and at least 7.5 mm in internal diameter packed with *hydrophilic silica gel for chromatography R* (5 µm to 10 µm), of a grade suitable for the separation of insulin monomer from dimers and polymers;
- as mobile phase at a flow rate of 0.5 mL/min a mixture consisting of 15 volumes of *glacial acetic acid R*, 20 volumes of *acetonitrile R* and 65 volumes of a 1.0 g/L solution of *arginine R*; filter and degas;
- as detector a spectrophotometer set at 276 nm.

Equilibration of the column. Before using a new column for chromatographic analysis, equilibrate by repeated injections of an insulin solution containing high molecular mass proteins. This can be done by at least three injections of the resolution solution. The column is equilibrated when repeatable results are obtained from two subsequent injections. If protamine-containing samples are to be analysed, the equilibration of the column is performed using a solution containing protamine.

Inject 100 µL of the resolution solution. When the chromatograms are recorded under the prescribed conditions, the retention times are: polymeric insulin complexes or covalent insulin-protamine complex: about 13 min to 17 min, covalent insulin dimer: about 17.5 min, insulin monomer: about 20 min, salts: about 22 min. If the sample solution contains preservatives, for example methyl paraben, *m*-cresol or phenol, these compounds elute later. The test is not valid unless the resolution, defined by the ratio of the height of the dimer peak to the height above the baseline of the valley separating the monomer and dimer peaks, is at least 2.0.

Inject 100 µL of the test solution. Record the chromatogram for approximately 35 min. In the chromatogram obtained, the sum of the areas of any peak with a retention time less than that of the insulin peak is not greater than 3.0 per cent (protamine containing preparations) or 2.0 per cent (non-protamine containing preparations) of the total area of the peaks. Disregard any peak with a retention time greater than that of the insulin peak.

Related proteins. Examine by liquid chromatography (2.2.29) as described under Assay, following the elution conditions as described in the table below:

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)	Comment
0 - 30	42	58	isocratic
30 - 44	42 → 11	58 → 89	linear gradient
44 - 50	11	89	isocratic

Maintain the solutions at 2 °C to 10 °C and use within 24 h. Perform a system suitability check (resolution, linearity) as described under Assay. If necessary, the relative proportions of the mobile phases may be adjusted to ensure complete elution of A21 desamido porcine insulin before commencement of the gradient. The profile of the gradient may also be adjusted to ensure complete elution of all insulin related impurities.

Inject 20 µL of the test solution and 20 µL of either reference solution (a), for insulin preparations containing 100 IU/mL, or reference solution (b), for insulin preparations containing 40 IU/mL. If necessary, adjust the injection volume to a volume between 10 µL and 20 µL in accordance with the results obtained in the test for linearity as described under Assay. Record the chromatograms for approximately 50 min. If necessary, make further adjustments to the mobile phase in order to ensure that the antimicrobial preservatives present in the test solution are well separated from the insulin and show a shorter retention time. A small reduction in the concentration of acetonitrile increases the retention time of the insulin peaks relatively more than those of the preservatives. In the chromatogram obtained with either reference solution (a), or reference solution (b), as appropriate, A21 desamido insulin appears as a small peak after the principal peak and has a retention time of about 1.3 relative to the principal peak, due to insulin. In the chromatogram obtained with the test solution, the area of the peak due to A21 desamido insulin is not greater than 5.0 per cent of the total area of the peaks; the sum of the areas of any other peaks, apart from those due to insulin and A21 desamido insulin is not greater than 6.0 per cent of the total area of the peaks. Disregard the peaks due to the preservatives and protamine (early eluting peaks).

Total zinc. Not more than the amount stated in the individual monograph, determined by atomic absorption spectrometry (2.2.23, Method I).

Use the following method, unless otherwise prescribed in the specific monograph.

Test solution. Shake the preparation gently and dilute a volume containing 200 IU of insulin to 25.0 mL with 0.01 M hydrochloric acid. Dilute if necessary to a suitable concentration of zinc (for example 0.4 µg to 1.6 µg of Zn per millilitre) with 0.01 M hydrochloric acid.

Reference solutions. Use solutions containing 0.40 µg, 0.80 µg, 1.00 µg, 1.20 µg and 1.60 µg of Zn per millilitre, freshly prepared by diluting zinc standard solution (5 mg/mL Zn) R with 0.01 M hydrochloric acid.

Measure the absorbance at 213.9 nm using a zinc hollow-cathode lamp as source of radiation and an air-acetylene flame of suitable composition (for example 11 L of air and 2 L of acetylene per minute).

Zinc in solution. Where applicable, not more than the amount stated in the individual monograph, determined by atomic absorption spectrometry (2.2.23, Method I).

Test solution. Centrifuge the preparation to be examined and dilute 1 mL of the clear supernatant obtained to 25.0 mL with water R. Dilute if necessary to a suitable concentration of zinc (for example 0.4 µg to 1.6 µg of Zn per millilitre) with water R.

Reference solutions. Use solutions containing 0.40 µg, 0.80 µg, 1.00 µg, 1.20 µg and 1.60 µg of Zn per millilitre, freshly prepared by diluting zinc standard solution (5 mg/mL Zn) R with 0.01 M hydrochloric acid.

Measure the absorbance at 213.9 nm using a zinc hollow-cathode lamp as source of radiation and an air-acetylene flame of suitable composition (for example 11 L of air and 2 L of acetylene per minute).

Bacterial endotoxins (2.6.14): less than 80 IU per 100 IU of insulin.

ASSAY

Examine by liquid chromatography (2.2.29).

Test solution. Add 4 µL of 6 M hydrochloric acid R per millilitre of the preparation to be examined, whether a suspension or a solution, to obtain a clear solution. When sampling a suspension, shake the material prior to sampling in order to obtain a homogeneous sample. If a suspension does not turn clear within 5 min of the initial addition of acid, add small aliquots of acid (less than 4 µL per millilitre) until a solution is obtained. For a preparation containing more than 100 IU/mL, an additional dilution with 0.01 M hydrochloric acid is necessary to avoid overloading the column.

Reference solution (a). For a preparation containing a single species of insulin, dissolve in 0.01 M hydrochloric acid, as appropriate, the contents of a vial of human insulin CRS, porcine insulin CRS or bovine insulin CRS to obtain a concentration of 4.0 mg/mL. For a preparation containing both bovine and porcine insulins, mix 1.0 mL of a solution containing 4.0 mg of bovine insulin CRS per millilitre of 0.01 M hydrochloric acid and 1.0 mL of a solution containing 4.0 mg of porcine insulin CRS per millilitre of 0.01 M hydrochloric acid. Reference solution (a) is used for the assay of insulin preparations containing 100 IU/mL.

Reference solution (b). Dilute 4.0 mL of reference solution (a) to 10.0 mL with 0.01 M hydrochloric acid. Reference solution (b) is used for the assay of insulin preparations containing 40 IU/mL.

Reference solution (c). Dissolve the contents of a vial of human insulin CRS in 0.01 M hydrochloric acid to obtain a concentration of 4.0 mg/mL.

Reference solution (d). Dissolve the contents of a vial of insulin porcine for system suitability CRS in 0.01 M hydrochloric acid to obtain a concentration of 4 mg/mL.

Reference solution (e). Dilute 1.0 mL of reference solution (a) to 10.0 mL with 0.01 M hydrochloric acid.

Reference solution (f). Dilute 1.0 mL of reference solution (b) to 10.0 mL with 0.01 M hydrochloric acid.

Resolution solution. Mix 1.0 mL of reference solution (c) and 1.0 mL of reference solution (d).

Maintain the solutions at 2 °C to 10 °C and use within 48 h. If an automatic injector is used, maintain the temperature at 2 °C to 10 °C.

The chromatographic procedure may be carried out using:

- a stainless steel column 0.25 m long and 4.6 mm in internal diameter packed with octadecylsilyl silica gel for chromatography R (5 µm);
- as mobile phase at a flow rate of 1 mL/min the following solutions prepared and maintained at a temperature not lower than 20 °C:

Mobile phase A. Dissolve 28.4 g of anhydrous sodium sulfate R in water for chromatography R and dilute to 1000 mL with the same solvent; add 2.7 mL of phosphoric acid R; adjust the pH to 2.3, if necessary, with ethanolamine R; filter and degas;

Mobile phase B. Mix 550 mL of mobile phase A with 450 mL of acetonitrile R1. Warm the solution to a temperature not lower than 20 °C in order to avoid precipitation (mixing of mobile phase A with acetonitrile is endothermic); filter and degas;

- as detector a spectrophotometer set at 214 nm; maintaining the temperature of the column at 40 °C.

01/2017:2675
corrected 10.1

Elute with a mixture of 42 volumes of mobile phase A and 58 volumes of mobile phase B, adjusted if necessary.

Inject 20 µL of the resolution solution and 20 µL of reference solution (d). Record the chromatogram of the resolution solution until the peak corresponding to the principal peak in the chromatogram obtained with reference solution (d) is clearly visible. In the chromatogram obtained with the resolution solution, identify the peaks due to porcine insulin and human insulin. The test is not valid unless the resolution between the peaks due to human insulin and porcine insulin is at least 1.2. If necessary, adjust the concentration of acetonitrile in the mobile phase until this resolution is achieved.

Inject 20 µL of the test solution and 20 µL of either reference solutions (a) and (e), for insulin preparations containing 100 IU/mL, or 20 µL of reference solutions (b) and (f), for insulin preparations containing 40 IU/mL. If necessary, make further adjustments of the mobile phase in order to ensure that the antimicrobial preservatives present in the test solution are well separated from the insulin and show shorter retention times. A small reduction in the concentration of acetonitrile increases the retention time of the insulin peaks relatively more than those of the preservatives. If necessary, after having carried out the chromatography of a solution wash the column with a mixture of equal volumes of *acetonitrile R1* and *water for chromatography R* for a sufficient time to ensure elution of any interfering substances before injecting the next solution. The test is not valid unless the area of the principal peak in the chromatogram obtained with reference solution (a) or (b) is 10 ± 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (e) or (f). If this test fails, adjust the injection volume between 10 µL and 20 µL, in order to be in the linearity range of the detector.

Calculate the content of insulin plus A21 desamido insulin from the area of the peak due to the bovine, porcine or human insulin and that of any peak due to the A21 desamido insulin, using the declared content of insulin plus A21 desamido insulin in *bovine insulin CRS*, *porcine insulin CRS* or *human insulin CRS*, as appropriate. For preparations containing both bovine and porcine insulin use the sum of the areas of both the bovine and porcine insulin peaks and of the peaks due to the A21 desamido insulin⁽¹⁾ derivatives.

STORAGE

Unless otherwise prescribed, store in a sterile, airtight, tamper-evident container, protected from light, at a temperature of 2 °C to 8 °C. Insulin preparations are not to be frozen.

LABELLING


The label states:

- the potency in International Units per millilitre;
- the concentration in terms of the number of milligrams of insulin per millilitre (for preparations containing both bovine insulin and porcine insulin the concentration is stated as the combined amount of both insulins);
- where applicable, that the substance is produced by enzymatic modification of porcine insulin;
- where applicable, that the substance is produced by recombinant DNA technology;
- where applicable, the animal species of origin;
- that the preparation must not be frozen;
- where applicable, that the preparation must be resuspended before use.



IRINOTECAN HYDROCHLORIDE TRIHYDRATE

Irinotecani hydrochloridum trihydricum



$C_{33}H_{39}ClN_6O_6 \cdot 3H_2O$
[136572-09-3]

M_r 677

DEFINITION

(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate hydrochloride trihydrate.

Content: 98.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: pale yellow or yellow, crystalline powder.

Solubility: sparingly soluble in water, in ethanol (96 per cent) and in methanol.

It shows polymorphism (5.9).

IDENTIFICATION

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: *irinotecan hydrochloride trihydrate CRS*.

If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in *methanol R*, evaporate to dryness and record new spectra using the residues.

B. Water (see Tests).

C. It gives reaction (a) of chlorides (2.3.1).

Dissolve 0.10 g in *water R* and dilute to 50 mL with the same solvent.

TESTS

Appearance of solution. The solution is clear (2.2.1) and not more intensely coloured than reference solution GY₂ (2.2.2, *Method II*).

Dissolve 0.200 g in *water R* with heating at 80 °C and dilute to 20 mL with the same solvent.

Enantiomeric purity. Liquid chromatography (2.2.29).

Solvent mixture: *diethylamine R*, *anhydrous ethanol R* (0.4:100 V/V).

Test solution. Dissolve 15.0 mg of the substance to be examined in the solvent mixture and dilute to 10.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b). Dissolve the contents of a vial of *irinotecan for system suitability 1 CRS* (containing impurity L) in 1 mL of the solvent mixture.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: *cellulose derivative of silica gel for chiral separation R* (10 µm).

(1) 100 IU are equivalent to 3.47 mg of human insulin, to 3.45 mg of porcine insulin and to 3.42 mg of bovine insulin.

Mobile phase: diethylamine R, anhydrous ethanol R, hexane R (0.2:50:50 V/V/V).

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 370 nm.

Injection: 20 µL.

Run time: 1.5 times the retention time of irinotecan.

Identification of impurities: use the chromatogram obtained with reference solution (b) to identify the peak due to impurity L.

Relative retention with reference to irinotecan (retention time = about 15 min): impurity L = about 0.7.

System suitability:

- **resolution:** minimum 1.5 between the peaks due to impurity L and irinotecan in the chromatogram obtained with reference solution (b).

Calculation of percentage content:

- for impurity L, use the concentration of irinotecan hydrochloride trihydrate in reference solution (a).

Limit:

- **impurity L:** maximum 0.15 per cent.

Related substances. Liquid chromatography (2.2.29). Carry out the test protected from light.

Solvent mixture: acetonitrile R, methanol R, mobile phase A (25:25:50 V/V/V).

Test solution. Dissolve 50.0 mg of the substance to be examined in the solvent mixture and dilute to 50.0 mL with the solvent mixture.

Reference solution (a). Dissolve 50.0 mg of irinotecan hydrochloride trihydrate CRS in the solvent mixture and dilute to 50.0 mL with the solvent mixture.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (c). Dissolve the contents of a vial of irinotecan for peak identification CRS (containing impurities C and E) in 1 mL of the solvent mixture.

Reference solution (d). Dissolve 5 mg of irinotecan for system suitability 2 CRS (containing impurity M) in the solvent mixture and dilute to 10 mL with the solvent mixture.

Column:

- **size:** $l = 0.25$ m, $\varnothing = 4.6$ mm;
- **stationary phase:** end-capped octadecylsilyl silica gel for chromatography with embedded polar groups R (5 µm).

Mobile phase:

- **mobile phase A:** dissolve 2.72 g of potassium dihydrogen phosphate R in 950 mL of water for chromatography R, adjust to pH 3.5 with dilute phosphoric acid R and dilute to 1000 mL with water for chromatography R;
- **mobile phase B:** methanol R2, acetonitrile R1 (40:60 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 2	80	20
2 - 42	80 → 30	20 → 70
42 - 47	30	70

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 220 nm.

Injection: 10 µL of the test solution and reference solutions (b), (c) and (d).

Identification of impurities: use the chromatogram supplied with irinotecan for peak identification CRS and the chromatogram obtained with reference solution (c) to identify the peaks due to impurities C and E; use the chromatogram obtained with reference solution (d) to identify the peak due to impurity M.

Relative retention with reference to irinotecan (retention time = about 17 min): impurity M = about 0.9; impurity C = about 1.3; impurity E = about 1.5.

System suitability:

- **resolution:** minimum 2.0 between the peaks due to impurity M and irinotecan in the chromatogram obtained with reference solution (d).

Calculation of percentage contents:

- **correction factor:** multiply the peak area of impurity M by 1.3;
- for each impurity, use the concentration of irinotecan hydrochloride trihydrate in reference solution (b).

Limits:

- **impurities C, E, M:** for each impurity, maximum 0.15 per cent;
- **unspecified impurities:** for each impurity, maximum 0.10 per cent;
- **total:** maximum 0.5 per cent;
- **reporting threshold:** 0.05 per cent.

Water (2.5.12): 7.0 per cent to 9.0 per cent, determined on 0.100 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: 10 µL of the test solution and reference solution (a).

Calculate the percentage content of $C_{33}H_{39}ClN_4O_6$ taking into account the assigned content of irinotecan hydrochloride trihydrate CRS.


STORAGE

In an airtight container, protected from light.


IMPURITIES

Specified impurities: C, E, L, M.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, D, F, G, H, K.




A. (4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate (11-desethyl irinotecan),




B. (4S)-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (9-hydroxycamptothecin),




- C. (4*S*)-4,8,11-triethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate (8-ethyl irinotecan),




- D. (4*S*)-4-ethyl-4-hydroxy-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-3,14(4*H*,12*H*)-dione (camptothecin),




- E. (4*S*)-4,11-diethyl-4,9-dihydroxy-1*H*-pyrano[3',4':6,7]-indolizino[1,2-*b*]quinoline-3,14(4*H*,12*H*)-dione (11-ethyl-9-hydroxycamptothecin),




- F. (4*S*)-4,11-diethyl-4-hydroxy-1*H*-pyrano[3',4':6,7]-indolizino[1,2-*b*]quinoline-3,14(4*H*,12*H*)-dione (11-ethylcamptothecin),




- G. (4*S*)-4,8,11-triethyl-4,9-dihydroxy-1*H*-pyrano[3',4':6,7]-indolizino[1,2-*b*]quinoline-3,14(4*H*,12*H*)-dione (8,11-diethyl-9-hydroxycamptothecin),




- H. (4*S*)-11-ethyl-4-hydroxy-4-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate (4-methyl irinotecan analogue),



- K. (4*S*)-4-ethyl-4-hydroxy-11-(1-hydroxypropyl)-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate,



- L. (4*R*)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate (irinotecan enantiomer).




- M. (4*S*)-4,11-diethyl-4,12-dihydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate (12-hydroxy irinotecan).

04/2020:1332



ISOPRENALINE HYDROCHLORIDE

Isoprenalini hydrochloridum



$C_{11}H_{18}ClNO_3$
[51-30-9]

M_r 247.7

DEFINITION

(1*RS*)-1-(3,4-Dihydroxyphenyl)-2-[(1-methylethyl)amino]-ethanol hydrochloride.

Content: 98.0 per cent to 101.5 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: freely soluble in water, sparingly soluble in ethanol (96 per cent), practically insoluble in methylene chloride.

IDENTIFICATION

First identification: B, C, E.

Second identification: A, C, D, E.

A. Melting point (2.2.14): 165 °C to 170 °C, with decomposition.

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: isoprenaline hydrochloride CRS.

C. Optical rotation (see Tests).

D. To 0.1 mL of solution S (see Tests) add 0.05 mL of *ferric chloride solution R1* and 0.9 mL of *water R*. A green colour is produced. Add dropwise *sodium hydrogen carbonate solution R*. The colour becomes blue and then red.

E. To 0.5 mL of solution S add 1.5 mL of *water R*. The solution gives reaction (a) of chlorides (2.3.1).

TESTS

Prepare the solutions immediately before use.

Solution S. Dissolve 2.5 g in *carbon dioxide-free water R* and dilute to 25.0 mL with the same solvent.

Appearance of solution. Solution S is clear (2.2.1) and not more intensely coloured than reference solution B₇ or BY₇ (2.2.2, *Method II*).

pH (2.2.3): 4.3 to 5.5.

Mix 5 mL of solution S and 5 mL of *carbon dioxide-free water R*.

Optical rotation (2.2.7): -0.10° to $+0.10^\circ$, determined on solution S.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 50.0 mg of the substance to be examined in the mobile phase and dilute to 10.0 mL with the mobile phase.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 5.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (b). Dissolve 2.5 mg of *orciprenaline sulfate CRS* in the mobile phase and dilute to 100 mL with the mobile phase.

Reference solution (c). To 5 mL of reference solution (a) add 5 mL of reference solution (b).

Reference solution (d). Dissolve 6.0 mg of *isoprenaline impurity A CRS* in the mobile phase and dilute to 50.0 mL with the mobile phase. Dilute 10.0 mL of the solution to 50.0 mL with the mobile phase.

Column:

- size: $l = 0.125$ m, $\varnothing = 4.0$ mm;
- stationary phase: octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase: *methanol R*, 11.5 g/L solution of *phosphoric acid R* (5:95 V/V).

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 280 nm.

Injection: 20 μ L.

Run time: 7 times the retention time of isoprenaline.

Identification of impurities: use the chromatogram obtained with reference solution (d) to identify the peak due to impurity A; use the chromatogram obtained with reference solution (b) to identify the peak due to orciprenaline.

Relative retention with reference to isoprenaline (retention time = about 4 min): orciprenaline = about 1.5; impurity A = about 1.8. If necessary, adjust the concentration of methanol in the mobile phase.

System suitability: reference solution (c):

- resolution: minimum 3.0 between the peaks due to isoprenaline and orciprenaline.

Limits:

- impurity A: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (d) (0.5 per cent);
- unspecified impurities: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- total: maximum 1.0 per cent;
- disregard limit: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Loss on drying (2.2.32): maximum 1.0 per cent, determined on 1.000 g by drying *in vacuo* at 15–25 °C for 4 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

In order to avoid overheating in the reaction medium, mix thoroughly throughout and stop the titration immediately after the end-point has been reached.

Dissolve 0.150 g in 10 mL of *anhydrous formic acid R* and add 50 mL of *acetic anhydride R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).


1 mL of 0.1 M *perchloric acid* is equivalent to 24.77 mg of C₁₁H₁₈ClNO₃.

STORAGE

In an airtight container, protected from light.

IMPURITIES

Specified impurities: A.




A. 1-(3,4-dihydroxyphenyl)-2-[(1-methylethyl)amino]ethanone.

01/2008:1117
corrected 10.1



ISOSORBIDE DINITRATE, DILUTED

Isosorbidi dinitras dilutus



C₆H₈N₂O₈

M_r 236.1

DEFINITION

Dry mixture of isosorbide dinitrate and *Lactose monohydrate* (0187) or *Mannitol* (0559).

Content: 95.0 per cent *m/m* to 105.0 per cent *m/m* of the content of 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate stated on the label.

CAUTION: undiluted isosorbide dinitrate may explode if subjected to percussion or excessive heat. Appropriate precautions must be taken and only very small quantities handled.

CHARACTERS

Appearance: undiluted isosorbide dinitrate is a fine, white or almost white, crystalline powder.

Solubility: undiluted isosorbide dinitrate is very slightly soluble in water, very soluble in acetone, sparingly soluble in ethanol (96 per cent).

The solubility of the diluted product depends on the diluent and its concentration.

IDENTIFICATION

First identification: A, C, D.

Second identification: B, C, D.

A. Infrared absorption spectrophotometry (2.2.24).

Preparation: discs prepared with the residue obtained in identification test D.

Comparison: isosorbide dinitrate CRS.

B. Thin-layer chromatography (2.2.27).

Test solution. Shake a quantity of the substance to be examined corresponding to 10 mg of isosorbide dinitrate with 10 mL of *ethanol* (96 per cent) *R* for 5 min and filter.

Reference solution. Shake a quantity of isosorbide dinitrate CRS corresponding to 10 mg of isosorbide dinitrate with 10 mL of *ethanol* (96 per cent) *R* for 5 min and filter.

Plate: TLC silica gel *G* plate *R*.

Mobile phase: *methanol R*, *methylene chloride R* (5:95 V/V).

Application: 10 µL.

Development: over a path of 15 cm.

Drying: in a current of air.

Detection: spray with freshly prepared *potassium iodide and starch solution R*; expose to ultraviolet light at 254 nm for 15 min and examine in daylight.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

C. Thin-layer chromatography (2.2.27).

Test solution. Shake a quantity of the substance to be examined corresponding to 0.10 g of lactose or mannitol with 10 mL of *water R*. Filter if necessary.

Reference solution (a). Dissolve 0.10 g of *lactose monohydrate R* in *water R* and dilute to 10 mL with the same solvent.

Reference solution (b). Dissolve 0.10 g of *mannitol R* in *water R* and dilute to 10 mL with the same solvent.

Reference solution (c). Mix equal volumes of reference solutions (a) and (b).

Plate: TLC silica gel *G* plate *R*.

Mobile phase: *water R*, *methanol R*, *anhydrous acetic acid R*, *ethylene chloride R* (10:15:25:50 V/V/V/V); measure the volumes accurately since a slight excess of water produces cloudiness.

Application: 1 µL; thoroughly dry the points of application.

Development A: over a path of 15 cm.

Drying A: in a current of warm air.

Development B: immediately, over a path of 15 cm, after renewing the mobile phase.

Drying B: in a current of warm air.

Detection: spray with *4-aminobenzoic acid solution R*, dry in a current of cold air until the acetone is removed, then heat at 100 °C for 15 min; allow to cool, spray with a 2 g/L solution of *sodium periodate R*, dry in a current of cold air, and heat at 100 °C for 15 min.

System suitability: reference solution (c):

- the chromatogram shows 2 clearly separated spots.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with reference solution (a) for lactose or to the principal spot in the chromatogram obtained with reference solution (b) for mannitol.

D. Shake a quantity of the substance to be examined corresponding to 25 mg of isosorbide dinitrate with 10 mL of acetone R for 5 min. Filter, evaporate to dryness at a temperature below 40 °C and dry the residue over diphosphorus pentoxide R at a pressure of 0.7 kPa for 16 h. The melting point (2.2.14) of the residue is 69 °C to 72 °C.**TESTS****Impurity A. Thin-layer chromatography (2.2.27).**

Test solution. Shake a quantity of the substance to be examined corresponding to 0.10 g of isosorbide dinitrate with 5 mL of *ethanol* (96 per cent) *R* and filter.

Reference solution. Dissolve 10 mg of *potassium nitrate R* in 1 mL of *water R* and dilute to 100 mL with *ethanol* (96 per cent) *R*.

Plate: TLC silica gel plate *R*.

Mobile phase: *glacial acetic acid R*, *acetone R*, *toluene R* (15:30:60 V/V/V).

Application: 10 µL.

Development: over a path of 15 cm.

Drying: in a current of air until the acetic acid is completely removed.

Detection: spray copiously with freshly prepared *potassium iodide and starch solution R*; expose to ultraviolet light at 254 nm for 15 min and examine in daylight.

Limit:

- **impurity A:** any spot due to impurity A is not more intense than the principal spot in the chromatogram obtained with the reference solution (0.5 per cent, calculated as potassium nitrate).

Impurities B and C. Liquid chromatography (2.2.29).

Test solution (a). Sonicate a quantity of the substance to be examined corresponding to 25.0 mg of isosorbide dinitrate with 20 mL of the mobile phase for 15 min and dilute to 25.0 mL with the mobile phase. Filter the solution through a suitable membrane filter.

Test solution (b). Dilute 1.0 mL of test solution (a) to 10.0 mL with the mobile phase.

Reference solution (a). Sonicate a quantity of isosorbide dinitrate CRS corresponding to 25.0 mg of isosorbide dinitrate with 20 mL of the mobile phase for 15 min and dilute to 25.0 mL with the mobile phase. Filter the solution through a suitable membrane filter.

Reference solution (b). Dilute 1.0 mL of reference solution (a) to 10.0 mL with the mobile phase.

Reference solution (c). Dissolve 10.0 mg of isosorbide-2-nitrate CRS (impurity B) in the mobile phase and dilute to 10.0 mL with the mobile phase. Dilute 0.1 mL of this solution to 20.0 mL with the mobile phase.

Reference solution (d). Dissolve 10.0 mg of isosorbide mononitrate CRS (impurity C) in the mobile phase and dilute to 10.0 mL with the mobile phase. Dilute 0.1 mL of this solution to 20.0 mL with the mobile phase.

Reference solution (e). Dissolve 5 mg of isosorbide-2-nitrate CRS (impurity B) in the mobile phase and dilute to 10 mL with the mobile phase. To 1 mL of this solution add 0.5 mL of reference solution (a) and dilute to 10 mL with the mobile phase.

Column:

- **size:** $l = 0.25$ m, $\varnothing = 4.6$ mm;
- **stationary phase:** aminopropylsilyl silica gel for chromatography *R* (10 µm).

Mobile phase: *anhydrous ethanol R*, *trimethylpentane R* (15:85 V/V).

Flow rate: 1 mL/min.

Detection: spectrophotometer at 210–215 nm.

Injection: 10 µL of test solution (a) and reference solutions (c), (d) and (e).

Retention time: isosorbide dinitrate = about 5 min; impurity B = about 8 min; impurity C = about 11 min.

System suitability: reference solution (e):

- **resolution:** minimum 6.0 between the peaks due to isosorbide dinitrate and impurity B.

Limits:

- **impurity B:** not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.5 per cent);
- **impurity C:** not more than the area of the principal peak in the chromatogram obtained with reference solution (d) (0.5 per cent).

ASSAY

Liquid chromatography (2.2.29) as described in the test for impurities B and C with the following modifications.

Detection: spectrophotometer at 230 nm.

Injection: 20 µL of test solution (b) and reference solution (b).

If the areas of the peaks from 2 successive injections of reference solution (b) do not agree to within 1.0 per cent, then inject a further 4 times and calculate, for the 6 injections, the relative standard deviation.

System suitability: reference solution (b):

- *repeatability*: maximum relative standard deviation of 2.0 per cent after 6 injections.

Calculate the content of isosorbide dinitrate as a percentage of the declared content.

STORAGE

Protected from light.


LABELLING

The label states the percentage content of isosorbide dinitrate.


IMPURITIES

Specified impurities: A, B, C.

A. inorganic nitrates,



B. 1,4:3,6-dianhydro-D-glucitol 2-nitrate (isosorbide 2-nitrate),




C. 1,4:3,6-dianhydro-D-glucitol 5-nitrate (isosorbide 5-nitrate, isosorbide mononitrate).

01/2008:1118
corrected 10.1

ISOSORBIDE MONONITRATE,
DILUTED

Isosorbidi mononitras dilutus



C₆H₉NO₆

*M*_r 191.1

DEFINITION

Dry mixture of isosorbide mononitrate and *Lactose monohydrate* (0187) or *Mannitol* (0559).

Content: 95.0 per cent *m/m* to 105.0 per cent *m/m* of the content of 1,4:3,6-dianhydro-D-glucitol 5-nitrate stated on the label.

CHARACTERS

Appearance: undiluted isosorbide mononitrate is a white or almost white, crystalline powder.

Solubility: undiluted isosorbide mononitrate is freely soluble in water, in acetone, in ethanol (96 per cent) and in methylene chloride.

The solubility of the diluted product depends on the diluent and its concentration.

IDENTIFICATION

First identification: A, C, D.

Second identification: B, C, D.

A. Infrared absorption spectrophotometry (2.2.24).

Preparation: discs prepared with the residue obtained in identification test D.

Comparison: isosorbide mononitrate CRS.

B. Thin-layer chromatography (2.2.27).

Test solution. Shake a quantity of the substance to be examined corresponding to 10 mg of isosorbide mononitrate with 10 mL of *ethanol* (96 per cent) R for 5 min and filter.

Reference solution. Dissolve 10 mg of isosorbide mononitrate CRS in *ethanol* (96 per cent) R and dilute to 10 mL with the same solvent.

Plate: TLC silica gel G plate R.

Mobile phase: *methanol* R, *methylene chloride* R (5:95 V/V).

Application: 10 µL.

Development: over a path of 15 cm.

Drying: in a current of air.

Detection: spray with freshly prepared *potassium iodide* and *starch* solution R. Expose to ultraviolet light at 254 nm for 15 min and examine in daylight.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

C. Thin-layer chromatography (2.2.27).

Test solution. Shake a quantity of the substance to be examined corresponding to 0.10 g of lactose or mannitol with 10 mL of *water* R; filter if necessary.

Reference solution (a). Dissolve 0.10 g of *lactose monohydrate* R in *water* R and dilute to 10 mL with the same solvent.

Reference solution (b). Dissolve 0.10 g of *mannitol* R in *water* R and dilute to 10 mL with the same solvent.

Reference solution (c). Mix equal volumes of reference solutions (a) and (b).

Plate: TLC silica gel G plate R.

Mobile phase: *water* R, *methanol* R, *anhydrous acetic acid* R, *ethylene chloride* R (10:15:25:50 V/V/V/V); measure the volumes accurately since a slight excess of water produces cloudiness.

Application: 1 µL; thoroughly dry the points of application.

Development A: over a path of 15 cm.

Drying A: in a current of warm air.

Development B: immediately, over a path of 15 cm, after renewing the mobile phase.

Drying B: in a current of warm air.

Detection: spray with 4-aminobenzoic acid solution R and dry in a current of cold air until the acetone is removed; heat at 100 °C for 15 min and allow to cool; spray with a 2 g/L solution of *sodium periodate* R and dry in a current of cold air; heat at 100 °C for 15 min.

System suitability: reference solution (c):

- the chromatogram shows 2 clearly separated spots.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with

reference solution (a) for lactose or to the principal spot in the chromatogram obtained with reference solution (b) for mannitol.

- D. Shake a quantity of the substance to be examined corresponding to 25 mg of isosorbide mononitrate with 10 mL of *acetone R* for 5 min. Filter, evaporate to dryness at a temperature below 40 °C and dry the residue over *diphosphorus pentoxide R* at a pressure of 0.7 kPa for 16 h. The melting point (2.2.14) of the residue is 89 °C to 91 °C.

TESTS

Impurity A. Thin-layer chromatography (2.2.27).

Test solution. Shake a quantity of the substance to be examined corresponding to 0.10 g of isosorbide mononitrate with 5 mL of *ethanol (96 per cent) R* and filter.

Reference solution. Dissolve 10 mg of *potassium nitrate R* in 1 mL of *water R* and dilute to 100 mL with *ethanol (96 per cent) R*.

Plate: TLC silica gel plate R.

Mobile phase: *glacial acetic acid R*, *acetone R*, *toluene R* (15:30:60 V/V/V).

Application: 10 µL.

Development: over a path of 15 cm.

Drying: in a current of air until the acetic acid is completely removed.

Detection: spray copiously with freshly prepared *potassium iodide and starch solution R*; expose to ultraviolet light at 254 nm for 15 min and examine in daylight.

Limit:

- **impurity A:** any spot due to impurity A is not more intense than the principal spot in the chromatogram obtained with the reference solution (0.5 per cent, calculated as potassium nitrate).

Impurities B and C. Liquid chromatography (2.2.29).

Test solution (a). Sonicate a quantity of the substance to be examined corresponding to 25.0 mg of isosorbide mononitrate with 20 mL of the mobile phase for 15 min and dilute to 25.0 mL with the mobile phase. Filter the solution through a suitable membrane filter.

Test solution (b). Dilute 1.0 mL of test solution (a) to 10.0 mL with the mobile phase.

Reference solution (a). Dissolve 25.0 mg of *isosorbide mononitrate CRS* in the mobile phase and dilute to 25.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (b). Dissolve 10.0 mg of *isosorbide-2-nitrate CRS* (impurity C) in the mobile phase and dilute to 10.0 mL with the mobile phase. Dilute 0.1 mL of this solution to 20.0 mL with the mobile phase.

Reference solution (c). Sonicate a quantity of *isosorbide dinitrate CRS* (impurity B) corresponding to 10.0 mg of isosorbide dinitrate in 15 mL of the mobile phase for 15 min and dilute to 20.0 mL with the mobile phase. Filter the solution through a suitable membrane filter. Dilute 0.1 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (d). Dissolve 5 mg of *isosorbide mononitrate CRS* and 5 mg of *isosorbide-2-nitrate CRS* (impurity C) in the mobile phase and dilute to 10 mL with the mobile phase. Dilute 1 mL of this solution to 10 mL with the mobile phase.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;

- **stationary phase:** *aminopropylsilyl silica gel for chromatography R* (10 µm).

Mobile phase: *anhydrous ethanol R*, *trimethylpentane R* (15:85 V/V).

Flow rate: 1 mL/min.

Detection: spectrophotometer at 210-215 nm.

Injection: 10 µL of test solution (a) and reference solutions (b), (c) and (d).

Retention time: impurity B = about 5 min; impurity C = about 8 min; isosorbide 5-nitrate = about 11 min.

System suitability: reference solution (d):

- **resolution:** minimum 4.0 between the peaks due to impurity C and isosorbide 5-nitrate.

Limits:

- **impurity B:** not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.5 per cent);
- **impurity C:** not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent).

ASSAY

Liquid chromatography (2.2.29) as described in the test for impurities B and C with the following modifications.

Detection: spectrophotometer at 230 nm.

Injection: 20 µL of test solution (b) and reference solution (a).

If the areas of the peaks from 2 successive injections of reference solution (a) do not agree to within 1.0 per cent, then inject a further 4 times and calculate, for the 6 injections, the relative standard deviation.

System suitability: reference solution (a):

- **repeatability:** maximum relative standard deviation of 2.0 per cent after 6 injections.

Calculate the content of isosorbide mononitrate as a percentage of the declared content.

STORAGE

Protected from light.


LABELLING

The label states the percentage content of isosorbide mononitrate.


IMPURITIES

Specified impurities: A, B, C.

A. inorganic nitrates,



B. 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate (isosorbide dinitrate),



C. 1,4:3,6-dianhydro-D-glucitol 2-nitrate (isosorbide 2-nitrate).

L


Levocarnitine.....	4439	Lisinopril dihydrate.....	4443
Levonorgestrel.....	4440		



01/2019:1339 – stationary phase: aminopropylsilyl silica gel for
corrected 10.1 chromatography R (10 µm);
 – temperature: 30 °C.

LEVOCARNITINE

Levocarnitinum



C₇H₁₅NO₃
 [541-15-1]

M_r 161.2

DEFINITION

(3R)-3-Hydroxy-4-(trimethylazaniumyl)butanoate.

Content: 98.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, crystalline powder or colourless crystals, hygroscopic.

Solubility: freely soluble in water, soluble in warm ethanol (96 per cent), practically insoluble in acetone.

IDENTIFICATION

First identification: A, B.

Second identification: A, C.

A. Specific optical rotation (see Tests).

B. Infrared absorption spectrophotometry (2.2.24).

Preparation: discs, prepared using substance previously dried *in vacuo* at 50 °C for 5 h.

Comparison: levocarnitine CRS.

C. To 1 mL of solution S (see Tests) add 9 mL of *water R*, 10 mL of *dilute sulfuric acid R* and 30 mL of *ammonium reineckate solution R*. A pink precipitate is formed. Allow to stand for 30 min. Filter and wash with *water R*, with *ethanol (96 per cent) R* and then with *acetone R* and dry at 80 °C. The precipitate melts (2.2.14) at 147 °C to 150 °C.

TESTS

Solution S. Dissolve 5.00 g in *carbon dioxide-free water R* prepared from *distilled water R* and dilute to 50.0 mL with the same solvent.

Appearance of solution. Solution S is clear (2.2.1) and colourless (2.2.2, *Method II*).

pH (2.2.3): 6.5 to 8.5.

Dilute 10 mL of solution S to 20 mL with *carbon dioxide-free water R*.

Specific optical rotation (2.2.7): – 32.0 to – 29.0 (anhydrous substance), determined on solution S at 25 °C.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 0.100 g of the substance to be examined in the mobile phase and dilute to 20.0 mL with the mobile phase.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (b). Dissolve 12.5 mg of *levocarnitine impurity A CRS* in *water R* and dilute to 50.0 mL with the same solvent. Dilute 2.0 mL of the solution to 20.0 mL with the mobile phase.

Reference solution (c). Dissolve 50 mg of the substance to be examined in 10 mL of reference solution (b).

Column:

– size: *l* = 0.30 m, Ø = 3.9 mm;

Mobile phase: mix 35 volumes of a 6.81 g/L solution of *potassium dihydrogen phosphate R* previously adjusted to pH 4.7 with *dilute sodium hydroxide solution R*, and 65 volumes of *acetonitrile R1*.

Flow rate: 1 mL/min.

Detection: spectrophotometer at 205 nm.

Injection: 25 µL.

Run time: twice the retention time of levocarnitine.

Identification of impurities: use the chromatogram obtained with reference solution (b) to identify the peak due to impurity A.

Relative retention with reference to levocarnitine (retention time = about 10 min): impurity A = about 1.1.

System suitability: reference solution (c):

– **resolution:** minimum 1.5 between the peaks due to levocarnitine and impurity A.

Limits:

- **impurity A:** not more than 0.6 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.3 per cent);
- **unspecified impurities:** for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- **total (excluding impurity A):** not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);
- **disregard limit:** 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Chlorides (2.4.4): maximum 200 ppm.

Dilute 2.5 mL of solution S to 15 mL with *water R*.

Sulfates (2.4.13): maximum 300 ppm.

Dilute 5 mL of solution S to 15 mL with *distilled water R*.

Water (2.5.12): maximum 1.0 per cent, determined on 2.00 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.125 g in a mixture of 3 volumes of *anhydrous formic acid R* and 50 volumes of *anhydrous acetic acid R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 16.12 mg of C₇H₁₅NO₃.


STORAGE

In an airtight container.


IMPURITIES

Specified impurities: A.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, C, D.




A. (2EZ)-4-(trimethylazaniumyl)but-2-enoate,



- B. (1R,3SR)-1,2,2-trimethylcyclopentane-1,3-dicarboxylic acid (camphoric acid),



- C. (2R)-4-amino-2-hydroxy-N,N,N-trimethyl-4-oxobutan-1-aminium (carnitinamide),




- D. (2EZ)-4-amino-N,N,N-trimethyl-4-oxobut-2-en-1-aminium.

01/2014:0926
corrected 10.1



LEVONORGESTREL

Levonorgestrelum



$C_{21}H_{28}O_2$
[797-63-7]

M_r 312.5

DEFINITION

13-Ethyl-17-hydroxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-one.

Content: 98.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: practically insoluble in water, sparingly soluble in methylene chloride, slightly soluble in ethanol (96 per cent).

IDENTIFICATION

A. Specific optical rotation (see Tests).

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: levonorgestrel CRS.

TESTS

Specific optical rotation (2.2.7): -35 to -30 .

Dissolve 0.200 g in methylene chloride R and dilute to 20.0 mL with the same solvent.

Related substances

A. Impurities A, B, H, K, M, O, S, U. Liquid chromatography (2.2.29).

Solvent mixture: water R, acetonitrile R (30:70 V/V).

Test solution. Dissolve 10.0 mg of the substance to be examined in 7 mL of acetonitrile R using sonication and dilute to 10.0 mL with water R.

Reference solution (a). Dissolve 5 mg of levonorgestrel for system suitability 1 CRS (containing impurities A, H, K, M, O and S) in 3.5 mL of acetonitrile R using sonication and dilute to 5 mL with water R.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (c). Dissolve 5.0 mg of levonorgestrel impurity B CRS in 35 mL of acetonitrile R and dilute to 50.0 mL with water R. Dilute 1.0 mL of the solution to 100.0 mL with the solvent mixture.

Reference solution (d). Dissolve 5.0 mg of norethisterone CRS (impurity U) in 35 mL of acetonitrile R and dilute to 50.0 mL with water R. Dilute 1.0 mL of the solution to 100.0 mL with the solvent mixture.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octylsilyl silica gel for chromatography with embedded polar groups R (5 μ m);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: acetonitrile R1, water for chromatography R (40:60 V/V);
- mobile phase B: acetonitrile R1;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 50	100 $\rightarrow$ 20	0 $\rightarrow$ 80

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 215 nm and, for impurity O, at 200 nm.

Injection: 50 μ L.

Identification of impurities: use the chromatograms supplied with levonorgestrel for system suitability 1 CRS and the chromatograms obtained with reference solution (a) at 215 nm to identify the peaks due to impurities A, H, K, M and S, and at 200 nm to identify the peak due to impurity O; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity B; use the chromatogram obtained with reference solution (d) to identify the peak due to impurity U.

Relative retention with reference to levonorgestrel (retention time = about 20 min): impurity H = about 0.5; impurity U = about 0.8; impurity K = about 0.85; impurity A = about 0.91; impurity M = about 0.95; impurity O = about 1.16; impurity B = about 1.26; impurity S = about 1.9.

System suitability:

- *signal-to-noise ratio*: minimum 60 for the principal peak in the chromatogram obtained with reference solution (b);
- *peak-to-valley ratio*: minimum 3.0, where H_p = height above the baseline of the peak due to impurity M and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to impurity A in the chromatogram obtained with reference solution (a).

Calculation of percentage contents:

- *correction factors*: multiply the peak areas of the following impurities by the corresponding correction factor: impurity A = 0.4; impurity M = 3.1; impurity O = 2.6;
- for impurity B, use the concentration of impurity B in reference solution (c);
- for impurity U, use the concentration of impurity U in reference solution (d);
- for impurities other than B and U, use the concentration of levonorgestrel in reference solution (b).

Limits:

- *impurities A, B, K*: for each impurity, maximum 0.3 per cent;
- *impurity O at 200 nm*: maximum 0.3 per cent;
- *impurities M, S, U*: for each impurity, maximum 0.2 per cent;
- *impurity H*: maximum 0.15 per cent;
- *unspecified impurities*: for each impurity, maximum 0.10 per cent;
- *sum of impurities other than O*: maximum 1.0 per cent;
- *reporting threshold*: 0.05 per cent.

B. Impurities V and W. Liquid chromatography (2.2.29).

Solvent mixture: water R, acetonitrile R (30:70 V/V).

Test solution. Dissolve 10.0 mg of the substance to be examined in 7 mL of acetonitrile R using sonication and dilute to 10.0 mL with water R.

Reference solution (a). Dissolve 5 mg of levonorgestrel for system suitability 2 CRS (containing impurities V and W) in 3.5 mL of acetonitrile R using sonication and dilute to 5 mL with water R.

Reference solution (b). Dissolve 5.0 mg of ethinylestradiol CRS in 35 mL of acetonitrile R using sonication and dilute to 50.0 mL with water R. Dilute 3.0 mL of the solution to 100.0 mL with the solvent mixture.

Column:

- *size*: $l = 0.15$ m, $\varnothing = 4.6$ mm;
- *stationary phase*: end-capped octadecylsilyl silica gel for chromatography compatible with 100 per cent aqueous mobile phases R (3 μ m).

Mobile phase:

- *mobile phase A*: acetonitrile R1, water for chromatography R (40:60 V/V);
- *mobile phase B*: water for chromatography R, acetonitrile R1 (10:90 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 1	92	8
1 - 3	92 → 82	8 → 18
3 - 6	82	18
6 - 16	82 → 60	18 → 40
16 - 21	60 → 0	40 → 100
21 - 32	0	100

Flow rate: 1 mL/min.

Detection: spectrophotometer at 200 nm.

Injection: 50 μ L.

Identification of impurities: use the chromatogram supplied with levonorgestrel for system suitability 2 CRS and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities V and W.

Relative retention with reference to levonorgestrel (retention time = about 12 min): impurity W = about 0.9; impurity V = about 1.9.

System suitability: reference solution (a):

- *resolution*: minimum 2.8 between the peaks due to impurity W and levonorgestrel.

Calculation of percentage contents:

- for each impurity, use the concentration of ethinylestradiol in reference solution (b).

Limits:

- *impurity W*: maximum 0.3 per cent;

- *impurity V*: maximum 0.15 per cent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.200 g in 45 mL of tetrahydrofuran R. Add 10 mL of a 100 g/L solution of silver nitrate R. After 1 min, titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.2.20). Carry out a blank titration.

1 mL of 0.1 M sodium hydroxide is equivalent to 31.25 mg of $C_{21}H_{28}O_2$.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: A, B, H, K, M, O, S, U, V, W.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): C, D, G, I, J, L, N, P, Q, R, T.




A. 13-ethyl-17-hydroxy-18,19-dinor-17 α -pregna-4,8(14)-dien-20-yn-3-one,




B. 13-ethyl-17-hydroxy-18,19-dinor-17 α -pregn-5(10)-en-20-yn-3-one,




C. 13-ethyl-3-ethynyl-18,19-dinor-17 α -pregna-3,5-dien-20-yn-17-ol,




D. 13-ethyl-18,19-dinor-17 α -pregn-4-en-20-yn-17-ol (3-deoxylevonorgestrel),




G. 13-ethyl-6 α ,17-dihydroxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-one (6 α -hydroxylevonorgestrel),




H. 13-ethyl-6 β ,17-dihydroxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-one (6 β -hydroxylevonorgestrel),




I. 13-ethyl-10,17-dihydroxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-one (10-hydroxylevonorgestrel),




J. 13-ethyl-17-hydroxy-18,19-dinor-17 α -pregn-4-en-20-yn-3,6-dione (6-oxolevonorgestrel),




K. 13-ethyl-17 β -hydroxygon-4-en-3-one (18-methylnandrolone),




L. 13-ethylgon-4-ene-3,17-dione (levodione),




M. 13-ethyl-17-hydroxy-18,19-dinor-17 α -pregna-4,6-dien-20-yn-3-one (Δ6-levonorgestrel),




N. 13-ethylgon-5(10)-ene-3,17-dione (Δ5(10)-levodione),




O. 13-ethyl-17-hydroxy-5 α -methoxy-18,19-dinor-17 α -pregn-20-yn-3-one (4,5-dihydro-5 α -methoxylevonorgestrel),




P. 13-ethyl-17-hydroxy-18,19-dinor-17 α -pregn-5-en-20-yn-3-one (Δ5-levonorgestrel),




Q. 13-ethyl-3-methoxygon-2,5(10)-dien-17 β -ol,




R. 13-ethyl-3-methoxygon-2,5(10)-dien-17-one,




S. 13-ethyl-3-methoxy-18,19-dinor-17 α -pregna-3,5-dien-20-yn-17-ol,




T. 13-ethyl-3-methoxy-18,19-dinor-17 α -pregna-2,5(10)-dien-20-yn-17-ol,



U. 17-hydroxy-19-nor-17 α -pregn-4-en-20-yn-3-one (norethisterone),



V. 13-ethyl-3-methoxy-18,19-dinor-17 α -pregna-1,3,5(10)-trien-20-yn-17-ol,




W. 13-ethyl-17-hydroxy-18,19-dinor-17 α -pregna-5,7,9-trien-20-yn-3-one.



04/2020:1120

LISINOPRIL DIHYDRATE

Lisinoprilum dihydricum



$C_{21}H_{31}N_3O_5 \cdot 2H_2O$
[83915-83-7]

M_r 441.5

DEFINITION

(2S)-1-[(2S)-6-Amino-2-[[[(1S)-1-carboxy-3-phenylpropyl]-amino]hexanoyl]pyrrolidine-2-carboxylic acid dihydrate.

Content: 98.5 per cent to 101.5 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: soluble in water, practically insoluble in anhydrous ethanol and in heptane.

IDENTIFICATION

A. Specific optical rotation (2.2.7): -47 to -43 (anhydrous substance).

Dissolve 0.5 g in zinc acetate solution R and dilute to 50.0 mL with the same solvent.

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: lisinopril dihydrate CRS.

TESTS

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 50.0 mg of the substance to be examined in mobile phase A and dilute to 10.0 mL with mobile phase A.

Reference solution (a). Dissolve 5 mg of lisinopril for system suitability A CRS (containing impurities A and E) in mobile phase A and dilute to 1 mL with mobile phase A.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with mobile phase A. Dilute 1.0 mL of this solution to 10.0 mL with mobile phase A.

Reference solution (c). Dissolve the contents of a vial of lisinopril impurity F CRS in 1 mL of mobile phase A.

Reference solution (d). Dissolve 5 mg of lisinopril for peak identification CRS (containing impurity G) in mobile phase A and dilute to 1 mL with mobile phase A.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: base-deactivated end-capped octadecylsilyl silica gel for chromatography R (5 μ m);
- temperature: 50 $^{\circ}$ C.

Mobile phase:

- mobile phase A: mix 3 volumes of acetonitrile R1 and 97 volumes of a 3.12 g/L solution of sodium dihydrogen phosphate R previously adjusted to pH 3.8 with dilute phosphoric acid R;
- mobile phase B: mix 20.5 volumes of acetonitrile R1 and 79.5 volumes of a 3.12 g/L solution of sodium dihydrogen phosphate R previously adjusted to pH 3.5 with dilute phosphoric acid R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 2	100	0
2 - 37	100 $\rightarrow$ 0	0 $\rightarrow$ 100
37 - 62	0	100

Flow rate: 1.6 mL/min.

Detection: spectrophotometer at 210 nm.

Injection: 50 μ L.

Identification of impurities: use the chromatogram supplied with lisinopril for system suitability A CRS and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities A and E; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity F; use the chromatogram supplied with lisinopril for peak identification CRS and the chromatogram obtained with reference solution (d) to identify the peak due to impurity G.

Relative retention with reference to lisinopril (retention time = about 14 min): impurity A = about 0.7; impurity E = about 1.2; impurity F = about 1.9; impurity G = about 2.9.

System suitability:

- resolution: minimum 1.5 between the peaks due to lisinopril and impurity E in the chromatogram obtained with reference solution (a);
 - signal-to-noise ratio: minimum 45 for the principal peak in the chromatogram obtained with reference solution (b).
- Calculation of percentage contents:**
- correction factor: multiply the peak area of impurity F by 2.1;
 - for each impurity, use the concentration of lisinopril dihydrate in reference solution (b).

Limits:

- impurities A, E, F: for each impurity, maximum 0.2 per cent;
- impurity G: maximum 0.15 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.5 per cent;
- reporting threshold: 0.05 per cent; disregard any peak with a retention time less than 3 min.

Water (2.5.12): 8.0 per cent to 9.5 per cent, determined on 0.200 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.350 g in 50 mL of *water R*. Titrate with 0.1 M *sodium hydroxide*, determining the end-point potentiometrically (2.2.20) at the 1st point of inflexion.


1 mL of 0.1 M *sodium hydroxide* is equivalent to 40.55 mg of $C_{21}H_{31}N_3O_5$.

IMPURITIES


Specified impurities: A, E, F, G.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10.


Control of impurities in substances for pharmaceutical use): B, C, D, H, I, J.




A. (2RS)-2-amino-4-phenylbutanoic acid,




B. 4-methylbenzenesulfonic acid,




C. (2S)-2-[(3S,8aS)-3-(4-aminobutyl)-1,4-dioxohexahydro-pyrrolo[1,2-a]pyrazin-2(1H)-yl]-4-phenylbutanoic acid (S,S,S-diketopiperazine),




D. (2S)-2-[(3S,8aR)-3-(4-aminobutyl)-1,4-dioxohexahydro-pyrrolo[1,2-a]pyrazin-2(1H)-yl]-4-phenylbutanoic acid (R,S,S-diketopiperazine),




E. (2S)-1-[(2S)-6-amino-2-[(1R)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid (lisinopril R,S,S-isomer),




F. (2S)-1-[(2S)-6-amino-2-[(1S)-1-carboxy-3-cyclohexylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid (cyclohexyl analogue),




G. (2S)-1-[(2S)-6-amino-2-[(2S)-1-[(5S)-5-[(1S)-1-carboxy-3-phenylpropyl]amino]-6-[(2S)-2-carboxypyrrolidin-1-yl]-6-oxohexyl]amino]-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid (lisinopril dimer),



H. (2S)-6-amino-2-[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoic acid,



I. (2S)-1-[(2S)-2,6-bis-[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid,



J. (2S)-1-[(2S)-6-[(2S)-6-amino-2-[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]-2-[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid.

M

Maize oil, refined.....	4447	Metformin hydrochloride.....	4448
Mercaptopurine monohydrate.....	4447	Mometasone furoate.....	4450



MAIZE OIL, REFINED

Maydis oleum raffinatum

DEFINITION

Fatty oil obtained from the seeds of *Zea mays* L. by mechanical expression or by extraction. It is then refined.

PRODUCTION

The oil is prepared using materials and methods designed to ensure that the content of brassicasterol (2.4.23) in the sterol fraction of the oil is not greater than 0.3 per cent.

CHARACTERS

Appearance: clear, light yellow or yellow oil.

Solubility: practically insoluble in water and in ethanol (96 per cent), miscible with light petroleum (bp: 40–60 °C) and with methylene chloride.

Relative density: about 0.920.

Refractive index: about 1.474.

IDENTIFICATION

First identification: B.

Second identification: A.

A. Identification of fatty oils by thin-layer chromatography (2.3.2).

Results: the chromatogram obtained with the test solution is similar to the chromatogram obtained with the reference solution.

B. Composition of fatty acids (see Tests).

TESTS

Acid value (2.5.1): maximum 0.5, or maximum 0.3 if intended for use in the manufacture of parenteral preparations, determined on 10.0 g.

Peroxide value (2.5.5, Method A): maximum 10.0, or maximum 5.0 if intended for use in the manufacture of parenteral preparations.

Unsaponifiable matter (2.5.7): maximum 2.8 per cent, determined on 5.0 g.

Alkaline impurities (2.4.19). It complies with the test.

Composition of fatty acids (2.4.22, Method A). Use the mixture of calibrating substances in Table 2.4.22.-3.

Composition of the fatty-acid fraction of the oil:

- **sum of fatty acids of chain length less than C_{16} :** maximum 0.6 per cent;
- **palmitic acid:** 8.6 per cent to 16.5 per cent;
- **stearic acid:** maximum 3.3 per cent;
- **oleic acid and isomer:** 20.0 per cent to 42.2 per cent;
- **linoleic acid:** 39.4 per cent to 65.6 per cent;
- **linolenic acid:** 0.5 per cent to 1.5 per cent;
- **arachidic acid:** maximum 0.8 per cent;
- **eicosenoic acid:** maximum 0.5 per cent;
- **behenic acid:** maximum 0.5 per cent;
- **any other fatty acid:** for each fatty acid, maximum 0.5 per cent.

Water (2.5.32): maximum 0.1 per cent, determined on 1.00 g.

STORAGE

Protected from light, at a temperature not exceeding 25 °C.

04/2020:1342 LABELLING

The label states:


- where applicable, that the substance is suitable for use in the manufacture of parenteral preparations;
- whether the oil is obtained by mechanical expression or by extraction.



04/2020:0096

MERCAPTOPURINE MONOHYDRATE

Mercaptopurinum monohydricum



$C_5H_4N_4S \cdot H_2O$
[6112-76-1]

M_r 170.2

DEFINITION

7H-Purine-6-thiol monohydrate.

Content: 98.5 per cent to 101.0 per cent (anhydrous substance).

CHARACTERS

Appearance: yellow, crystalline powder.

Solubility: practically insoluble in water, slightly soluble in ethanol (96 per cent), practically insoluble in heptane. It dissolves in solutions of alkali hydroxides.

IDENTIFICATION

- A. Dissolve 20 mg in 5 mL of *dimethyl sulfoxide* R and dilute to 100 mL with a 10.3 g/L solution of *hydrochloric acid* R. Dilute 5 mL of this solution to 200 mL with a 10.3 g/L solution of *hydrochloric acid* R. Examined between 230 nm and 350 nm (2.2.25), the solution shows only 1 absorption maximum, at 325 nm.
- B. Dissolve about 20 mg in 20 mL of *ethanol* (96 per cent) R heated to 60 °C and add 1 mL of a saturated solution of *mercuric acetate* R in *ethanol* (96 per cent) R. A white precipitate is formed.
- C. Dissolve about 20 mg in 20 mL of *ethanol* (96 per cent) R heated to 60 °C and add 1 mL of a 10 g/L solution of *lead acetate* R in *ethanol* (96 per cent) R. A yellow precipitate is formed.

TESTS

Related substances. Liquid chromatography (2.2.29). Prepare the solutions immediately before use.

Test solution. Dissolve 12.0 mg of the substance to be examined in 2.5 mL of *methanol* R and dilute to 100.0 mL with a 0.1 per cent V/V solution of *anhydrous formic acid* R.

Reference solution (a). Dissolve 3.0 mg of *mercaptopurine impurity B* CRS and 4.5 mg of *mercaptopurine impurity A* CRS in mobile phase A and dilute to 250.0 mL with mobile phase A. Dilute 1.0 mL of the solution to 100.0 mL with mobile phase A.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with a 0.1 per cent V/V solution of *anhydrous formic acid* R.

Reference solution (c). Dissolve 3 mg of *mercaptopurine impurity D* CRS in 10 mL of *dimethyl sulfoxide* R and dilute to 250 mL with mobile phase A. Dilute 1 mL of the solution to 100 mL with mobile phase A.

Column:

- **size:** $l = 0.10$ m, $\varnothing = 4.6$ mm;

- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (3 µm);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: methanol R, 0.1 per cent V/V solution of anhydrous formic acid R (2:98 V/V);
- mobile phase B: methanol R, 0.1 per cent V/V solution of anhydrous formic acid R (50:50 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 8	100	0
8 - 20	100 → 0	0 → 100
20 - 25	0	100

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 260 nm.

Injection: 50 µL.

Autosampler: set at 4 °C.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peaks due to impurities A and B; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity D.

Relative retention with reference to mercaptopurine (retention time = about 6 min): impurity B = about 0.3; impurity A = about 0.5; impurity D = about 3.5.

System suitability: reference solution (a):

- resolution: minimum 5.0 between the peaks due to impurities B and A.

Calculation of percentage contents:

- correction factor: multiply the peak area of impurity D by 0.25;
- for impurities A and B, use the concentration of the corresponding impurity in reference solution (a);
- for impurities other than A and B, use the concentration of mercaptopurine monohydrate in reference solution (b).

Limits:

- impurity A: maximum 0.15 per cent;
- impurities B, D: for each impurity, maximum 0.10 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.3 per cent;
- reporting threshold: 0.05 per cent.

Water (2.5.12): 10.0 per cent to 12.0 per cent, determined on 0.250 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.100 g in 50 mL of dimethylformamide R. Titrate with 0.1 M tetrabutylammonium hydroxide, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M tetrabutylammonium hydroxide is equivalent to 15.22 mg of C₅H₄N₄S.

STORAGE


Protected from light.

IMPURITIES


Specified impurities: A, B, D.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10.


Control of impurities in substances for pharmaceutical use): C.




A. 1,7-dihydro-6H-purin-6-one (hypoxanthine),



B. 7H-purin-6-amine (adenine),



C. 6,6'-sulfanediyldi-7H-purine,




D. 6,6'-disulfanediyldi-7H-purine.



04/2020:0931

METFORMIN HYDROCHLORIDE

Metformini hydrochloridum



C₄H₁₂ClN₅
[1115-70-4]

M_r 165.6

DEFINITION

1,1-Dimethylbiguanide hydrochloride.

Content: 98.5 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white crystals.

Solubility: freely soluble in water, slightly soluble in ethanol (96 per cent), practically insoluble in acetone and in methylene chloride.

IDENTIFICATION

First identification: B, E.

Second identification: A, C, D, E.

A. Melting point (2.2.14): 222 °C to 226 °C.

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: metformin hydrochloride CRS.

C. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 20 mg of the substance to be examined in water R and dilute to 5 mL with the same solvent.

Reference solution. Dissolve 20 mg of *metformin hydrochloride CRS* in *water R* and dilute to 5 mL with the same solvent.

Plate: TLC silica gel G plate R.

Mobile phase: glacial acetic acid R, butanol R, water R (10:40:50 V/V/V); use the upper layer.

Application: 5 µL.

Development: over 3/4 of the plate.

Drying: at 100-105 °C for 15 min.

Detection: spray with a mixture of equal volumes of a 100 g/L solution of *sodium nitroprusside R*, a 100 g/L solution of *potassium ferricyanide R* and a 100 g/L solution of *sodium hydroxide R*, prepared 20 min before use.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

D. Dissolve about 5 mg in *water R* and dilute to 100 mL with the same solvent. To 2 mL of the solution add 0.25 mL of *strong sodium hydroxide solution R* and 0.10 mL of *α-naphthol solution R*. Mix and allow to stand in iced water for 15 min. Add 0.5 mL of *sodium hypobromite solution R* and mix. A pink colour develops.

E. It gives reaction (a) of chlorides (2.3.1).

TESTS

Solution S. Dissolve 2.0 g in *water R* and dilute to 20 mL with the same solvent.

Appearance of solution. Solution S is clear (2.2.1) and colourless (2.2.2, *Method II*). Heat the solution to 50 °C and cool to room temperature.

Impurity F. Liquid chromatography (2.2.29).

Derivatisation solution. Prepare the solution immediately before use. Dilute 1 mL of *fluorodinitrobenzene R* in 100.0 mL of *acetonitrile R*.

Blank solution. To 5.0 mL of *acetonitrile R* add 100 µL of *triethylamine R1* and 1.0 mL of the derivatisation solution. Shake well and heat at 60 °C for 30 min. After cooling, dilute to 10.0 mL with *acetonitrile R*.

Test solution. Prepare the solution immediately before use. Suspend 10.0 mg of the substance to be examined in 5.0 mL of *acetonitrile R* and sonicate for 5 min. Add 100 µL of *triethylamine R1* and 1.0 mL of the derivatisation solution. Shake well and heat at 60 °C for 30 min. After cooling, dilute to 10.0 mL with *acetonitrile R*. Filter or centrifuge at 800 g for 5 min before use.

Reference solution. Dilute 1.0 mL of *metformin impurity F CRS* in 100.0 mL of *acetonitrile R*. Dilute 2.5 mL of the solution to 100.0 mL with *acetonitrile R*. To 1.0 mL of this solution add successively 5.0 mL of *acetonitrile R*, 100 µL of *triethylamine R1* and 1.0 mL of the derivatisation solution. Shake well and heat at 60 °C for 30 min. After cooling, dilute to 10.0 mL with *acetonitrile R*.

Column:

- size: $l = 0.125$ m, $\varnothing = 3$ mm;
- stationary phase: spherical end-capped octadecylsilyl silica gel for chromatography R1 (5 µm);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: phosphoric acid R, water for chromatography R (0.1:99.9 V/V);
- mobile phase B: *acetonitrile R*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 10	60 → 45	40 → 55
10 - 11	45 → 25	55 → 75
11 - 15	25	75

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 380 nm.

Injection: 5 µL.

Identification of impurities: use the chromatograms obtained with the blank solution and the reference solution to identify the peak due to the impurity F derivative.

Retention time: impurity F derivative = about 4 min.

System suitability: reference solution:

- resolution: minimum 3.0 between the peak due to the impurity F derivative and the nearby eluting peaks due to the derivatisation reagent.

Limit:

- impurity F: not more than the area of the corresponding peak in the chromatogram obtained with the reference solution (0.05 per cent).

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 50.0 mg of the substance to be examined in the mobile phase and dilute to 10.0 mL with the mobile phase.

Reference solution (a). Dissolve 20.0 mg of *metformin impurity A CRS* in *water R* and dilute to 100.0 mL with the same solvent. Dilute 1.0 mL of the solution to 200.0 mL with the mobile phase.

Reference solution (b). Dilute 1.0 mL of the test solution to 50.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 20.0 mL with the mobile phase.

Reference solution (c). Dissolve 10 mg of *melamine R* (impurity D) in about 90 mL of *water R*. Add 5 mL of the test solution and dilute to 100 mL with *water R*. Dilute 1 mL of this solution to 50 mL with the mobile phase.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: strong cation-exchange silica gel for chromatography R (10 µm).

Mobile phase: 17 g/L solution of *ammonium dihydrogen phosphate R* adjusted to pH 3.0 with *phosphoric acid R*.

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 218 nm.

Injection: 20 µL.

Run time: twice the retention time of metformin.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peak due to impurity A; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity D.

Relative retention with reference to metformin (retention time = about 14 min): impurity A = about 0.3; impurity D = about 0.4.

System suitability: reference solution (c):

- resolution: minimum 10 between the peaks due to impurity D and metformin.

Limits:

- impurity A: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (a) (0.02 per cent);
- unspecified impurities: for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent);
- total: maximum 0.2 per cent;

04/2020:1449

- *disregard limit*: 0.3 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.03 per cent); do not disregard the peak due to impurity A.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 5 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY


Dissolve 0.100 g in 4 mL of *anhydrous formic acid R*. Add 80 mL of *acetonitrile R*. Carry out the titration immediately. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 16.56 mg of $C_{27}H_{30}Cl_2O_6$.


IMPURITIES

Specified impurities: A, F.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, C, D, E.




A. cyanoguanidine,




B. (4,6-diamino-1,3,5-triazin-2-yl)guanidine,




C. N^2,N^2 -dimethyl-1,3,5-triazine-2,4,6-triamine (*N,N*-dimethylmelamine),



D. 1,3,5-triazine-2,4,6-triamine (melamine),



E. 1-methylbiguanide,




F. *N*-methylmethanamine (dimethylamine).



MOMETASONE FUROATE

Mometasoni furoas



$C_{27}H_{30}Cl_2O_6$
[83919-23-7]

M_r 521.4

DEFINITION

9,21-Dichloro-11 β -hydroxy-16 α -methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate.

Content: 98.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white powder.

Solubility: practically insoluble in water, soluble in acetone and in methylene chloride, slightly soluble in ethanol (96 per cent).

IDENTIFICATION

First identification: A, D, E.

Second identification: B, C.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: mometasone furoate CRS.

B. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 10 mg of the substance to be examined in the mobile phase and dilute to 10.0 mL with the mobile phase.

Reference solution. Dissolve 10 mg of mometasone furoate CRS in the mobile phase and dilute to 10.0 mL with the mobile phase.

Plate: TLC silica gel F_{254} plate R.

Mobile phase: methanol R, methylene chloride R (10:90 V/V).

Application: 10 μ L; the volume may be adapted based on the type of plate used.

Development: over 3/4 of the plate.

Drying: in air.

Detection: spray with a solution prepared as follows: dissolve 0.25 g of 2,4-dihydroxybenzaldehyde R in glacial acetic acid R, dilute to 50 mL with the same solvent and add a mixture of 12.5 mL of sulfuric acid R and 37.5 mL of glacial acetic acid R; heat the plate at 90 °C for 35 min or until the spots appear and allow to cool; examine in daylight and in ultraviolet light at 365 nm.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

C. Mix 80 mg with 0.30 g of *anhydrous sodium carbonate R* and ignite in a crucible until an almost white residue is obtained. Allow to cool and dissolve the residue in 5 mL of *dilute nitric acid R*; filter. To 1 mL of the filtrate add 1 mL of *water R*. The solution gives reaction (a) of chlorides (2.3.1).

D. Examine the chromatograms obtained in the assay.

Results: the principal peak in the chromatogram obtained with test solution (b) is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (c).

E. Loss on drying (see Tests).

TESTS

Specific optical rotation (2.2.7): + 50 to + 55 (dried substance).

Dissolve 50.0 mg in *ethanol* (96 per cent) *R* and dilute to 10.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29). Prepare the solutions immediately before use.

Solvent mixture. Mix 200 mL of *acetonitrile R* and 200 mL of *water R*, then add 0.4 mL of *acetic acid R*.

Test solution (a). Dissolve 25.0 mg of the substance to be examined in 15 mL of *acetonitrile R* and dilute to 50.0 mL with the solvent mixture.

Test solution (b). Dilute 5.0 mL of test solution (a) to 25.0 mL with the solvent mixture.

Reference solution (a). Dissolve 5 mg of *mometasone furoate for system suitability CRS* (containing impurities C and J) in 3 mL of *acetonitrile R* and dilute to 10 mL with the solvent mixture.

Reference solution (b). Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (c). Dissolve 25.0 mg of *mometasone furoate monohydrate CRS* in 15 mL of *acetonitrile R* and dilute to 50.0 mL with the solvent mixture. Dilute 5.0 mL of the solution to 25.0 mL with the solvent mixture.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography *R* (5 μ m).

Mobile phase: *acetonitrile R*, *water for chromatography R* (50:50 V/V).

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 254 nm.

Injection: 20 μ L of test solution (a) and reference solutions (a) and (b).

Run time: 3.5 times the retention time of mometasone furoate.

Identification of impurities: use the chromatogram supplied with *mometasone furoate for system suitability CRS* and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities C and J.

Relative retention with reference to mometasone furoate (retention time = about 24 min): impurity C = about 0.9; impurity J = about 1.5.

System suitability: reference solution (a):

- resolution: minimum 2.5 between the peaks due to impurity C and mometasone furoate.

Limits:

- impurity J: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.15 per cent);
- unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);
- total: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.3 per cent);
- disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution (b) and reference solution (c).


Calculate the percentage content of $C_{27}H_{30}Cl_2O_6$ taking into account the assigned content of *mometasone furoate monohydrate CRS*.

IMPURITIES


Specified impurities: J.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10.


Control of impurities in substances for pharmaceutical use: A, B, C, D, E, F, G, H, I, K, L, M, N, O, P, Q, R, S, T, U.




A. 21-chloro-16 α -methyl-3,20-dioxopregna-1,4,9(11)-trien-17-yl furan-2-carboxylate,




B. 9-chloro-17 β -(2,2-dioxo-2,5-dihydro-1,2 λ^6 -oxathiol-4-yl)-11 β -hydroxy-16 α -methyl-3-oxoandrosta-1,4-dien-17 α -yl furan-2-carboxylate,




C. 21-chloro-16 α -methyl-3,11,20-trioxopregna-1,4-dien-17-yl furan-2-carboxylate,




D. 21-chloro-9,11 β -epoxy-16 α -methyl-3,20-dioxo-9 β -pregna-1,4-dien-17-yl furan-2-carboxylate,




E. 9,21-dichloro-16 α -methyl-3,20-dioxopregna-1,4-diene-11 β ,17-diyl di(furan-2-carboxylate),




F. 9,21-dichloro-11 β -hydroxy-16 α -methyl-3,6,20-trioxopregna-1,4-dien-17-yl furan-2-carboxylate,




G. 9,21-dichloro-11 β ,17-dihydroxy-16 α -methylpregna-1,4-diene-3,20-dione (mometasone),




H. 9-chloro-11 β ,21-dihydroxy-16 α -methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate,




I. 6 ξ -(acetyloxy)-9,21-dichloro-11 β -hydroxy-16 α -methyl-3,20-dioxo-5 ξ -pregn-1-en-17-yl furan-2-carboxylate,




J. 9,21-dichloro-11 β -hydroxy-6 α ,16 α -dimethyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate,




K. 9-chloro-11 β ,17,21-trihydroxy-16 α -methylpregna-1,4-diene-3,20-dione,




L. 9,11 β -epoxy-17,21-dihydroxy-16 α -methyl-9 β -pregna-1,4-diene-3,20-dione,




M. 9-chloro-11 β ,17-dihydroxy-16 α -methylpregna-1,4-diene-3,20-dione,




N. 9-chloro-11 β ,17-dihydroxy-16 α -methyl-3,20-dioxopregna-1,4-dien-21-yl methanesulfonate,




O. 9-chloro-11 β ,17-dihydroxy-16 α -methyl-3,20-dioxopregna-1,4-dien-21-yl acetate,




P. 9-chloro-11 β ,17-dihydroxy-16 α -methyl-3,20-dioxopregna-1,4-dien-21-yl furan-2-carboxylate,




Q. 21-chloro-9,11 β -epoxy-17-hydroxy-16 α -methyl-9 β -pregna-1,4-diene-3,20-dione,



- R. 9-chloro-11 β -hydroxy-21-[(methanesulfonyl)oxy]-16 α -methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate,



- S. 9,21-dichloro-11 β -hydroxy-16 β -methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate,



- T. 9,21-dichloro-11 β -hydroxy-16 α -methyl-3,20-dioxopregna-1,4-dien-17-yl 5-chlorofuran-2-carboxylate,
U. unknown structure.

N


Nandrolone decanoate..	4457	Nomegestrol acetate..	4459
------------------------------	------	-----------------------------	------



01/2008:1992
corrected 10.1

NANDROLONE DECANOATE

Nandroloni decanoas



$C_{28}H_{44}O_3$
[360-70-3]

M_r 428.7

DEFINITION

3-Oxoestr-4-en-17 β -yl decanoate.

Content: 97.0 per cent to 103.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: practically insoluble in water, very soluble in ethanol (96 per cent) and in methylene chloride.

IDENTIFICATION

A. Melting point (2.2.14): 34 °C to 38 °C.

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: nandrolone decanoate CRS.

TESTS

Appearance of solution. The solution is clear (2.2.1) and not more intensely coloured than reference solution Y_6 (2.2.2, Method II).

Dissolve 0.20 g in 10 mL of methanol R.

Specific optical rotation (2.2.7): + 35.0 to + 40.0 (dried substance).

Dissolve 0.200 g in anhydrous ethanol R and dilute to 20.0 mL with the same solvent.

Impurities A, B, C. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 50 mg of the substance to be examined in methylene chloride R and dilute to 5.0 mL with the same solvent.

Reference solution (a). Dilute 1.0 mL of the test solution to 10.0 mL with methylene chloride R.

Reference solution (b). Dilute 1.0 mL of reference solution (a) to 10.0 mL with methylene chloride R.

Reference solution (c). Dilute 1.0 mL of reference solution (a) to 20.0 mL with methylene chloride R.

Reference solution (d). Dissolve 5 mg of nandrolone decanoate for system suitability CRS (containing impurities A, B, C) in 0.5 mL of methylene chloride R.

Plate: TLC silica gel plate R.

Mobile phase: acetone R, heptane R (30:70 V/V).

Application: 10 μ L of the test solution and reference solutions (b), (c) and (d).

Development: over 2/3 of the plate.

Drying: in air.

Detection: treat with alcoholic solution of sulfuric acid R and heat at 130 °C until the spots appear. Examine in ultraviolet light at 366 nm.

Retardation factors: nandrolone decanoate = about 0.37; impurity A = about 0.45; impurity B = about 0.55; impurity C = about 0.58.

System suitability: reference solution (d):

- the chromatogram shows 4 clearly separated spots.

Limits:

- **impurity A:** any spot due to impurity A is not more intense than the principal spot in the chromatogram obtained with reference solution (b) (1.0 per cent);
- **impurities B, C:** any spot due to impurity B or C is not more intense than the principal spot in the chromatogram obtained with reference solution (c) (0.5 per cent).

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 25 mg of the substance to be examined in methanol R and dilute to 10.0 mL with the same solvent.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with methanol R. Dilute 1.0 mL of this solution to 10.0 mL with methanol R.

Reference solution (b). Dissolve 5 mg of nandrolone decanoate for peak identification CRS (containing impurities D, F, G, H, I, K, L) in methanol R and dilute to 2.0 mL with the same solvent.

Column:

- **size:** l = 0.15 m, $\varnothing$ = 3.9 mm;
- **stationary phase:** end-capped octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase:

- **mobile phase A:** water for chromatography R;
- **mobile phase B:** acetonitrile R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	35	65
5 - 40	35 $\rightarrow$ 0	65 $\rightarrow$ 100
40 - 75	0	100
75 - 80	0 $\rightarrow$ 35	100 $\rightarrow$ 65

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 254 nm.

Injection: 20 μ L.

Relative retention with reference to nandrolone decanoate (retention time = about 30 min): impurity D = about 0.05; impurity F = about 0.6; impurity K = about 0.7; impurity L = about 0.9; impurity G = about 0.97; impurity H = about 1.1; impurity I = about 1.2.

System suitability: reference solution (b):

- **peak-to-valley ratio:** minimum 1.5, where H_p = height above the baseline of the peak due to impurity G and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to nandrolone decanoate.

Limits:

- **correction factors:** for the calculation of contents, multiply the peak areas of the following impurities by the corresponding correction factor: impurity D = 0.5; impurity F = 0.6; impurity H = 1.1; impurity I = 1.3; impurity K = 0.8;
- **impurities D, F, G, H, I, K, L:** for each impurity, not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);
- **unspecified impurities:** for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- **total:** not more than 15 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.5 per cent);
- **disregard limit:** 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying *in vacuo* at a pressure not exceeding 0.7 kPa for 4 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 10.0 mg in *anhydrous ethanol R* and dilute to 100.0 mL with the same solvent. Dilute 5.0 mL of this solution to 50.0 mL with *anhydrous ethanol R*. Measure the absorbance (2.2.25) at the absorption maximum at 240 nm. Calculate the content of $C_{28}H_{44}O_3$ taking the specific absorbance to be 407.


STORAGE

Under nitrogen, protected from light and at a temperature of 2 °C to 8 °C.


IMPURITIES

Specified impurities: A, B, C, D, F, G, H, I, K, L.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): E, J.




A. 3-oxo-5α-estrane-17β-yl decanoate,




B. 3-methoxyestra-1,3,5(10)-trien-17β-yl decanoate,




C. 3,3-dimethoxy-5α-estrane-17β-yl decanoate,




D. 17β-hydroxyestr-4-en-3-one,




E. 6α-hydroxy-3-oxoestr-4-en-17β-yl decanoate,




F. 3,6-dioxoestr-4-en-17β-yl decanoate,




G. 3-oxoestra-4,8(14)-dien-17β-yl decanoate,




H. 3-oxoestr-4-en-17β-yl undecanoate,




I. 3-oxoestr-4-en-17β-yl dodecanoate,



J. 5α-estr-3-ene-3,17β-diyl didecanoate,



K. 3-oxoestr-4-en-17β-yl octanoate,




L. 3-oxoestr-4-en-17β-yl nonanoate.



04/2020:1551

NOMEGESTROL ACETATE

Nomegestroli acetat



$C_{23}H_{30}O_4$
[58652-20-3]

 M_r 370.5

DEFINITION

6-Methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate.

Content: 98.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: practically insoluble in water, freely soluble in acetone, soluble in ethanol (96 per cent), practically insoluble in heptane.

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: nomegestrol acetate for ID and assay CRS.

TESTS

Appearance of solution. The solution is clear (2.2.1) and not more intensely coloured than reference solution Y_5 (2.2.2, Method II).

Dissolve 1.0 g in *methylene chloride R* and dilute to 10 mL with the same solvent.

Specific optical rotation (2.2.7): -64.0 to -60.0 (dried substance).

Dissolve 0.500 g in *anhydrous ethanol R* and dilute to 25.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 25.0 mg of the substance to be examined in *methanol R* and dilute to 50.0 mL with the same solvent.

Reference solution (a). Dissolve 25.0 mg of nomegestrol acetate for ID and assay CRS in *methanol R* and dilute to 50.0 mL with the same solvent.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (c). Dissolve 25.0 mg of nomegestrol acetate impurity A CRS in *methanol R* and dilute to 100.0 mL with the same solvent. Dilute 0.25 mL of the solution to 25.0 mL with reference solution (a).

Reference solution (d). Dissolve the contents of a vial of nomegestrol acetate impurity B CRS in 1 mL of *methanol R*.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase: acetonitrile for chromatography R, *methanol R1*, water for chromatography R (24:38:38 V/V/V).

Flow rate: 1.3 mL/min.

Detection: spectrophotometer at 245 nm and at 290 nm.

Injection: 10 μ L of the test solution and reference solutions (b), (c), (d).

Run time: 1.5 times the retention time of nomegestrol acetate.

Identification of impurities: use the chromatogram obtained with reference solution (c) at 245 nm to identify the peak due to impurity A; use the chromatogram obtained with reference solution (d) at 290 nm to identify the peak due to impurity B.

Relative retention with reference to nomegestrol acetate (retention time = about 17 min): impurity B = about 0.6; impurity A = about 1.1.

System suitability: reference solution (c) at 245 nm:

- peak-to-valley ratio: minimum 5, where H_p = height above the baseline of the peak due to impurity A and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to nomegestrol acetate.

Calculation of percentage contents:

- for each impurity at 245 nm, use the concentration of impurity A in reference solution (c);
- for each impurity at 290 nm, use the concentration of nomegestrol acetate in reference solution (b).

Limits:

- impurity A at 245 nm: maximum 0.2 per cent;
- impurity B at 290 nm: maximum 0.15 per cent;
- unspecified impurities at 245 nm and at 290 nm: for each impurity, maximum 0.10 per cent;
- sum of impurities other than A at 245 nm and 290 nm: maximum 0.3 per cent;
- reporting threshold at 245 nm and at 290 nm: 0.05 per cent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications:

Detection: spectrophotometer at 290 nm.

Injection: test solution and reference solution (a).


Calculate the percentage content of $C_{23}H_{30}O_4$ taking into account the assigned content of nomegestrol acetate for ID and assay CRS.

STORAGE


Protected from light.

IMPURITIES

Specified impurities: A, B.



A. 6α-methyl-3,20-dioxo-19-norpregn-4-en-17-yl acetate,



B. 17-hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione (nomegestrol).

O

Oxfendazole for veterinary use..... 4463 Oxymetazoline hydrochloride..... 4464

04/2020:1458 *Detection*: spectrophotometer at 254 nm.*Injection*: 20 µL.*Run time*: 6 times the retention time of oxfendazole.

Identification of impurities: use the chromatogram obtained with reference solution (c) to identify the peak due to impurity A; use the chromatogram obtained with reference solution (d) to identify the peak due to impurity B; use the chromatogram obtained with reference solution (b) to identify the peak due to impurity C; use the chromatogram supplied with *oxfendazole with impurity D CRS* and the chromatogram obtained with reference solution (e) to identify the peak due to impurity D.

Relative retention with reference to oxfendazole (retention time = about 7 min): impurity C = about 0.4; impurity B = about 1.9; impurity D = about 2.7; impurity A = about 5.4.

System suitability: reference solution (b):

- *resolution*: minimum 4.0 between the peaks due to impurity C and oxfendazole.

Limits:

- *impurity B*: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (d) (2.0 per cent);
- *impurity A*: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (c) (1.0 per cent);
- *impurities C, D*: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent);
- *unspecified impurities*: not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.20 per cent);
- *total*: maximum 3.0 per cent;
- *disregard limit*: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent).

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying *in vacuo* at 105 °C for 2 h.

Sulfated ash (2.4.14): maximum 0.2 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.250 g in 3 mL of *anhydrous formic acid R*. Add 40 mL of *anhydrous acetic acid R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).


1 mL of 0.1 M *perchloric acid* is equivalent to 31.53 mg of $C_{15}H_{13}N_3O_3S$.

STORAGE


Protected from light.

IMPURITIES

Specified impurities: A, B, C, D.




A. methyl [5-(phenylsulfanyl)-1H-benzimidazol-2-yl]carbamate (fenbendazole),



B. methyl [5-(phenylsulfonyl)-1H-benzimidazol-2-yl]carbamate,

OXFENDAZOLE FOR VETERINARY USE

Oxfendazolum ad usum veterinarium



$C_{15}H_{13}N_3O_3S$
[53716-50-0]

M_r 315.3

DEFINITION

Methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate.

Content: 97.5 per cent to 100.5 per cent (dried substance).

CHARACTERS

Appearance: white or almost white powder.

Solubility: practically insoluble in water, slightly soluble in ethanol (96 per cent) and in methylene chloride.

It shows polymorphism (5.9).

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: *oxfendazole CRS*.

If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in *ethanol* (96 per cent) R, evaporate to dryness and record new spectra using the residues.

TESTS

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 25.0 mg of the substance to be examined in the mobile phase and dilute to 100.0 mL with the mobile phase.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase.

Reference solution (b). In order to prepare impurity C *in situ*, add 0.25 mL of *strong hydrogen peroxide solution R* to 10 mL of the test solution, then dilute to 25 mL with the mobile phase.

Reference solution (c). Dissolve 5.0 mg of *fenbendazole CRS* (impurity A) in the mobile phase and dilute to 100.0 mL with the mobile phase. Dilute 1.0 mL of the solution to 20.0 mL with the mobile phase.

Reference solution (d). Dissolve 10.0 mg of *oxfendazole impurity B CRS* in the mobile phase and dilute to 100.0 mL with the mobile phase. Dilute 1.0 mL of the solution to 20.0 mL with the mobile phase.


Reference solution (e). Dissolve 5 mg of *oxfendazole with impurity D CRS* in the mobile phase and dilute to 20 mL with the mobile phase.

Column:


- *size*: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- *stationary phase*: end-capped octadecylsilyl silica gel for chromatography R (5 µm).

Mobile phase: mix 36 volumes of *acetonitrile R* and 64 volumes of a 2 g/L solution of *sodium pentanesulfonate R* previously adjusted to pH 2.7 with a 2.8 per cent V/V solution of *sulfuric acid R*.

Flow rate: 1 mL/min.



C. 5-(phenylsulfinyl)-1H-benzimidazol-2-amine,




D. N,N'-bis[5-(phenylsulfinyl)-1H-benzimidazol-2-yl]urea.

01/2013:0943
corrected 10.1

OXYMETAZOLINE HYDROCHLORIDE

Oxymetazolini hydrochloridum

C₁₆H₂₅ClN₂O
[2315-02-8]M_r 296.8

DEFINITION

3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol hydrochloride.

Content: 99.0 per cent to 101.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: freely soluble in water and in ethanol (96 per cent).

IDENTIFICATION

First identification: A, D.

Second identification: B, C, D.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: oxymetazoline hydrochloride CRS.

B. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 20 mg of the substance to be examined in a mixture of equal volumes of *ethyl acetate* R and *methanol* R and dilute to 5 mL with the same mixture of solvents.Reference solution. Dissolve 20 mg of oxymetazoline hydrochloride CRS in a mixture of equal volumes of *ethyl acetate* R and *methanol* R and dilute to 5 mL with the same mixture of solvents.

Plate: TLC silica gel G plate R.

Mobile phase: diethylamine R, cyclohexane R, anhydrous ethanol R (6:15:79 V/V/V).

Application: 5 µL.

Development: over 2/3 of the plate.

Drying: in a current of warm air for 5 min, then allow to cool.

Detection: spray with a freshly prepared 5.0 g/L solution of *potassium ferricyanide* R in *ferric chloride solution* R2; examine in daylight.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

C. Dissolve about 2 mg in 1 mL of *water* R, then add 0.2 mL of a 50 g/L solution of *sodium nitroprusside* R and 0.2 mL of *dilute sodium hydroxide solution* R. Allow to stand for 10 min. Add 2 mL of *sodium hydrogen carbonate solution* R. A violet colour develops.

D. It gives reaction (a) of chlorides (2.3.1).

TESTS

Appearance of solution. The solution is clear (2.2.1) and not more intensely coloured than reference solution BY₇ (2.2.2, Method II).Dissolve 2.5 g in *water* R and dilute to 50 mL with the same solvent.**Acidity or alkalinity.** Dissolve 0.25 g in *carbon dioxide-free water* R and dilute to 25 mL with the same solvent. Add 0.1 mL of *methyl red solution* R and 0.2 mL of 0.01 M *hydrochloric acid*. The solution is red. Not more than 0.4 mL of 0.01 M *sodium hydroxide* is required to change the colour of the indicator to yellow.**Related substances.** Liquid chromatography (2.2.29). Prepare the solutions immediately before use.Test solution. Dissolve 50.0 mg of the substance to be examined in *water* R and dilute to 50.0 mL with the same solvent.Reference solution (a). Dilute 5.0 mL of the test solution to 100.0 mL with *water* R. Dilute 2.0 mL of this solution to 100.0 mL with *water* R.Reference solution (b). Dissolve 5.0 mg of oxymetazoline impurity A CRS and 5 mg of the substance to be examined in *water* R and dilute to 50.0 mL with the same solvent. Dilute 10.0 mL of the solution to 50.0 mL with *water* R.Reference solution (c). Dilute 1.0 mL of reference solution (b) to 20.0 mL with *water* R.

Column:

- size: *l* = 0.25 m, Ø = 4.6 mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography with embedded polar groups R (5 µm).

Mobile phase:

- mobile phase A: 1.36 g/L solution of *potassium dihydrogen phosphate* R adjusted to pH 3.0 with *phosphoric acid* R;
- mobile phase B: *acetonitrile* for chromatography R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	70	30
5 - 20	70 → 15	30 → 85
20 - 35	15	85

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 220 nm.

Injection: 10 µL.

Relative retention with reference to oxymetazoline (retention time = about 5.0 min): impurity A = about 0.9.

System suitability: reference solution (b):

- resolution: minimum 4.0 between the peaks due to impurity A and oxymetazoline.

Limits:

- impurity A: not more than 1.5 times the area of the corresponding peak in the chromatogram obtained with reference solution (c) (0.15 per cent);
- unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- total: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);

- *disregard limit*: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Water (2.5.32): maximum 0.3 per cent, determined on 1.00 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY


Dissolve 0.200 g in a mixture of 20 mL of *acetic anhydride R* and 20 mL of *anhydrous acetic acid R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 29.68 mg of $C_{16}H_{25}ClN_2O$.


IMPURITIES

Specified impurities: A.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, C, D, E.




A. N-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]acetamide,




B. 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-1H-imidazole (xylometazoline),



C. 2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]-acetamide,



D. 2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]-acetic acid,



E. 2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]-acetonitrile.


P

Pentoxifylline..	4469	Primaquine diphosphate.....	4476
Perindopril <i>tert</i> -butylamine..	4470	Pyrantel embonate.....	4478
Prazosin hydrochloride.....	4473	Pyrimethamine..	4479
Prednicarbate..	4475		



PENTOXIFYLLINE

Pentoxifyllinum



$C_{13}H_{18}N_4O_3$
[6493-05-6]

M_r 278.3

DEFINITION

3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: soluble in water, freely soluble in methylene chloride, sparingly soluble in ethanol (96 per cent).

IDENTIFICATION

First identification: A, B.

Second identification: A, C, D.

A. Melting point (2.2.14): 103 °C to 107 °C.

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: pentoxifylline CRS.

C. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 20 mg of the substance to be examined in *methanol R* and dilute to 10 mL with the same solvent.

Reference solution. Dissolve 20 mg of *pentoxifylline CRS* in *methanol R* and dilute to 10 mL with the same solvent.

Plate: TLC silica gel F_{254} plate R.

Mobile phase: *methanol R*, *ethyl acetate R* (15:85 V/V).

Application: 5 µL.

Development: over 2/3 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with the reference solution.

D. It gives the reaction of xanthines (2.3.1).

TESTS

Solution S. Dissolve 2.5 g in *carbon dioxide-free water R* prepared from *distilled water R* and dilute to 50 mL with the same solvent.

Appearance of solution. A 40 per cent V/V solution of solution S is clear (2.2.1) and not more intensely coloured than reference solution Y_7 (2.2.2, *Method II*).

Acidity. To 8 mL of solution S add 12 mL of *carbon dioxide-free water R* and 0.05 mL of *bromothymol blue solution R1*. The solution is green or yellow. Not more than 0.2 mL of 0.01 M *sodium hydroxide* is required to change the colour of the indicator to blue.

Related substances. Liquid chromatography (2.2.29).

Solution A: 5.44 g/L solution of *potassium dihydrogen phosphate R*.

Solvent mixture: *methanol R*, solution A (50:50 V/V).

04/2020:0851 Test solution. Dissolve 50.0 mg of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.

Reference solution (a). Dilute 2.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 5.0 mL of this solution to 100.0 mL with the solvent mixture.

Reference solution (b). Dilute 10.0 mL of reference solution (a) to 50.0 mL with the solvent mixture.

Reference solution (c). Dissolve 2 mg of *caffeine R* (impurity F) and 2 mg of *theophylline R* (impurity C) in the solvent mixture, add 1 mL of the test solution and dilute to 10 mL with the solvent mixture.

Reference solution (d). Dissolve 5.0 mg of *caffeine R* (impurity F), 5.0 mg of *theobromine R* (impurity A) and 5.0 mg of *theophylline R* (impurity C) in the solvent mixture and dilute to 100.0 mL with the solvent mixture. Dilute 1.0 mL of the solution to 25.0 mL with the solvent mixture.

Column:

- **size:** $l = 0.25$ m, $\varnothing = 4.0$ mm;
- **stationary phase:** base-deactivated end-capped octylsilyl silica gel for chromatography R (5 µm);
- **temperature:** 30 °C.

Mobile phase:

- **mobile phase A:** *methanol R*, solution A (30:70 V/V);
- **mobile phase B:** solution A, *methanol R* (30:70 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 6	85	15
6 - 13	85 → 10	15 → 90
13 - 30	10	90
30 - 35	10 → 85	90 → 15
35 - 45	85	15

Flow rate: 1 mL/min.

Detection: spectrophotometer at 272 nm.

Injection: 10 µL.

Relative retention with reference to pentoxifylline (retention time = about 12 min): impurity A = about 0.3; impurity C = about 0.4; impurity F = about 0.5; impurity J = about 1.6.

System suitability: reference solution (c):

- **resolution:** minimum 4.0 between the peaks due to impurities C and F.

Limits:

- **impurities A, C, F:** for each impurity, not more than the area of the corresponding peak in the chromatogram obtained with reference solution (d) (0.1 per cent);
- **impurity J:** not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent);
- **any other impurity:** for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent);
- **total:** not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);
- **disregard limit:** the area of the principal peak in the chromatogram obtained with reference solution (b) (0.02 per cent).

Chlorides (2.4.4): maximum 100 ppm.

Place 20 mL of solution S in a separating funnel and shake with 2 quantities, each of 20 mL, of 2-methylpropanol R. Dilute 10 mL of the aqueous layer to 15 mL with *water R*.

Sulfates (2.4.13): maximum 200 ppm, determined on 15 mL of solution S.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying *in vacuo* at 60 °C.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.200 g in 5 mL of *anhydrous acetic acid* R. Add 20 mL of *acetic anhydride* R. Titrate with 0.1 M *perchloric acid* determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 27.83 mg of $C_{13}H_{18}N_4O_5$.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: A, C, F, J.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, D, E, G, H, I, K.




A. theobromine,




B. 3-methyl-3,7-dihydro-1H-purine-2,6-dione,




C. theophylline,




D. 1-(3-hydroxypropyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione,




E. 1,1'-methylenebis(3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione),




F. caffeine,




G. 3,7-dimethyl-6-(5-oxohexyloxy)-3,7-dihydro-2H-purin-2-one,




H. 3-methyl-1,7-bis(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione,



I. 1-benzyl-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione,



J. 1-[(5E)-11-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)-5-methyl-7-oxoundec-5-enyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione,




K. 1,1'-(propane-1,3-diyl)bis(3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione).



04/2020:2019

PERINDOPRIL *tert*-BUTYLAMINE

tert-Butylamini perindoprilum



$C_{23}H_{43}N_3O_5$
[107133-36-8]

M_r 441.6

DEFINITION

2-Methylpropan-2-amine (2S,3aS,7aS)-1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]propanoyl]octahydro-1H-indole-2-carboxylate.

Content: 99.0 per cent to 101.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, slightly hygroscopic, crystalline powder.

Solubility: freely soluble in water and in ethanol (96 per cent), soluble or sparingly soluble in methylene chloride.

It shows polymorphism (5.9).

IDENTIFICATION

A. Specific optical rotation (2.2.7): – 69 to – 66 (anhydrous substance).

Dissolve 0.250 g in *ethanol* (96 per cent) R and dilute to 25.0 mL with the same solvent.

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: *perindopril tert*-butylamine CRS.

If the spectra obtained show differences, dissolve the substance to be examined and the reference substance separately in *methylene chloride* R, evaporate to dryness and record new spectra using the residues.

C. Examine the chromatograms obtained in the test for impurity A.

Results: in the chromatogram obtained with the test solution a spot is observed with the same R_F as the spot with the higher R_F in the chromatogram obtained with reference solution (c) (*tert*-butylamine).

TESTS

Impurity A. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 0.20 g of the substance to be examined in *methanol* R and dilute to 10.0 mL with the same solvent.

Reference solution (a). Dissolve 5 mg of *perindopril impurity A* CRS in *methanol* R and dilute to 25.0 mL with the same solvent.

Reference solution (b). Dilute 5.0 mL of reference solution (a) to 20.0 mL with *methanol* R.

Reference solution (c). To 5 mL of reference solution (a) add 5 mL of a 20 g/L solution of 1,1-dimethylethylamine R in *methanol* R.

Plate: TLC silica gel plate R.

Mobile phase: *glacial acetic acid* R, *toluene* R, *methanol* R (1:40:60 V/V/V).

Application: 10 µL of the test solution and reference solutions (b) and (c).

Development: over 2/3 of the plate.

Drying: in a current of warm air.

Detection: expose to iodine vapour for at least 20 h.

System suitability: reference solution (c):

- the chromatogram shows 2 clearly separated spots.

Limit:

- **impurity A:** any spot due to impurity A is not more intense than the spot in the chromatogram obtained with reference solution (b) (0.25 per cent).

Stereochemical purity. Liquid chromatography (2.2.29).

Test solution. Dissolve 20 mg of the substance to be examined in *ethanol* (96 per cent) R and dilute to 10.0 mL with the same solvent.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with *ethanol* (96 per cent) R. Dilute 1.0 mL of this solution to 10.0 mL with *ethanol* (96 per cent) R.

Reference solution (b). Dissolve 10 mg of *perindopril for stereochemical purity* CRS (containing impurity I) in *ethanol* (96 per cent) R and dilute to 5 mL with the same solvent.

Column:

- **size:** $l = 0.25$ m, $\varnothing = 4.6$ mm;
- **stationary phase:** *base-deactivated end-capped octadecylsilyl silica gel for chromatography* R (5 µm);
- **temperature:** 50 °C for the column and the tubing preceding the column (the method has been developed with a temperature of 50 °C for at least 30 cm of the tubing preceding the column).

Mobile phase: mix, in the following order, 21.7 volumes of *acetonitrile* R1, 0.3 volumes of *pentanol* R, and 78 volumes of a 1.50 g/L solution of *sodium heptanesulfonate* R previously adjusted to pH 2.0 with a mixture of equal volumes of *perchloric acid* R and *water for chromatography* R.

Flow rate: 0.8 mL/min.

Detection: spectrophotometer at 215 nm.

Equilibration: minimum 4 h.

Injection: 10 µL.

Identification of impurities: use the chromatogram supplied with *perindopril for stereochemical purity* CRS and the chromatogram obtained with reference solution (b) to identify the peak due to impurity I.

Run time: 1.5 times the retention time of perindopril.

Relative retention with reference to perindopril (retention time = about 100 min): impurity I = about 0.9.

System suitability:

- the chromatogram obtained with reference solution (b) is similar to the chromatogram supplied with *perindopril for stereochemical purity* CRS;
- **signal-to-noise ratio:** minimum 3 for the principal peak in the chromatogram obtained with reference solution (a);
- **peak-to-valley ratio:** minimum 3, where H_p = height above the baseline of the peak due to impurity I and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to perindopril in the chromatogram obtained with reference solution (b).

Limits:

- **impurity I:** not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent);
- **unspecified impurities:** for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- **disregard limit:** disregard any peak with a relative retention with reference to perindopril of less than 0.6 or more than 1.4.

Related substances. Liquid chromatography (2.2.29). Prepare the solutions immediately before use or maintain them at a temperature below 10 °C.

Test solution. Dissolve 60 mg of the substance to be examined in mobile phase A and dilute to 20.0 mL with mobile phase A.

Reference solution (a). Dissolve 3 mg of *perindopril for peak identification* CRS (containing impurities B, E, F, H and K) in 1 mL of mobile phase A.

Reference solution (b). Dilute 1.0 mL of the test solution to 200.0 mL with mobile phase A.

Reference solution (c). Dilute 1.0 mL of reference solution (b) to 10.0 mL with mobile phase A.

Column:

- **size:** $l = 0.15$ m, $\varnothing = 4$ mm;
- **stationary phase:** *end-capped octylsilyl silica gel for chromatography* R (5 µm);
- **temperature:** 60 °C for the column and the tubing preceding the column.

Mobile phase:

- **mobile phase A:** *water for chromatography* R adjusted to pH 2.5 with a mixture of equal volumes of *perchloric acid* R; and *water for chromatography* R;

- *mobile phase B*: 0.03 per cent V/V solution of *perchloric acid R* in *acetonitrile R1*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 – 5	95	5
5 – 60	95 → 40	5 → 60

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 215 nm.

Injection: 20 µL.

Identification of impurities: use the chromatogram supplied with *perindopril for peak identification CRS* and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities B, E, F, H and K.

Relative retention with reference to perindopril (retention time = about 25 min): impurity B = about 0.68; impurity K = about 0.72; impurity E = about 1.2; impurity F = about 1.6; impurity H = about 1.8 (impurity H may be eluted as 1 or 2 peaks).

System suitability: reference solution (a):

- *peak-to-valley ratio*: minimum 3, where H_p = height above the baseline of the peak due to impurity B and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to impurity K.

Limits:

- *impurity E*: not more than 0.8 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.4 per cent);
- *impurity B*: not more than 0.6 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.3 per cent);
- *impurities F, H*: for each impurity, not more than 0.4 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent);
- *unspecified impurities*: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);
- *total*: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent);
- *disregard limit*: the area of the principal peak in the chromatogram obtained with reference solution (c) (0.05 per cent).

Water (2.5.12): maximum 1.0 per cent, determined on 0.50 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.160 g in 50 mL of *anhydrous acetic acid R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 22.08 mg of $C_{23}H_{43}N_3O_5$.

STORAGE


In an airtight container.

IMPURITIES


Specified impurities: A, B, E, F, H, I.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities


for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): C, D, G, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z, AA, BB, CC.




A. (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid,




B. (2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-carboxybutyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid (perindoprilat),




C. (2S)-2-[(3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydro-pyrazino[1,2-a]indol-2(1H)-yl]pentanoic acid,




D. (2S)-2-[(3S,5aS,9aS,10aR)-3-methyl-1,4-dioxodecahydro-pyrazino[1,2-a]indol-2(1H)-yl]pentanoic acid,




E. (2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-[(1-methylethoxy)carbonyl]butyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid,




F. ethyl (2S)-2-[(3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydro-pyrazino[1,2-a]indol-2(1H)-yl]pentanoate,




G. (2S,3aS,7aS)-1-[(2S)-2-[(5RS)-3-cyclohexyl-2,4-dioxo-5-propylimidazolidin-1-yl]propanoyl]octahydro-1H-indole-2-carboxylic acid,




- H. (2S,3aS,7aS)-1-[(2S)-2-[(5R)-3-cyclohexyl-2-(cyclohexylimino)-4-oxo-5-propylimidazolidin-1-yl]propanoyl]octahydro-1H-indole-2-carboxylic acid,




- I. (2R,3aR,7aR)-1-[(2R)-2-[(1S)-1-(ethoxycarbonyl)-butyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid ((±)-1''-*epi*-perindopril),




- J. (2S,3aS,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid,




- K. (3S,5aS,9aS,10aS)-3-methyldecahydropyrazino[1,2-a]indole-1,4-dione,




- L. (2S,3aS,7aS)-1-acetyloctahydro-1H-indole-2-carboxylic acid,




- M. (2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-(methoxycarbonyl)-butyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid,



- N. (2S)-3-cyclohexyl-2-[(2S)-2-[(1S)-1-(ethoxycarbonyl)-butyl]amino]propanoyl]amino]propanoic acid,



- O. (2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)-butyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid,



- 1-2-[[1-(ethoxycarbonyl)butyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid,

- P. (2R,3aR,7aR)-, (2'SR)-, (1''RS)-: (±)-2'-*epi*-perindopril,

- Q. (2R,3aR,7aR)-, (2'RS)-, (1''RS)-: (±)-7a-*epi*-perindopril,

- R. (2R,3aSR,7aR)-, (2'RS)-, (1''RS)-: (±)-3a-*epi*-perindopril,

- S. (2SR,3aR,7aR)-, (2'RS)-, (1''RS)-: (±)-2-*epi*-perindopril,

- T. (2R,3aR,7aR)-, (2'SR)-, (1''SR)-: (±)-1'',2'-*di-epi*-perindopril,

- U. (2R,3aR,7aSR)-, (2'RS)-, (1''SR)-: (±)-1'',7a-*di-epi*-perindopril,

- V. (2SR,3aSR,7aR)-, (2'RS)-, (1''RS)-: (±)-2,3a-*di-epi*-perindopril,

- W. (2SR,3aR,7aR)-, (2'RS)-, (1''SR)-: (±)-1'',2-*di-epi*-perindopril,

- X. (2SR,3aR,7aSR)-, (2'RS)-, (1''RS)-: (±)-2,7a-*di-epi*-perindopril,

- Y. (2SR,3aR,7aR)-, (2'SR)-, (1''RS)-: (±)-2,2'-*di-epi*-perindopril,

- Z. (2R,3aSR,7aR)-, (2'RS)-, (1''SR)-: (±)-1'',3a-*di-epi*-perindopril,

- AA. (2R,3aSR,7aSR)-, (2'RS)-, (1''RS)-: (±)-3a,7a-*di-epi*-perindopril,

- BB. (2R,3aSR,7aR)-, (2'SR)-, (1''RS)-: (±)-2',3a-*di-epi*-perindopril,


- CC. (2R,3aR,7aSR)-, (2'SR)-, (1''RS)-: (±)-2',7a-*di-epi*-perindopril.

04/2020:0856



PRAZOSIN HYDROCHLORIDE

Prazosini hydrochloridum



C₁₉H₂₂ClN₅O₄
[19237-84-4]

M_r 419.9

DEFINITION

[4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone hydrochloride.

Content: 98.5 per cent to 101.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white powder.

Solubility: very slightly soluble in water, slightly soluble in ethanol (96 per cent) and in methanol, practically insoluble in acetone.

IDENTIFICATION

First identification: A, C.

Second identification: B, C.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: prazosin hydrochloride CRS.

B. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 10 mg of the substance to be examined in a mixture of 1 volume of *diethylamine R*, 10 volumes of *methanol R* and 10 volumes of *methylene chloride R* and dilute to 10 mL with the same mixture of solvents.

Reference solution. Dissolve 10 mg of *prazosin hydrochloride CRS* in a mixture of 1 volume of *diethylamine R*, 10 volumes of *methanol R* and 10 volumes of *methylene chloride R* and dilute to 10 mL with the same mixture of solvents.

Plate: TLC silica gel GF₂₅₄ plate R.

Mobile phase: *diethylamine R*, *ethyl acetate R* (5:95 V/V).

Application: 10 µL.

Development: over 2/3 of the plate.

Drying: in a current of warm air.

Detection: examine in ultraviolet light at 254 nm.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with the reference solution.

C. Dissolve about 2 mg in 2 mL of *water R*. The solution gives reaction (a) of chlorides (2.3.1).

TESTS

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 50.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (b). Dilute 1 mL of the test solution to 10 mL with the mobile phase. Use 1 mL of this solution to dissolve the contents of a vial of *prazosin impurity A CRS*.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 µm).

Mobile phase: mix 50 volumes of *methanol R* and 50 volumes of a solution containing 3.5 g/L of *sodium pentanesulfonate R* and 3.6 g/L of *tetramethylammonium hydroxide R* previously adjusted to pH 5.0 with *glacial acetic acid R*.

Flow rate: 1 mL/min.

Detection: spectrophotometer at 254 nm.

Injection: 20 µL.

Run time: 4 times the retention time of prazosin.

Identification of impurities: use the chromatogram obtained with reference solution (b) to identify the peak due to impurity A.

Relative retention with reference to prazosin (retention time = about 8 min): impurity A = about 0.8.

System suitability: reference solution (b):

- resolution: minimum 3.0 between the peaks due to impurity A and prazosin.

Calculation of percentage contents:

- for each impurity, use the concentration of prazosin hydrochloride in reference solution (a).

Limits:

- impurity A: maximum 0.2 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.5 per cent;
- reporting threshold: 0.05 per cent.

Iron: maximum 100 ppm.

Atomic absorption spectrometry (2.2.23, *Method I*).

Test solution. To 1.0 g add dropwise about 1.5 mL of *nitric acid R*. After fuming has subsided, evaporate on a water-bath and ignite by gradually raising the temperature from 150 °C to 1000 ± 50 °C, maintaining the final temperature for 1 h. Cool, dissolve the residue in 20 mL of *dilute hydrochloric acid R*, evaporate to about 5 mL and dilute to 25.0 mL with *dilute hydrochloric acid R*.

Reference solutions. Prepare the reference solutions using *iron standard solution (8 ppm Fe) R*, diluted as necessary with *water R*.

Source: iron hollow-cathode lamp.

Wavelength: 248 nm.

Flame: air-acetylene.

Water (2.5.12): maximum 0.5 per cent, determined on 1.00 g using a mixture of equal volumes of *methanol R* and *methylene chloride R* as solvent.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

In order to avoid overheating in the reaction medium, mix thoroughly throughout the titration and stop the titration immediately after the end-point has been reached.

Dissolve 0.350 g in a mixture of 20 mL of *anhydrous formic acid R* and 30 mL of *acetic anhydride R*. Titrate quickly with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 41.99 mg of C₁₉H₂₂ClN₅O₄.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: A.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, C, D, E.




A. 2-chloro-6,7-dimethoxyquinazolin-4-amine,




B. (piperazin-1,4-diyl)bis[(furan-2-yl)methanone],



C. 6,7-dimethoxy-2-(piperazin-1-yl)quinazolin-4-amine,



D. (furan-2-yl)(piperazin-1-yl)methanone,




E. 2,2'-(piperazin-1,4-diyl)bis(6,7-dimethoxyquinazolin-4-amine).



04/2020:1467

PREDNICARBATE

Prednicarbatum



$C_{27}H_{36}O_8$
[73771-04-7]

M_r 488.6

DEFINITION

11 β -Hydroxy-3,20-dioxopregna-1,4-diene-17,21-diyl 17-(ethyl carbonate) 21-propanoate.

Content: 97.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: practically insoluble in water, freely soluble in acetone and in ethanol (96 per cent), sparingly soluble in propylene glycol.

It shows polymorphism (5.9).

IDENTIFICATION

First identification: A.

Second identification: B.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: prednicarbate CRS.

If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in the minimum volume of ethanol (96 per cent) R, evaporate to dryness on a water-bath and record new spectra using the residues.

B. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 10 mg of the substance to be examined in the mobile phase and dilute to 10.0 mL with the mobile phase.

Reference solution. Dissolve 10 mg of prednicarbate CRS in the mobile phase and dilute to 10.0 mL with the mobile phase.

Plate: TLC silica gel F_{254} plate R.

Mobile phase: methanol R, methylene chloride R (10:90 V/V).

Application: 5 μ L; the volume may be adapted based on the type of plate used.

Development: over 3/4 of the plate.

Drying: in air.

Detection: spray with a solution prepared as follows: dissolve 0.25 g of 2,4-dihydroxybenzaldehyde R in glacial acetic acid R, dilute to 50 mL with the same solvent and add a mixture of 12.5 mL of sulfuric acid R and 37.5 mL of glacial acetic acid R; heat the plate at 90 °C for 35 min or until the spots appear and allow to cool; examine in daylight and in ultraviolet light at 365 nm.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

TESTS

Specific optical rotation (2.2.7): + 60 to + 66 (dried substance).

Dissolve 0.250 g in ethanol (96 per cent) R and dilute to 25.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29). Prepare the solutions immediately before use.

Test solution. Dissolve 30.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase.

Reference solution (a). Dissolve 3 mg of prednicarbate for system suitability A CRS (containing impurities B, C, D, E and F) in the mobile phase and dilute to 5 mL with the mobile phase.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (c). Dissolve 30.0 mg of prednicarbate CRS in the mobile phase and dilute to 50.0 mL with the mobile phase.

Column:

- size: l = 0.125 m, $\varnothing$ = 4 mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase: acetonitrile for chromatography R, water for chromatography R (50:60 V/V).

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 243 nm.

Injection: 20 μ L of the test solution and reference solutions (a) and (b).

Run time: twice the retention time of prednicarbate.

Identification of impurities: use the chromatogram supplied with prednicarbate for system suitability A CRS and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities B, C, D, E and F.

Relative retention with reference to prednicarbate (retention time = about 20 min): impurity B = about 0.25; impurity C = about 0.35; impurity D = about 0.39; impurity E = about 0.6; impurity F = about 1.2.

System suitability: reference solution (a):

- *resolution*: minimum 3.0 between the peaks due to prednicarbate and impurity F; minimum 1.5 between the peaks due to impurities C and D.

Calculation of percentage contents:

- for each impurity, use the concentration of prednicarbate in reference solution (b).

Limits:

- *impurity F*: maximum 0.8 per cent;
- *impurity C*: maximum 0.5 per cent;
- *impurity E*: maximum 0.3 per cent;
- *impurities B, D*: for each impurity, maximum 0.2 per cent;
- *unspecified impurities*: for each impurity, maximum 0.10 per cent;
- *total*: maximum 2.0 per cent;
- *reporting threshold*: 0.05 per cent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution and reference solution (c).

Calculate the percentage content of $C_{27}H_{36}O_8$ taking into account the assigned content of *prednicarbate CRS*.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: B, C, D, E, F.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use): A.




- A. 11β,17,21-trihydroxypregna-1,4-diene-3,20-dione (prednisolone),




- B. ethyl 11β,21-dihydroxy-3,20-dioxopregna-1,4-dien-17-yl carbonate (prednisolone 17-ethylcarbonate),




- C. 11β,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl propanoate (prednisolone 21-propanoate),



- D. ethyl 11β,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl carbonate (prednisolone 21-ethylcarbonate),



- E. 11β-hydroxy-3,20-dioxopregna-1,4-dien-17,21-diyl 21-acetate 17-(ethyl carbonate) (prednisolone 21-acetate 17-ethylcarbonate),




- F. 11β-hydroxy-3,20-dioxopregna-4-ene-17,21-diyl 17-(ethyl carbonate) 21-propanoate (1,2-dihydroprednicarbate).

01/2019:0635
corrected 10.1



PRIMAQUINE DIPHOSPHATE

Primaquini diphosphas



$C_{15}H_{27}N_3O_9P_2$
[63-45-6]

M_r 455.3

DEFINITION

(4*RS*)-*N*⁴-(6-Methoxyquinolin-8-yl)pentane-1,4-diamine bis(dihydrogen phosphate).

Content: 98.5 per cent to 101.5 per cent (dried substance).

CHARACTERS

Appearance: orange, crystalline powder.

Solubility: soluble in water, practically insoluble in ethanol (96 per cent).

mp: about 200 °C, with decomposition.

IDENTIFICATION

First identification: B, D.

Second identification: A, C, D.

A. Ultraviolet and visible absorption spectrophotometry (2.2.25).

Test solution (a). Dissolve 15 mg in a 1.03 g/L solution of hydrochloric acid R and dilute to 100.0 mL with the same solution.

Test solution (b). Dilute 5.0 mL of test solution (a) to 50.0 mL with a 1.03 g/L solution of hydrochloric acid R.

Spectral range: 310–450 nm for test solution (a); 215–310 nm for test solution (b).

Absorption maxima: at 332 nm and 415 nm for test solution (a); at 225 nm, 265 nm and 282 nm for test solution (b).

Specific absorbance at the absorption maxima:

- at 332 nm: 45 to 52 for test solution (a);
- at 415 nm: 27 to 35 for test solution (a);
- at 225 nm: 495 to 515 for test solution (b);
- at 265 nm: 335 to 350 for test solution (b);
- at 282 nm: 330 to 345 for test solution (b).

B. Infrared absorption spectrophotometry (2.2.24).

Examine the substances in discs prepared as follows: dissolve separately 0.1 g of the substance to be examined and 0.1 g of the reference substance in 5 mL of water R, add 2 mL of dilute ammonia R2 and 5 mL of methylene chloride R, then shake. Dry the methylene chloride layer over 0.5 g of anhydrous sodium sulfate R. Prepare a blank disc using about 0.3 g of potassium bromide R. Apply dropwise to the disc 0.1 mL of the methylene chloride layer, allowing the methylene chloride to evaporate between applications. Dry the disc at 50 °C for 2 min.

Comparison: primaquine diphosphate CRS.

C. Thin-layer chromatography (2.2.27). Carry out all operations as rapidly as possible, protected from light. Prepare the solutions immediately before use.

Test solution. Dissolve 0.20 g of the substance to be examined in 5 mL of water R and dilute to 10 mL with methanol R. Dilute 1 mL of this solution to 10 mL with a mixture of equal volumes of methanol R and water R.

Reference solution. Dissolve 20 mg of primaquine diphosphate CRS in 5 mL of water R and dilute to 10 mL with methanol R.

Plate: TLC silica gel GF₂₅₄ plate R.

Pretreatment: wash the plate with the mobile phase and allow to dry in air.

Mobile phase: concentrated ammonia R, methanol R, methylene chloride R (1:40:60 V/V/V).

Application: 5 µL.

Development: over 2/3 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with the reference solution.

D. Dissolve 50 mg in 5 mL of water R. Add 2 mL of dilute sodium hydroxide solution R and shake with 2 quantities, each of 5 mL, of methylene chloride R. The aqueous layer, acidified by addition of nitric acid R, gives reaction (b) of phosphates (2.3.1).

TESTS

Related substances. Liquid chromatography (2.2.29).

Test solution. Use a freshly prepared solution. Dissolve 25.0 mg of the substance to be examined in mobile phase A, using sonication if necessary, and dilute to 50.0 mL with mobile phase A.

Reference solution (a). Dissolve 5 mg of primaquine for system suitability CRS (containing impurity A) in mobile phase A and dilute to 10 mL with mobile phase A.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with mobile phase A. Dilute 1.0 mL of this solution to 10.0 mL with mobile phase A.

Column:

- size: $l = 0.15$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octylsilyl silica gel for chromatography with embedded polar groups R (5 µm);
- temperature: 25 °C.

Mobile phase:

- mobile phase A: trifluoroacetic acid R, tetrahydrofuran R, acetonitrile R, water for chromatography R (0.1/1/9/90 V/V/V/V);
- mobile phase B: acetonitrile R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 – 15	100	0
15 – 40	100 → 50	0 → 50

Flow rate: 1.2 mL/min.

Detection: spectrophotometer at 265 nm.

Injection: 25 µL.

Relative retention with reference to primaquine (retention time = about 13 min): impurity A = about 0.86.

System suitability: reference solution (a):

- resolution: minimum 2.0 between the peaks due to impurity A and primaquine.

Calculation of percentage contents:

- for each impurity, use the concentration of primaquine diphosphate in reference solution (b).

Limits:

- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.5 per cent;
- reporting threshold: 0.05 per cent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

ASSAY

Dissolve 0.200 g in 40 mL of anhydrous acetic acid R, heating gently. Allow to cool and titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).


1 mL of 0.1 M perchloric acid is equivalent to 22.77 mg of C₁₅H₂₇N₃O₉P₂.

STORAGE


Protected from light.

IMPURITIES


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use): A, B, C, D.




A. (4RS)-N¹-(6-methoxyquinolin-8-yl)pentane-1,4-diamine (quinocide),



B. 6-methoxy-8-nitroquinoline,



C. 6-methoxyquinolin-8-amine,




D. 2-[(4RS)-4-[(6-methoxyquinolin-8-yl)amino]pentyl]-1H-isindole-1,3(2H)-dione.



04/2020:1680

PYRANTEL EMBONATE

Pyranteli embonas



$C_{34}H_{30}N_2O_6S$
[22204-24-6]

 M_r 594.7

DEFINITION

1-Methyl-2-[(E)-2-(thiophen-2-yl)eth-1-en-1-yl]-1,4,5,6-tetrahydropyrimidine hydrogen 4,4'-methylenebis(3-hydroxynaphthalene-2-carboxylate).

Content: 98.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: pale yellow or yellow powder.

Solubility: practically insoluble in water, soluble in dimethyl sulfoxide, practically insoluble in methanol.

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: pyrantel embonate CRS.

TESTS

Related substances. Liquid chromatography (2.2.29). Prepare the solutions immediately before use and protect from light.

Solvent mixture. Mix 5 volumes of glacial acetic acid R and 5 volumes of water for chromatography R, then add 2 volumes of diethylamine R with cooling.

Test solution (a). Dissolve 0.800 g of the substance to be examined in 7 mL of the solvent mixture and dilute to 100.0 mL with acetonitrile R.

Test solution (b). Dilute 1.0 mL of test solution (a) to 10.0 mL with the mobile phase.

Reference solution (a). Dissolve 10 mg of pyrantel impurity A CRS in the solvent mixture, add 2.5 mL of test solution (b) and dilute to 50 mL with the solvent mixture. Dilute 2 mL of this solution to 100 mL with the solvent mixture.

Reference solution (b). Dilute 1.0 mL of test solution (b) to 200.0 mL with the mobile phase.

Reference solution (c). Dissolve 8.0 mg of pyrantel impurity D CRS in acetonitrile R and dilute to 10.0 mL with the same solvent. Dilute 1.0 mL of the solution to 100.0 mL with acetonitrile R.

Reference solution (d). Dissolve 8.0 mg of pyrantel impurity C CRS in acetonitrile R and dilute to 10.0 mL with the same solvent. Dilute 1.0 mL of the solution to 100.0 mL with acetonitrile R.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: silica gel for chromatography R (5 μ m);
- temperature: 30 °C.

Mobile phase: solvent mixture, acetonitrile for chromatography R (72:928 V/V).

Flow rate: 1 mL/min.

Detection: spectrophotometer at 288 nm and, for impurity D, at 238 nm.

Injection: 20 μ L of test solution (b) and reference solutions (a), (b) and (d); for impurity D, 50 μ L of test solution (a) and reference solution (c).

Run time: 4 times the retention time of pyrantel.

Identification of impurities: use the chromatogram obtained with reference solution (d) to identify the peak due to impurity C; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity D.

Relative retention with reference to pyrantel (retention time = about 11 min): impurity C = about 0.3; embonic acid = about 0.5; impurity A = about 1.3; impurity D = about 2.2.

System suitability: reference solution (a):

- resolution: minimum 4.0 between the peaks due to pyrantel and impurity A.

Calculation of percentage contents:

- for impurity D, use the concentration of impurity D in reference solution (c);
- for impurity C, use the concentration of impurity C in reference solution (d);
- for impurities other than C and D, use the concentration of pyrantel embonate in reference solution (b).

Limits:

- impurity D: maximum 0.2 per cent;
- impurity C: maximum 0.10 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- sum of impurities other than C and D (excluding embonic acid): maximum 0.3 per cent;
- reporting threshold: 0.05 per cent.

Chlorides (2.4.4): maximum 360 ppm.

To 0.46 g add 10 mL of dilute nitric acid R and 30 mL of water R. Heat on a water-bath for 5 min. Cool, dilute to 50 mL with water R, mix well and filter.

Sulfates (2.4.13): maximum 0.1 per cent.

To 0.50 g add 2.5 mL of dilute nitric acid R and dilute to 50 mL with distilled water R. Heat on a water-bath for 5 min, shake for 2 min, cool and filter.

Iron (2.4.9): maximum 75 ppm.

Ignite 0.66 g at 800 ± 50 °C for 2 h. Dissolve the residue in 2.5 mL of dilute hydrochloric acid R with gentle heating for 10 min. Cool and dilute to 50 mL with water R.

Loss on drying (2.2.32): maximum 1.0 per cent, determined on 1.000 g by drying *in vacuo* at 60 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

To 0.450 g add 10 mL of *acetic anhydride R* and 50 mL of *glacial acetic acid R*, heat at 50 °C and stir for 10 min. Allow to cool (a clear solution is not obtained). Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20). Carry out a blank titration.

1 mL of 0.1 M *perchloric acid* is equivalent to 59.47 mg of $C_{34}H_{30}N_2O_6S$.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: C, D.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B.




A. 1-methyl-2-[(Z)-2-(thiophen-2-yl)eth-1-en-1-yl]-1,4,5,6-tetrahydropyrimidine,



B. (E)-N-[3-(methylamino)propyl]-3-(thiophen-2-yl)prop-2-enamide,



C. thiophene-2-carbaldehyde,




D. 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine.



04/2020:0288

PYRIMETHAMINE

Pyrimethaminum



$C_{12}H_{13}ClN_4$
[58-14-0]

M_r 248.7

DEFINITION

5-(4-Chlorophenyl)-6-ethylpyrimidine-2,4-diamine.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder or colourless crystals.

Solubility: practically insoluble in water, slightly soluble in ethanol (96 per cent).

IDENTIFICATION

First identification: B.

Second identification: A, C.

A. Melting point (2.2.14): 239 °C to 243 °C.

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: *pyrimethamine CRS*.

C. Thin-layer chromatography (2.2.27).

Solvent mixture: *methanol R*, *methylene chloride R* (10:90 V/V).

Test solution. Dissolve 0.1 g of the substance to be examined in the solvent mixture and dilute to 100 mL with the solvent mixture.

Reference solution. Dissolve 0.1 g of *pyrimethamine CRS* in the solvent mixture and dilute to 100 mL with the solvent mixture.

Plate: TLC silica gel F_{254} plate R.

Mobile phase: *methylene chloride R*, *propanol R*, *glacial acetic acid R*, *toluene R* (4:8:12:76 V/V/V/V).

Application: 20 µL.

Development: over 2/3 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with the reference solution.

TESTS

Solution S. Shake 1.0 g with 50 mL of *carbon dioxide-free water R* for 2 min and filter.

Appearance of solution. Prepare the solution immediately before use. Dissolve 0.25 g in a mixture of 1 volume of *methanol R* and 3 volumes of *methylene chloride R* and dilute to 10 mL with the same mixture of solvents. The solution is clear (2.2.1) and not more intensely coloured than reference solution BY₆ (2.2.2, *Method II*).

Acidity or alkalinity. To 10 mL of solution S add 0.05 mL of *phenolphthalein solution R1*. The solution is colourless. Not more than 0.2 mL of 0.01 M *sodium hydroxide* is required to change the colour of the indicator to pink. Add 0.4 mL of 0.01 M *hydrochloric acid* and 0.05 mL of *methyl red solution R*. The solution is red or orange.

Related substances. Liquid chromatography (2.2.29).

Solvent mixture: mobile phase A, mobile phase B (50:50 V/V).

Test solution. Dissolve 10.0 mg of the substance to be examined in 4 mL of the solvent mixture using sonication and dilute to 10.0 mL with the solvent mixture.

Reference solution (a). Dissolve 10 mg of the substance to be examined and 10 mg of *pyrimethamine impurity B CRS* in 50 mL of the solvent mixture using sonication and dilute to 100 mL with the solvent mixture.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Column:

– size: $l = 0.25$ m, $\varnothing = 4.6$ mm;

- stationary phase: end-capped octadecylsilyl silica gel for chromatography R1 (5 µm);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: dissolve 2.72 g of potassium dihydrogen phosphate R in 900 mL of water for chromatography R, adjust to pH 8.0 with ammonia R and dilute to 1000 mL with water for chromatography R;
- mobile phase B: acetonitrile R1;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 6	65	35
6 - 20	65 → 40	35 → 60
20 - 35	40 → 55	60 → 45

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 210 nm.

Injection: 10 µL.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peak due to impurity B.

Relative retention with reference to pyrimethamine (retention time = about 15 min): impurity B = about 0.8.

System suitability: reference solution (a):

- resolution: minimum 5.0 between the peaks due to impurity B and pyrimethamine.

Calculation of percentage contents:

- for each impurity, use the concentration of pyrimethamine in reference solution (b).

Limits:

- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.3 per cent;
- reporting threshold: 0.05 per cent.

Sulfates (2.4.13): maximum 80 ppm, determined on solution S. Prepare the standard using a mixture of 2.5 mL of sulfate standard solution (10 ppm SO₄) R and 12.5 mL of distilled water R.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 0.500 g by drying in an oven at 105 °C for 4 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.200 g in 25 mL of anhydrous acetic acid R with gentle heating and allow to cool. Titrate with 0.1 M perchloric acid determining the end-point potentiometrically (2.2.20).


1 mL of 0.1 M perchloric acid is equivalent to 24.87 mg of C₁₂H₁₃ClN₄.

STORAGE


Protected from light.

IMPURITIES


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, C, D.




A. (2E)-2-(4-chlorophenyl)-3-oxopentanenitrile,



B. 5-(4-chlorophenyl)-6-methylpyrimidine-2,4-diamine,



C. (4-chlorophenyl)acetonitrile,



D. (E)-(4-chlorophenyl)(2-ethyl-1,3-dioxolan-2-yl)acetonitrile.

R


Rabeprazole sodium hydrate.....	4483	Rosuvastatin tablets.....	4487
Rosuvastatin calcium.....	4484		



04/2016:2331
corrected 10.1

RABEPRAZOLE SODIUM HYDRATE

Rabeprazolum natricum hydricum



$C_{18}H_{20}N_3NaO_3S \cdot xH_2O$ M_r 381.4 (anhydrous substance)
[891191-56-3]

DEFINITION

Sodium 2-[(RS)-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl]sulfonyl]benzimidazol-1-ide hydrate.

Content: 97.5 per cent to 102.0 per cent (anhydrous substance).

It contains a variable quantity of water.

CHARACTERS

Appearance: white or slightly yellowish-white, hygroscopic, amorphous or crystalline powder.

Solubility: very soluble to freely soluble in water, freely soluble in anhydrous ethanol, practically insoluble in heptane.

It shows polymorphism (5.9).

IDENTIFICATION

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: rabeprazole sodium hydrate CRS.

If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in *methanol R*, evaporate to dryness and record new spectra using the residues.

B. Water (see Tests).

C. It gives reaction (a) of sodium (2.3.1).

TESTS

pH (2.2.3): 9.5 to 11.5.

Dissolve 0.100 g in *carbon dioxide-free water R* and dilute to 10 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29). Carry out the test protected from light.

Solvent mixture: *methanol R*, 0.1 M phosphate buffer solution pH 11.3 R (20:80 V/V).

Test solution (a). Dissolve 20.0 mg of the substance to be examined in the solvent mixture and dilute to 20.0 mL with the solvent mixture.

Test solution (b). Dilute 5.0 mL of test solution (a) to 50.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b). Dissolve 5 mg of rabeprazole for system suitability CRS (containing impurities A and H) in the solvent mixture and dilute to 5 mL with the solvent mixture.

Reference solution (c). Dissolve 20.0 mg of rabeprazole sodium hydrate CRS in the solvent mixture and dilute to 20.0 mL with the solvent mixture. Dilute 5.0 mL of the solution to 50.0 mL with the solvent mixture.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: base-deactivated end-capped octadecylsilyl silica gel for chromatography R (5 μ m);

– temperature: 45 °C.

Mobile phase:

- mobile phase A: mix 5 volumes of *acetonitrile R* and 95 volumes of a 4.35 g/L solution of *dipotassium hydrogen phosphate R* previously adjusted to pH 7.0 with *phosphoric acid R*;
- mobile phase B: *methanol R*;
- mobile phase C: *acetonitrile R*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)	Mobile phase C (per cent V/V)
0 - 2	100	0	0
2 - 7	100 → 85	0	0 → 15
7 - 27	85 → 30	0 → 40	15 → 30
27 - 32	30 → 15	40 → 55	30

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 280 nm.

Autosampler: set at 6 °C.

Injection: 5 μ L of test solution (a) and reference solutions (a) and (b).

Identification of impurities: use the chromatogram supplied with rabeprazole for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A and H.

Relative retention with reference to rabeprazole (retention time = about 19 min): impurity A = about 0.9; impurity H = about 0.98.

System suitability: reference solution (b):

- peak-to-valley ratio: minimum 1.5, where H_p = height above the baseline of the peak due to impurity H and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to rabeprazole.

Calculation of percentage contents:

- for each impurity, use the concentration of rabeprazole sodium hydrate in reference solution (a).

Limits:

- impurity A: maximum 0.15 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.5 per cent;
- reporting threshold: 0.05 per cent.

Water (2.5.12): 1.5 per cent to 7.0 per cent, determined on 0.200 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution (b) and reference solution (c).

Calculate the percentage content of $C_{18}H_{20}N_3NaO_3S$ taking into account the assigned content of rabeprazole sodium hydrate CRS.


STORAGE

In an airtight container, protected from light.


IMPURITIES

Specified impurities: A.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. **Control of impurities in substances for pharmaceutical use:** B, C, D, E, F, G, H, I, K.




A. 2-[[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]-methyl]sulfonyl]-1H-benzimidazole,




B. 2-[[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]-methyl]sulfanyl]-1H-benzimidazole,




C. 1-(1H-benzimidazol-2-yl)-3-methyl-4-oxo-1,4-dihydropyridine-2-carboxylic acid,




D. 2-[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide,




E. 2-[(RS)-[(4-methoxy-3-methylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole,




F. 1H-benzimidazole-2-thiol,




G. 2-[[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl]sulfanyl]-1H-benzimidazole,



H. 2-[(RS)-[(4-chloro-3-methylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole,



I. 2-[[[1H-benzimidazol-2-yl)sulfonyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide,




K. 1H-benzimidazol-2-ol.



04/2020:2631

ROSUVASTATIN CALCIUM

Rosuvastatinum calcicum



$C_{44}H_{54}CaF_2N_6O_{12}S_2$
[147098-20-2]

M_r 1001

DEFINITION

Calcium bis[(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate].

Content: 97.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, hygroscopic powder.

Solubility: slightly soluble in water, freely soluble in methylene chloride, practically insoluble in anhydrous ethanol.

IDENTIFICATION

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: rosuvastatin calcium CRS.

B. Enantiomeric purity (see Tests).

C. It gives reaction (b) of calcium (2.3.1).

TESTS

Enantiomeric purity. Liquid chromatography (2.2.29). Carry out the test protected from light.

Solvent mixture: acetonitrile R, water R (25:75 V/V).

Test solution. Dissolve 25.0 mg of the substance to be examined in 6 mL of acetonitrile R and dilute to 25.0 mL with water R.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b). Dissolve the contents of a vial of rosuvastatin impurity G CRS in 1 mL of the test solution.

Column:

– size: $l = 0.15$ m, $\varnothing = 4.6$ mm;

– stationary phase: cellulose derivative of silica gel for chiral separation R (5 μ m);

– temperature: 35 °C.

Mobile phase: acetonitrile for chromatography R, 0.1 per cent V/V solution of trifluoroacetic acid R (25:75 V/V).

Flow rate: 0.5 mL/min.

Detection: spectrophotometer at 242 nm.

Injection: 10 μ L.

Run time: 2.6 times the retention time of rosuvastatin.

Identification of impurities: use the chromatogram obtained with reference solution (b) to identify the peak due to impurity G.

Relative retention with reference to rosuvastatin (retention time = about 29 min): impurity G = about 0.9.

System suitability: reference solution (b):

- **resolution:** minimum 1.5 between the peaks due to impurity G and rosuvastatin.

Calculation of percentage content:

- for impurity G, use the concentration of rosuvastatin calcium in reference solution (a).

Limit:

- **impurity G:** maximum 0.15 per cent.

Impurity L. Liquid chromatography (2.2.29). Carry out the test protected from light.

Solvent mixture: acetonitrile R, water R (50:50 V/V).

Test solution. Dissolve 20.0 mg of the substance to be examined in 50 mL of acetonitrile R and dilute to 100.0 mL with water R.

Reference solution (a). Dissolve 5 mg of rosuvastatin for impurity L identification CRS in 10 mL of acetonitrile R and dilute to 20 mL with water R.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Column:

- **size:** $l = 0.15$ m, $\varnothing = 4.6$ mm;
- **stationary phase:** end-capped solid core octylsilyl silica gel for chromatography R (2.7 μ m).

Mobile phase: to 650 mL of a 0.02 per cent V/V solution of trifluoroacetic acid R, add 350 mL of a mixture of 1 volume of ethanol (96 per cent) R and 2 volumes of acetonitrile for chromatography R.

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 243 nm.

Injection: 10 μ L.

Run time: 3 times the retention time of rosuvastatin.

Identification of impurities: use the chromatogram supplied with rosuvastatin for impurity L identification CRS and the chromatogram obtained with reference solution (a) to identify the peak due to impurity L.

Relative retention with reference to rosuvastatin (retention time = about 22 min): impurity L = about 1.1.

System suitability: reference solution (a):

- **peak-to-valley ratio:** minimum 2.5, where H_p = height above the baseline of the peak due to impurity L and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to rosuvastatin.

Calculation of percentage content:

- **correction factor:** multiply the peak area of impurity L by 1.8;
- for impurity L, use the concentration of rosuvastatin calcium in reference solution (b).

Limit:

- **impurity L:** maximum 0.15 per cent.

Related substances. Liquid chromatography (2.2.29). Carry out the test protected from light and prepare the solutions immediately before use.

Solvent mixture: acetonitrile R, water R (25:75 V/V).

Test solution. Dissolve 35.0 mg of the substance to be examined in 12 mL of acetonitrile R and dilute to 50.0 mL with water R.

Reference solution (a). Dissolve 35.0 mg of rosuvastatin calcium CRS in 12 mL of acetonitrile R and dilute to 50.0 mL with water R.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (c). Dissolve 7 mg of rosuvastatin for system suitability CRS (containing impurities A, B and C) in 2.5 mL of acetonitrile R and dilute to 10 mL with water R.

Reference solution (d). Dissolve the contents of a vial of rosuvastatin impurity mixture CRS (impurities D and K) in 1 mL of the solvent mixture.

Reference solution (e). Dissolve 7 mg of rosuvastatin for peak identification CRS (containing impurity M) in 2.5 mL of acetonitrile R and dilute to 10 mL with water R.

Column:

- **size:** $l = 0.15$ m, $\varnothing = 3.0$ mm;
- **stationary phase:** base-deactivated end-capped octadecylsilyl silica gel for chromatography R (3 μ m);
- **temperature:** 40 °C.

Mobile phase:

- **mobile phase A:** 1 per cent V/V solution of trifluoroacetic acid R, acetonitrile for chromatography R, water for chromatography R (1:29:70 V/V/V);
- **mobile phase B:** 1 per cent V/V solution of trifluoroacetic acid R, water for chromatography R, acetonitrile for chromatography R (1:24:75 V/V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 30	100	0
30 - 50	100 → 60	0 → 40
50 - 60	60 → 0	40 → 100
60 - 70	0	100

Flow rate: 0.75 mL/min.

Detection: spectrophotometer at 242 nm.

Injection: 10 μ L of the test solution and reference solutions (b), (c), (d) and (e).

Identification of impurities: use the chromatogram supplied with rosuvastatin for system suitability CRS and the chromatogram obtained with reference solution (c) to identify the peaks due to impurities A, B and C; use the chromatogram supplied with rosuvastatin impurity mixture CRS and the chromatogram obtained with reference solution (d) to identify the peaks due to impurities D and K; use the chromatogram supplied with rosuvastatin for peak identification CRS and the chromatogram obtained with reference solution (e) to identify the peak due to impurity M.

Relative retention with reference to rosuvastatin (retention time = about 25 min): impurity M = about 0.8; impurity A = about 0.9; impurity B = about 1.1; impurity C = about 1.5; impurity D = about 1.9; impurity K = about 2.0.

System suitability: reference solution (c):

- **resolution:** minimum 2.0 between the peaks due to rosuvastatin and impurity B.

Calculation of percentage contents:

- **correction factor:** multiply the peak area of impurity C by 1.4;
- for each impurity, use the concentration of rosuvastatin calcium in reference solution (b).

Limits:

- **impurity C:** maximum 0.8 per cent;
- **impurity B:** maximum 0.5 per cent;
- **impurity A:** maximum 0.2 per cent;
- **impurities D, K, M:** for each impurity, maximum 0.15 per cent;
- **unspecified impurities:** for each impurity, maximum 0.10 per cent;

- *total*: maximum 1.2 per cent;
- *reporting threshold*: 0.05 per cent.

Water (2.5.12): maximum 6.1 per cent, determined on 0.100 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution and reference solution (a).

Calculate the percentage content of $C_{44}H_{54}CaF_2N_6O_{12}S_2$ taking into account the assigned content of *rosuvastatin calcium CRS*.


STORAGE

In an airtight container, protected from light, at a temperature of 2 °C to 8 °C.


IMPURITIES

Specified impurities: A, B, C, D, G, K, L, M.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): E, F, J.




- A. (3*R*,5*S*,6*E*)-7-[2-(2-*N*-dimethyl-2-hydroxypropane-1-sulfonamido)-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid,




- B. (3*R*,5*R*,6*E*)-7-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid,




- C. (3*R*,6*E*)-7-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoic acid,




- D. *N*-[4-(4-fluorophenyl)-5-[(1*E*)-2-[(2*S*,4*R*)-4-hydroxy-6-oxooxan-2-yl]ethen-1-yl]-6-(propan-2-yl)pyrimidin-2-yl]-*N*-methylmethanesulfonamide,




- E. (3*R*,5*S*,6*E*)-7-[4-(4-fluorophenyl)-2-[(2*E*)-2-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-2-hydroxy-*N*-methylethane-1-sulfonamido]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid,




- F. *tert*-butyl[(4*R*,6*S*)-6-[(1*E*)-2-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]ethen-1-yl]-2,2-dimethyl-1,3-dioxan-4-yl]acetate,




- G. (3*S*,5*R*,6*E*)-7-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid,




- J. (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-[(1E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-N-methylethene-1-sulfonamido]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid,



- K. (2E,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-5-hydroxyhepta-2,6-dienoic acid,



- L. (3E,5E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyheptanoic acid,



- M. (3R,5S,6E)-7-[2-(N-methylmethanesulfonamido)-4-phenyl-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid,



04/2020:3008

ROSUVASTATIN TABLETS

Rosuvastatini compressi

DEFINITION

Tablets containing *Rosuvastatin calcium* (2631).

They comply with the monograph *Tablets* (0478) and the following additional requirements.

Content: 93.0 per cent to 105.0 per cent of the content of rosuvastatin ($C_{22}H_{28}FN_3O_6S$) stated on the label.

IDENTIFICATION

- A. Record the UV spectrum of the principal peak in the chromatograms obtained with the solutions used in the assay, with a diode array detector in the range 210–400 nm.

Results: the UV spectrum of the principal peak in the chromatogram obtained with the test solution is similar to the UV spectrum of the principal peak in the chromatogram obtained with reference solution (a).

- B. Examine the chromatograms obtained in the assay.

Results: the principal peak in the chromatogram obtained with the test solution is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (a).

TESTS

Related substances. Liquid chromatography (2.2.29). Carry out the test protected from light and prepare the solutions immediately before use.

Solvent mixture: acetonitrile R, water R (25:75 V/V).

Test solution. To an appropriate number of tablets (at least 6) add at least 50 mL of water R and shake vigorously until the tablets have disintegrated completely. Add a suitable volume of acetonitrile R and again shake vigorously. Add a suitable volume of water R to obtain a ratio of acetonitrile to water of 25:75 V/V. Filter through a poly(vinylidene difluoride) filter and dilute with the solvent mixture, if necessary, to obtain a concentration of rosuvastatin calcium of 1 mg/mL.

Reference solution (a). To 25.0 mg of *rosuvastatin calcium CRS* add 25 mL of water R and allow to stand for at least 10 min. Sonicate for about 30 min until dissolved, shaking every 10 min. Add 12.5 mL of acetonitrile R, mix well and dilute to 50.0 mL with water R. Dilute 1.0 mL of the solution to 50.0 mL with the solvent mixture.

Reference solution (b). Dissolve 7 mg of *rosuvastatin for system suitability CRS* (containing impurities A, B and C) in 2.5 mL of acetonitrile R and dilute to 10 mL with water R.

Reference solution (c). Dissolve the contents of a vial of *rosuvastatin impurity mixture CRS* (containing impurity D) in 1 mL of the solvent mixture.

Reference solution (d). Dissolve 2 mg of *rosuvastatin ethyl ester R* (impurity FP-A) in 20 mL of the solvent mixture. Dilute 1 mL of the solution to 100 mL with the solvent mixture.

Column:

- size: $l = 0.15$ m, $\varnothing = 3.0$ mm;
- stationary phase: end-capped octadecylsilyl amorphous organosilica polymer for chromatography R (3.5 μ m);
- temperature: 40 °C.

Mobile phase:

- mobile phase A: 1 per cent V/V solution of trifluoroacetic acid R, acetonitrile for chromatography R, water for chromatography R (1:31:68 V/V/V);
- mobile phase B: 1 per cent V/V solution of trifluoroacetic acid R, water for chromatography R, acetonitrile for chromatography R (1:37:66 V/V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 26	100	0
26 - 36	100 → 20	0 → 80
36 - 46	20	80

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 242 nm.

Injection: 10 μ L.

Identification of impurities: use the chromatogram supplied with *rosuvastatin for system suitability CRS* and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A, B and C; use the chromatogram

supplied with *rosuvastatin impurity mixture CRS* and the chromatogram obtained with reference solution (c) to identify the peak due to impurity D; use the chromatogram obtained with reference solution (d) to identify impurity FP-A.

Relative retention with reference to rosuvastatin (retention time = about 11 min): impurity A = about 0.9; impurity B = about 1.1; impurity C = about 1.7; impurity D = about 2.2; impurity FP-A = about 3.1.

System suitability: reference solution (b):

- *peak-to-valley ratio*: minimum 2.0, where H_p = height above the baseline of the peak due to impurity B and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to rosuvastatin.

Calculation of percentage contents:

- *correction factor*: multiply the peak area of impurity C by 1.4;
- for each impurity, use the concentration of rosuvastatin calcium in reference solution (a).

Limits:

- *impurities C, D*: for each impurity, maximum 1.5 per cent;
- *impurity FP-A*: maximum 0.5 per cent;
- *unspecified impurities*: for each impurity, maximum 0.2 per cent;
- *total*: maximum 2.5 per cent;
- *reporting threshold*: 0.1 per cent; disregard the peaks due to impurities A and B.

Dissolution (2.9.3, Apparatus 2). Carry out the test protected from light.

The tablets comply with the test and the acceptance criterion described below, unless otherwise justified and authorised.

Dissolution medium (0.05 M citrate buffer solution pH 6.6). Dissolve 147.0 g of sodium citrate R in 2 L of water R, add 3.3 g of anhydrous citric acid R and dilute to 10 L with the same solvent. If necessary, adjust to pH 6.6 ± 0.05 with sodium citrate R or anhydrous citric acid R. Use 900 mL of the medium.

Rotation speed: 50 r/min.

Time: 30 min.

Analysis. Liquid chromatography (2.2.29).

Test solution. The samples withdrawn from the dissolution vessel and filtered, using a poly(vinylidene difluoride) filter.

Reference solution. To 25.0 mg of *rosuvastatin calcium CRS* add 25 mL of water R and allow to stand for at least 10 min. Sonicate for about 30 min until dissolved, shaking every 10 min. Add 12.5 mL of acetonitrile R, mix well and dilute to 50.0 mL with water R. Dilute a suitable volume of the solution with the dissolution medium to obtain a concentration of rosuvastatin corresponding to the theoretical concentration of rosuvastatin in the test solution, based on the labelled content of the tablets.

Column:

- *size*: $l = 0.05$ m, $\varnothing = 4.6$ mm;
- *stationary phase*: end-capped octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase: phosphoric acid R, acetonitrile for chromatography R, water for chromatography R (0.1:40:60 V/V/V).

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 242 nm.

Injection: 20 μ L.

Run time: 5 min.

System suitability: reference solution:

- *repeatability*: maximum relative standard deviation of 1.0 per cent determined on 6 injections.

Calculate the amount of dissolved rosuvastatin ($C_{22}H_{28}FN_3O_6S$), expressed as a percentage of the content stated on the label, taking into account the assigned content of *rosuvastatin calcium CRS* and a conversion factor of 0.96.

Acceptance criterion:

- $Q = 75$ per cent after 30 min.

ASSAY

Liquid chromatography (2.2.29). Carry out the test protected from light.

Solvent mixture: acetonitrile R, water R (25:75 V/V).

Test solution. To an appropriate number of tablets (at least 6) add at least 50 mL of water R and shake vigorously until the tablets have disintegrated completely. Add a suitable volume of acetonitrile R and again shake vigorously. Add a suitable volume of water R to obtain a ratio of acetonitrile to water of 25:75 V/V. Filter through a poly(vinylidene difluoride) filter and dilute with the solvent mixture, if necessary, to obtain a concentration of rosuvastatin calcium of 0.1 mg/mL.

Reference solution (a). To 25.0 mg of *rosuvastatin calcium CRS* add 25 mL of water R and allow to stand for at least 10 min. Sonicate for about 30 min until dissolved, shaking every 10 min. Add 12.5 mL of acetonitrile R, mix well and dilute to 50.0 mL with water R. Dilute 1.0 mL of the solution to 5.0 mL with the solvent mixture.

Reference solution (b). Dissolve 7 mg of *rosuvastatin for system suitability CRS* (containing impurities A, B and C) in 2.5 mL of acetonitrile R and dilute to 10 mL with water R.

Column:

- *size*: $l = 0.15$ m, $\varnothing = 3.0$ mm;
- *stationary phase*: end-capped octadecylsilyl amorphous organosilica polymer for chromatography R (3.5 μ m);
- *temperature*: 40 °C.

Mobile phase:

- *mobile phase A*: 1 per cent V/V solution of trifluoroacetic acid R, acetonitrile for chromatography R, water for chromatography R (1:31:68 V/V/V);
- *mobile phase B*: 1 per cent V/V solution of trifluoroacetic acid R, acetonitrile for chromatography R (1:100 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 14	100	0
14 - 15	100 $\rightarrow$ 10	0 $\rightarrow$ 90

Flow rate: 0.7 mL/min.

Detection: spectrophotometer at 242 nm.

Injection: 10 μ L.

Identification of impurities: use the chromatogram supplied with *rosuvastatin for system suitability CRS* and the chromatogram obtained with reference solution (b) to identify the peak to impurity B.

Relative retention with reference to rosuvastatin (retention time = about 11 min): impurity B = about 1.1.

System suitability:


- *repeatability*: maximum relative standard deviation of 1.0 per cent determined on 6 injections of reference solution (a);
- *peak-to-valley ratio*: minimum 2.0, where H_p = height above the baseline of the peak due to impurity B and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to rosuvastatin in the chromatogram obtained with reference solution (b).

Calculate the percentage content of rosuvastatin ($C_{22}H_{28}FN_3O_6S$) taking into account the assigned content of *rosuvastatin calcium CRS* and a conversion factor of 0.96.


IMPURITIES

Specified impurities: C, D, FP-A.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph): A, B, FP-B.




A. (3*R*,5*S*,6*E*)-7-[2-(2-*N*-dimethyl-2-hydroxypropane-1-sulfonamido)-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid,




B. (3*R*,5*RS*,6*E*)-7-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid,




C. (3*R*,6*E*)-7-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoic acid,



D. *N*-[4-(4-fluorophenyl)-5-[(1*E*)-2-[(2*S*,4*R*)-4-hydroxy-6-oxooxan-2-yl]ethen-1-yl]-6-(propan-2-yl)pyrimidin-2-yl]-*N*-methylmethanesulfonamide,



FP-A. ethyl (3*R*,5*S*,6*E*)-7-[4-(4-fluorophenyl)-2-(*N*-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate (rosuvastatin ethyl ester),



FP-B. (3*R*,5*S*)-5-[(6*RS*)-8-fluoro-2-(*N*-methylmethanesulfonamido)-4-(propan-2-yl)-5,6-dihydrobenzo[*h*]quinazolin-6-yl]-3,5-dihydroxypentanoic acid.

S

Sodium sulfate decahydrate.....	4493	Sulfamethizole.....	4494
Squalane.....	4493		

01/2019:0100
corrected 10.1

SODIUM SULFATE DECAHYDRATE

Natrii sulfas decahydricus

Na₂SO₄·10H₂O
[7727-73-3]M_r 322.2

DEFINITION

Disodium sulfate decahydrate.

Content: 98.5 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder or colourless, transparent crystals.*Solubility*: freely soluble in water, practically insoluble in ethanol (96 per cent). It partly dissolves in its own water of crystallisation at about 33 °C.

IDENTIFICATION

- A. It gives reaction (a) of sulfates (2.3.1).
 B. It gives reaction (a) of sodium (2.3.1).
 C. Loss on drying (see Tests).

TESTS

Solution S. Dissolve 5.0 g in *carbon dioxide-free water R* prepared from *distilled water R* and dilute to 100 mL with the same solvent.**Appearance of solution.** Solution S is clear (2.2.1) and colourless (2.2.2, *Method II*).**Acidity or alkalinity.** To 10 mL of solution S add 0.1 mL of *bromothymol blue solution R1*. Not more than 0.5 mL of 0.01 M *hydrochloric acid* or 0.01 M *sodium hydroxide* is required to change the colour of the indicator.**Chlorides** (2.4.4): maximum 200 ppm.Dilute 5 mL of solution S to 15 mL with *water R*.**Calcium** (2.4.3): maximum 200 ppm, if intended for use in the manufacture of parenteral preparations.Dilute 10 mL of solution S to 15 mL with *distilled water R*.**Iron** (2.4.9): maximum 40 ppm, if intended for use in the manufacture of parenteral preparations.Dilute 5 mL of solution S to 10 mL with *water R*.**Magnesium**: maximum 100 ppm, if intended for use in the manufacture of parenteral preparations.To 10 mL of solution S add 1 mL of *glycerol (85 per cent) R*, 0.15 mL of *titan yellow solution R*, 0.25 mL of *ammonium oxalate solution R* and 5 mL of *dilute sodium hydroxide solution R* and shake. Any pink colour in the test solution is not more intense than that in a standard prepared at the same time in the same manner using a mixture of 5 mL of *magnesium standard solution (10 ppm Mg) R* and 5 mL of *water R*.**Loss on drying** (2.2.32): 52.0 per cent to 57.0 per cent, determined on 1.000 g by drying at 30 °C for 1 h, then at 130 °C.

ASSAY

Pack 20 g of *strongly acidic ion-exchange resin R* into a glass column, at least 20 cm long and 20 mm in internal diameter, and cover it with *water R*. After 5 min, wash the resin with *water R* until the pH of the eluate is about 6 to 7 using a *pH indicator strip R*. Keep the resin covered with *water R*. Dissolve 1.100 g of the substance to be examined in 10 mL of *water R* in a beaker. Load the solution onto the column and pass throughthe resin at a flow rate of about 4 mL/min until the resin is just covered with the solution. Using about 200 mL of *water R*, rinse the beaker and pass the rinsings through the column at the same flow rate. Check that the pH of the last eluate is about 6 to 7 using a *pH indicator strip R*.Titrate the eluate with 1 M *sodium hydroxide*, determining the end-point potentiometrically (2.2.20).1 mL of 1 M *sodium hydroxide* is equivalent to 71.00 mg of Na₂SO₄.

LABELLING


The label states, where applicable, that the substance is suitable for use in the manufacture of parenteral preparations.

04/2020:1630



SQUALANE

Squalanum

C₃₀H₆₂
[111-01-3]M_r 422.8

DEFINITION

(6E,10E,15E,19E)-2,6,10,15,19,23-Hexamethyltetracosane (perhydrosqualene). It may be of vegetable (unsaponifiable matter of olive oil), animal (shark liver oil) or synthetic origin.

Content: 96.0 per cent to 103.0 per cent.

PRODUCTION

The origin of the squalane (vegetable, animal or synthetic) is stated by the manufacturer.

CHARACTERS

Appearance: clear, colourless, oily liquid.*Solubility*: practically insoluble in water, miscible with most fats and oils, freely soluble in acetone and in cyclohexane, practically insoluble in ethanol (96 per cent).*Relative density*: about 0.815.

IDENTIFICATION

- A. Infrared absorption spectrophotometry (2.2.24).

Comparison: *squalane CRS*.

- B. Refractive index (see Tests).

TESTS

Appearance. The substance to be examined is clear (2.2.1) and colourless (2.2.2, *Method II*).**Refractive index** (2.2.6): 1.450 to 1.454.**Acid value** (2.5.1): maximum 0.2.**Iodine value** (2.5.4, *Method A*): maximum 4.0.**Saponification value** (2.5.6): maximum 3.0.**Total ash** (2.4.16): maximum 0.5 per cent, determined on 1.000 g.

ASSAY

Gas chromatography (2.2.28).

Internal standard solution. To 1.0 mL of *dimethylacetamide R* add 100.0 mL of *heptane R*.

Test solution. Dissolve 0.100 g of the substance to be examined in the internal standard solution and dilute to 25.0 mL with the same solution.

Reference solution (a). Dissolve 0.100 g of *squalane* CRS in the internal standard solution and dilute to 25.0 mL with the same solution.

Reference solution (b). To 0.1 mL of *methyl erucate* R add 0.100 g of the substance to be examined, dissolve in the internal standard solution and dilute to 25 mL with the same solution.

Column:

- **material:** fused silica;
- **size:** $l = 30$ m, $\varnothing = 0.32$ mm;
- **stationary phase:** *methylpolysiloxane* R (film thickness 1 μ m).

Carrier gas: *helium* for chromatography R.

Flow rate: 1.7 mL/min.

Split ratio: 1:12.

Temperature:

	Time (min)	Temperature (°C)
Column	0 - 39	60 → 290
	39 - 50	290
Injection port		275
Detector		300

Detection: flame ionisation.

Injection: 1 μ L.

Relative retention with reference to *squalane* (retention time = about 41 min): internal standard = about 0.2; *methyl erucate* = about 0.9; *cyclosqualane* = 1.05.

System suitability: reference solution (b):

- **resolution:** minimum 5 between the peaks due to *methyl erucate* and *squalane*.

Calculate the percentage content of $C_{30}H_{62}$ using the chromatogram obtained with reference solution (a) and taking into account the assigned content of *squalane* CRS.

LABELLING


The label states the origin of *squalane* (vegetable, animal or synthetic).



04/2020:0637

SULFAMETHIZOLE

Sulfamethizolum



$C_9H_{10}N_4O_2S_2$
[144-82-1]

M_r 270.3

DEFINITION

4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzene-1-sulfonamide.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or yellowish-white, crystalline powder or crystals.

Solubility: very slightly soluble in water, soluble in acetone, sparingly soluble in ethanol (96 per cent). It dissolves in dilute solutions of alkali hydroxides and in dilute mineral acids.

mp: about 210 °C.

IDENTIFICATION

First identification: A.

Second identification: B.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: *sulfamethizole* CRS.

B. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 30 mg of the substance to be examined in *acetone* R and dilute to 3 mL with the same solvent.

Reference solution. Dissolve 30 mg of *sulfamethizole* CRS in *acetone* R and dilute to 3 mL with the same solvent.

Plate: TLC silica gel F_{254} plate R.

Mobile phase: *methanol* R, *methylene chloride* R (15:85 V/V).

Application: 2 μ L; the volume may be adapted based on the type of plate used.

Development: over 3/4 of the plate.

Drying: at 100-105 °C.

Detection A: examine in ultraviolet light at 254 nm.

Results A: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with the reference solution.

Detection B: spray with a 40 g/L solution of *copper acetate* R and examine in daylight.

Results B: the principal spot in the chromatogram obtained with the test solution is similar in colour to the principal spot in the chromatogram obtained with the reference solution.

TESTS

Appearance of solution. The solution is not more intensely coloured than reference solution Y_5 , BY_5 or GY_5 (2.2.2, Method II).

Dissolve 1.0 g in a mixture of 5 mL of *dilute sodium hydroxide* solution R and 5 mL of *water* R.

Acidity. To 1.25 g add 25 mL of *carbon dioxide-free water* R and heat at 70 °C for 5 min. Cool for about 15 min in iced water and filter. To 20 mL of the filtrate add 0.1 mL of *bromothymol blue* solution R1. Not more than 0.5 mL of 0.1 M *sodium hydroxide* is required to change the colour of the indicator.

Related substances. Liquid chromatography (2.2.29).

Solvent mixture: *methanol* R, *water* R (15:85 V/V).

Test solution. Dissolve 20.0 mg of the substance to be examined in 1 mL of *methanol* R, sonicate if necessary and dilute to 20.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b). Dissolve 2 mg of *sulfamethizole* for system suitability CRS (containing impurities B, C and D) in 0.1 mL of *methanol* R, sonicate if necessary and dilute to 2 mL with the solvent mixture.

Column:

- **size:** $l = 0.25$ m, $\varnothing = 4.6$ mm;
- **stationary phase:** *end-capped octadecylsilyl silica gel* for chromatography compatible with 100 per cent aqueous mobile phases R (5 μ m);
- **temperature:** 30 °C.

Mobile phase:

- **mobile phase A:** *acetic acid* R, *methanol* R, *water* for chromatography R (1:14:85 V/V/V);

- *mobile phase B*: acetic acid R, methanol R (1:99 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 20	100	0
20 - 40	100 → 30	0 → 70
40 - 45	30	70

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 254 nm.

Injection: 20 µL.

Identification of impurities: use the chromatogram supplied with sulfamethizole for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities B, C and D.

Relative retention with reference to sulfamethizole (retention time = about 17 min): impurity B = about 0.23; impurity C = about 0.24; impurity D = about 1.9.

System suitability: reference solution (b):

- *resolution*: minimum 1.5 between the peaks due to impurities B and C.

Calculation of percentage contents:

- *correction factor*: multiply the peak area of impurity D by 1.4;
- for each impurity, use the concentration of sulfamethizole in reference solution (a).

Limits:

- *impurity D*: maximum 0.2 per cent;
- *unspecified impurities*: for each impurity, maximum 0.10 per cent;
- *total*: maximum 0.5 per cent;
- *reporting threshold*: 0.05 per cent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Carry out the determination of primary aromatic amino-nitrogen (2.5.8), using 0.2500 g and determining the end-point electrometrically.

1 mL of 0.1 M sodium nitrite is equivalent to 27.03 mg of $C_9H_{10}N_4O_2S_2$.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: D.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, C.




A. hydrazinecarbothioamide (thiosemicarbazide),



B. 4-aminobenzene-1-sulfonamide (sulfanilamide),



C. 5-methyl-1,3,4-thiadiazol-2-amine,



D. 4-(4-aminobenzene-1-sulfonamido)-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzene-1-sulfonamide.

T


Testosterone.....	4499	Tiaprofenic acid.. ..	4503
Thiocolchicoside hydrate.....	4500	Tranexamic acid.....	4504



04/2020:1373

TESTOSTERONE

Testosteronum



$C_{19}H_{28}O_2$
[58-22-0]

 M_r 288.4

DEFINITION

17β-Hydroxyandrost-4-en-3-one.

Content: 98.0 per cent to 102.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white crystalline powder, or colourless or yellowish-white crystals.

Solubility: practically insoluble in water, freely soluble in ethanol (96 per cent) and in methylene chloride, practically insoluble in fatty oils.

mp: about 155 °C.

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: testosterone for ID and assay CRS.

TESTS

Specific optical rotation (2.2.7): + 106 to + 114 (dried substance).

Dissolve 0.250 g in *anhydrous ethanol R* and dilute to 25.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Solvent mixture: acetonitrile R, water R (30:70 V/V).

Test solution. Dissolve 35.0 mg of the substance to be examined in 30 mL of acetonitrile R and dilute to 100.0 mL with water R.

Reference solution (a). Dissolve 9 mg of testosterone for system suitability A CRS (containing impurities C, G and K) in 8 mL of acetonitrile R and dilute to 25 mL with water R.

Reference solution (b). Dissolve 7.0 mg of testosterone impurity I CRS in 30 mL of acetonitrile R and dilute to 100.0 mL with water R. Dilute 1.0 mL of the solution to 100.0 mL with the solvent mixture.

Reference solution (c). Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (d). Dissolve 35.0 mg of testosterone for ID and assay CRS in 30 mL of acetonitrile R and dilute to 100.0 mL with water R.

Column:

- size: $l = 0.10$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped solid core phenylhexylsilyl silica gel for chromatography R (2.7 μ m);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: water for chromatography R;
- mobile phase B: acetonitrile for chromatography R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 2.7	65	35
2.7 - 7	65 → 63	35 → 37
7 - 10	63 → 10	37 → 90
10 - 12	10	90

Flow rate: 1.5 mL/min.

Detection: spectrophotometer at 242 nm, and for impurity I, at 290 nm.

Injection: 20 μ L of the test solution and reference solutions (a), (b) and (c).

Identification of impurities: use the chromatogram supplied with testosterone for system suitability A CRS and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities C, G and K; use the chromatogram obtained with reference solution (b) to identify the peak due to impurity I.

Relative retention with reference to testosterone (retention time = about 4 min): impurity I = about 0.84; impurity K = about 0.86; impurity G = about 1.1; impurity C = about 1.3.

System suitability: reference solution (a):

- peak-to-valley ratio: minimum 2.0, where H_p = height above the baseline of the peak due to impurity G and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to testosterone.

Calculation of percentage contents:

- for impurity I, use the concentration of impurity I in reference solution (b);
- for impurities other than I, use the concentration of testosterone in reference solution (c).

Limits:

- impurity C: maximum 0.3 per cent;
- impurity I at 290 nm: maximum 0.2 per cent;
- impurity K: maximum 0.15 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 0.6 per cent;
- reporting threshold: 0.05 per cent.

Loss on drying (2.2.32): maximum 1.0 per cent, determined on 0.500 g by drying in an oven at 105 °C for 2 h.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: 5 μ L of the test solution and reference solution (d).

Calculate the percentage content of $C_{19}H_{28}O_2$ taking into account the assigned content of testosterone for ID and assay CRS.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: C, I, K.



Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, E, G, H, J, L, M.




A. androst-4-ene-3,17-dione (androstenedione),




B. 3-ethoxyandrosta-3,5-dien-17-one (androstenedione ethylenelether),

C. 17α-hydroxyandrost-4-en-3-one (17-*epi*-testosterone),


E. 3-oxoandrost-4-en-17-yl acetate (testosterone acetate),




G. androsta-1,4-diene-3,17-dione (androstadienedione),




H. 17β-hydroxyandrosta-1,4-dien-3-one (boldenone),




I. 17β-hydroxyandrosta-4,6-dien-3-one (Δ6-testosterone),




J. 3-methoxyandrosta-3,5-dien-17-one (androstenedione methylenelether),



K. 17β-hydroxyandrosta-4,8-dien-3-one,



L. 17β-hydroxyandrosta-4,9(11)-dien-3-one,




M. 17β-hydroxyandrosta-4,8(14)-dien-3-one.

04/2016:2814
corrected 10.1

THI COLCHICOSIDE HYDRATE

Thiocolchicosidum hydricum

 $C_{27}H_{33}NO_{10}S \cdot xH_2O$
[1622135-03-8] M_r 563.6 (anhydrous substance)

DEFINITION

N-[(7*S*,12*aR*)-3-(β-*D*-Glucopyranosyloxy)-1,2-dimethoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]acetamide.*Content*: 96.0 per cent to 102.0 per cent (anhydrous substance).
It contains a variable quantity of water.

CHARACTERS

Appearance: yellow crystalline powder, slightly hygroscopic.*Solubility*: sparingly soluble in water, slightly soluble in ethanol (96 per cent), practically insoluble in acetone.

mp: about 272 °C.

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: thiocolchicoside hydrate CRS.

TESTS

Appearance of solution. The solution is clear (2.2.1).Dissolve 0.100 g in *methanol R* and dilute to 10 mL with the same solvent.

Specific optical rotation (2.2.7): – 600 to – 570 (anhydrous substance).

Dissolve 0.500 g in *water R* and dilute to 100.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29). Carry out the test protected from light.

Test solution (a). Dissolve 20.0 mg of the substance to be examined in *methanol R* and dilute to 20.0 mL with the same solvent.

Test solution (b). Dilute 1.0 mL of test solution (a) to 10.0 mL with *methanol R*.

Reference solution (a). Dilute 1.0 mL of test solution (a) to 100.0 mL with *methanol R*. Dilute 2.0 mL of this solution to 10.0 mL with *methanol R*.

Reference solution (b). Dissolve 5 mg of *thiocolchicoside for system suitability CRS* (containing impurities D, E, G, H, K and L) in *methanol R* and dilute to 5 mL with the same solvent.

Reference solution (c). Dissolve 20.0 mg of *thiocolchicoside hydrate CRS* in *methanol R* and dilute to 20.0 mL with the same solvent. Dilute 1.0 mL of the solution to 10.0 mL with *methanol R*.

Column:

- size: $l = 0.10$ m, $\varnothing = 2.1$ mm;
- stationary phase: end-capped ethylene-bridged phenylsilyl silica gel for chromatography (hybrid material) *R* (1.7 μ m);
- temperature: 25 °C.

Mobile phase:

- mobile phase A: dissolve 0.22 g of *ammonium formate R* in 350 mL of *water for chromatography R* and mix with 25 mL of *tetrahydrofuran R*;
- mobile phase B: dilute 45 μ L of *anhydrous formic acid R* in 900 mL of *acetonitrile R* and mix with 100 mL of *tetrahydrofuran R*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 2	99	1
2 - 6	99 → 92	1 → 8
6 - 7.5	92 → 70	8 → 30
7.5 - 8.8	70 → 50	30 → 50
8.8 - 9.2	50 → 2	50 → 98
9.2 - 10	2	98

Flow rate: 0.4 mL/min.

Detection: spectrophotometer at 370 nm.

Injection: 1.0 μ L of test solution (a) and reference solutions (a) and (b).

Identification of impurities: use the chromatogram supplied with *thiocolchicoside for system suitability CRS* and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities D, E, G, H, K and L.

Relative retention with reference to *thiocolchicoside* (retention time = about 6 min): impurity D = about 0.2; impurity H = about 0.4; impurity G = about 0.7; impurity K = about 0.8; impurity E = about 1.05; impurity L = about 1.11.

System suitability:

- signal-to-noise ratio: minimum 50 for the principal peak in the chromatogram obtained with reference solution (a);
- peak-to-valley ratio: minimum 1.5, where H_p = height above the baseline of the peak due to impurity E and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to *thiocolchicoside* in the chromatogram obtained with reference solution (b).

Calculation of percentage contents:

- correction factors: multiply the peak areas of the following impurities by the corresponding correction factor: impurity D = 1.7; impurity H = 2.8;
- for each impurity, use the concentration of *thiocolchicoside hydrate* in reference solution (a).

Limits:

- impurity E: maximum 1.0 per cent;
- impurity H: maximum 0.7 per cent;
- impurity K: maximum 0.3 per cent;
- impurities D, G: for each impurity, maximum 0.2 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 2.5 per cent;
- reporting threshold: 0.05 per cent; disregard the peak due to impurity L.

Water (2.5.12): maximum 2.5 per cent, determined on 0.500 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution (b) and reference solution (c).

Calculate the percentage content of $C_{27}H_{33}NO_{10}S$ taking into account the assigned content of *thiocolchicoside hydrate CRS*.


STORAGE

In an airtight container, protected from light.


IMPURITIES

Specified impurities: D, E, G, H, K.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, C, J, L.




A. N-[(7S,12aR)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide (colchicine),




B. N-[(7S,12aR)-1,2,3-trimethoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide (thiocolchicine),




- C. *N*-[(7*S*,12*aR*_a)-3-hydroxy-1,2-dimethoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]acetamide (3-*O*-demethylthiocolchicine),




- D. *N*-[(7*S*,12*aR*_a)-3-(β-D-glucopyranosyloxy)-1,2,10-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]acetamide (colchicoside),




- E. *N*-[(7*S*,12*aR*_a)-3-(β-D-glucopyranosyloxy)-1,2-dimethoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]formamide (*N*-deacetyl-*N*-formylthiocolchicoside),




- G. (7*S*,12*aR*_a)-7-amino-3-(β-D-glucopyranosyloxy)-1,2-dimethoxy-10-(methylsulfanyl)-6,7-dihydrobenzo[*a*]heptalen-9(5*H*)-one (*N*-deacetylthiocolchicoside),




- H. *N*-[(7*S*,12*aR*_a)-3-(β-D-glucopyranosyloxy)-1,2-dimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]acetamide (10-demethoxycolchicoside),



- J. *N*-[(7*S*,12*aR*_a)-3-(β-D-glucopyranosyloxy)-1,2-dimethoxy-10-(methylsulfonyl)-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]acetamide (thiocolchicoside *S*-oxide),



- K. *N*-[(7*S*,12*aR*_a)-3-(β-D-glucopyranosyloxy)-2-hydroxy-1-methoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]acetamide or *N*-[(7*S*,12*aR*_a)-3-(β-D-glucopyranosyloxy)-1-hydroxy-2-methoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]acetamide,




- L. *N*-[(7*S*,12*aS*_a)-3-(β-D-glucopyranosyloxy)-1,2-dimethoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetrahydrobenzo[*a*]heptalen-7-yl]acetamide (12*aS*_a-thiocolchicoside).



04/2020:1157

TIAPROFENIC ACID

Acidum tiaprofenicum



$C_{14}H_{12}O_3S$
[33005-95-7]

M_r 260.3

DEFINITION

(2*RS*)-2-(5-Benzoylthiophen-2-yl)propanoic acid.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: practically insoluble in water, freely soluble in acetone, in ethanol (96 per cent) and in methylene chloride.

IDENTIFICATION

First identification: C.

Second identification: A, B, D.

A. Melting point (2.2.14): 95 °C to 99 °C.

B. Ultraviolet and visible absorption spectrophotometry (2.2.25).

Test solution. Dissolve 25.0 mg in *ethanolic hydrochloric acid R* and dilute to 50.0 mL with the same solvent.

Dilute 1.0 mL of this solution to 50.0 mL with *ethanolic hydrochloric acid R*.

Spectral range: 220-350 nm.

Absorption maximum: 305 nm.

Shoulder: 262 nm.

Specific absorbance at the absorption maximum: 550 to 590.

C. Infrared absorption spectrophotometry (2.2.24).

Comparison: tiaprofenic acid CRS.

D. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 10 mg of the substance to be examined in *methylene chloride R* and dilute to 10 mL with the same solvent.

Reference solution (a). Dissolve 10 mg of *tiaprofenic acid CRS* in *methylene chloride R* and dilute to 10 mL with the same solvent.

Reference solution (b). Dissolve 10 mg of *ketoprofen CRS* in *methylene chloride R* and dilute to 10 mL with the same solvent. Dilute 1 mL of this solution to 2 mL with reference solution (a).

Plate: TLC silica gel F_{254} plate R.

Mobile phase: acetic acid R, methylene chloride R, acetone R (1:20:80 V/V/V).

Application: 10 µL.

Development: over 3/4 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

Retardation factors: tiaprofenic acid = about 0.3; ketoprofen = about 0.4.

System suitability: reference solution (b):

- the chromatogram shows 2 clearly separated principal spots.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).

TESTS

Appearance of solution. The solution is clear (2.2.1) and not more intensely coloured than reference solution Y_6 (2.2.2, Method II).

Dissolve 2.0 g in *ethanol* (96 per cent) R and dilute to 20 mL with the same solvent.

Optical rotation (2.2.7): -0.10° to $+0.10^\circ$.

Dissolve 0.50 g in *ethyl acetate R* and dilute to 10.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 20.0 mg of the substance to be examined in the mobile phase and dilute to 20.0 mL with the mobile phase.

Reference solution (a). Dilute 1.0 mL of the test solution to 50.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (b). Dilute 5.0 mL of reference solution (a) to 10.0 mL with the mobile phase.

Reference solution (c). Dissolve 10.0 mg of *tiaprofenic acid impurity C CRS* in the mobile phase and dilute to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 50.0 mL with the mobile phase.

Reference solution (d). Dilute 1 mL of reference solution (a) to 2 mL with reference solution (c).

Column:

– size: $l = 0.25$ m, $\varnothing = 4.6$ mm;

– stationary phase: silica gel for chromatography R (5 µm).

Mobile phase: water for chromatography R, glacial acetic acid R, hexane R, methylene chloride R (0.25:20:500:500 V/V/V/V); add the water to the acetic acid, then hexane and methylene chloride; sonicate the mixture for 2 min. Do not degas with helium during analysis.

Flow rate: 1 mL/min.

Detection: spectrophotometer at 250 nm.

Injection: 20 µL.

Run time: twice the retention time of tiaprofenic acid.

Identification of impurities: use the chromatogram obtained with reference solution (c) to identify the peak due to impurity C.

Relative retention with reference to tiaprofenic acid (retention time = about 14 min): impurity C = about 0.86.

System suitability: reference solution (d):

- resolution: minimum 3.0 between the peaks due to impurity C and tiaprofenic acid.

Limits:

- impurity C: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (c) (0.2 per cent);
- unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);
- sum of impurities other than C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent);
- disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying *in vacuo* at 60 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.250 g in 25 mL of *ethanol* (96 per cent) R. Add 25 mL of *water* R and 0.5 mL of *phenolphthalein solution* R. Titrate with 0.1 M *sodium hydroxide*.

1 mL of 0.1 M *sodium hydroxide* is equivalent to 26.03 mg of $C_{14}H_{12}O_3S$.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: C.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, D, E, F.




A. (5-ethylthiophen-2-yl)phenylmethanone,




B. 1-(5-benzoylthiophen-2-yl)ethanone,




C. (2RS)-2-(5-benzoylthiophen-3-yl)propanoic acid,



D. benzoic acid,



E. (2RS)-2-(thiophen-2-yl)propanoic acid,




F. (5-bromothiophen-2-yl)phenylmethanone.



04/2020:0875

TRANEXAMIC ACID

Acidum tranexamicum



$C_8H_{15}NO_2$
[1197-18-8]

M_r 157.2

DEFINITION

(1*r*,4*r*)-4-(Aminomethyl)cyclohexane-1-carboxylic acid.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: freely soluble in water and in glacial acetic acid, practically insoluble in acetone and in ethanol (96 per cent).

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: tranexamic acid CRS.

TESTS

pH (2.2.3): 7.0 to 8.0.

Dissolve 2.5 g in *carbon dioxide-free water* R and dilute to 50 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 0.200 g of the substance to be examined in *water* R and dilute to 20.0 mL with the same solvent.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with *water* R. Dilute 1.0 mL of this solution to 20.0 mL with *water* R.

Reference solution (b). Dissolve 5.0 mg of *tranexamic acid impurity D* CRS in *water* R and dilute to 50.0 mL with the same solvent.

Reference solution (c). Dilute 5.0 mL of reference solution (b) to 100.0 mL with *water* R.

Reference solution (d). Dissolve 2.5 mg of *tranexamic acid impurity E* CRS in *water* R and dilute to 50.0 mL with the same solvent. Dilute 1.0 mL of the solution to 10.0 mL with *water* R.

Reference solution (e). Dissolve 2.5 mg of *tranexamic acid impurity C* CRS, 2.5 mg of *tranexamic acid impurity F* CRS and 7.5 mg of *tranexamic acid impurity B* CRS in 25 mL of *water* R. Mix 1 mL of the solution, 1 mL of reference solution (b) and 18 mL of the test solution.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 μ m).

Mobile phase: dissolve 11.0 g of *anhydrous sodium dihydrogen phosphate* R in 500 mL of *water for chromatography* R and add 5 mL of *triethylamine* R and 1.4 g of *sodium laurilsulfate* R1; adjust to pH 2.0 with *phosphoric acid* R and dilute to 600 mL with *water for chromatography* R; add 400 mL of *methanol* R2.

Flow rate: 0.9 mL/min.

Detection: spectrophotometer at 210 nm.

Injection: 40 μ L of the test solution and reference solutions (a), (c), (d) and (e).

Run time: 2.5 times the retention time of tranexamic acid.

Identification of impurities: use the chromatogram obtained with reference solution (c) to identify the peak due to impurity D; use the chromatogram obtained with reference solution (d) to identify the peak due to impurity E; use the chromatogram obtained with reference solution (e) to identify the peaks due to impurities B, C and F.

Relative retention with reference to tranexamic acid (retention time = about 10 min): impurity F = about 0.3; impurity C = about 1.1; impurity D = about 1.2; impurity E = about 1.3; impurity B = about 1.5.

System suitability: reference solution (e):

- **resolution:** minimum 2.0 between the peaks due to tranexamic acid and impurity C; minimum 1.5 between the peaks due to impurities C and D.

Calculation of percentage contents:

- **correction factors:** multiply the peak areas of the following impurities by the corresponding correction factor: impurity B = 1.3; impurity C = 0.4; impurity F = 0.6;
- for impurities C and D, use the concentration of impurity D in reference solution (c);
- for impurities E and F, use the concentration of impurity E in reference solution (d);
- for impurities other than C, D, E and F, use the concentration of tranexamic acid in reference solution (a).

Limits:

- **impurity B:** maximum 0.15 per cent;
- **impurities C, D, E, F:** for each impurity, maximum 0.05 per cent;
- **unspecified impurities:** for each impurity, maximum 0.05 per cent;
- **total:** maximum 0.2 per cent;
- **reporting threshold:** 0.03 per cent.

Halides expressed as chlorides (2.4.4): maximum 140 ppm.

Dissolve 1.2 g in *water R* and dilute to 50 mL with the same solvent.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 2 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.140 g in 20 mL of *anhydrous acetic acid R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).


1 mL of 0.1 M *perchloric acid* is equivalent to 15.72 mg of $C_8H_{15}NO_2$.

IMPURITIES


Specified impurities: B, C, D, E, F.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general


acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A.




A. (1*r*,4*r*,1'*r*,4'*r*)-4,4'-[azanediylbis(methylene)]di(cyclohexane-1-carboxylic acid),




B. (1*s*,4*s*)-4-(aminomethyl)cyclohexane-1-carboxylic acid,




C. (4*RS*)-4-(aminomethyl)cyclohex-1-ene-1-carboxylic acid,



D. 4-(aminomethyl)benzoic acid,



E. (1*r*,4*r*)-4-[[(1*r*,4*r*)-4-(aminomethyl)cyclohexane-1-carboxamido]methyl]cyclohexane-1-carboxylic acid,



F. (1*r*,4*r*)-4-(formamidomethyl)cyclohexane-1-carboxylic acid.

X


Xylometazoline hydrochloride..... 4509



01/2008:1162
corrected 10.1

XYLOMETAZOLINE HYDROCHLORIDE

Xylometazolini hydrochloridum



$C_{16}H_{25}ClN_2$
[1218-35-5]

M_r 280.8

DEFINITION

2-[4-(1,1-Dimethylethyl)-2,6-dimethylbenzyl]-4,5-dihydro-1H-imidazole hydrochloride.

Content: 99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: freely soluble in water, in ethanol (96 per cent) and in methanol.

IDENTIFICATION

First identification: A, E.

Second identification: B, C, D, E.

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: xylometazoline hydrochloride CRS.

B. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 20 mg of the substance to be examined in *methanol R* and dilute to 5 mL with the same solvent.

Reference solution. Dissolve 20 mg of xylometazoline hydrochloride CRS in *methanol R* and dilute to 5 mL with the same solvent.

Plate: TLC silica gel G plate R.

Mobile phase: concentrated ammonia R, *methanol R* (5:100 V/V).

Application: 5 µL.

Development: over 2/3 of the plate.

Drying: in air.

Chlorine treatment: at the bottom of a chromatographic tank place a beaker containing a mixture of 1 volume of *hydrochloric acid R1*, 1 volume of *water R* and 2 volumes of a 15 g/L solution of *potassium permanganate R*. Close the tank and allow to stand for 15 min. Place the dried plate in the tank and reclose the tank. Leave the plate in contact with the chlorine vapour for 5 min. Withdraw the plate and place it in a current of cold air until the excess of chlorine is removed and an area of the coating below the points of application does not give a blue colour with a drop of *potassium iodide and starch solution R*.

Detection: spray with *potassium iodide and starch solution R*.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

C. Dissolve about 0.5 mg in 1 mL of *methanol R*. Add 0.5 mL of a freshly prepared 50 g/L solution of *sodium nitroprusside R* and 0.5 mL of a 20 g/L solution of *sodium hydroxide R*.

Allow to stand for 10 min and add 1 mL of an 80 g/L solution of *sodium hydrogen carbonate R*. A violet colour develops.

D. Dissolve 0.2 g in 1 mL of *water R*, add 2.5 mL of *ethanol (96 per cent) R* and 2 mL of 1 M *sodium hydroxide*. Mix thoroughly and examine in ultraviolet light at 365 nm. The solution shows no fluorescence or at most the same fluorescence as a blank solution prepared in the same manner. The identification is not valid unless a solution prepared in the same manner using *naphazoline hydrochloride CRS* instead of the substance to be examined shows a distinct bluish fluorescence.

E. It gives reaction (a) of chlorides (2.3.1).

TESTS

Appearance of solution. The solution is clear (2.2.1) and not more intensely coloured than reference solution Y_6 (2.2.2, *Method II*).

Dissolve 2.5 g in *water R* and dilute to 50.0 mL with the same solvent.

Acidity or alkalinity. Dissolve 0.25 g in *carbon dioxide-free water R* and dilute to 25 mL with the same solvent. Add 0.1 mL of *methyl red solution R* and 0.1 mL of 0.01 M *hydrochloric acid*. The solution is red. Not more than 0.2 mL of 0.01 M *sodium hydroxide* is required to change the colour of the indicator to yellow.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 50.0 mg of the substance to be examined in *water R* and dilute to 50.0 mL with the same solvent. Allow to stand for 1 h before injection.

Reference solution (a). Dilute 5.0 mL of the test solution to 100.0 mL with *water R*. Dilute 2.0 mL of this solution to 100.0 mL with *water R*.

Reference solution (b). Dissolve 5.0 mg of xylometazoline impurity A CRS and 5 mg of the substance to be examined in *water R* and dilute to 50.0 mL with the same solvent. Dilute 10.0 mL of this solution to 50.0 mL with *water R*.

Reference solution (c). Dilute 5.0 mL of reference solution (b) to 50.0 mL with *water R*.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography with embedded polar groups R (5 µm).

Mobile phase:

- mobile phase A: 1.36 g/L solution of *potassium dihydrogen phosphate R* adjusted to pH 3.0 with *phosphoric acid R*;
- mobile phase B: acetonitrile for chromatography R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 5	70	30
5 - 20	70 → 15	30 → 85
20 - 35	15	85

Flow rate: 1.0 mL/min.

Detection: spectrophotometer at 220 nm.

Injection: 10 µL.

Relative retention with reference to xylometazoline (retention time = about 7.2 min): impurity A = about 0.79.

System suitability: reference solution (b):

- resolution: minimum 2.5 between the peaks due to impurity A and xylometazoline.

Limits:

- impurity A: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (c) (0.2 per cent);

- *unspecified impurities*: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- *total*: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);
- *disregard limit*: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.200 g in 25 mL of *anhydrous acetic acid* R and add 10 mL of *acetic anhydride* R. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 28.08 mg of $C_{16}H_{25}ClN_2$.


STORAGE

Protected from light.


IMPURITIES

Specified impurities: A.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): B, C, D, E, F.




A. *N*-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]acetamide,




B. 2-(chloromethyl)-5-(1,1-dimethylethyl)-1,3-dimethylbenzene,




C. [4-(1,1-dimethylethyl)-2,6-dimethylphenyl]acetonitrile,



D. 1-(1,1-dimethylethyl)-3,5-dimethylbenzene,



E. ethane-1,2-diamine mono(4-methylbenzenesulfonate),



F. [4-(1,1-dimethylethyl)-2,6-dimethylphenyl]acetic acid.

Z

Zanamivir hydrate.....	4513	Zolpidem tartrate.....	4516
Zoledronic acid monohydrate.....	4514		



- 04/2020:2611 – stationary phase: amino alkyl vinyl polymer for chromatography R (5 µm);
– temperature: 30 °C.

Mobile phase: 0.7 g/L solution of sulfuric acid R previously adjusted to pH 5.5 with dilute ammonia R3, acetonitrile R1 (40:60 V/V).

Flow rate: 1.5 mL/min.

Detection: spectrophotometer at 234 nm.

Preconditioning of the column: prior to first use, rinse with a 0.7 g/L solution of ammonium sulfate R at 1.5 mL/min at 30 °C for about 1 h; prior to each use, rinse with the mobile phase for at least 8 h.

Injection: 20 µL of test solution (a) and reference solutions (b), (c) and (e).

Run time: 3 times the retention time of zanamivir.

Identification of impurities: use the chromatogram supplied with zanamivir for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A, B, C and E; use the chromatogram obtained with reference solution (e) to identify the peak due to impurity F.

Relative retention with reference to zanamivir (retention time = about 9 min): impurity F = about 0.3; impurity B = about 0.6; impurity C = about 0.75; impurity E = about 0.8; impurity A = about 2.6.

System suitability:

- signal-to-noise ratio: minimum 10 for the principal peak in the chromatogram obtained with reference solution (e);
- peak-to-valley ratio: minimum 2.5, where H_p = height above the baseline of the peak due to impurity E and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to impurity C in the chromatogram obtained with reference solution (b).

Calculation of percentage contents:

- for impurity F, use the concentration of impurity F in reference solution (e);
- for impurities other than F, use the concentration of zanamivir hydrate in reference solution (c).

Limits:

- impurity A: maximum 0.5 per cent;
- impurity B: maximum 0.3 per cent;
- impurity C: maximum 0.2 per cent;
- impurity F: maximum 0.01 per cent;
- unspecified impurities: for each impurity, maximum 0.10 per cent;
- total: maximum 1.2 per cent;
- reporting threshold: 0.05 per cent, except for impurity F.

Loss on drying (2.2.32): 4.0 per cent to 9.0 per cent, determined on 1.000 g by drying *in vacuo* at 105 °C.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection: test solution (b) and reference solution (a).

Calculate the percentage content of $C_{12}H_{20}N_4O_7$ taking into account the assigned content of zanamivir for assay CRS.

STORAGE

In an airtight container, protected from light.


IMPURITIES

Specified impurities: A, B, C, F.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general

ZANAMIVIR HYDRATE

Zanamivirum hydricum



$C_{12}H_{20}N_4O_7 \cdot xH_2O$
[551942-41-7]

M_r 332.3 (anhydrous substance)

DEFINITION

(2R,3R,4S)-3-Acetamido-4-carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid hydrate.

Content: 97.0 per cent to 102.0 per cent (dried substance).

It contains a variable quantity of water.

CHARACTERS

Appearance: white or almost white, slightly hygroscopic powder.

Solubility: slightly soluble in water, practically insoluble in ethanol (96 per cent) and in methylene chloride.

IDENTIFICATION

A. Specific optical rotation (see Tests).

B. Infrared absorption spectrophotometry (2.2.24).

Comparison: zanamivir hydrate CRS.

TESTS

Specific optical rotation (2.2.7): + 36.0 to + 38.5 (dried substance).

Dissolve 0.250 g in 25.0 mL of water R; sonicate until dissolution is complete.

Related substances. Liquid chromatography (2.2.29).

Test solution (a). Dissolve 23.0 mg of the substance to be examined in 20 mL of water R and dilute to 50.0 mL with acetonitrile R1.

Test solution (b). Dilute 5.0 mL of test solution (a) to 50.0 mL with the mobile phase.

Reference solution (a). Dissolve 23.0 mg of zanamivir for assay CRS in 20 mL of water R and dilute to 50.0 mL with acetonitrile R1. Dilute 5.0 mL of the solution to 50.0 mL with the mobile phase.

Reference solution (b). Dissolve 5 mg of zanamivir for system suitability CRS (containing impurities A, B, C and E) in 6 mL of water R and dilute to 10 mL with acetonitrile R1.

Reference solution (c). Dilute 1.0 mL of test solution (a) to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.


Reference solution (d). Dissolve 3.0 mg of zanamivir impurity F CRS in the mobile phase and dilute to 100.0 mL with the mobile phase.

Reference solution (e). Dilute 1.0 mL of reference solution (d) to 100.0 mL with the mobile phase. Dilute 3.0 mL of this solution to 20.0 mL with the mobile phase.

Column:


- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;

acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): D, E, H.




A. (2R,3R,4S)-3-acetamido-2-[(1R,2R)-3-[[[(2R,3R,4S)-3-acetamido-6-carboxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-4-yl]carbamoyl]oxy]-1,2-dihydroxypropyl]-4-carbamimidamido-3,4-dihydro-2H-pyran-6-carboxylic acid,


B. unknown structure,




C. (2R,3R,4S)-3-acetamido-4-amino-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid,




D. (2R,3R,4S)-3-acetamido-4-(carbamoylamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid,



E. (2R,3R,4S)-3-acetamido-4-(N'-carbamimidoyl-carbamimidamido)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid,



F. 1H-pyrazole-1-carboximidamide,




H. (2R,3R,4R)-3-acetamido-4-carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid.



04/2020:2743

ZOLEDRONIC ACID MONOHYDRATE

Acidum zoledronicum monohydricum



C₅H₁₀N₂O₇P₂·H₂O
[165800-06-6]

M_r 290.1

DEFINITION

[1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis-(phosphonic acid) monohydrate.

Content: 99.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, crystalline powder.

Solubility: slightly soluble in water, practically insoluble in anhydrous ethanol and in heptane.

IDENTIFICATION

A. Infrared absorption spectrophotometry (2.2.24).

Comparison: zoledronic acid monohydrate CRS.

B. Water (see Tests).

TESTS

Appearance of solution. The solution is clear (2.2.1) and not more intensely coloured than reference solution B₇ or BY₇ (2.2.2, *Method II*).

Dissolve 0.5 g in a 4 g/L solution of *sodium hydroxide R* and dilute to 50.0 mL with the same solution.

pH (2.2.3): 1.8 to 2.8.

Dissolve 0.150 g in *carbon dioxide-free water R* and dilute to 50.0 mL with the same solvent. Sonicate for 10 min, if necessary.

Related substances. Liquid chromatography (2.2.29).

Solution A. Dissolve 10.8 g of *sodium octanesulfonate R* and 37 mg of *sodium edetate R* in *water for chromatography R*, add 10 mL of *perchloric acid R* and 2 mL of *phosphoric acid R* and dilute to 1000 mL with *water for chromatography R*.

Test solution. Dissolve 40.0 mg of the substance to be examined in the mobile phase, sonicate for 30 min, and dilute to 20.0 mL with the mobile phase.

Reference solution (a). Dissolve 2 mg of *zoledronic acid impurity A CRS*, 5 mg of *zoledronic acid impurity B CRS* and 2 mg of *sodium nitrate R* in the mobile phase and dilute to 50 mL with the mobile phase. To 1 mL of the solution add 7 mL of the mobile phase and dilute to 20 mL with the test solution.

Reference solution (b). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: end-capped phenylhexylsilyl silica gel for chromatography R (5 μ m);
- temperature: 20 °C.

Mobile phase: acetonitrile R1, solution A (4:96 V/V).

Flow rate: 0.6 mL/min.

Detection: spectrophotometer at 215 nm.

Preconditioning: precondition the instrument and the column once before each series of injections as follows:

- **instrument:** rinse the instrument without a column with a 25 per cent V/V solution of acetic acid R at 5 mL/min for about 20 min. Then, rinse with water for chromatography R at 5 mL/min for about 2 h;
- **column:** rinse the column with the mobile phase at 0.6 mL/min for about 1 h. During the rinsing, inject the test solution 15 times, applying a run time of about 3 min for each injection.

Injection: 10 μ L.

Run time: 5 times the retention time of zoledronic acid.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peaks due to impurities A and B and the nitrate ion.

Relative retention with reference to zoledronic acid (retention time = about 6 min): nitrate = about 0.6; impurity B = about 0.7; impurity A = about 0.9.

System suitability: reference solution (a):

- **resolution:** minimum 1.5 between the peaks due to impurity A and zoledronic acid; minimum 1.5 between the peaks due to the nitrate ion and impurity B.

Calculation of percentage contents:

- **correction factor:** multiply the peak area of impurity B by 1.9;
- for each impurity, use the concentration of zoledronic acid monohydrate in reference solution (b).

Limits:

- **impurity B:** maximum 0.5 per cent;
- **unspecified impurities:** for each impurity, maximum 0.10 per cent;
- **total:** maximum 0.5 per cent;
- **reporting threshold:** 0.05 per cent, disregard the peak due to the nitrate ion.

Impurities E and F. Liquid chromatography (2.2.29).

Test solution. Dissolve 50.0 mg of the substance to be examined in mobile phase B, sonicate if necessary, and dilute to 10.0 mL with mobile phase B.

Reference solution (a). Dissolve 95.0 mg of anhydrous sodium dihydrogen phosphate R and 79.0 mg of phosphorous acid R (impurity E) in water R and dilute to 100.0 mL with the same solvent.

Reference solution (b). Dissolve 34.0 mg of sodium chloride R in water R and dilute to 100.0 mL with the same solvent.

Reference solution (c). To 1.0 mL of reference solution (a) add 0.5 mL of reference solution (b) and dilute to 100.0 mL with mobile phase B.

Reference solution (d). Dilute 0.1 mL of reference solution (a) to 100 mL with mobile phase B.

Precolumn:

- size: $l = 0.05$ m, $\varnothing = 4.0$ mm;
- stationary phase: anion-exchange resin R (13 μ m).

Column:

- size: $l = 0.25$ m, $\varnothing = 4.0$ mm;
- stationary phase: anion-exchange resin R (9 μ m);
- temperature: 30 °C.

Mobile phase:

- mobile phase A: carbon dioxide-free water R;
- mobile phase B: 4.0 g/L solution of sodium hydroxide R in carbon dioxide-free water R;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 13	80 → 70	20 → 30
13 - 17	70 → 60	30 → 40
17 - 29	60	40

Flow rate: 1.0 mL/min.

Detection: conductivity detector; use a self-regenerating anion suppressor.

Injection: 20 μ L.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peaks due to impurities E and F; use the chromatogram obtained with reference solution (b) to identify the peak due to the chloride ion.

Relative retention with reference to chloride (retention time = about 5 min): impurity E = about 1.2; impurity F = about 3.4.

System suitability:

- **resolution:** minimum 1.5 between the peaks due to the chloride ion and impurity E in the chromatogram obtained with reference solution (c);
- **signal-to-noise ratio:** minimum 10 for the peak due to impurity F in the chromatogram obtained with reference solution (d).

Calculation of percentage contents:

- for each impurity, use the concentration of the corresponding impurity in reference solution (c).

Limits:

- **impurities E, F:** for each impurity, maximum 0.15 per cent.

Water (2.5.12): 5.0 per cent to 7.5 per cent, determined on 0.100 g.

ASSAY


Dissolve 0.150 g in 50 mL of carbon dioxide-free water R. Sonicate for 10 min, if necessary. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.2.20). Read the volume added at the 3rd inflexion point.

1 mL of 0.1 M sodium hydroxide is equivalent to 9.07 mg of C₅H₁₀N₂O₇P₂.


IMPURITIES

Specified impurities: B, E, F.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, C, D.




A. [1-(2-hydroxy-2,2-diphosphonoethyl)-1H-imidazol-3-ium-3-yl]acetate,




B. 1,3-bis(2-hydroxy-2,2-diphosphonoethyl)-1H-imidazol-3-ium,




C. 1H-imidazole,



D. (1H-imidazol-1-yl)acetic acid,



E. phosphonic acid (phosphorous acid),




F. phosphoric acid.

04/2020:1280



ZOLPIDEM TARTRATE

Zolpidemi tartras



$C_{42}H_{48}N_6O_8$
[99294-93-6]

M_r 765

DEFINITION

Bis[*N,N*-dimethyl-2-[6-methyl-2-(4-methylphenyl)-imidazo[1,2-*a*]pyridin-3-yl]acetamide] (2*R*,3*R*)-2,3-dihydroxybutanedioate.

Content: 98.5 per cent to 101.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white, hygroscopic, crystalline powder.

Solubility: slightly soluble in water, sparingly soluble in methanol, practically insoluble in methylene chloride.

IDENTIFICATION

First identification: A, C.

Second identification: B, C.

A. Infrared absorption spectrophotometry (2.2.24).

Preparation: dissolve 0.10 g in 10 mL of a 10.3 g/L solution of hydrochloric acid R. Add 10 mL of water R. Add dropwise with stirring 1 mL of dilute ammonia R2. Filter and collect the resulting precipitate. Wash the precipitate with water R and then dry at 105 °C for 2 h. Examine the precipitate as a disc.

Comparison: repeat the operations using 0.10 g of zolpidem tartrate CRS.

B. Thin-layer chromatography (2.2.27).

Test solution. Dissolve 50 mg of the substance to be examined in 5 mL of methanol R, add 0.1 mL of diethylamine R and dilute to 10 mL with methanol R.

Reference solution (a). Dissolve 50 mg of zolpidem tartrate CRS in 5 mL of methanol R, add 0.1 mL of diethylamine R and dilute to 10 mL with methanol R.

Reference solution (b). Dissolve 50 mg of flunitrazepam CRS in 5 mL of methylene chloride R and dilute to 10 mL with the same solvent. Mix 1 mL of this solution and 1 mL of reference solution (a).

Plate: TLC silica gel F_{254} plate R.

Mobile phase: diethylamine R, cyclohexane R, ethyl acetate R (10:45:45 V/V/V).

Application: 5 μ L.

Development: over 2/3 of the plate.

Drying: in air.

Detection: examine in ultraviolet light at 254 nm.

Retardation factors: zolpidem = about 0.3; flunitrazepam = about 0.5.

System suitability: reference solution (b):

– the chromatogram shows 2 clearly separated spots.

Results: the principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).

C. Dissolve about 0.1 g in 1 mL of methanol R, heating gently. 0.1 mL of this solution gives reaction (b) of tartrates (2.3.1).

TESTS

Appearance of solution. The solution is clear (2.2.1) and not more intensely coloured than reference solution Y_6 or BY_6 (2.2.2, Method II). Prepare the solutions protected from light and carry out the test as rapidly as possible.

Triturate 0.25 g with 0.125 g of tartaric acid R. Dissolve the mixture in 20 mL of water R and dilute to 25 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 25.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase.

Reference solution (a). Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Reference solution (b). Dissolve 2.5 mg of zolpidem for system suitability CRS (containing impurities A and B) in the mobile phase and dilute to 5 mL with the mobile phase.

Column:

- size: $l = 0.15$ m, $\varnothing = 3.9$ mm;
- stationary phase: end-capped octadecylsilyl silica gel for chromatography R (4 μ m).

Mobile phase: mix 18 volumes of acetonitrile R, 23 volumes of methanol R and 59 volumes of a 5.6 g/L solution of phosphoric acid R previously adjusted to pH 5.5 with triethylamine R.

Flow rate: 1.5 mL/min.

Detection: spectrophotometer at 254 nm.

Injection: 20 μ L.

Run time: 4 times the retention time of zolpidem.

Identification of impurities: use the chromatogram supplied with zolpidem for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A and B.

Relative retention with reference to zolpidem (retention time = about 7 min): tartaric acid = about 0.1; impurity A = about 0.8; impurity B = about 3.6.

System suitability: reference solution (b):

- *resolution:* minimum 2.0 between the peaks due to impurity A and zolpidem.

Calculation of percentage contents:

- for each impurity, use the concentration of zolpidem tartrate in reference solution (a).

Limits:

- *impurity B:* maximum 0.15 per cent;
- *unspecified impurities:* for each impurity, maximum 0.10 per cent;
- *total:* maximum 0.2 per cent;
- *reporting threshold:* 0.05 per cent; disregard the peak due to tartaric acid.

Water (2.5.12): maximum 3.0 per cent, determined on 0.500 g.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.300 g in a mixture of 20 mL of *anhydrous acetic acid R* and 20 mL of *acetic anhydride R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20). Carry out a blank titration.

1 mL of 0.1 M *perchloric acid* is equivalent to 38.24 mg of $C_{42}H_{48}N_6O_8$.


STORAGE

In an airtight container, protected from light.


IMPURITIES

Specified impurities: B.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, C, D, E, F.




A. *N,N*-dimethyl-2-[7-methyl-2-(4-methylphenyl)-imidazo[1,2-*a*]pyridin-3-yl]acetamide,




B. 2-[2-(3-bromo-4-methylphenyl)-6-methylimidazo[1,2-*a*]pyridin-3-yl]-*N,N*-dimethylacetamide,




C. 4-(4-methylphenyl)-4-oxobutanoic acid,



D. (3*RS*)-3-bromo-*N,N*-dimethyl-4-(4-methylphenyl)-4-oxobutanamide,



E. (2*E*)-*N,N*-dimethyl-4-(4-methylphenyl)-4-oxobut-2-enamide,



F. *N,N*-dimethyl-4-(4-methylphenyl)-4-oxobutanamide.

INDEX

To aid users the index includes a reference to the supplement in which the latest version of a text can be found.

For example: Altizide.....10.1-4374

means the monograph Altizide can be found on page 4374 of Supplement 10.1.

Note that where no reference to a supplement is made, the text can be found in the principal volume.

English index	4521	Latin index	4557
---------------------	------	-------------------	------

1. General notices	3	2.2.66. Detection and measurement of radioactivity	119
2.1. Apparatus	15	2.2.7. Optical rotation	26
2.1.1. Droppers	15	2.2.8. Viscosity	27
2.1.2. Comparative table of porosity of sintered-glass filters..	15	2.2.9. Capillary viscometer method	27
2.1.3. Ultraviolet ray lamps for analytical purposes	15	2.3. Identification	129
2.1.4. Sieves	16	2.3.1. Identification reactions of ions and functional groups	129
2.1.5. Tubes for comparative tests	17	2.3.2. Identification of fatty oils by thin-layer chromatography	132
2.1.6. Gas detector tubes	17	2.3.3. Identification of phenothiazines by thin-layer chromatography	133
2.2. Physical and physico-chemical methods	21	2.3.4. Odour	133
2.2.1. Clarity and degree of opalescence of liquids	21	2.4. Limit tests	137
2.2.10. Viscosity - Rotating viscometer method	28	2.4.1. Ammonium	137
2.2.11. Distillation range	30	2.4.10. Lead in sugars	142
2.2.12. Boiling point	31	2.4.11. Phosphates	142
2.2.13. Determination of water by distillation	31	2.4.12. Potassium	142
2.2.14. Melting point - capillary method	32	2.4.13. Sulfates	142
2.2.15. Melting point - open capillary method	33	2.4.14. Sulfated ash	142
2.2.16. Melting point - instantaneous method	33	2.4.15. Nickel in polyols	143
2.2.17. Drop point	33	2.4.16. Total ash	143
2.2.18. Freezing point	35	2.4.17. Aluminium	143
2.2.19. Amperometric titration	35	2.4.18. Free formaldehyde	143
2.2.2. Degree of coloration of liquids	22	2.4.19. Alkaline impurities in fatty oils	144
2.2.20. Potentiometric titration	35	2.4.2. Arsenic	137
2.2.21. Fluorimetry	36	2.4.20. Determination of elemental impurities	144
2.2.22. Atomic emission spectrometry	36	2.4.21. Foreign oils in fatty oils by thin-layer chromatography	147
2.2.23. Atomic absorption spectrometry	37	2.4.22. Composition of fatty acids by gas chromatography ..	147
2.2.24. Absorption spectrophotometry, infrared	39	2.4.23. Sterols in fatty oils	150
2.2.25. Absorption spectrophotometry, ultraviolet and visible	42	2.4.24. Identification and control of residual solvents	10.1-4323
2.2.26. Paper chromatography	46	2.4.25. Ethylene oxide and dioxan	157
2.2.27. Thin-layer chromatography	47	2.4.26. <i>N,N</i> -Dimethylaniline	158
2.2.28. Gas chromatography	48	2.4.27. Heavy metals in herbal drugs and herbal drug preparations	158
2.2.29. Liquid chromatography	49	2.4.28. 2-Ethylhexanoic acid	160
2.2.3. Potentiometric determination of pH	24	2.4.29. Composition of fatty acids in oils rich in omega-3 acids	161
2.2.30. Size-exclusion chromatography	51	2.4.3. Calcium	138
2.2.31. Electrophoresis	51	2.4.30. Ethylene glycol and diethylene glycol in ethoxylated substances	163
2.2.32. Loss on drying	57	2.4.31. Nickel in hydrogenated vegetable oils	163
2.2.33. Nuclear magnetic resonance spectrometry	58	2.4.32. Total cholesterol in oils rich in omega-3 acids	163
2.2.34. Thermal analysis	61	2.4.4. Chlorides	138
2.2.35. Osmolality	63	2.4.5. Fluorides	138
2.2.36. Potentiometric determination of ionic concentration using ion-selective electrodes	64	2.4.6. Magnesium	138
2.2.37. X-ray fluorescence spectrometry	65	2.4.7. Magnesium and alkaline-earth metals	139
2.2.38. Conductivity	66	2.4.8. Heavy metals	139
2.2.39. Molecular mass distribution in dextrans	68	2.4.9. Iron	142
2.2.4. Approximate pH of solutions	25	2,4-Dichlorobenzyl alcohol	2390
2.2.40. Near-infrared spectroscopy	70	2.5. Assays	167
2.2.41. Circular dichroism	75	2.5.1. Acid value	167
2.2.42. Density of solids	76	2.5.10. Oxygen-flask method	170
2.2.43. Mass spectrometry	77	2.5.11. Complexometric titrations	170
2.2.44. Total organic carbon in water for pharmaceutical use	79	2.5.12. Water: semi-micro determination	171
2.2.45. Supercritical fluid chromatography	80	2.5.13. Aluminium in adsorbed vaccines	171
2.2.46. Chromatographic separation techniques	80	2.5.14. Calcium in adsorbed vaccines	172
2.2.47. Capillary electrophoresis	10.1-4315	2.5.15. Phenol in immunosera and vaccines	172
2.2.48. Raman spectroscopy	92	2.5.16. Protein in polysaccharide vaccines	172
2.2.49. Falling ball and automatic rolling ball viscometer methods	94	2.5.17. Nucleic acids in polysaccharide vaccines	172
2.2.5. Relative density	25	2.5.18. Phosphorus in polysaccharide vaccines	172
2.2.54. Isoelectric focusing	95	2.5.19. <i>O</i> -Acetyl in polysaccharide vaccines	173
2.2.55. Peptide mapping	97	2.5.2. Ester value	167
2.2.56. Amino acid analysis	100	2.5.20. Hexosamines in polysaccharide vaccines	173
2.2.57. Inductively coupled plasma-atomic emission spectrometry	106	2.5.21. Methylpentoses in polysaccharide vaccines	173
2.2.58. Inductively coupled plasma-mass spectrometry	108	2.5.22. Uronic acids in polysaccharide vaccines	174
2.2.59. Glycan analysis of glycoproteins	109	2.5.23. Sialic acid in polysaccharide vaccines	174
2.2.6. Refractive index	26	2.5.24. Carbon dioxide in gases	174
2.2.61. Characterisation of crystalline solids by microcalorimetry and solution calorimetry	115	2.5.25. Carbon monoxide in gases	175
2.2.63. Direct amperometric and pulsed electrochemical detection	117	2.5.26. Nitrogen monoxide and nitrogen dioxide in gases ..	176
2.2.64. Peptide identification by nuclear magnetic resonance spectrometry	118	2.5.27. Oxygen in gases	176
2.2.65. Voltametric titration	119	2.5.28. Water in gases	176

2.5.29. Sulfur dioxide	177	2.7.12. Assay of heparin in coagulation factors	281
2.5.3. Hydroxyl value	167	2.7.13. Assay of human anti-D immunoglobulin	282
2.5.30. Oxidising substances	177	2.7.14. Assay of hepatitis A vaccine	284
2.5.31. Ribose in polysaccharide vaccines	177	2.7.15. Assay of hepatitis B vaccine (rDNA)	285
2.5.32. Water: micro determination	178	2.7.16. Assay of pertussis vaccine (acellular)	286
2.5.33. Total protein	178	2.7.17. Assay of human antithrombin III	288
2.5.34. Acetic acid in synthetic peptides	181	2.7.18. Assay of human coagulation factor II	288
2.5.35. Nitrous oxide in gases	182	2.7.19. Assay of human coagulation factor X	289
2.5.36. Anisidine value	182	2.7.2. Microbiological assay of antibiotics	262
2.5.37. Methyl, ethyl and isopropyl methanesulfonate in methanesulfonic acid	182	2.7.20. <i>In vivo</i> assay of poliomyelitis vaccine (inactivated) ..	289
2.5.38. Methyl, ethyl and isopropyl methanesulfonate in active substances	183	2.7.21. Assay of human von Willebrand factor	290
2.5.39. Methanesulfonyl chloride in methanesulfonic acid	184	2.7.22. Assay of human coagulation factor XI	291
2.5.4. Iodine value	167	2.7.23. Numeration of CD34/CD45+ cells in haematopoietic products	292
2.5.40. Methyl, ethyl and isopropyl toluenesulfonate in active substances	185	2.7.24. Flow cytometry	293
2.5.41. Methyl, ethyl and isopropyl benzenesulfonate in active substances	186	2.7.25. Assay of human plasmin inhibitor	295
2.5.5. Peroxide value	168	2.7.27. Flocculation value (Lf) of diphtheria and tetanus toxins and toxoids (Ramon assay)	295
2.5.6. Saponification value	169	2.7.28. Colony-forming cell assay for human haematopoietic progenitor cells	296
2.5.7. Unsaponifiable matter	169	2.7.29. Nucleated cell count and viability	297
2.5.8. Determination of primary aromatic amino- nitrogen	169	2.7.30. Assay of human protein C	299
2.5.9. Determination of nitrogen by sulfuric acid digestion	170	2.7.31. Assay of human protein S	300
2.6. Biological tests	191	2.7.32. Assay of human α -1-proteinase inhibitor	300
2.6.1. Sterility	191	2.7.34. Assay of human C1-esterase inhibitor	301
2.6.10. Histamine	200	2.7.35. Immunonephelometry for vaccine component assay	301
2.6.11. Depressor substances	200	2.7.4. Assay of human coagulation factor VIII	268
2.6.12. Microbiological examination of non-sterile products: microbial enumeration tests	201	2.7.5. Assay of heparin	269
2.6.13. Microbiological examination of non-sterile products: test for specified micro-organisms	205	2.7.6. Assay of diphtheria vaccine (adsorbed)	269
2.6.14. Bacterial endotoxins	209	2.7.7. Assay of pertussis vaccine (whole cell)	274
2.6.15. Prekallikrein activator	213	2.7.8. Assay of tetanus vaccine (adsorbed)	275
2.6.16. Tests for extraneous agents in viral vaccines for human use	214	2.7.9. Test for Fc function of immunoglobulin	279
2.6.17. Test for anticomplementary activity of immunoglobulin	216	2.8. Methods in pharmacognosy	305
2.6.18. Test for neurovirulence of live virus vaccines	218	2.8.1. Ash insoluble in hydrochloric acid	305
2.6.2. Mycobacteria	194	2.8.10. Solubility in alcohol of essential oils	306
2.6.20. Anti-A and anti-B haemagglutinins	218	2.8.11. Assay of 1,8-cineole in essential oils	307
2.6.21. Nucleic acid amplification techniques	219	2.8.12. Essential oils in herbal drugs	307
2.6.22. Activated coagulation factors	224	2.8.13. Pesticide residues	308
2.6.24. Avian viral vaccines: tests for extraneous agents in seed lots	224	2.8.14. Tannins in herbal drugs	310
2.6.25. Avian live virus vaccines: tests for extraneous agents in batches of finished product	227	2.8.15. Bitterness value	310
2.6.26. Test for anti-D antibodies in human immunoglobu- lin	230	2.8.16. Dry residue of extracts	311
2.6.27. Microbiological examination of cell-based preparations	231	2.8.17. Loss on drying of extracts	311
2.6.30. Monocyte-activation test	233	2.8.18. Determination of aflatoxin B ₁ in herbal drugs	311
2.6.31. Microbiological examination of herbal medicinal products for oral use and extracts used in their preparation	239	2.8.2. Foreign matter	305
2.6.33. Residual pertussis toxin	241	2.8.20. Herbal drugs: sampling and sample preparation	313
2.6.34. Host-cell protein assays	244	2.8.21. Test for aristolochic acids in herbal drugs	314
2.6.35. Quantification and characterisation of residual host-cell DNA	248	2.8.22. Determination of ochratoxin A in herbal drugs	316
2.6.36. Microbiological examination of live biotherapeutic products: tests for enumeration of microbial contaminants	250	2.8.23. Microscopic examination of herbal drugs	317
2.6.38. Microbiological examination of live biotherapeutic products: tests for specified micro-organisms	255	2.8.24. Foam index	317
2.6.7. Mycoplasmas	194	2.8.25. High-performance thin-layer chromatography of herbal drugs and herbal drug preparations	318
2.6.8. Pyrogens	199	2.8.3. Stomata and stomatal index	305
2.7. Biological assays	261	2.8.4. Swelling index	306
2.7.1. Immunochemical methods	261	2.8.5. Water in essential oils	306
2.7.10. Assay of human coagulation factor VII	280	2.8.6. Foreign esters in essential oils	306
2.7.11. Assay of human coagulation factor IX	281	2.8.7. Fatty oils and resinified essential oils in essential oils	306
		2.8.8. Odour and taste of essential oils	306
		2.8.9. Residue on evaporation of essential oils	306
		2.9. Pharmaceutical technical procedures	323
		2.9.1. Disintegration of tablets and capsules	323
		2.9.10. Ethanol content	339
		2.9.11. Test for methanol and 2-propanol	342
		2.9.12. Sieve test	343
		2.9.14. Specific surface area by air permeability	343
		2.9.16. Flowability	346
		2.9.17. Test for extractable volume of parenteral preparations	347
		2.9.18. Preparations for inhalation: aerodynamic assessment of fine particles	347
		2.9.19. Particulate contamination: sub-visible particles	360
		2.9.2. Disintegration of suppositories and pessaries	325

2.9.20. Particulate contamination: visible particles	362	3.2.2. Plastic containers and closures for pharmaceutical use.....	459
2.9.22. Softening time determination of lipophilic suppositories	363	3.2.2.1. Plastic containers for aqueous solutions for infusion.....	460
2.9.23. Gas pycnometric density of solids	364	3.2.3. Sterile plastic containers for human blood and blood components (see 3.3.4.)	471
2.9.25. Dissolution test for medicated chewing gums	365	3.2.4. Empty sterile containers of plasticised poly(vinyl chloride) for human blood and blood components (see 3.3.5.).....	473
2.9.26. Specific surface area by gas adsorption	369	3.2.5. Sterile containers of plasticised poly(vinyl chloride) for human blood containing anticoagulant solution (see 3.3.6.).....	474
2.9.27. Uniformity of mass of delivered doses from multidose containers	372	3.2.6. Sets for the transfusion of blood and blood components (see 3.3.7.).....	475
2.9.29. Intrinsic dissolution.....	372	3.2.8. Sterile single-use plastic syringes (see 3.3.8.)	477
2.9.3. Dissolution test for solid dosage forms.....	326	3.2.9. Rubber closures for containers for aqueous parenteral preparations, for powders and for freeze-dried powders.....	460
2.9.31. Particle size analysis by laser light diffraction.....	373	3.3. Containers for human blood and blood components, and materials used in their manufacture; transfusion sets and materials used in their manufacture; syringes	463
2.9.32. Porosity and pore-size distribution of solids by mercury porosimetry	377	3.3.1. Materials for containers for human blood and blood components.....	465
2.9.33. Characterisation of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD)	379	3.3.2. Materials based on plasticised poly(vinyl chloride) for containers for human blood and blood components.....	465
2.9.34. Bulk density and tapped density of powders.....	384	3.3.3. Materials based on plasticised poly(vinyl chloride) for tubing used in sets for the transfusion of blood and blood components	468
2.9.35. Powder fineness.....	387	3.3.4. Sterile plastic containers for human blood and blood components	471
2.9.36. Powder flow	387	3.3.5. Empty sterile containers of plasticised poly(vinyl chloride) for human blood and blood components.....	473
2.9.37. Optical microscopy.....	390	3.3.6. Sterile containers of plasticised poly(vinyl chloride) for human blood containing anticoagulant solution	474
2.9.38. Particle-size distribution estimation by analytical sieving	392	3.3.7. Sets for the transfusion of blood and blood components.....	475
2.9.39. Water-solid interactions: determination of sorption-desorption isotherms and of water activity.....	394	3.3.8. Sterile single-use plastic syringes	477
2.9.4. Dissolution test for transdermal patches	333	3-O-Desacyl-4'-monophosphoryl lipid A.....	2355
2.9.40. Uniformity of dosage units.....	398	4. Reagents.....	481
2.9.41. Friability of granules and spheroids	400	4.1. Reagents, standard solutions, buffer solutions	481
2.9.42. Dissolution test for lipophilic solid dosage forms ..	401	4.1.1. Reagents	481
2.9.43. Apparent dissolution	403	4.1.1. Reagents	10.1-4331
2.9.44. Preparations for nebulisation: characterisation.....	404	4.1.2. Standard solutions for limit tests	598
2.9.45. Wettability of porous solids including powders.....	406	4.1.3. Buffer solutions	602
2.9.47. Demonstration of uniformity of dosage units using large sample sizes.....	409	4.2. Volumetric analysis.....	609
2.9.49. Powder flow properties by shear cell methods.....	411	4.2.1. Primary standards for volumetric solutions.....	609
2.9.5. Uniformity of mass of single-dose preparations	335	4.2.1. Primary standards for volumetric solutions.....	10.1-4331
2.9.52. Scanning electron microscopy	414	4.2.2. Volumetric solutions.....	609
2.9.6. Uniformity of content of single-dose preparations....	336	4-Aminobenzoic acid	1819
2.9.7. Friability of uncoated tablets	336	5.1. General texts on microbiology	619
2.9.8. Resistance to crushing of tablets	337	5.10. Control of impurities in substances for pharmaceutical use.....	763
2.9.9. Measurement of consistency by penetrometry	337	5.11. Characters section in monographs	769
3.1. Materials used for the manufacture of containers	423	5.1.1. Methods of preparation of sterile products	619
3.1.1. Materials for containers for human blood and blood components (see 3.3.1.)	465	5.1.10. Guidelines for using the test for bacterial endotoxins	639
3.1.10. Materials based on non-plasticised poly(vinyl chloride) for containers for non-injectable, aqueous solutions.....	437	5.1.11. Determination of bactericidal, fungicidal or yeasticidal activity of antiseptic medicinal products.....	643
3.1.11. Materials based on non-plasticised poly(vinyl chloride) for containers for solid dosage forms for oral administration.....	439	5.1.2. Biological indicators and related microbial preparations used in the manufacture of sterile products.....	622
3.1.1.1. Materials based on plasticised poly(vinyl chloride) for containers for human blood and blood components (see 3.3.2.).....	465	5.12. Reference standards.....	773
3.1.1.2. Materials based on plasticised poly(vinyl chloride) for tubing used in sets for the transfusion of blood and blood components (see 3.3.3.)	468	5.1.3. Efficacy of antimicrobial preservation	625
3.1.13. Plastic additives.....	441	5.14. Gene transfer medicinal products for human use	779
3.1.14. Materials based on plasticised poly(vinyl chloride) for containers for aqueous solutions for intravenous infusion.....	445	5.1.4. Microbiological quality of non-sterile pharmaceutical preparations and substances for pharmaceutical use.....	627
3.1.15. Polyethylene terephthalate for containers for preparations not for parenteral use.....	448	5.1.5. Application of the F_0 concept to steam sterilisation of aqueous preparations	628
3.1.3. Polyolefins.....	423	5.15. Functionality-related characteristics of excipients.....	793
3.1.4. Polyethylene without additives for containers for parenteral preparations and for ophthalmic preparations..	426	5.1.6. Alternative methods for control of microbiological quality	628
3.1.5. Polyethylene with additives for containers for parenteral preparations and for ophthalmic preparations.....	427	5.16. Crystallinity.....	797
3.1.6. Polypropylene for containers and closures for parenteral preparations and ophthalmic preparations.....	431	5.17. Recommendations on methods for dosage forms testing.....	801
3.1.7. Poly(ethylene - vinyl acetate) for containers and tubing for total parenteral nutrition preparations.....	434		
3.1.8. Silicone oil used as a lubricant	436		
3.1.9. Silicone elastomer for closures and tubing	436		
3.2. Containers.....	453		
3.2.1. Glass containers for pharmaceutical use.....	453		

5.1.7. Viral safety	637	Acetic acid in synthetic peptides (2.5.34.)	181
5.17.1. Recommendations on dissolution testing	801	Acetone	1747
5.1.8. Microbiological quality of herbal medicinal products for oral use and extracts used in their preparation	638	Acetylcholine chloride	1748
5.19. Extemporaneous preparation of radiopharmaceuticals	807	Acetylcysteine	1749
5.1.9. Guidelines for using the test for sterility	639	β-Acetyldigoxin	1750
5.2. General texts on biological products	647	Acetylene intermix (1 per cent) in nitrogen	1752
5.20. Elemental impurities	815	Acetylsalicylic acid	1753
5.21. Chemometric methods applied to analytical data	819	Acetyltryptophan, N-	1755
5.2.1. Terminology used in monographs on biological products	647	Acetyltyrosine, N-	1757
5.2.11. Carrier proteins for the production of conjugated polysaccharide vaccines for human use	674	Achyranthes bidentata root	1293
5.2.12. Raw materials of biological origin for the production of cell-based and gene therapy medicinal products	675	Aciclovir	1758
5.2.13. Healthy chicken flocks for the production of inactivated vaccines for veterinary use	679	Acid value (2.5.1.)	167
5.2.14. Substitution of <i>in vivo</i> method(s) by <i>in vitro</i> method(s) for the quality control of vaccines	679	Acidum picricum for homoeopathic preparations	1698
5.2.2. Chicken flocks free from specified pathogens for the production and quality control of vaccines	647	Acidum succinicum for homoeopathic preparations	1698
5.22. Names of herbal drugs used in traditional Chinese medicine	10.1-4335	Acitretin	1760
5.2.3. Cell substrates for the production of vaccines for human use	650	Actinobacillus vaccine (inactivated), porcine	1139
5.23. Monographs on herbal drug extracts (information chapter)	843	Activated charcoal	2162
5.2.4. Cell cultures for the production of veterinary vaccines	654	Activated coagulation factors (2.6.22.)	224
5.24. Chemical imaging	847	Adapalene	1761
5.25. Process analytical technology	10.1-4339	Additives, plastic (3.1.13.)	441
5.2.5. Substances of animal origin for the production of immunological veterinary medicinal products	656	Adenine	1762
5.2.6. Evaluation of safety of veterinary vaccines and immunosera	658	Adenosine	1763
5.2.7. Evaluation of efficacy of veterinary vaccines and immunosera	661	Adenovirus vaccine (inactivated), canine	1079
5.2.8. Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products	661	Adenovirus vaccine (live), canine	1080
5.2.9. Evaluation of safety of each batch of immunosera for veterinary use	673	Adipic acid	1765
5.3. Statistical analysis of results of biological assays and tests	685	Adonis vernalis for homoeopathic preparations	10.1-4369
5.4. Residual solvents	717	Adrenaline	1766
5.5. Alcoholimetric tables	727	Adrenaline tartrate	1767
5.6. Assay of interferons	741	Adsorption, gas, specific surface area by (2.9.26.)	369
5.7. Table of physical characteristics of radionuclides mentioned in the European Pharmacopoeia	745	Aerodynamic assessment of fine particles in preparations for inhalation (2.9.18.)	347
5.8. Pharmacopoeial harmonisation	755	Aflatoxin B ₁ in herbal drugs, determination of (2.8.18.)	311
5.9. Polymorphism	759	Agar	1295
A		Agaricus phalloides for homoeopathic preparations	1699
Abacavir sulfate	1733	Agnus castus fruit	1295
Abbreviations and symbols (1.)	3	Agnus castus fruit dry extract	1296
Abelmoschi corolla	1289	Agrimony	1297
Absorption spectrophotometry, infrared (2.2.24.)	39	Air, medicinal	1768
Absorption spectrophotometry, ultraviolet and visible (2.2.25.)	42	Air, synthetic medicinal	1770
Acacia	1290	Akebia stem	1298
Acacia, dried dispersion	1734	Alanine	1771
Acamprosate calcium	1736	Albendazole	1773
Acanthopanax bark	1292	Albumin solution, human	2832
Acarbose	1736	Alchemilla	1300
Acebutolol hydrochloride	1738	Alcoholimetric tables (5.5.)	727
Aceclofenac	1740	Alcuronium chloride	1774
Acemetacin	1742	Alendronate trihydrate, sodium	3798
Acesulfame potassium	1744	Alexandrian senna pods	10.1-4363
Acetate trihydrate, sodium	3797	Alfacalcidol	1776
Acetazolamide	1745	Alfadex	1777
Acetic acid, glacial	1746	Alfentanil hydrochloride hydrate	1778
		Alfuzosin hydrochloride	1780
		Alginate, sodium	3799
		Alginic acid	1781
		Alimemazine hemitartrate	1782
		Alkaline impurities in fatty oils (2.4.19.)	144
		Alkaline-earth metals and magnesium (2.4.7.)	139
		Allantoin	1783
		Allergen products	861
		Allergen products, animal epithelia and outgrowths for	1854
		Allergen products, Hymenoptera venoms for	2908
		Allergen products, mites for	3281
		Allergen products, moulds for	3302
		Allergen products, pollens for	3583
		Allium sativum for homoeopathic preparations	1701
		Allopurinol	1784
		all- <i>rac</i> -α-Tocopherol	4057
		all- <i>rac</i> -α-Tocopheryl acetate	4059
		Almagate	1786
		Almond oil, refined	1787
		Almond oil, virgin	1787
		Almotriptan malate	10.1-4373
		Aloes, Barbados	1301

- Aloes, Cape 1302
 Aloes dry extract, standardised 1303
 Alovudine (¹⁸F) injection 1181
 Alphacyclodextrin 1777
 Alprazolam 1788
 Alprenolol hydrochloride 1790
 Alprostadil 1791
 Alteplase for injection 1793
 Alternative methods for control of microbiological quality
 (5.1.6.) 628
 Altizide **10.1**-4374
 Alum 1798
 Aluminium (2.4.17.) 143
 Aluminium chloride hexahydrate 1798
 Aluminium hydroxide, hydrated, for adsorption 1798
 Aluminium in adsorbed vaccines (2.5.13.) 171
 Aluminium magnesium silicate 1799
 Aluminium oxide, hydrated 1801
 Aluminium phosphate gel 1802
 Aluminium phosphate, hydrated 1803
 Aluminium sodium silicate 1803
 Aluminium stearate 1804
 Aluminium sulfate 1806
 Alverine citrate 1807
 Amantadine hydrochloride 1808
 Ambroxol hydrochloride 1809
 Amfetamine sulfate 1810
 Amidotrizoate, sodium 3800
 Amidotrizoic acid dihydrate 1812
 Amikacin 1813
 Amikacin sulfate 1815
 Amiloride hydrochloride dihydrate **10.1**-4375
 Amino acid analysis (2.2.56.) 100
 Aminobenzoic acid, 4- 1819
 Aminocaproic acid 1821
 Aminoglutethimide 1821
 Aminophylline 4008
 Aminophylline hydrate 4009
 Aminosalicylate dihydrate, sodium 3801
 Amiodarone hydrochloride 1823
 Amisulpride 1825
 Amitriptyline hydrochloride 1826
 Amlodipine besilate 1827
 Ammonia (¹³N) injection 1183
 Ammonia solution, concentrated 1829
 Ammonio methacrylate copolymer (type A) 1830
 Ammonio methacrylate copolymer (type B) 1831
 Ammonium (2.4.1.) 137
 Ammonium bromide 1832
 Ammonium carbonicum for homoeopathic preparations 1701
 Ammonium chloride 1832
 Ammonium glycyrrhizate 1833
 Ammonium hydrogen carbonate 1834
 Amobarbital 1834
 Amobarbital sodium 1835
 Amomum fruit 1304
 Amomum fruit, round 1604
 Amorolfine hydrochloride 1836
 Amoxicillin sodium 1838
 Amoxicillin trihydrate 1840
 Amperometric detection, direct, and pulsed electrochemical
 detection (2.2.63.) 117
 Amperometric titration (2.2.19.) 35
 Amphotericin B 1842
 Ampicillin 1844
 Ampicillin sodium 1846
 Ampicillin trihydrate 1849
 Amylmetacresol 1851
 Anacardium for homoeopathic preparations 1702
 Anaemia vaccine (live), chicken, infectious 1122
 Anaesthetic ether 2577
 Analysis, thermal (2.2.34.) 61
 Analytical sieving, particle-size distribution estimation by
 (2.9.38.) 392
 Anamirta cocculus for homoeopathic preparations 1708
 Anastrozole 1852
 Andrographis herb 1305
 Anemarrhena asphodeloides rhizome 1307
 Angelica archangelica root 1309
 Angelica dahurica root 1310
 Angelica pubescens root 1312
 Angelica sinensis root 1314
 Animal anti-T lymphocyte immunoglobulin for human
 use 1858
 Animal epithelia and outgrowths for allergen products 1854
 Animal immunosera for human use 871
 Animal spongiform encephalopathies, products with risk of
 transmitting agents of 884
 Animal spongiform encephalopathy agents, minimising the
 risk of transmitting via human and veterinary medicinal
 products (5.2.8.) 661
 Anise oil 1315
 Aniseed 1317
 Anisidine value (2.5.36.) 182
 Antazoline hydrochloride 1855
 Anthrax spore vaccine (live) for veterinary use 1055
 Anthrax vaccine for human use (adsorbed, prepared from
 culture filtrates) 947
 Anti-A and anti-B haemagglutinins (2.6.20.) 218
 Antibiotics, microbiological assay of (2.7.2.) 262
 Antibodies (anti-D) in human immunoglobulin, test for
 (2.6.26.) 230
 Antibodies for human use, monoclonal 878
 Anticoagulant and preservative solutions for human blood
 1856
 Anticomplementary activity of immunoglobulin (2.6.17.) 216
 Anti-D antibodies in human immunoglobulin, test for
 (2.6.26.) 230
 Anti-D immunoglobulin for intravenous administration,
 human 2835
 Anti-D immunoglobulin, human 2834
 Anti-D immunoglobulin, human, assay of (2.7.13.) 282
 Antimicrobial preservation, efficacy of (5.1.3.) 625
 Antiseptic medicinal products, determination of bactericidal,
 fungicidal or yeasticidal activity of (5.1.11.) 643
 Antiserum, European viper venom 1174
 Anti-T lymphocyte immunoglobulin for human use,
 animal 1858
 Antithrombin III concentrate, human 2835
 Antithrombin III, human, assay of (2.7.17.) 288
 Apis for homoeopathic preparations 1703
 Apomorphine hydrochloride hemihydrate 1862
 Apparatus (2.1.) 15
 Apparent dissolution (2.9.43.) 403
 Application of the F_0 concept to steam sterilisation of aqueous
 preparations (5.1.5.) 628
 Approximate pH of solutions (2.2.4.) 25
 Aprepitant 1863
 Aprotinin 1864
 Aprotinin concentrated solution 1867
 Arachis oil, hydrogenated 1869
 Arachis oil, refined 1870
 Arginine 1870
 Arginine aspartate 1871
 Arginine hydrochloride 1872
 Argon 1873
 Aripiprazole 1874
 Aristolochic acids in herbal drugs, test for (2.8.21) 314
 Arnica flower 1318
 Arnica tincture 1320
 Arsenic (2.4.2.) 137
 Arsenicum album for homoeopathic preparations 1704
 Arsenious trioxide for homoeopathic preparations 1704
 Articaine hydrochloride 1876
 Artichoke leaf 1321

Artichoke leaf dry extract.....	1323	Avian paramyxovirus 1 (Newcastle disease) vaccine (live)	1136
Ascorbate, calcium	2045	Avian paramyxovirus 3 vaccine (inactivated) for turkeys..	1068
Ascorbate, sodium	3802	Avian tuberculin purified protein derivative.....	4119
Ascorbic acid	1877	Avian viral tenosynovitis vaccine (live)	1069
Ascorbyl palmitate.....	1879	Avian viral vaccines: tests for extraneous agents in seed lots (2.6.24.)	224
Ash insoluble in hydrochloric acid (2.8.1.)	305	Azaperone for veterinary use	1900
Ash leaf	1324	Azathioprine.....	1901
Ash, sulfated (2.4.14.).....	142	Azelastine hydrochloride	1902
Ash, total (2.4.16.)	143	Azithromycin	1904
Asparagine monohydrate.....	10.1 -4376		
Aspartame.....	1881	B	
Aspartic acid.....	1883	B19 virus (B19V), validation of nucleic acid amplification techniques for the quantification of B19V DNA in plasma pools: guidelines.....	219
Assay of 1,8-cineole in essential oils (2.8.11.)	307	Bacampicillin hydrochloride	1911
Assay of diphtheria vaccine (adsorbed) (2.7.6.).....	269	Bacitracin.....	1913
Assay of heparin (2.7.5.)	269	Bacitracin zinc.....	1917
Assay of heparin in coagulation factors (2.7.12.)	281	Baclofen	1921
Assay of hepatitis A vaccine (2.7.14.)	284	Bacterial endotoxins (2.6.14.).....	209
Assay of hepatitis B vaccine (rDNA) (2.7.15.)	285	Bacterial endotoxins, guidelines for using the test for (5.1.10.)	639
Assay of human α -1-proteinase inhibitor (2.7.32.)	300	Bactericidal, fungicidal or yeasticidal activity of antiseptic medicinal products, determination of (5.1.11.).....	643
Assay of human anti-D immunoglobulin (2.7.13.)	282	Baical skullcap root	1331
Assay of human antithrombin III (2.7.17.).....	288	Bambuterol hydrochloride	1922
Assay of human C1-esterase inhibitor (2.7.34.)	301	Barbados aloes	1301
Assay of human coagulation factor II (2.7.18.).....	288	Barbary wolfberry fruit.....	1332
Assay of human coagulation factor IX (2.7.11.)	281	Barbital.....	1923
Assay of human coagulation factor VII (2.7.10.).....	280	Barium chloratum for homoeopathic preparations	1705
Assay of human coagulation factor VIII (2.7.4.)	268	Barium chloride dihydrate for homoeopathic preparations	1705
Assay of human coagulation factor X (2.7.19.)	289	Barium sulfate.....	1924
Assay of human coagulation factor XI (2.7.22.)	291	Basic butylated methacrylate copolymer	1925
Assay of human plasmin inhibitor (2.7.25.)	295	BCG for immunotherapy.....	948
Assay of human protein C (2.7.30.).....	299	BCG vaccine, freeze-dried	949
Assay of human protein S (2.7.31.)	300	Bearberry leaf.....	1333
Assay of human von Willebrand factor (2.7.21.)	290	Beclometasone dipropionate	1926
Assay of interferons (5.6.).....	741	Beclometasone dipropionate monohydrate.....	1929
Assay of pertussis vaccine (acellular) (2.7.16.).....	286	Beeswax, white	1931
Assay of pertussis vaccine (whole cell) (2.7.7.)	274	Beeswax, yellow.....	1932
Assay of poliomyelitis vaccine (inactivated), <i>in vivo</i> (2.7.20.)	289	Belamcanda chinensis rhizome.....	1334
Assay of tetanus vaccine (adsorbed) (2.7.8.)	275	Belladonna for homoeopathic preparations.....	1705
Assays (2.5.).....	167	Belladonna leaf.....	1336
Astragalus mongholicus root	1325	Belladonna leaf dry extract, standardised	1337
Atazanavir sulfate	10.1 -4378	Belladonna leaf tincture, standardised.....	1338
Atenolol.....	10.1 -4380	Belladonna, prepared	1339
Atomic absorption spectrometry (2.2.23.)	37	Benazepril hydrochloride	1932
Atomic emission spectrometry (2.2.22.).....	36	Bendroflumethiazide.....	1934
Atomic emission spectrometry, inductively coupled plasma- (2.2.57.)	106	Benperidol	1935
Atomoxetine hydrochloride	1889	Benserazide hydrochloride	1936
Atorvastatin calcium trihydrate.....	1890	Bentonite.....	1938
Atovaquone.....	1892	Benzalkonium chloride.....	1938
Atractylodes lancea rhizome	1327	Benzalkonium chloride solution.....	1940
Atractylodes rhizome, largehead	1328	Benzathine benzylpenicillin tetrahydrate	1951
Atracurium besilate	1894	Benzathine penicillin G tetrahydrate	1951
Atropine	1897	Benzathine penicillin V tetrahydrate	3531
Atropine sulfate.....	1898	Benzathine phenoxymethylpenicillin tetrahydrate	3531
Aucklandia root	1329	Benzbromarone.....	1942
Aujeszký's disease vaccine (inactivated) for pigs	1055	Benzenesulfonate (methyl, ethyl and isopropyl) in active substances (2.5.41.).....	186
Aujeszký's disease vaccine (live) for pigs for parenteral administration.....	1057	Benzethonium chloride	1943
Aurothiomalate, sodium	3804	Benzocaine.....	10.1 -4385
Aurum chloratum natronatum for homoeopathic preparations	1704	Benzoic acid	1945
Automatic rolling ball and falling ball viscometer methods (2.2.49.)	94	Benzoin, Siam	1341
Avian infectious bronchitis vaccine (inactivated).....	1059	Benzoin, Sumatra.....	1341
Avian infectious bronchitis vaccine (live).....	1060	Benzoin tincture, Siam.....	1342
Avian infectious bursal disease vaccine (inactivated)	1062	Benzoin tincture, Sumatra	1343
Avian infectious bursal disease vaccine (live)	1063	Benzoyl peroxide, hydrous	1946
Avian infectious encephalomyelitis vaccine (live)	1065	Benzylamine hydrochloride	1947
Avian infectious laryngotracheitis vaccine (live)	1066	Benzyl alcohol	1949
Avian live virus vaccines: tests for extraneous agents in batches of finished product (2.6.25.).....	227		
Avian paramyxovirus 1 (Newcastle disease) vaccine (inactivated)	1134		

- Benzyl benzoate 1950
 Benzylpenicillin (benzathine) tetrahydrate 1951
 Benzylpenicillin potassium 1953
 Benzylpenicillin (procaine) monohydrate 1955
 Benzylpenicillin sodium 1957
 Betacarotene 1959
 Betacyclodextrin 1960
 Betacyclodextrin, poly(hydroxypropyl) ether 2901
 Betacyclodextrin, sodium 4-sulfonatobutyl ether 3935
 Betadex 1960
 Betahistine dihydrochloride 1962
 Betahistine mesilate 1963
 Betamethasone 1964
 Betamethasone acetate 1966
 Betamethasone dipropionate 1968
 Betamethasone sodium phosphate 1970
 Betamethasone valerate 1971
 Betaxolol hydrochloride 1973
 Bezafibrate 1975
 Bicalutamide 1976
 Bifonazole 1977
 Bilberry fruit, dried 1343
 Bilberry fruit dry extract, fresh, refined and standardised .. 1442
 Bilberry fruit, fresh 1344
 Biological assays (2.7.) 261
 Biological assays and tests, statistical analysis of results of (5.3.) 685
 Biological indicators and related microbial preparations used in the manufacture of sterile products (5.1.2.) 622
 Biological products, general texts on (5.2.) 647
 Biological products, terminology used in monographs on (5.2.1.) 647
 Biological tests (2.6.) 191
 Biotherapeutic products for human use, live 876
 Biotherapeutic products (live), microbiological examination of (tests for enumeration of microbial contaminants) (2.6.36.) 250
 Biotherapeutic products (live), microbiological examination of (tests for specified micro-organisms) (2.6.38.) 255
 Biotin 1979
 Biperiden hydrochloride 1980
 Biphasic insulin injection 2953
 Biphasic isophane insulin injection 2953
 Birch leaf 1345
 Bisacodyl 1982
 Bismuth subcarbonate 1983
 Bismuth subgallate 1984
 Bismuth subnitrate, heavy 1985
 Bismuth subsalicylate 1986
 Bisoprolol fumarate 1986
 Bistort rhizome 1347
 Bitter fennel 1433
 Bitter-fennel fruit oil 1348
 Bitter-fennel herb oil 1350
 Bitterness value (2.8.15.) 310
 Bitter-orange epicarp and mesocarp 1352
 Bitter-orange flower 1353
 Bitter-orange-epicarp and mesocarp tincture 1353
 Bitter-orange-flower oil 1550
 Black cohosh 1355
 Black horehound 1358
 Blackcurrant leaf 1359
 Bleomycin sulfate 1989
 Blood and blood components, human, empty sterile containers of plasticised poly(vinyl chloride) for (3.3.5.) 473
 Blood and blood components, human, materials based on plasticised poly(vinyl chloride) for containers for (3.3.2.) 465
 Blood and blood components, human, materials for containers for (3.3.1.) 465
 Blood and blood components, human, sterile plastic containers for (3.3.4.) 471
 Blood and blood components, materials based on plasticised poly(vinyl chloride) for tubing used in sets for the transfusion of (3.3.3.) 468
 Blood and blood components, sets for the transfusion of (3.3.7.) 475
 Blood containing anticoagulant solution, human, sterile containers of plasticised poly(vinyl chloride) for (3.3.6.) .. 474
 Blood, human anticoagulant and preservative solutions for 1856
 Bogbean leaf 1360
 Boiling point (2.2.12.) 31
 Boldine 1990
 Boldo leaf 1361
 Boldo leaf dry extract 1363
 Borage (starflower) oil, refined 1992
 Borax 1992
 Bordetella bronchiseptica vaccine (live) for dogs 1070
 Boric acid 1993
 Botulinum antitoxin 1169
 Botulinum toxin type A for injection 1993
 Botulinum toxin type B for injection 1995
 Bovine leptospirosis vaccine (inactivated) 1071
 Bovine parainfluenza virus vaccine (live) 1073
 Bovine respiratory syncytial virus vaccine (live) 1074
 Bovine rhinotracheitis vaccine (inactivated), infectious ... 1120
 Bovine rhinotracheitis vaccine (live), infectious 1121
 Bovine serum 1996
 Bovine tuberculin purified protein derivative 4120
 Bovine viral diarrhoea vaccine (inactivated) 1075
 Brimonidine tartrate 1998
 Bromazepam 1999
 Bromhexine hydrochloride 2000
 Bromocriptine mesilate 2001
 Bromperidol 2003
 Bromperidol decanoate 2005
 Brompheniramine maleate 2007
 Bronchitis vaccine (inactivated), infectious, avian 1059
 Bronchitis vaccine (live), infectious, avian 1060
 Brotizolam 2008
 Brucellosis vaccine (live) (*Brucella melitensis* Rev. 1 strain) for veterinary use 1076
 Buccal tablets and sublingual tablets 922
 Buckwheat herb 1364
 Budesonide 2009
 Bufexamac 2011
 Buffer solutions (4.1.3.) 602
 Buflomedil hydrochloride 2012
 Bulk density and tapped density of powders (2.9.34.) 384
 Bumetanide 2014
 Bupivacaine hydrochloride 2015
 Bupleurum root 1365
 Buprenorphine 2017
 Buprenorphine hydrochloride 2019
 Bursal disease vaccine (inactivated), infectious, avian 1062
 Bursal disease vaccine (live), infectious, avian 1063
 Buserelin 2020
 Buspirone hydrochloride 2022
 Busulfan 2024
 Butcher's broom 1367
 Butyl parahydroxybenzoate 2025
 Butylated methacrylate copolymer, basic 1925
 Butylhydroxyanisole 2026
 Butylhydroxytoluene 2027

C
 Cabergoline 2031
 Cachets 907
 Cadmium sulfate hydrate for homoeopathic preparations 1707
 Cadmium sulfuricum for homoeopathic preparations 1707
 Caffeine 2032
 Caffeine monohydrate 2033

Calcifediol monohydrate	2035	Capsules, oromucosal	922
Calcipotriol	2036	Capsules, rectal	934
Calcipotriol monohydrate	2038	Capsules, soft	906
Calcitonin (salmon)	2040	Capsules, vaginal	941
Calcitriol	2043	Captopril	2075
Calcium (2.4.3.)	138	Caraway fruit	1376
Calcium acetate	2044	Caraway oil	1377
Calcium ascorbate	2045	Carbachol	2078
Calcium carbonate	2046	Carbamazepine	2078
Calcium carboxymethylcellulose	2093	Carbasalate calcium	2080
Calcium chloride dihydrate	2047	Carbidopa	2081
Calcium chloride hexahydrate	2047	Carbimazole	2083
Calcium dobesilate monohydrate	2048	Carbocisteine	2084
Calcium edetate, sodium	3807	Carbomers	2085
Calcium fluoratum for homoeopathic preparations	1707	Carbon dioxide	2086
Calcium folinate hydrate	2049	Carbon dioxide in gases (2.5.24.)	174
Calcium glucoheptonate	2051	Carbon monoxide	2088
Calcium gluconate	2052	Carbon monoxide (¹⁵ O)	1184
Calcium gluconate, anhydrous	2052	Carbon monoxide in gases (2.5.25.)	175
Calcium gluconate for injection	2053	Carbon monoxide intermix (5 per cent) in nitrogen	2089
Calcium glycerophosphate	2054	Carboplatin	2089
Calcium hydrogen phosphate	2055	Carboprost trometamol	2090
Calcium hydrogen phosphate dihydrate	2056	Carboxymethylcellulose	2092
Calcium hydroxide	2057	Carboxymethylcellulose calcium	2093
Calcium in adsorbed vaccines (2.5.14.)	172	Carboxymethylcellulose sodium	2093
Calcium iodatum for homoeopathic preparations	1708	Carboxymethylcellulose sodium, cross-linked	2318
Calcium iodide tetrahydrate for homoeopathic preparations	1708	Carboxymethylcellulose sodium, low-substituted	2094
Calcium lactate	2058	Carisoprodol	2091
Calcium lactate monohydrate	2058	Carmellose	2092
Calcium lactate pentahydrate	2059	Carmellose calcium	2093
Calcium lactate trihydrate	2059	Carmellose sodium	2093
Calcium levofolinate hydrate	2060	Carmellose sodium and microcrystalline cellulose	3269
Calcium levulinate dihydrate	2062	Carmellose sodium, low-substituted	2094
Calcium pantothenate	2063	Carmustine	2095
Calcium pentetate (sodium) for radiopharmaceutical preparations	1223	Carnauba wax	2096
Calcium phosphate	2065	Carprofen for veterinary use	2097
Calcium stearate	2065	Carrageenan	2098
Calcium sulfate dihydrate	2067	Carrier proteins for the production of conjugated polysaccharide vaccines for human use (5.2.11.)	674
Calendula flower	10.1 -4353	Carteolol hydrochloride	2099
Calf coronavirus diarrhoea vaccine (inactivated)	1077	Carvedilol	2101
Calf rotavirus diarrhoea vaccine (inactivated)	1078	Cascara	1378
Calicivirus vaccine (inactivated), feline	1106	Cascara dry extract, standardised	1380
Calicivirus vaccine (live), feline	1107	Cassia oil	1381
Camphor, D-	2067	Castor oil, hydrogenated	10.1 -4389
Camphor, racemic	2069	Castor oil, polyoxyl	3144
Candesartan cilexetil	2070	Castor oil, polyoxyl hydrogenated	3144
Canine adenovirus vaccine (inactivated)	1079	Castor oil, refined	2103
Canine adenovirus vaccine (live)	1080	Castor oil, virgin	2104
Canine distemper vaccine (live)	1081	Catgut, sterile	1269
Canine leptospirosis vaccine (inactivated)	1082	Catgut, sterile, in distributor for veterinary use	1281
Canine parainfluenza virus vaccine (live)	1084	CD34/CD45+ cells in haematopoietic products, numeration of (2.7.23.)	292
Canine parvovirus vaccine (inactivated)	1085	Cefaclor	2105
Canine parvovirus vaccine (live)	1086	Cefadroxil monohydrate	2106
Cape aloes	1302	Cefalexin monohydrate	2108
Cape jasmine fruit	1369	Cefalotin sodium	2109
Capecitabine	2072	Cefamandole nafate	2111
Capillary electrophoresis (2.2.47.)	10.1 -4315	Cefapirin sodium	2112
Capillary viscometer method (2.2.9.)	27	Cefatrizine propylene glycol	2113
Caprylate, sodium	3808	Cefazolin sodium	2114
Caprylic acid	2073	Cefepime dihydrochloride monohydrate	2117
Caprylocaproyl macroglycerides	2074	Cefixime	2119
Capsicum	1371	Cefoperazone sodium	2120
Capsicum oleoresin, refined and standardised	1373	Cefotaxime sodium	2122
Capsicum soft extract, standardised	1374	Cefoxitin sodium	2124
Capsicum tincture, standardised	1375	Cefpodoxime proxetil	2126
Capsules	906	Cefprozil monohydrate	2128
Capsules and tablets, disintegration of (2.9.1.)	323	Cefradine	2130
Capsules, gastro-resistant	907	Ceftazidime pentahydrate	2132
Capsules, hard	906	Ceftazidime pentahydrate with sodium carbonate for injection	2134
Capsules, intrauterine	914	Ceftriaxone sodium	2136
Capsules, modified-release	907		

Cefuroxime axetil	2138	Chlorobutanol hemihydrate	2183
Cefuroxime sodium	2139	Chlorocresol	2184
Celandine, greater	1463	Chloroquine phosphate	2185
Celecoxib	2141	Chloroquine sulfate	2186
Celiprolol hydrochloride	2142	Chlorphenamine maleate	2187
Cell count and viability, nucleated (2.7.29.)	297	Chlorpromazine hydrochloride	2188
Cell cultures for the production of veterinary vaccines (5.2.4.)	654	Chlorprothixene hydrochloride	2189
Cell substrates for the production of vaccines for human use (5.2.3.)	650	Chlortalidone	2191
Cell-based and gene therapy medicinal products, raw materials of biological origin for the production of (5.2.12.)	675	Chlortetracycline hydrochloride	10.1 -4390
Cell-based preparations, microbiological examination of (2.6.27.)	231	Cholecalciferol	2195
Cellulose acetate	2143	Cholecalciferol concentrate (oily form)	2197
Cellulose acetate butyrate	2144	Cholecalciferol concentrate (powder form)	2198
Cellulose acetate phthalate	2145	Cholecalciferol concentrate (water-dispersible form)	2199
Cellulose, microcrystalline	2146	Cholera vaccine (inactivated), fowl	1117
Cellulose (microcrystalline) and carmellose sodium	3269	Cholera vaccine (inactivated, oral)	951
Cellulose, powdered	2150	Cholesterol	2201
Centauray	1382	Cholesterol for parenteral use	2202
Centella	1383	Cholesterol in oils rich in omega-3 acids, total (2.4.32.)	163
Cetirizine dihydrochloride	2153	Choline ([¹⁴ C]methyl) injection	1185
Cetostearyl alcohol	2155	Chondroitin sulfate sodium	2203
Cetostearyl alcohol (type A), emulsifying	2156	Chromatographic separation techniques (2.2.46.)	80
Cetostearyl alcohol (type B), emulsifying	2157	Chromatography, gas (2.2.28.)	48
Cetostearyl isononanoate	2159	Chromatography, liquid (2.2.29.)	49
Cetostearyl sulfate, sodium	3810	Chromatography, paper (2.2.26.)	46
Cetrimide	2159	Chromatography, size-exclusion (2.2.30.)	51
Cetyl alcohol	2160	Chromatography, supercritical fluid (2.2.45.)	80
Cetyl palmitate	2160	Chromatography, thin-layer (2.2.27.)	47
Cetylpyridinium chloride	2161	Chromium (⁵¹ Cr) edetate injection	1186
Ceylon cinnamon bark oil	1391	Chymotrypsin	2205
Ceylon cinnamon leaf oil	1391	Ciclesonide	2206
CFC assay for human haematopoietic progenitor cells (2.7.28.)	296	Ciclopirox	2208
Chamomile flower, Roman	1384	Ciclopirox olamine	2209
Characterisation of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD) (2.9.33.)	379	Ciclosporin	2210
Characterisation of crystalline solids by microcalorimetry and solution calorimetry (2.2.61.)	115	Cilastatin sodium	2212
Characterisation of preparations for nebulisation (2.9.44.)	404	Cilazapril	2214
Characters section in monographs (5.11.)	769	Cimetidine	2215
Charcoal, activated	2162	Cimetidine hydrochloride	2217
Chemical imaging (5.24.)	847	Cinchocaine hydrochloride	2218
Chemical precursors for radiopharmaceutical preparations	863	Cinchona bark	1387
Chemometric methods applied to analytical data (5.21.)	819	Cinchona liquid extract, standardised	1389
Chenodeoxycholic acid	2163	Cineole	2220
Chewable tablets	939	Cineole in essential oils, 1,8-, assay of (2.8.11.)	307
Chewing gums, medicated	907	Cineole type niaouli oil	1554
Chewing gums, medicated, dissolution test for (2.9.25.)	365	Cinnamon	1390
Chicken anaemia vaccine (live), infectious	1122	Cinnamon bark oil, Ceylon	1391
Chicken flocks free from specified pathogens for the production and quality control of vaccines (5.2.2.)	647	Cinnamon leaf oil, Ceylon	1391
Chinese goldthread rhizome	1386	Cinnarizine	2221
Chitosan hydrochloride	2164	Ciprofibrate	2222
Chlamydiosis vaccine (inactivated), feline	1108	Ciprofloxacin	2223
Chloral hydrate	2165	Ciprofloxacin hydrochloride	2225
Chlorambucil	2166	Circular dichroism (2.2.41.)	75
Chloramine	4074	Cisatracurium besilate	2226
Chloramphenicol	2167	Cisplatin	2231
Chloramphenicol palmitate	2168	Citalopram hydrobromide	2232
Chloramphenicol sodium succinate	2170	Citalopram hydrochloride	2234
Chlorcyclizine hydrochloride	2171	Citric acid	2235
Chlordiazepoxide	2172	Citric acid monohydrate	2236
Chlordiazepoxide hydrochloride	2173	Citronella oil	1392
Chlorhexidine diacetate	2174	Cladribine	2237
Chlorhexidine digluconate solution	2176	Clarithromycin	2238
Chlorhexidine dihydrochloride	2178	Clarity and degree of opalescence of liquids (2.2.1.)	21
Chlorides (2.4.4.)	138	Clary sage oil	1393
Chlormadinone acetate	2180	Classical swine-fever vaccine (live, prepared in cell cultures)	1159
Chlorobutanol	2182	Clazuril for veterinary use	2241
		Clebopride malate	2243
		Clemastine fumarate	2244
		Clematis armandii stem	1394
		Clenbuterol hydrochloride	2246
		Clindamycin hydrochloride	2247
		Clindamycin phosphate	2248
		Clioquinol	2251
		Clobazam	2252

Clobetasol propionate	10.1-4392	Colestyramine	2305
Clobetasone butyrate	2255	Colibacillosis vaccine (inactivated), neonatal piglet	1132
Clodronate disodium tetrahydrate	2257	Colibacillosis vaccine (inactivated), neonatal ruminant	1133
Clofazimine	2258	Colistimethate sodium	2306
Clofibrate	2259	Colistin sulfate	2309
Clomifene citrate	2260	Colloidal anhydrous silica	3787
Clomipramine hydrochloride	2261	Colloidal hydrated silica	3788
Clonazepam	2263	Colloidal silica, hydrophobic	3789
Clonidine hydrochloride	2264	Colloidal silver, for external use	3790
Clopidogrel	2265	Colony-forming cell assay for human haematopoietic progenitor cells (2.7.28.)	296
Clopidogrel besilate	2267	Colophony	1401
Clopidogrel hydrochloride	2268	Coloration of liquids (2.2.2.)	22
Clopidogrel hydrogen sulfate	2270	Common selfheal fruit-spike	1401
Clorazepate, dipotassium monohydrate	2439	Common stinging nettle for homoeopathic preparations ..	1728
Closantel sodium dihydrate for veterinary use	2272	Comparative table of porosity of sintered-glass filters (2.1.2.)	15
Clostridium botulinum vaccine for veterinary use	1087	Complexometric titrations (2.5.11.)	170
Clostridium chauvoei vaccine for veterinary use	1088	Composition of fatty acids by gas chromatography (2.4.22.)	147
Clostridium novyi (type B) vaccine for veterinary use	1088	Composition of fatty acids in oils rich in omega-3 acids (2.4.29.)	161
Clostridium perfringens vaccine for veterinary use	1090	Compressed lozenges	922
Clostridium septicum vaccine for veterinary use	1092	Concentrated solutions for haemodialysis	2798
Closures and containers for parenteral preparations and ophthalmic preparations, polypropylene for (3.1.6.)	431	Concentrated solutions for haemofiltration and haemodiafiltration	2801
Closures and containers for pharmaceutical use, plastic (3.2.2.)	459	Concentrates for injections or infusions	924
Closures and tubing, silicone elastomer for (3.1.9.)	436	Concentrates for intrauterine solutions	914
Closures for containers for aqueous parenteral preparations, for powders and for freeze-dried powders, rubber (3.2.9.)	460	Conductivity (2.2.38.)	66
Clotrimazole	2273	Coneflower herb, purple	1589
Clove	1396	Coneflower root, narrow-leaved	1548
Clove oil	1396	Coneflower root, pale	1568
Cloxacillin sodium	2275	Coneflower root, purple	1591
Clozapine	2276	Conjugated estrogens	2561
Coagulation factor II, human, assay of (2.7.18.)	288	Conjugated polysaccharide vaccines for human use, carrier proteins for the production of (5.2.11.)	674
Coagulation factor IX, human	2846	Consistency by penetrometry, measurement of (2.9.9.)	337
Coagulation factor IX, human, assay of (2.7.11.)	281	Containers (3.2.)	453
Coagulation factor IX (rDNA) concentrated solution, human	2848	Containers and closures for parenteral preparations and ophthalmic preparations, polypropylene for (3.1.6.)	431
Coagulation factor IX (rDNA) powder for solution for injection, human	2853	Containers and closures for pharmaceutical use, plastic (3.2.2.)	459
Coagulation factor VII, human	2838	Containers and tubing for total parenteral nutrition preparations, poly(ethylene - vinyl acetate) for (3.1.7.)	434
Coagulation factor VII, human, assay of (2.7.10.)	280	Containers for aqueous solutions for infusion, plastic (3.2.2.1.)	460
Coagulation factor VIIa (rDNA) concentrated solution, human	2840	Containers for aqueous solutions for intravenous infusion, materials based on, plasticised poly(vinyl chloride) for (3.1.14.)	445
Coagulation factor VIII, human	2844	Containers for human blood and blood components, and materials used in their manufacture; transfusion sets and materials used in their manufacture; syringes (3.3.)	463
Coagulation factor VIII, human, assay of (2.7.4.)	268	Containers for human blood and blood components, materials based on plasticised poly(vinyl chloride) for (3.3.2.)	465
Coagulation factor VIII (rDNA), human	2845	Containers for human blood and blood components, materials for (3.3.1.)	465
Coagulation factor X, assay of (2.7.19.)	289	Containers for human blood and blood components, plastic, sterile (3.3.4.)	471
Coagulation factor XI, human	2855	Containers for non-injectable aqueous solutions, materials based on non-plasticised poly(vinyl chloride) for (3.1.10.)	437
Coagulation factor XI, human, assay of (2.7.22.)	291	Containers for parenteral preparations and for ophthalmic preparations, polyethylene with additives for (3.1.5.)	427
Coagulation factors, activated (2.6.22.)	224	Containers for parenteral preparations and for ophthalmic preparations, polyethylene without additives for (3.1.4.) ..	426
Coagulation factors, assay of heparin (2.7.12.)	281	Containers for pharmaceutical use, glass (3.2.1.)	453
Coated granules	912	Containers for preparations not for parenteral use, polyethylene terephthalate for (3.1.15.)	448
Coated tablets	938	Containers for solid dosage forms for oral administration, materials based on non-plasticised poly(vinyl chloride) for (3.1.11.)	439
Cocaine hydrochloride	2278	Containers, materials used for the manufacture of (3.1.)	423
Coccidiosis vaccine (live) for chickens	1094		
Cocculus for homoeopathic preparations	1708		
Cocoa butter	2279		
Coconut oil, refined	2279		
Cocoyl caprylocaprate	2280		
Codeine hydrochloride dihydrate	2281		
Codeine monohydrate	2283		
Codeine phosphate hemihydrate	2285		
Codeine phosphate sesquihydrate	2288		
Codergocrine mesilate	2290		
Cod-liver oil, farmed	2291		
Cod-liver oil (type A)	2295		
Cod-liver oil (type B)	2299		
Codonopsis root	1397		
Coix seed	1398		
Cola	1400		
Colchicine	2303		
Cold-water vibriosis vaccine (inactivated) for salmonids ..	1163		

- Containers of plasticised poly(vinyl chloride) for human blood and blood components, empty sterile (3.3.5.) 473
- Containers of plasticised poly(vinyl chloride) for human blood containing anticoagulant solution, sterile (3.3.6.) 474
- Contamination, microbial: microbial enumeration tests (2.6.12.) 201
- Contamination, microbial: microbial enumeration tests (live biotherapeutic products) (2.6.36.) 250
- Contamination, microbial: test for specified micro-organisms (2.6.13.) 205
- Contamination, microbial: tests for specified micro-organisms (live biotherapeutic products) (2.6.38.) 255
- Content uniformity of single-dose preparations (2.9.6.) 336
- Control of impurities in substances for pharmaceutical use (5.10.) 763
- Control of microbiological quality, alternative methods for (5.1.6.) 628
- Copolymer, basic butylated methacrylate 1925
- Copolymer, grafted, macrogol poly(vinyl alcohol) 3140
- Copolymer, methacrylic acid - ethyl acrylate (1:1) 3214
- Copolymer, methacrylic acid - ethyl acrylate (1:1) dispersion 30 per cent 3216
- Copolymer, methacrylic acid - methyl methacrylate (1:1) 3217
- Copolymer, methacrylic acid - methyl methacrylate (1:2) 3218
- Copolymer (type A), ammonio methacrylate 1830
- Copolymer (type B), ammonio methacrylate 1831
- Copovidone 2311
- Copper acetate monohydrate for homoeopathic preparations 1711
- Copper for homoeopathic preparations 1712
- Copper sulfate 2313
- Copper sulfate pentahydrate 2314
- Copper tetramibi tetrafluoroborate for radiopharmaceutical preparations 1187
- Coriander 1403
- Coriander oil 1404
- Coronavirus diarrhoea vaccine (inactivated), calf 1077
- Cortisone acetate 2315
- Corydalis rhizome 1405
- Cotton, absorbent 2316
- Cottonseed oil, hydrogenated 2317
- Couch grass rhizome 1407
- Creams 936
- Cresol, crude 2318
- Crocus for homoeopathic preparations 1710
- Cromoglicate, sodium 3813
- Croscarmellose sodium 2318
- Crospovidone 2319
- Crotamiton 2321
- Crystalline and partially crystalline solids, characterisation by X-ray powder diffraction (XRPD) of (2.9.33.) 379
- Crystalline solids, characterisation by microcalorimetry and solution calorimetry (2.2.61.) 115
- Crystallinity (5.16.) 797
- Cuprum aceticum for homoeopathic preparations 1711
- Cuprum metallicum for homoeopathic preparations 1712
- Cutaneous application, liquid preparations for 916
- Cutaneous application, powders for 925
- Cutaneous application, semi-solid preparations for 935
- Cutaneous application, veterinary liquid preparations for 941
- Cutaneous foams 916
- Cutaneous patches 935
- Cyanocobalamin 2322
- Cyanocobalamin (⁵⁷Co) capsules 1188
- Cyanocobalamin (⁵⁷Co) solution 1188
- Cyanocobalamin (⁵⁸Co) capsules 1189
- Cyanocobalamin (⁵⁸Co) solution 1189
- Cyclamate, sodium 3814
- Cyclizine hydrochloride 2323
- Cyclopentolate hydrochloride 2324
- Cyclophosphamide 2326
- Cyproheptadine hydrochloride 2326
- Cyproterone acetate 2327
- Cysteine hydrochloride monohydrate 2329
- Cystine 2331
- Cytarabine 2332
- ## D
- Dacarbazine 2337
- Dalteparin sodium 2338
- Danaparoid sodium 2340
- Dandelion herb with root 1408
- Dandelion root 1409
- Dapsone 2342
- Daunorubicin hydrochloride 2343
- D-Camphor 2067
- Decyl oleate 2344
- Deferiprone 2344
- Deferiprone oral solution 2345
- Deferiprone tablets 2346
- Deferoxamine mesilate 2347
- Degree of coloration of liquids (2.2.2.) 22
- Dembrexine hydrochloride monohydrate for veterinary use 2350
- Demeclocycline hydrochloride 10.1-4397
- Demonstration of uniformity of dosage units using large sample sizes (2.9.47.) 409
- Density of powders, bulk density and tapped (2.9.34.) 384
- Density of solids (2.2.42.) 76
- Density of solids, gas pycnometric (2.9.23.) 364
- Density, relative (2.2.5.) 25
- Dental type silica 3788
- Depressor substances (2.6.11.) 200
- Deptropine citrate 2353
- Dequalinium chloride 2354
- Desacyl-4'-monophosphoryl lipid A, 3-O- 2355
- Desflurane 2357
- Desipramine hydrochloride 2358
- Deslanoside 2359
- Desloratadine 2360
- Desmopressin 2361
- Desogestrel 2363
- Detection and measurement of radioactivity (2.2.66.) 119
- Detection, direct amperometric and pulsed electrochemical (2.2.63.) 117
- Detector tubes, gas (2.1.6.) 17
- Determination of aflatoxin B₁ in herbal drugs (2.8.18.) 311
- Determination of bactericidal, fungicidal or yeasticidal activity of antiseptic medicinal products (5.1.11.) 643
- Determination of elemental impurities (2.4.20.) 144
- Determination of nitrogen by sulfuric acid digestion (2.5.9.) 170
- Determination of primary aromatic amino-nitrogen (2.5.8.) 169
- Determination of water by distillation (2.2.13.) 31
- Detomidine hydrochloride for veterinary use 2364
- Devil's claw dry extract 1410
- Devil's claw root 1411
- Dexamethasone 2365
- Dexamethasone acetate 2367
- Dexamethasone isonicotinate 2369
- Dexamethasone sodium phosphate 2370
- Dexamfetamine sulfate 2373
- Dexchlorpheniramine maleate 2374
- Dexpanthenol 2375
- Dextran 1 for injection 2376
- Dextran 40 for injection 2377
- Dextran 60 for injection 2378
- Dextran 70 for injection 2379
- Dextranomer 2380
- Dextrans, molecular mass distribution in (2.2.39.) 68
- Dextrin 2380
- Dextromethorphan hydrobromide 2381

Dextromoramide tartrate	2382	Diphtheria, tetanus, pertussis (acellular, component) and hepatitis B (rDNA) vaccine (adsorbed)	963
Dextropropoxyphene hydrochloride.....	2383	Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)	964
Dextrose	2758	Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)	966
Dextrose monohydrate.....	2761	Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	968
Diacerein.....	2384	Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	970
Diazepam	2386	Diphtheria, tetanus, pertussis (whole cell) and poliomyelitis (inactivated) vaccine (adsorbed)	973
Diazoxide	2388	Diphtheria, tetanus, pertussis (whole cell), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	974
Dibrompropamide diisetonate	2388	Diphtheria vaccine (adsorbed).....	977
Dibutyl phthalate	2389	Diphtheria vaccine (adsorbed), assay of (2.7.6.)	269
Dichlorobenzyl alcohol, 2,4-	2390	Diphtheria vaccine (adsorbed, reduced antigen content) ..	978
Dichloromethane.....	3235	Dipivefrine hydrochloride	2437
Diclazuril for veterinary use.....	2391	Dipotassium clorazepate monohydrate	2439
Diclofenac potassium	2393	Dipotassium phosphate	2440
Diclofenac sodium.....	2394	Diprophylline	10.1 -4399
Dicloxacillin sodium	2396	Dipyridamole	2442
Dicyclomine hydrochloride.....	2397	Direct amperometric and pulsed electrochemical detection (2.2.63.)	117
Dicycloverine hydrochloride.....	2397	Dirithromycin	2444
Didanosine	2398	Disintegration of suppositories and pessaries (2.9.2.)	325
Dienogest	2400	Disintegration of tablets and capsules (2.9.1.)	323
Diethyl phthalate	2402	Disodium clodronate tetrahydrate	2257
Diethylcarbamazine citrate.....	2403	Disodium edetate.....	2445
Diethylene glycol and ethylene glycol in ethoxylated substances (2.4.30.).....	163	Disodium etidronate	2589
Diethylene glycol monoethyl ether	2404	Disodium pamidronate pentahydrate	3474
Diethylene glycol palmitostearate.....	2405	Disodium phosphate	2446
Diethylstilbestrol.....	2406	Disodium phosphate dihydrate.....	2447
Diffraction, laser light, particle size analysis by (2.9.31.) ...	373	Disodium phosphate dodecahydrate.....	2447
Difloxacin hydrochloride trihydrate for veterinary use....	2407	Disopyramide	2448
Digitalis for homoeopathic preparations.....	1712	Disopyramide phosphate	2449
Digitalis leaf.....	1412	Dispersible tablets.....	939
Digitoxin	2409	Dissolution, apparent (2.9.43.).....	403
Digoxin	2410	Dissolution, intrinsic (2.9.29.)	372
Dihydralazine sulfate, hydrated	2413	Dissolution test for lipophilic solid dosage forms (2.9.42.)..	401
Dihydrocodeine hydrogen tartrate.....	2414	Dissolution test for medicated chewing gums (2.9.25.).....	365
Dihydroergocristine mesilate	2415	Dissolution test for solid dosage forms (2.9.3.)	326
Dihydroergotamine mesilate.....	2418	Dissolution test for transdermal patches (2.9.4.).....	333
Dihydrostreptomycin sulfate for veterinary use.....	2420	Dissolution testing, recommendations on (5.17.1.)	801
Dihydrotachysterol	2422	Distemper vaccine (live), canine.....	1081
Diltiazem hydrochloride.....	2423	Distemper vaccine (live) for mustelids	1097
Dimenhydrinate.....	2425	Distillation range (2.2.11.)	30
Dimercaprol	2426	Distribution estimation by analytical sieving, particle-size (2.9.38.)	392
Dimethyl sulfoxide	10.1 -4398	Disulfiram	2450
Dimethylacetamide	2428	Dithranol	2451
Dimethylaniline, <i>N,N</i> - (2.4.26.)	158	DL-Methionine	3225
Dimeticone	2429	DL- α -Tocopheryl hydrogen succinate.....	4062
Dimetindene maleate	2429	DNA, residual host-cell, quantification and characterisation of (2.6.35.)	248
Dinoprost trometamol	2431	Dobesilate monohydrate, calcium	2048
Dinoprostone	2432	Dobutamine hydrochloride.....	2452
Dioscorea nipponica rhizome.....	1413	Docetaxel	2453
Dioscorea oppositifolia rhizome.....	1414	Docetaxel trihydrate	2455
Diosmin	2433	Docusate sodium	2457
Dioxan and ethylene oxide (2.4.25.).....	157	Dodecyl gallate.....	2457
Dip concentrates	942	Dog rose.....	1415
Diphenhydramine hydrochloride	2435	Domperidone	2458
Diphenoxylate hydrochloride.....	2436	Domperidone maleate.....	2460
Diphtheria and tetanus toxins and toxoids, flocculation value (Lf) of, (Ramon assay) (2.7.27.).....	295	Donepezil hydrochloride	10.1 -4400
Diphtheria and tetanus vaccine (adsorbed)	952	Donepezil hydrochloride monohydrate.....	10.1 -4401
Diphtheria and tetanus vaccine (adsorbed, reduced antigen(s) content).....	953	Dopamine hydrochloride	2461
Diphtheria antitoxin.....	1170	Dopexamine dihydrochloride	2463
Diphtheria, tetanus and hepatitis B (rDNA) vaccine (adsorbed)	954	Dorzolamide hydrochloride	2464
Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed)	955		
Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content).....	956		
Diphtheria, tetanus and pertussis (whole cell) vaccine (adsorbed)	958		
Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content).....	959		
Diphtheria, tetanus, pertussis (acellular, component) and haemophilus type b conjugate vaccine (adsorbed)	961		

- Dosage forms (glossary) 905
 Dosage units, demonstration of uniformity using large sample sizes (2.9.47.) 409
 Dosage units, uniformity of (2.9.40.) 398
 Dosulepin hydrochloride 2466
 DOTATOC (gallium (⁶⁸Ga)) injection 1208
 Doxapram hydrochloride 2467
 Doxazosin mesilate 2468
 Doxepin hydrochloride 2470
 Doxorubicin hydrochloride 2471
 Doxycycline hyclate 2472
 Doxycycline monohydrate 2474
 Doxylamine hydrogen succinate 2476
 Dronedrone hydrochloride 2477
 Drop point (2.2.17.) 33
 Droperidol 2478
 Droppers (2.1.1.) 15
 Drops (nasal) and sprays (liquid nasal) 919
 Drops, oral 918
 Drospirenone 2480
 Dry extracts 868
 Dry residue of extracts (2.8.16.) 311
 Drying, loss on (2.2.32.) 57
 Drynaria rhizome 1416
 Duck plague vaccine (live) 1098
 Duck viral hepatitis type I vaccine (live) 1099
 Duloxetine hydrochloride 2481
 Dutasteride 2483
 Dwarf lilyturf tuber **10.1**-4354
 Dwarf pine oil 1419
 Dydrogesterone 2485
- E**
- Ear drops and ear sprays 908
 Ear powders 909
 Ear preparations 908
 Ear preparations, semi-solid 908
 Ear sprays and ear drops 908
 Ear tampons 909
 Ear washes 909
 Ebastine 2489
 Eclipta herb 1420
 Econazole 2490
 Econazole nitrate 2491
 Edetate (chromium (⁵¹Cr)) injection 1186
 Edetate, disodium 2445
 Edetate, sodium calcium 3807
 Edetic acid 2492
 Edotreotide (gallium (⁶⁸Ga)) injection 1208
 Edrophonium chloride 2493
 Effervescent granules 912
 Effervescent powders 927
 Effervescent tablets 939
 Efficacy of antimicrobial preservation (5.1.3.) 625
 Efficacy of veterinary vaccines and immunosera, evaluation of (5.2.7.) 661
 Egg drop syndrome '76 vaccine (inactivated) 1100
 Egg phospholipids for injection 2494
 Elder flower 1421
 Electrochemical detection, pulsed, and direct amperometric detection (2.2.63.) 117
 Electrophoresis (2.2.31.) 51
 Electrophoresis, capillary (2.2.47.) **10.1**-4315
 Elemental impurities (5.20.) 815
 Elemental impurities, determination of (2.4.20.) 144
 Eleutherococcus 1423
 Emedastine difumarate 2496
 Empty sterile containers of plasticised poly(vinyl chloride) for human blood and blood components (3.3.5.) 473
 Emulsifying cetostearyl alcohol (type A) 2156
 Emulsifying cetostearyl alcohol (type B) 2157
 Emulsions, solutions and suspensions, oral 917
- Enalapril maleate 2497
 Enalaprilat dihydrate 2499
 Encephalitis vaccine (inactivated), tick-borne 1043
 Encephalomyelitis vaccine (live), infectious, avian 1065
 Endotoxins, bacterial (2.6.14.) 209
 Endotoxins, bacterial, guidelines for using the test for (5.1.10.) 639
 Enilconazole for veterinary use 2500
 Enoxaparin sodium 2502
 Enoxolone 2504
 Enrofloxacin for veterinary use 2505
 Entacapone 2507
 Entecavir monohydrate 2508
 Enteric redmouth disease vaccine (inactivated) for rainbow trout 1102
 Enumeration of microbial contaminants in live biotherapeutic products (2.6.36.) 250
 Enzootic pneumonia vaccine (inactivated), porcine 1141
 Ephedra herb 1425
 Ephedrine 2510
 Ephedrine hemihydrate 2511
 Ephedrine hydrochloride 2511
 Ephedrine hydrochloride, racemic 2513
 Epinastine hydrochloride 2513
 Epinephrine 1766
 Epinephrine tartrate 1767
 Epirubicin hydrochloride 2514
 Eplerenone 2516
 Eptacog alfa (activated) concentrated solution 2840
 Equine herpesvirus vaccine (inactivated) 1103
 Equine influenza vaccine (inactivated) 1104
 Equisetum stem 1426
 Ergocalciferol 2518
 Ergoloid mesilates 2290
 Ergometrine maleate **10.1**-4407
 Ergotamine tartrate 2521
 Erysipelas vaccine (inactivated), swine 1158
 Erythritol 2522
 Erythromycin 2524
 Erythromycin estolate 2527
 Erythromycin ethylsuccinate 2531
 Erythromycin lactobionate 2533
 Erythromycin stearate 2537
 Erythropoietin concentrated solution 2540
 Escitalopram 2544
 Escitalopram oxalate **10.1**-4408
 Eserine salicylate 3554
 Esketamine hydrochloride 2548
 Esomeprazole magnesium dihydrate 2549
 Esomeprazole magnesium trihydrate 2551
 Esomeprazole sodium 2553
 Essential oils 864
 Essential oils, assay of 1,8-cineole in (2.8.11.) 307
 Essential oils, fatty oils and resinified essential oils in (2.8.7.) 306
 Essential oils, foreign esters in (2.8.6.) 306
 Essential oils in herbal drugs (2.8.12.) 307
 Essential oils, odour and taste (2.8.8.) 306
 Essential oils, residue on evaporation (2.8.9.) 306
 Essential oils, solubility in alcohol (2.8.10.) 306
 Essential oils, water in (2.8.5.) 306
 Ester value (2.5.2.) 167
 Estradiol benzoate 2555
 Estradiol hemihydrate 2556
 Estradiol valerate 2557
 Estriol 2559
 Estrogens, conjugated 2561
 Etacrynic acid 2563
 Etamsylate 2565
 Etanercept 2566
 Ethacridine lactate monohydrate 2570
 Ethambutol hydrochloride 2571
 Ethanol (96 per cent) 2573

Ethanol, anhydrous.....	2575	Eye preparations	909
Ethanol content (2.9.10.)	339	Eye preparations, semi-solid	910
Ether	2577		
Ether, anaesthetic.....	2577	F	
Ethinylestradiol.....	2578	F_0 concept to steam sterilisation of aqueous preparations, application of (5.1.5.)	628
Ethionamide	2580	Factor II, human coagulation, assay of (2.7.18.)	288
Ethosuximide	2581	Factor IX, human coagulation	2846
Ethoxylated substances, ethylene glycol and diethylene glycol in (2.4.30.)	163	Factor IX, human coagulation, assay of (2.7.11.)	281
Ethyl acetate	2582	Factor IX (rDNA) concentrated solution, human coagulation	2848
Ethyl acrylate - methacrylic acid copolymer (1:1).....	3214	Factor IX (rDNA) powder for solution for injection, human coagulation	2853
Ethyl acrylate - methacrylic acid copolymer (1:1) dispersion 30 per cent	3216	Factor VII, human coagulation.....	2838
Ethyl oleate	2583	Factor VII, human coagulation, assay of (2.7.10.)	280
Ethyl parahydroxybenzoate	2583	Factor VIIa (rDNA) concentrated solution, human coagulation	2840
Ethyl parahydroxybenzoate sodium.....	3816	Factor VIII, human coagulation	2844
Ethylcellulose.....	2585	Factor VIII, human coagulation, assay of (2.7.4.)	268
Ethylene glycol and diethylene glycol in ethoxylated substances (2.4.30.)	163	Factor VIII (rDNA), human coagulation	2845
Ethylene glycol monopalmitostearate	2586	Factor X, human coagulation, assay of (2.7.19.)	289
Ethylene glycol monostearate.....	2586	Factor XI, human coagulation	2855
Ethylene oxide and dioxan (2.4.25.)	157	Factor XI, human coagulation, assay of (2.7.22.)	291
Ethylenediamine	2587	Falling ball and automatic rolling ball viscometer methods (2.2.49.)	94
Ethylhexanoic acid, 2- (2.4.28.).....	160	Famotidine.....	2609
Ethylmorphine hydrochloride.....	2587	Fat, hard	2811
Etidronate disodium.....	2589	Fat, hard with additives.....	2812
Etilefrine hydrochloride.....	2589	Fatty acids, composition by gas chromatography (2.4.22.) ..	147
Etodolac	2591	Fatty acids in oils rich in omega-3 acids, composition of (2.4.29.)	161
Etofenamate.....	2593	Fatty oils, alkaline impurities in (2.4.19.)	144
Etomidate.....	2595	Fatty oils and resinified essential oils in essential oils (2.8.7.)	306
Etoposide	2596	Fatty oils, foreign oils in, by thin-layer chromatography (2.4.21.)	147
Eucalyptus leaf	1428	Fatty oils, identification by thin-layer chromatography (2.3.2.)	132
Eucalyptus oil.....	1429	Fatty oils, sterols in (2.4.23.).....	150
Eucommia bark.....	1430	Fatty oils, vegetable.....	901
Eugenol	2599	Fc function of immunoglobulin, test for (2.7.9.).....	279
European goldenrod.....	1460	Febantel for veterinary use	2610
European viper venom antiserum	1174	Feeding stuffs for veterinary use, medicated, premixes for..	927
Evaluation of efficacy of veterinary vaccines and immunosera (5.2.7.)	661	Felbinac	2611
Evaluation of safety of each batch of immunosera for veterinary use (5.2.9.).....	673	Feline calicivirus vaccine (inactivated).....	1106
Evaluation of safety of veterinary vaccines and immunosera (5.2.6.)	658	Feline calicivirus vaccine (live).....	1107
Evening primrose oil, refined.....	2601	Feline chlamydiosis vaccine (inactivated)	1108
Everolimus.....	2601	Feline infectious enteritis (feline panleucopenia) vaccine (inactivated)	1109
Evodia fruit.....	1431	Feline infectious enteritis (feline panleucopenia) vaccine (live)	1110
Excipients, functionality-related characteristics of (5.1.5.) ..	793	Feline leukaemia vaccine (inactivated)	1112
Exemestane	10.1-4410	Feline panleucopenia vaccine (inactivated).....	1109
Extemporaneous preparation of radiopharmaceuticals (5.19.)	807	Feline panleucopenia vaccine (live)	1110
Extractable volume of parenteral preparations, test for (2.9.17.)	347	Feline viral rhinotracheitis vaccine (inactivated)	1113
Extracts, dry	868	Feline viral rhinotracheitis vaccine (live)	1114
Extracts, dry residue of (2.8.16.).....	311	Felodipine	2612
Extracts, herbal drug	865	Felypressin	2614
Extracts, herbal drug, monographs on (information chapter) (5.23.)	843	Fenbendazole for veterinary use.....	2615
Extracts, liquid (fluid).....	867	Fenbufen	2616
Extracts, loss on drying of (2.8.17.).....	311	Fennel, bitter	1433
Extracts, soft.....	867	Fennel, sweet	1434
Extracts used in the preparation of herbal medicinal products for oral use, microbiological examination (2.6.31.)	239	Fenofibrate.....	2617
Extracts used in the preparation of herbal medicinal products for oral use, microbiological quality (5.1.8.)	638	Fenoterol hydrobromide.....	2618
Extracts, water for preparation of.....	4206	Fentanyl.....	2619
Extraneous agents in viral vaccines for human use, tests for (2.6.16.)	214	Fentanyl citrate.....	2621
Extraneous agents: tests in batches of finished product of avian live virus vaccines (2.6.25.)	227	Fenticonazole nitrate.....	2622
Extraneous agents: tests in seed lots of avian viral vaccines (2.6.24.)	224	Fenugreek	1435
Eye drops	909	Fermentation, products of.....	882
Eye lotions	910	Ferric chloride hexahydrate.....	2624
		Ferrous fumarate.....	2624
		Ferrous gluconate	2625

Ferrous sulfate, dried.....	2626	Foams, rectal.....	935
Ferrous sulfate heptahydrate.....	2627	Foams, vaginal.....	941
Ferrum metallicum for homoeopathic preparations.....	1714	Folic acid hydrate.....	2690
FET (¹⁸ F) injection.....	1201	Folinate hydrate, calcium.....	2049
Feverfew.....	1436	Follitropin.....	2691
Fexofenadine hydrochloride.....	2628	Follitropin concentrated solution.....	2697
Fibrin sealant kit.....	2630	Foot-and-mouth disease (ruminants) vaccine (inactivated).....	1115
Fibrinogen, human.....	2856	Foreign esters in essential oils (2.8.6.).....	306
Filgrastim concentrated solution.....	2631	Foreign matter (2.8.2.).....	305
Filgrastim injection.....	2634	Foreign oils in fatty oils by thin-layer chromatography (2.4.21.).....	147
Films, orodispersible.....	922	Formaldehyde, free (2.4.18.).....	143
Finasteride.....	2636	Formaldehyde solution (35 per cent).....	2703
Fineness, powder (2.9.35.).....	387	Formic acid.....	2703
Fingolimod hydrochloride.....	2637	Formoterol fumarate dihydrate.....	2704
Fipronil for veterinary use.....	2639	Foscarnet sodium hexahydrate.....	2706
Fish oil, rich in omega-3 acids.....	2639	Fosfomycin calcium.....	2708
Flavoxate hydrochloride.....	2642	Fosfomycin sodium.....	2709
Flecainide acetate.....	2643	Fosfomycin trometamol.....	2710
Fleeceflower root.....	1437	Fosinopril sodium.....	2711
Flocculation value (Lf) of diphtheria and tetanus toxins and toxoids (Ramon assay) (2.7.27.).....	295	Fourstamen stephania root.....	1438
Flow cytometry (2.7.24.).....	293	Fowl cholera vaccine (inactivated).....	1117
Flowability (2.9.16.).....	346	Fowl-pox vaccine (live).....	1118
FLT (¹⁸ F) injection.....	1181	Framycetin sulfate.....	2714
Flubendazole.....	2644	Frangula bark.....	1439
Flucloxacillin magnesium octahydrate.....	2645	Frangula bark dry extract, standardised.....	1441
Flucloxacillin sodium.....	2647	Frankincense, Indian.....	1480
Fluconazole.....	2649	Fraxinus chinensis bark.....	10.1 -4356
Flucytosine.....	2650	Free formaldehyde (2.4.18.).....	143
Fludarabine phosphate.....	2652	Freezing point (2.2.18.).....	35
Fludeoxyglucose (¹⁸ F) injection.....	1190	Fresh bilberry fruit dry extract, refined and standardised..	1442
Fludrocortisone acetate.....	2654	Friability of granules and spheroids (2.9.41.).....	400
Flumazenil.....	2655	Friability of uncoated tablets (2.9.7.).....	336
Flumazenil (N-[¹¹ C]methyl) injection.....	1192	Fructose.....	2715
Flumequine.....	2657	Fucus.....	1494
Flumetasone pivalate.....	2658	Fulvestrant.....	2716
Flunarizine dihydrochloride.....	2659	Fumitory.....	1444
Flunitrazepam.....	2660	Functional groups and ions, identification reactions of (2.3.1.).....	129
Flunixin meglumine for veterinary use.....	2661	Functionality-related characteristics of excipients (5.15.)...	793
Fluocinolone acetonide.....	2662	Fungicidal, bactericidal or yeasticidal activity of antiseptic medicinal products, determination of (5.1.11.).....	643
Fluocortolone pivalate.....	10.1 -4415	Furosemide.....	2718
Fluorescein.....	2666	Furunculosis vaccine (inactivated, oil-adjuvanted, injectable) for salmonids.....	1119
Fluorescein sodium.....	2667	Fusidate, sodium.....	3818
Fluoride (¹⁸ F) solution for radiolabelling.....	1194	Fusidic acid.....	2719
Fluorides (2.4.5.).....	138		
Fluorimetry (2.2.21.).....	36	G	
Fluorocholine (¹⁸ F) injection.....	1195	Gabapentin.....	2725
Fluorodeoxythymidine (¹⁸ F) injection.....	1181	Gadobutrol monohydrate.....	2726
Fluorodopa (¹⁸ F) (prepared by electrophilic substitution) injection.....	1197	Gadodiamide hydrate.....	2728
Fluorodopa (¹⁸ F) (prepared by nucleophilic substitution) injection.....	1198	Galactose.....	2730
Fluoroethyl-L-tyrosine (¹⁸ F) injection.....	1201	Galantamine hydrobromide.....	2731
Fluoromisonidazole (¹⁸ F) injection.....	1204	Gallium (⁶⁷ Ga) citrate injection.....	1206
Fluorouracil.....	2669	Gallium (⁶⁸ Ga) chloride solution for radiolabelling.....	1206
Fluoxetine hydrochloride.....	2670	Gallium (⁶⁸ Ga) DOTATOC injection.....	1208
Flupentixol dihydrochloride.....	2672	Gallium (⁶⁸ Ga) edotreotide injection.....	1208
Fluphenazine decanoate.....	10.1 -4416	Gammacyclodextrin.....	10.1 -4423
Fluphenazine dihydrochloride.....	2675	Gammadex.....	10.1 -4423
Fluphenazine enantate.....	10.1 -4418	Ganciclovir.....	2735
Flurazepam monohydrochloride.....	2679	Gargles.....	921
Flurbiprofen.....	2680	Garlic for homoeopathic preparations.....	1701
Fluspirilene.....	2681	Garlic powder.....	1446
Flutamide.....	2682	Gas adsorption, specific surface area by (2.9.26.).....	369
Fluticasone propionate.....	2683	Gas chromatography (2.2.28.).....	48
Flutrimazole.....	2685	Gas detector tubes (2.1.6.).....	17
Fluvastatin sodium.....	2686	Gas pycnometric density of solids (2.9.23.).....	364
Fluvoxamine maleate.....	2688	Gases, carbon dioxide in (2.5.24.).....	174
FMISO (¹⁸ F) injection.....	1204	Gases, carbon monoxide in (2.5.25.).....	175
Foam index (2.8.24.).....	317		
Foams, cutaneous.....	916		
Foams, intrauterine.....	914		
Foams, medicated.....	911		

Gases, nitrogen monoxide and nitrogen dioxide in (2.5.26.)	176	Gonadotrophin, equine serum, for veterinary use	2783
Gases, nitrous oxide in (2.5.35.)	182	Goserelin	2783
Gases, oxygen in (2.5.27.)	176	Grafted copolymer, macrogol poly(vinyl alcohol)	3140
Gases, water in (2.5.28.)	176	Gramicidin	2785
Gas-gangrene antitoxin, mixed	1170	Granisetron hydrochloride	2787
Gas-gangrene antitoxin (novyi)	1171	Granules	912
Gas-gangrene antitoxin (perfringens)	1171	Granules and powders for oral solutions and suspensions	917
Gas-gangrene antitoxin (septicum)	1172	Granules and powders for syrups	918
Gastrodia rhizome	1447	Granules and spheroids, friability of (2.9.41.)	400
Gastro-resistant capsules	907	Granules, coated	912
Gastro-resistant granules	913	Granules, effervescent	912
Gastro-resistant tablets	938	Granules, gastro-resistant	913
Gefitinib	2737	Granules, modified-release	912
Gelatin	2738	Greater celandine	1463
Gels	936	Green tea	1464
Gels for injections	925	Griseofulvin	2788
Gemcitabine hydrochloride	2739	Guaiaicol	2789
Gemfibrozil	2740	Guaifenesin	2791
Gene transfer medicinal products for human use (5.14.)	779	Guanethidine monosulfate	2792
General notices (1.)	3	Guar	1466
General texts on biological products (5.2.)	647	Guar galactomannan	2793
General texts on microbiology (5.1.)	619	Guarana	1467
Genetically modified cells	779	Guidelines for using the test for bacterial endotoxins (5.1.10.)	639
Gentamicin sulfate	2742	Guidelines for using the test for sterility (5.1.9.)	639
Gentian root	1448		
Gentian tincture	1449	H	
Gestodene	2744	Haemagglutinins, anti-A and anti-B (2.6.20.)	218
Ginger	1450	Haematopoietic products, numeration of CD34/CD45+ cells in (2.7.23.)	292
Gingival solutions	921	Haematopoietic progenitor cells, human, colony-forming cell assay for (2.7.28.)	296
Ginkgo dry extract, refined and quantified	1451	Haematopoietic stem cells, human	2857
Ginkgo leaf	1454	Haemodiafiltration and haemofiltration, concentrated solutions for	2801
Ginseng	1455	Haemodiafiltration and haemofiltration, solutions for	2803
Ginseng dry extract	1457	Haemodialysis, concentrated solutions for	2798
Glass containers for pharmaceutical use (3.2.1.)	453	Haemodialysis solutions, concentrated, water for diluting	2797
Glibenclamide	2746	Haemodialysis, solutions for	2798
Gliclazide	2747	Haemofiltration and haemodiafiltration, concentrated solutions for	2801
Glimepiride	2749	Haemofiltration and haemodiafiltration, solutions for	2803
Glipizide	2751	Haemophilus type b and meningococcal group C conjugate vaccine	979
Glossary (dosage forms)	905	Haemophilus type b (conjugate), diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed)	961
Glucagon, human	2753	Haemophilus type b (conjugate), diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)	970
Glucoheptonate, calcium	2051	Haemophilus type b (conjugate), diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA) and poliomyelitis (inactivated) vaccine (adsorbed)	968
Glucosamine hydrochloride	2754	Haemophilus type b (conjugate), diphtheria, tetanus, pertussis (whole cell) and poliomyelitis (inactivated) vaccine (adsorbed)	974
Glucosamine sulfate potassium chloride	2755	Haemophilus type b conjugate vaccine	980
Glucosamine sulfate sodium chloride	2757	Haemorrhagic disease vaccine (inactivated), rabbit	1147
Glucose	2758	Halofantrine hydrochloride	2805
Glucose, liquid	2759	Haloperidol	2806
Glucose, liquid, spray-dried	2760	Haloperidol decanoate	2808
Glucose monohydrate	2761	Halothane	2809
Glutamic acid	2762	Hamamelis bark	1468
Glutathione	2763	Hamamelis leaf	1469
Glycan analysis of glycoproteins (2.2.59.)	109	Hard capsules	906
Glycerol	2765	Hard fat	2811
Glycerol (85 per cent)	2766	Hard fat with additives	2812
Glycerol dibehenate	2767	Hard paraffin	3483
Glycerol distearate	2768	Harmonisation, pharmacopoeial (5.8.)	755
Glycerol formal	2769	Hawthorn berries	10.1-4357
Glycerol monocaprylate	2770	Hawthorn leaf and flower	1471
Glycerol monocaprylocaprate	2771	Hawthorn leaf and flower dry extract	1472
Glycerol monolinoleate	2772		
Glycerol mono-oleate	2773		
Glycerol monostearate 40-55	2774		
Glycerol triacetate	4083		
Glyceryl trinitrate solution	2775		
Glycine	2777		
Glycoproteins, glycan analysis of (2.2.59.)	109		
Glycopyrronium bromide	2779		
Glycyrrhizate ammonium	1833		
Goldenrod	1458		
Goldenrod, European	1460		
Goldenseal rhizome	1461		
Gonadorelin acetate	2781		
Gonadotrophin, chorionic	2782		

- Hawthorn leaf and flower liquid extract, quantified 1473
- HCP assays (2.6.34.) 244
- Healthy chicken flocks for the production of inactivated vaccines for veterinary use (5.2.13.) 679
- Heavy bismuth subnitrate 1985
- Heavy kaolin 3031
- Heavy magnesium carbonate 3153
- Heavy magnesium oxide 3159
- Heavy metals (2.4.8.) 139
- Heavy metals in herbal drugs and herbal drug preparations (2.4.27.) 158
- Hedera helix for homoeopathic preparations 1715
- Helium 2814
- Heparin, assay of (2.7.5.) 269
- Heparin calcium 2814
- Heparin in coagulation factors, assay of (2.7.12.) 281
- Heparin sodium 2816
- Heparins, low-molecular-mass 2818
- Hepatitis A immunoglobulin, human 2858
- Hepatitis A (inactivated, adsorbed) and typhoid polysaccharide vaccine 982
- Hepatitis A (inactivated) and hepatitis B (rDNA) vaccine (adsorbed) 983
- Hepatitis A vaccine, assay of (2.7.14.) 284
- Hepatitis A vaccine (inactivated, adsorbed) 984
- Hepatitis A vaccine (inactivated, virosome) 985
- Hepatitis B immunoglobulin for intravenous administration, human 2859
- Hepatitis B immunoglobulin, human 2858
- Hepatitis B (rDNA), diphtheria and tetanus vaccine (adsorbed) 954
- Hepatitis B (rDNA), diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed) 963
- Hepatitis B (rDNA), diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed) 968
- Hepatitis B vaccine (rDNA) 988
- Hepatitis B vaccine (rDNA), assay of (2.7.15.) 285
- Hepatitis C virus (HCV), validation of nucleic acid amplification techniques for the detection of HCV RNA in plasma pools: guidelines 219
- Hepatitis type I vaccine (live), viral, duck 1099
- Heptaminol hydrochloride 2821
- Herbal drug extracts 865
- Herbal drug extracts, monographs on (information chapter) (5.2.3.) 843
- Herbal drug preparations 869
- Herbal drugs 869
- Herbal drugs and herbal drug preparations, heavy metals in (2.4.27.) 158
- Herbal drugs and herbal drug preparations, high-performance thin-layer chromatography of (2.8.25.) 318
- Herbal drugs, determination of aflatoxin B₁ in (2.8.18.) 311
- Herbal drugs, essential oils in (2.8.12.) 307
- Herbal drugs for homoeopathic preparations 1680
- Herbal drugs: introduction 1289
- Herbal drugs, microscopic examination of (2.8.23.) 317
- Herbal drugs: sampling and sample preparation (2.8.20.) 313
- Herbal drugs, tannins in (2.8.14.) 310
- Herbal drugs, test for aristolochic acids in (2.8.21) 314
- Herbal medicinal products for oral use and extracts used in their preparation, microbiological examination (2.6.31.) 239
- Herbal medicinal products for oral use and extracts used in their preparation, microbiological quality (5.1.8.) 638
- Herbal preparations 869
- Herbal substances 869
- Herbal teas 870
- Herbal teas, instant 871
- Herpes zoster (shingles) vaccine (live) 1036
- Herpesvirus vaccine (inactivated), equine 1103
- Hexamidine diisetonate 2822
- Hexetidine 2823
- Hexosamines in polysaccharide vaccines (2.5.20.) 173
- Hexylresorcinol 2824
- High-molecular-mass macrogols 3147
- High-performance thin-layer chromatography of herbal drugs and herbal drug preparations (2.8.25.) 318
- Histamine (2.6.10.) 200
- Histamine dihydrochloride 2825
- Histaminum for homoeopathic preparations 1716
- Histidine 2826
- Histidine hydrochloride monohydrate 2827
- Homatropine hydrobromide 2829
- Homatropine methylbromide 2830
- Homoeopathic pillules, coated 1697
- Homoeopathic pillules, impregnated 1697
- Homoeopathic preparations 1679
- Homoeopathic preparations, acidum picrinicum for 1698
- Homoeopathic preparations, acidum succinicum for 1698
- Homoeopathic preparations, Adonis vernalis for **10.1**-4369
- Homoeopathic preparations, Agaricus phalloides for 1699
- Homoeopathic preparations, Allium sativum for 1701
- Homoeopathic preparations, ammonium carbonicum for 1701
- Homoeopathic preparations, Anacardium for 1702
- Homoeopathic preparations, Apis for 1703
- Homoeopathic preparations, arsenicum album for 1704
- Homoeopathic preparations, aurum chloratum natronatum for 1704
- Homoeopathic preparations, barium chloratum for 1705
- Homoeopathic preparations, Belladonna for 1705
- Homoeopathic preparations, cadmium sulfuricum for 1707
- Homoeopathic preparations, calcium fluoratum for 1707
- Homoeopathic preparations, calcium iodatum for 1708
- Homoeopathic preparations, Coccus for 1708
- Homoeopathic preparations, Crocus for 1710
- Homoeopathic preparations, cuprum aceticum for 1711
- Homoeopathic preparations, cuprum metallicum for 1712
- Homoeopathic preparations, digitalis for 1712
- Homoeopathic preparations, ferrum metallicum for 1714
- Homoeopathic preparations, hedera helix for 1715
- Homoeopathic preparations, herbal drugs for 1680
- Homoeopathic preparations, histaminum for 1716
- Homoeopathic preparations, hydrastis canadensis for 1716
- Homoeopathic preparations, hyoscyamus for 1717
- Homoeopathic preparations, hypericum for 1718
- Homoeopathic preparations: introduction 1679
- Homoeopathic preparations, kalium bichromicum for 1721
- Homoeopathic preparations, magnesium fluoratum for **10.1**-4370
- Homoeopathic preparations, magnesium phosphoricum for 1722
- Homoeopathic preparations, mother tinctures for 1681
- Homoeopathic preparations, Nux-vomica for 1723
- Homoeopathic preparations, petroleum rectificatum for 1725
- Homoeopathic preparations, pillules for 1696
- Homoeopathic preparations, selenium for 1725
- Homoeopathic preparations, Staphysagria for 1726
- Homoeopathic preparations, sulfur for 1727
- Homoeopathic preparations, Urtica dioica for 1728
- Homoeopathic stocks (methods of preparation of) and potentisation 1682
- Homoeopathic preparations, Ignatia for 1719
- Honey 2831
- Honey bee for homoeopathic preparations 1703
- Hop strobile 1474
- Horse-chestnut 1475
- Horse-chestnut dry extract, standardised 1477
- Host-cell DNA, residual, quantification and characterisation of (2.6.35.) 248
- Host-cell protein assays (2.6.34.) 244
- Houttuynia herb 1478
- Human α -1-proteinase inhibitor 2869
- Human α -1-proteinase inhibitor, assay of (2.7.32.) 300
- Human albumin injection, iodinated (¹²⁵I) 1210
- Human albumin solution 2832

Human anti-D immunoglobulin	2834	Hydrogenated cottonseed oil.....	2317
Human anti-D immunoglobulin, assay of (2.7.13.)	282	Hydrogenated soya-bean oil.....	3872
Human anti-D immunoglobulin for intravenous administration.....	2835	Hydrogenated vegetable oils, nickel in (2.4.31.)	163
Human antithrombin III, assay of (2.7.17.).....	288	Hydrogenated wool fat.....	4215
Human antithrombin III concentrate	2835	Hydromorphone hydrochloride.....	2890
Human C1-esterase inhibitor.....	2837	Hydrophobic colloidal silica.....	3789
Human C1-esterase inhibitor, assay of (2.7.34.).....	301	Hydrous wool fat	4216
Human coagulation factor II, assay of (2.7.18.).....	288	Hydroxocobalamin acetate	2892
Human coagulation factor IX.....	2846	Hydroxocobalamin chloride.....	2893
Human coagulation factor IX, assay of (2.7.11.)	281	Hydroxocobalamin sulfate.....	2894
Human coagulation factor IX (rDNA) concentrated solution	2848	Hydroxycarbamide	2895
Human coagulation factor IX (rDNA) powder for solution for injection	2853	Hydroxychloroquine sulfate	2896
Human coagulation factor VII.....	2838	Hydroxyethyl salicylate	2897
Human coagulation factor VII, assay of (2.7.10.).....	280	Hydroxyethyl starches	3892
Human coagulation factor VIIa (rDNA) concentrated solution	2840	Hydroxyethylcellulose	2898
Human coagulation factor VIII.....	2844	Hydroxyethylmethylcellulose.....	3237
Human coagulation factor VIII, assay of (2.7.4.)	268	Hydroxyl value (2.5.3.).....	167
Human coagulation factor VIII (rDNA)	2845	Hydroxypropyl starch.....	3888
Human coagulation factor X, assay of (2.7.19.).....	289	Hydroxypropyl starch, pregelatinised	3890
Human coagulation factor XI.....	2855	Hydroxypropylbetadex.....	2901
Human coagulation factor XI, assay of (2.7.22.)	291	Hydroxypropylcellulose	2903
Human fibrinogen	2856	Hydroxypropylcellulose, low-substituted	2904
Human glucagon.....	2753	Hydroxypropylmethylcellulose	2914
Human haematopoietic progenitor cells, colony-forming cell assay for (2.7.28.).....	296	Hydroxypropylmethylcellulose phthalate	2916
Human haematopoietic stem cells.....	2857	Hydroxyzine hydrochloride.....	2906
Human hepatitis A immunoglobulin	2858	Hymecromone.....	2907
Human hepatitis B immunoglobulin	2858	Hymenoptera venoms for allergen products.....	2908
Human hepatitis B immunoglobulin for intravenous administration.....	2859	Hyoscine	2909
Human insulin	2951	Hyoscine butylbromide.....	2910
Human measles immunoglobulin	2859	Hyoscine hydrobromide	2911
Human normal immunoglobulin for intramuscular administration.....	2860	Hyoscyamine sulfate.....	2913
Human normal immunoglobulin for intravenous administration.....	2862	Hyoscyamus for homoeopathic preparations	1717
Human normal immunoglobulin for subcutaneous administration.....	2864	Hypericum.....	1631
Human papillomavirus vaccine (rDNA)	989	Hypericum for homoeopathic preparations.....	1718
Human plasma for fractionation	2865	Hypromellose	2914
Human plasma (pooled and treated for virus inactivation)	2867	Hypromellose phthalate	2916
Human plasmin inhibitor, assay of (2.7.25.).....	295		
Human protein C, assay of (2.7.30.).....	299	I	
Human protein S, assay of (2.7.31.).....	300	Ibuprofen	2921
Human prothrombin complex	2870	Iceland moss.....	1480
Human rabies immunoglobulin	2871	ICH (5.8.).....	755
Human rubella immunoglobulin	2872	Ichthammol	2923
Human tetanus immunoglobulin	2873	Identification (2.3.).....	129
Human varicella immunoglobulin	2875	Identification and control of residual solvents (2.4.24.)	10.1-4323
Human varicella immunoglobulin for intravenous administration.....	2875	Identification of fatty oils by thin-layer chromatography (2.3.2.)	132
Human von Willebrand factor	2875	Identification of phenothiazines by thin-layer chromatography (2.3.3.)	133
Human von Willebrand factor, assay of (2.7.21.)	290	Identification reactions of ions and functional groups (2.3.1.)	129
Hyaluronate, sodium	3821	Idoxuridine.....	2924
Hyaluronidase	2877	Ifosfamide	2925
Hydralazine hydrochloride.....	2878	Ignatia for homoeopathic preparations	1719
Hydrastis canadensis for homoeopathic preparations.....	1716	Imatinib mesilate	2926
Hydrochloric acid, concentrated	2879	Imidacloprid for veterinary use	2929
Hydrochloric acid, dilute	2879	Imipenem monohydrate	2930
Hydrochlorothiazide	2879	Imipramine hydrochloride	2931
Hydrocodone hydrogen tartrate 2.5-hydrate	2881	Immunochemical methods (2.7.1.)	261
Hydrocortisone	2883	Immunoglobulin for human use, anti-T lymphocyte, animal	1858
Hydrocortisone acetate	2886	Immunoglobulin for intramuscular administration, human normal.....	2860
Hydrocortisone hydrogen succinate.....	2888	Immunoglobulin for intravenous administration, human anti-D	2835
Hydrogen peroxide solution (3 per cent)	2889	Immunoglobulin for intravenous administration, human hepatitis B.....	2859
Hydrogen peroxide solution (30 per cent)	2890	Immunoglobulin for intravenous administration, human normal.....	2862
Hydrogenated arachis oil.....	1869	Immunoglobulin for intravenous administration, human varicella.....	2875
Hydrogenated castor oil.....	10.1-4389		

- Immunoglobulin for subcutaneous administration, human normal..... 2864
- Immunoglobulin, human anti-D..... 2834
- Immunoglobulin, human anti-D, assay of (2.7.13.)..... 282
- Immunoglobulin, human hepatitis A..... 2858
- Immunoglobulin, human hepatitis B..... 2858
- Immunoglobulin, human measles..... 2859
- Immunoglobulin, human rabies..... 2871
- Immunoglobulin, human rubella..... 2872
- Immunoglobulin, human tetanus..... 2873
- Immunoglobulin, human varicella..... 2875
- Immunoglobulin, test for anticomplementary activity of (2.6.17.)..... 216
- Immunoglobulin, test for Fc function of (2.7.9.)..... 279
- Immunological veterinary medicinal products, substances of animal origin for the production of (5.2.5.)..... 656
- Immunonephelometry for vaccine component assay (2.7.35.)..... 301
- Immunosera and vaccines, phenol in (2.5.15.)..... 172
- Immunosera and vaccines, veterinary, evaluation of efficacy of (5.2.7.)..... 661
- Immunosera and vaccines, veterinary, evaluation of safety (5.2.6.)..... 658
- Immunosera for human use, animal..... 871
- Immunosera for veterinary use..... 873
- Immunosera for veterinary use, evaluation of the safety of each batch (5.2.9.)..... 673
- Implants..... 925
- Impurities, elemental, determination of (2.4.20.)..... 144
- Impurities in substances for pharmaceutical use, control of (5.10.)..... 763
- In vitro* method(s) for the quality control of vaccines, substitution of *in vivo* method(s) by (5.2.14.)..... 679
- In vivo* assay of poliomyelitis vaccine (inactivated) (2.7.20.)..... 289
- Inactivated vaccines for veterinary use, healthy chicken flocks for the production of (5.2.13.)..... 679
- Indapamide..... 2932
- Index, foam (2.8.24.)..... 317
- Indian frankincense..... 1480
- Indicators, approximate pH of solutions (2.2.4.)..... 25
- Indigo plant leaf..... 1481
- Indinavir sulfate..... 2934
- Indium (¹¹¹In) chloride solution..... 1211
- Indium (¹¹¹In) oxine solution..... 1212
- Indium (¹¹¹In) pentetate injection..... 1213
- Indometacin..... 2936
- Inductively coupled plasma-atomic emission spectrometry (2.2.57.)..... 106
- Inductively coupled plasma-mass spectrometry (2.2.58.)..... 108
- Infectious bovine rhinotracheitis vaccine (inactivated)..... 1120
- Infectious bovine rhinotracheitis vaccine (live)..... 1121
- Infectious bronchitis vaccine (inactivated), avian..... 1059
- Infectious bronchitis vaccine (live), avian..... 1060
- Infectious bursal disease vaccine (inactivated), avian..... 1062
- Infectious bursal disease vaccine (live), avian..... 1063
- Infectious chicken anaemia vaccine (live)..... 1122
- Infectious encephalomyelitis vaccine (live), avian..... 1065
- Infectious enteritis vaccine (inactivated), feline..... 1109
- Infectious enteritis vaccine (live), feline..... 1110
- Infectious laryngotracheitis vaccine (live), avian..... 1066
- Infectious pancreatic necrosis vaccine (inactivated, oil-adjuvanted, injectable) for salmonids..... 1124
- Infectious rhinotracheitis vaccine (live), turkey..... 1162
- Infliximab concentrated solution..... 2938
- Influenza vaccine (inactivated), equine..... 1104
- Influenza vaccine (inactivated), porcine..... 1142
- Influenza vaccine (live, nasal)..... 992
- Influenza vaccine (split virion, inactivated)..... 995
- Influenza vaccine (surface antigen, inactivated)..... 996
- Influenza vaccine (surface antigen, inactivated, prepared in cell cultures)..... 998
- Influenza vaccine (surface antigen, inactivated, virosome)..... 1000
- Influenza vaccine (whole virion, inactivated)..... 1002
- Influenza vaccine (whole virion, inactivated, prepared in cell cultures)..... 1003
- Infrared absorption spectrophotometry (2.2.24.)..... 39
- Infusions..... 924
- Inhalation gas, krypton (^{81m}Kr)..... 1217
- Inhalation powders..... 931
- Inhalation, preparations for..... 927
- Inhalation, preparations for: aerodynamic assessment of fine particles (2.9.18.)..... 347
- Injectable insulin preparations..... 10.1-4427
- Injections..... 923
- Injections, gels for..... 925
- Injections or infusions, concentrates for..... 924
- Injections or infusions, powders for..... 924
- Inositol, *myo*-..... 2944
- Inserts, ophthalmic..... 910
- Instant herbal teas..... 871
- Insulin aspart..... 2945
- Insulin glargine..... 2949
- Insulin, human..... 2951
- Insulin injection, biphasic..... 2953
- Insulin injection, biphasic isophane..... 2953
- Insulin injection, isophane..... 2954
- Insulin injection, soluble..... 2954
- Insulin lispro..... 2954
- Insulin, porcine..... 2957
- Insulin preparations, injectable..... 10.1-4427
- Insulin zinc injectable suspension..... 2961
- Insulin zinc injectable suspension (amorphous)..... 2962
- Insulin zinc injectable suspension (crystalline)..... 2962
- Interferon alfa-2 concentrated solution..... 2963
- Interferon beta-1a concentrated solution..... 2965
- Interferon gamma-1b concentrated solution..... 2968
- Interferons, assay of (5.6.)..... 741
- International System (SI) units (1.)..... 3
- Intramammary preparations for veterinary use..... 913
- Intraruminal delivery systems..... 913
- Intrauterine capsules..... 914
- Intrauterine foams..... 914
- Intrauterine preparations for veterinary use..... 914
- Intrauterine solutions, suspensions..... 914
- Intrauterine sticks..... 914
- Intrauterine tablets..... 914
- Intrinsic dissolution (2.9.29.)..... 372
- Iobenguane (¹²³I) injection..... 1213
- Iobenguane (¹³¹I) injection for diagnostic use..... 1214
- Iobenguane (¹³¹I) injection for therapeutic use..... 1215
- Iobenguane sulfate for radiopharmaceutical preparations..... 1216
- Iodinated (¹²⁵I) human albumin injection..... 1210
- Iodinated povidone..... 3615
- Iodine..... 2971
- Iodine value (2.5.4.)..... 167
- Iodixanol..... 2971
- Iodohippurate (sodium) dihydrate for radiopharmaceutical preparations..... 1234
- Iodomethylnorcholesterol (¹³¹I) injection..... 1217
- Iohexol..... 2974
- Ionic concentration, potentiometric determination of using ion-selective electrodes (2.2.36.)..... 64
- Ions and functional groups, identification reactions of (2.3.1.)..... 129
- Ion-selective electrodes, potentiometric determination of ionic concentration (2.2.36.)..... 64
- Iopamidol..... 2978
- Iopanoic acid..... 2980
- Iopromide..... 2981
- Iotrolan..... 2984
- Ioxaglic acid..... 2986
- Ipecacuanha liquid extract, standardised..... 1483

Ipecacuanha, prepared	1483	Lactose	3054
Ipecacuanha root	1485	Lactose monohydrate	3055
Ipecacuanha tincture, standardised	1486	Lactulose	3056
Ipratropium bromide	2988	Lactulose, liquid	3058
Irbesartan	2990	Lamivudine	3060
Irinotecan hydrochloride trihydrate	10.1 -4429	Lamotrigine	3063
Iron (2.4.9.)	142	Lansoprazole	3064
Iron for homeopathic preparations	1714	Largehead atractylodes rhizome	1328
Irrigation, preparations for	932	Laryngotracheitis vaccine (live), infectious, avian	1066
Isatis root	1487	Laser light diffraction, particle size analysis by (2.9.31.)	373
Isoconazole	2993	Laurilsulfate, sodium	3827
Isoconazole nitrate	2994	Lauromacrogol 400	3065
Isoelectric focusing (2.2.54.)	95	Lauroyl macrogolglycerides	3068
Isoflurane	2996	Lavender flower	1497
Isoleucine	2997	Lavender oil	1499
Isomalt	2998	Lavender oil, spike	1630
Isoniazid	3000	Lead in sugars (2.4.10.)	142
Isophane insulin injection	2954	Leflunomide	3069
Isoprenaline hydrochloride	10.1 -4431	Lemon oil	1500
Isoprenaline sulfate	3002	Lemon verbena leaf	1502
Isopropyl alcohol	3003	Leptospirosis vaccine (inactivated), bovine	1071
Isopropyl isostearate	3004	Leptospirosis vaccine (inactivated), canine	1082
Isopropyl myristate	3004	Letrozole	3070
Isopropyl palmitate	3005	Leucine	3071
Isosorbide dinitrate, diluted	10.1 -4432	Leukaemia vaccine (inactivated), feline	1112
Isosorbide mononitrate, diluted	10.1 -4434	Leuporelin	3073
Isotherms (sorption-desorption) and water activity, determination of (water-solid interactions) (2.9.39.)	394	Levamisole for veterinary use	3074
Isotretinoin	3009	Levamisole hydrochloride	3075
Isoxsuprine hydrochloride	3010	Levetiracetam	3077
Ispaghula husk	1488	Levocabastine hydrochloride	3078
Ispaghula seed	1489	Levocarnitine	10.1 -4439
Isradipine	3012	Levodopa	3082
Itraconazole	3013	Levodropropizine	3083
Ivermectin	3015	Levofloxacin hemihydrate	3085
Ivy leaf	1489	Levofolate hydrate, calcium	2060
J		Levomenthol	3086
Java tea	1491	Levomepromazine hydrochloride	3087
Javanese turmeric	1652	Levomepromazine maleate	3088
Josamycin	3021	Levomethadone hydrochloride	3089
Josamycin propionate	3023	Levonorgestrel	10.1 -4440
Juniper	1492	Levothyroxine sodium	3094
Juniper oil	1493	Levulinate dihydrate, calcium	2062
K		Lidocaine	3095
Kalium bichromicum for homeopathic preparations	1721	Lidocaine hydrochloride monohydrate	3097
Kanamycin acid sulfate	3029	Light liquid paraffin	3483
Kanamycin monosulfate	3030	Light magnesium carbonate	3153
Kaolin, heavy	3031	Light magnesium oxide	3160
Kelp	1494	Lightyellow sophora root	1503
Ketamine hydrochloride	3031	Ligusticum root and rhizome	1505
Ketobemidone hydrochloride	3032	Lime flower	1506
Ketoconazole	3033	Limit tests (2.4.)	137
Ketoprofen	3035	Limit tests, standard solutions for (4.1.2.)	598
Ketorolac trometamol	3037	Lincomycin hydrochloride	3098
Ketotifen hydrogen fumarate	3038	Linen thread, sterile, in distributor for veterinary use	1282
Knotgrass	1495	Linoleoyl macrogolglycerides	3100
Krypton (^{81m} Kr) inhalation gas	1217	Linseed	1507
Kudzu vine root	1496	Linseed oil, virgin	3101
Kudzu vine root, Thomson	1644	Liothyronine sodium	3101
L		Lipophilic solid dosage forms, dissolution test for (2.9.42.)	401
Labetalol hydrochloride	3043	Liquid chromatography (2.2.29.)	49
Lacosamide	3045	Liquid extraction preparations	867
Lacosamide infusion	3046	Liquid (fluid) extracts	867
Lacosamide oral solution	3047	Liquid glucose	2759
Lacosamide tablets	3049	Liquid glucose, spray-dried	2760
Lactic acid	3050	Liquid lactulose	3058
Lactic acid, (S)-	3051	Liquid maltitol	3171
Lactitol monohydrate	3051	Liquid paraffin	3484
Lactobionic acid	3053	Liquid paraffin, light	3483
		Liquid preparations for cutaneous application	916
		Liquid preparations for cutaneous application, veterinary ..	941
		Liquid preparations for oral use	916
		Liquid sorbitol (crystallising)	3867

- Liquid sorbitol (non-crystallising) 3867
 Liquid sorbitol, partially dehydrated..... 3868
 Liquid sucrose 3908
 Liquids, clarity and degree of opalescence of (2.2.1.) 21
 Liquorice dry extract for flavouring purposes..... 1508
 Liquorice root 1509
 Lisinopril dihydrate..... **10.1**-4443
 Lithium carbonate 3104
 Lithium citrate 3105
 Live biotherapeutic products for human use 876
 Live biotherapeutic products, microbiological examination
 of (tests for enumeration of microbial contaminants)
 (2.6.36.) 250
 Live biotherapeutic products, microbiological examination of
 (tests for specified micro-organisms) (2.6.38.) 255
 L-Methionine ($[^{14}\text{C}]$ methyl) injection 1220
 Lobeline hydrochloride..... 3105
 Lomustine 3107
 Long pepper 1510
 Loosetrife 1511
 Loperamide hydrochloride..... 3108
 Loperamide oxide monohydrate..... 3109
 Lopinavir..... 3111
 Loratadine..... 3114
 Lorazepam..... 3116
 Losartan potassium 3117
 Loss on drying (2.2.32.) 57
 Loss on drying of extracts (2.8.17.) 311
 Lovage root 1512
 Lovastatin 3120
 Low-molecular-mass heparins..... 2818
 Low-substituted carmellose sodium..... 2094
 Low-substituted hydroxypropylcellulose 2904
 Lozenges and pastilles..... 922
 Lozenges, compressed..... 922
 Lubricant, silicone oil (3.1.8.)..... 436
 Lufenuron for veterinary use 3121
 Lutetium (^{177}Lu) solution for radiolabelling..... 1218
 Lycopodium lucidus herb..... 1514
 Lymeccycline..... 3123
 Lynestrenol 3125
 Lyophilisates, oral 939
 Lysine acetate 3126
 Lysine hydrochloride..... 3127
- M**
- Macrogol 15 hydroxystearate 3133
 Macrogol 20 glycerol monostearate..... 3134
 Macrogol 30 dipolyhydroxystearate 3135
 Macrogol 40 sorbitol heptaoleate..... 3135
 Macrogol 6 glycerol caprylocaprate..... 3133
 Macrogol cetostearyl ether..... 3136
 Macrogol isotridecyl ether..... 3137
 Macrogol lauryl ether..... 3137
 Macrogol oleate..... 3139
 Macrogol oleyl ether..... 3140
 Macrogol poly(vinyl alcohol) grafted copolymer 3140
 Macrogol stearate..... 3142
 Macrogol stearyl ether 3142
 Macrogolglycerol cocoates..... 3143
 Macrogolglycerol hydroxystearate..... 3144
 Macrogolglycerol ricinoleate..... 3144
 Macrogols 3145
 Macrogols, high-molecular-mass 3147
 Magaldrate..... 3148
 Magnesium (2.4.6.)..... 138
 Magnesium acetate tetrahydrate..... 3149
 Magnesium aluminium silicate..... 1799
 Magnesium aluminometasilicate..... 3150
 Magnesium and alkaline-earth metals (2.4.7.)..... 139
 Magnesium aspartate dihydrate..... 3151
 Magnesium carbonate, heavy..... 3153
 Magnesium carbonate, light..... 3153
 Magnesium chloride 4.5-hydrate..... 3154
 Magnesium chloride hexahydrate 3155
 Magnesium citrate 3155
 Magnesium citrate dodecahydrate..... 3156
 Magnesium citrate nonahydrate 3157
 Magnesium fluoratum for homoeopathic preparations..... **10.1**-
 4370
 Magnesium gluconate 3157
 Magnesium glycerophosphate..... 3158
 Magnesium hydroxide..... 3158
 Magnesium lactate dihydrate 3159
 Magnesium oxide, heavy 3159
 Magnesium oxide, light..... 3160
 Magnesium peroxide..... 3161
 Magnesium phosphoricum for homoeopathic
 preparations 1722
 Magnesium pidolate 3161
 Magnesium stearate..... 3163
 Magnesium sulfate heptahydrate 3165
 Magnesium trisilicate 3165
 Magnolia biondii flower bud..... 1515
 Magnolia officinalis bark 1517
 Magnolia officinalis flower 1519
 Maize oil, refined **10.1**-4447
 Maize starch 3167
 Malathion..... 3167
 Maleic acid..... 3168
 Malic acid 3169
 Mallow flower..... 1520
 Mallow leaf 1521
 Maltitol..... 3170
 Maltitol, liquid 3171
 Maltodextrin..... 3172
 Mandarin epicarp and mesocarp..... 1522
 Mandarin oil..... 1524
 Manganese gluconate 3173
 Manganese glycerophosphate, hydrated 3174
 Manganese sulfate monohydrate 3174
 Mannheimia vaccine (inactivated) for cattle..... 1125
 Mannheimia vaccine (inactivated) for sheep 1126
 Mannitol 3175
 Maprotiline hydrochloride 3177
 Marbofloxacin for veterinary use 3178
 Marek's disease vaccine (live)..... 1128
 Marshmallow leaf 1525
 Marshmallow root 1526
 Mass spectrometry (2.2.43.) 77
 Mass spectrometry, inductively coupled plasma- (2.2.58.).. 108
 Mass uniformity of delivered doses from multidose containers
 (2.9.27.) 372
 Mass uniformity of single-dose preparations (2.9.5.) 335
 Mastic..... 1526
 Mate leaf..... 1527
 Materials based on non-plasticised poly(vinyl chloride)
 for containers for non-injectable, aqueous solutions
 (3.1.10.) 437
 Materials based on non-plasticised poly(vinyl chloride) for
 containers for solid dosage forms for oral administration
 (3.1.11.) 439
 Materials based on plasticised poly(vinyl chloride) for
 containers for aqueous solutions for intravenous infusion
 (3.1.14.) 445
 Materials based on plasticised poly(vinyl chloride) for
 containers for human blood and blood components
 (3.3.2.) 465
 Materials based on plasticised poly(vinyl chloride) for
 tubing used in sets for the transfusion of blood and blood
 components (3.3.3.)..... 468
 Materials for containers for human blood and blood
 components (3.3.1.)..... 465
 Materials used for the manufacture of containers (3.1.)..... 423
 Matricaria flower 1529

Matricaria liquid extract	1530	Methacrylic acid - methyl methacrylate copolymer (1:2) ..	3218
Matricaria oil	1531	Methadone hydrochloride	3219
Meadowsweet	1533	Methane	3220
Measles immunoglobulin, human	2859	Methane intermix (2 per cent) in nitrogen	3221
Measles, mumps and rubella vaccine (live)	1005	Methanesulfonate (methyl, ethyl and isopropyl) in active substances (2.5.38.)	183
Measles, mumps, rubella and varicella vaccine (live)	1006	Methanesulfonic acid, methanesulfonyl chloride in (2.5.39.)	184
Measles vaccine (live)	1007	Methanesulfonic acid, methyl, ethyl and isopropyl methanesulfonate in (2.5.37.)	182
Measurement and detection of radioactivity (2.2.66.)	119	Methanesulfonyl chloride in methanesulfonic acid (2.5.39.)	184
Measurement of consistency by penetrometry (2.9.9.)	337	Methanol	3222
Mebendazole	3180	Methanol and 2-propanol, test for (2.9.11.)	342
Mebeverine hydrochloride	3181	Methenamine	3223
Meclozine dihydrochloride	3183	Methionine	3223
Medicated chewing gums	907	Methionine ([¹⁴ C]methyl) injection, L-	1220
Medicated chewing gums, dissolution test for (2.9.25.)	365	Methionine, DL-	3225
Medicated feeding stuffs for veterinary use, premixes for ..	927	Methods in pharmacognosy (2.8.)	305
Medicated foams	911	Methods of preparation of homoeopathic stocks and potentisation	1682
Medicated plasters	936	Methods of preparation of sterile products (5.1.1.)	619
Medicated tampons	940	Methotrexate	3225
Medicated vaginal tampons	941	Methyl, ethyl and isopropyl benzenesulfonate in active substances (2.5.41.)	186
Medicinal air	1768	Methyl, ethyl and isopropyl methanesulfonate in active substances (2.5.38.)	183
Medicinal air, synthetic	1770	Methyl, ethyl and isopropyl methanesulfonate in methanesulfonic acid (2.5.37.)	182
Medium-chain triglycerides	4096	Methyl, ethyl and isopropyl toluenesulfonate in active substances (2.5.40.)	185
Medronic acid for radiopharmaceutical preparations	1219	Methyl methacrylate - methacrylic acid copolymer (1:1) ..	3217
Medroxyprogesterone acetate	3184	Methyl methacrylate - methacrylic acid copolymer (1:2) ..	3218
Mefenamic acid	3186	Methyl nicotinate	3228
Mefloquine hydrochloride	3187	Methyl parahydroxybenzoate	3229
Megestrol acetate	3189	Methyl parahydroxybenzoate, sodium	3830
Meglumine	3191	Methyl salicylate	3230
Meldonium dihydrate	3192	Methylcellulose	3231
Melilot	1534	Methylidopa	3233
Melissa leaf	1536	Methylene blue	3250
Melissa leaf dry extract	1537	Methylene chloride	3235
Meloxicam	3193	Methylergometrine maleate	3236
Melphalan	3194	Methylhydroxyethylcellulose	3237
Melting point - capillary method (2.2.14.)	32	Methylpentoses in polysaccharide vaccines (2.5.21.)	173
Melting point - instantaneous method (2.2.16.)	33	Methylphenidate hydrochloride	3238
Melting point - open capillary method (2.2.15.)	33	Methylphenobarbital	3239
Menadione	3196	Methylprednisolone	3240
Meningococcal group A, C, W135 and Y conjugate vaccine	1009	Methylprednisolone acetate	3243
Meningococcal group C and haemophilus type b conjugate vaccine	979	Methylprednisolone hydrogen succinate	3245
Meningococcal group C conjugate vaccine	1010	Methylpyrrolidone, N-	3246
Meningococcal polysaccharide vaccine	1012	Methylrosanilinium chloride	3247
Menthol, racemic	3197	Methyltestosterone	3249
Mepivacaine hydrochloride	3198	Methylthioninium chloride hydrate	3250
Meprobamate	3200	Metixene hydrochloride	3251
Mepyramine maleate	3200	Metoclopramide	3252
Mercaptopurine monohydrate	10.1-4447	Metoclopramide hydrochloride monohydrate	3253
Mercuric chloride	3202	Metolazone	3255
Mercury porosimetry, porosity and pore-size distribution of solids by (2.9.32.)	377	Metoprolol succinate	3256
Meropenem trihydrate	3203	Metoprolol tartrate	3258
Mesalazine	3204	Metrifonate	3259
Mesna	3207	Metronidazole	3261
Mesterolone	3208	Metronidazole benzoate	3262
Mestranol	3209	Mexiletine hydrochloride	3263
Metabisulfite, potassium	3607	Mianserin hydrochloride	3264
Metabisulfite, sodium	3829	Miconazole	3266
Metacresol	3210	Miconazole nitrate	3267
Metal catalyst or metal reagent residues (5.20.)	815	Micro determination of water (2.5.32.)	178
Metal catalyst or metal reagent residues, determination of (2.4.20.)	144	Microbial enumeration tests (microbiological examination of non-sterile products) (2.6.12.)	201
Metamizole sodium monohydrate	3211	Microbiological assay of antibiotics (2.7.2.)	262
Metered-dose preparations for inhalation, non-pressurised	930	Microbiological examination of cell-based preparations (2.6.27.)	231
Metered-dose preparations for inhalation, pressurised	928		
Metformin hydrochloride	10.1-4448		
Methacrylate copolymer, basic butylated	1925		
Methacrylic acid - ethyl acrylate copolymer (1:1)	3214		
Methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 per cent	3216		
Methacrylic acid - methyl methacrylate copolymer (1:1) ..	3217		

Microbiological examination of herbal medicinal products for oral use and extracts used in their preparation (2.6.31.)...	239	Multidose containers, uniformity of mass of delivered doses (2.9.27.)	372
Microbiological examination of live biotherapeutic products: tests for enumeration of microbial contaminants (2.6.36.)	250	Mumps, measles and rubella vaccine (live)	1005
Microbiological examination of live biotherapeutic products: tests for specified micro-organisms (2.6.38.)	255	Mumps, measles, rubella and varicella vaccine (live)	1006
Microbiological examination of non-sterile products: microbial enumeration tests (2.6.12.)	201	Mumps vaccine (live)	1014
Microbiological examination of non-sterile products: test for specified micro-organisms (2.6.13.)	205	Mupirocin	3309
Microbiological quality, alternative methods for control of (5.1.6.)	628	Mupirocin calcium	3310
Microbiological quality of herbal medicinal products for oral use and extracts used in their preparation (5.1.8.)	638	Mycobacteria (2.6.2.)	194
Microbiological quality of non-sterile pharmaceutical preparations and substances for pharmaceutical use (5.1.4.)	627	Mycophenolate mofetil	3312
Microbiology, general texts on (5.1.)	619	Mycophenolate sodium	3314
Microcalorimetry and solution calorimetry, characterisation of crystalline solids by (2.2.61.)	115	Mycoplasma gallisepticum vaccine (inactivated)	1129
Microcrystalline cellulose	2146	Mycoplasmas (2.6.7.)	194
Microcrystalline cellulose and carmellose sodium	3269	myo-Inositol	2944
Microscopic examination of herbal drugs (2.8.23)	317	Myrrh	1546
Microscopy, optical (2.9.37.)	390	Myrrh tincture	1547
Microscopy, scanning electron (2.9.52.)	414	Myxomatosis vaccine (live) for rabbits	1131
Midazolam	3270		
Milbemycin oxime for veterinary use	3272	N	
Milk thistle dry extract, refined and standardised	1538	Nabumetone	3317
Milk thistle fruit	1539	N-Acetyltryptophan	1755
Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (5.2.8.)	661	N-Acetyltyrosine	1757
Minocycline hydrochloride dihydrate	3275	Nadolol	3318
Minoxidil	3277	Nadroparin calcium	3319
Mint oil, partly dementholised	1541	Naftidrofuryl hydrogen oxalate	3322
Mirtazapine	3278	Nalidixic acid	3323
Misoprostol	3279	Naloxone hydrochloride dihydrate	3325
Mites for allergen products	3281	Naltrexone hydrochloride	3327
Mitomycin	3282	Names of herbal drugs used in traditional Chinese medicine (5.22.)	10.1-4335
Mitoxantrone hydrochloride	3283	Nandrolone decanoate	10.1-4457
Modafinil	3285	Naphazoline hydrochloride	3330
Modified-release capsules	907	Naphazoline nitrate	3331
Modified-release granules	912	Naproxen	3333
Modified-release tablets	939	Naproxen sodium	3335
Mofetil mycophenolate	3312	Narrow-leaved coneflower root	1548
Molecular mass distribution in dextrans (2.2.39.)	68	Nasal drops and liquid nasal sprays	919
Molgramostim concentrated solution	3286	Nasal powders	920
Molsidomine	3288	Nasal preparations	918
Molybdate dihydrate, sodium	3831	Nasal preparations, semi-solid	920
Mometasone furoate	10.1-4450	Nasal sprays (liquid) and nasal drops	918
Mometasone furoate monohydrate	3293	Nasal sticks	920
Monoclonal antibodies for human use	878	Nasal washes	920
Monocyte-activation test (2.6.30.)	233	Nateglinide	3337
Monographs on herbal drug extracts (information chapter) (5.23.)	843	Near-infrared spectroscopy (2.2.40.)	70
Monophosphoryl lipid A, 3-O-desacyl-4'-	2355	Nebulisation, characterisation of preparations for (2.9.44.)	404
Montelukast sodium	3295	Nebulisation, liquid preparations for	928
Morantel hydrogen tartrate for veterinary use	3298	Neohesperidin-dihydrochalcone	3339
Morphine hydrochloride	3299	Neomycin sulfate	3340
Morphine sulfate	3300	Neonatal piglet colibacillosis vaccine (inactivated)	1132
Moss, Iceland	1480	Neonatal ruminant colibacillosis vaccine (inactivated)	1133
Mother tinctures for homoeopathic preparations	1681	Neostigmine bromide	3342
Motherwort	1542	Neostigmine metilsulfate	3343
Moulds for allergen products	3302	Neroli oil	1550
Moutan bark	1543	Netilmicin sulfate	3344
Mouthwashes	921	Nettle leaf	1551
Moxidectin for veterinary use	3303	Nettle root	1553
Moxifloxacin hydrochloride	3306	Neurovirulence test of live viral vaccines (2.6.18.)	218
Moxonidine	3308	Nevirapine	3346
Mucoadhesive preparations	922	Nevirapine hemihydrate	3347
Mullein flower	1545	Newcastle disease vaccine (inactivated)	1134
		Newcastle disease vaccine (live)	1136
		Niaouli oil, cineole type	1554
		Nicardipine hydrochloride	3348
		Nicergoline	3349
		Nickel in hydrogenated vegetable oils (2.4.31.)	163
		Nickel in polyols (2.4.15.)	143
		Niclosamide	3351
		Niclosamide monohydrate	3352
		Nicorandil	3353
		Nicotinamide	3354
		Nicotine	3355

Nicotine ditartrate dihydrate.....	3356	O	
Nicotine resinate.....	3357	O-Acetyl in polysaccharide vaccines (2.5.19.).....	173
Nicotinic acid.....	3359	Oak bark.....	1557
Nifedipine.....	3360	Octoxinol 10.....	3405
Niflumic acid.....	3362	Octreotide.....	3405
Nifuroxazide.....	3363	Octyl gallate.....	3407
Nikethamide.....	3364	Octyldodecanol.....	3407
Nilotinib hydrochloride monohydrate.....	3365	Odour (2.3.4.).....	133
Nilutamide.....	3367	Odour and taste of essential oils (2.8.8.).....	306
Nimesulide.....	3368	Ofloxacin.....	3408
Nimodipine.....	3369	Oils, essential.....	864
Nitrazepam.....	3371	Oils, fatty, identification by thin-layer chromatography (2.3.2.).....	132
Nitrendipine.....	3372	Oils, fatty, vegetable.....	901
Nitric acid.....	3373	Oils rich in omega-3 acids, composition of fatty acids in (2.4.29.).....	161
Nitric oxide.....	3373	Oils rich in omega-3 acids, total cholesterol in (2.4.32.).....	163
Nitrofurantoin.....	3374	Ointments.....	936
Nitrofurantoin.....	3375	Olanzapine.....	3410
Nitrogen.....	3376	Oleic acid.....	3411
Nitrogen determination by sulfuric acid digestion (2.5.9.)..	170	Oleoresins.....	868
Nitrogen determination, primary aromatic amino (2.5.8.)..	169	Oleoyl macroglycerides.....	3411
Nitrogen, low-oxygen.....	3377	Oleyl alcohol.....	3412
Nitrogen monoxide and nitrogen dioxide in gases (2.5.26.).....	176	Olive leaf.....	1557
Nitroprusside, sodium.....	3832	Olive leaf dry extract.....	1559
Nitrous oxide.....	3377	Olive oil, refined.....	3413
Nitrous oxide in gases (2.5.35.).....	182	Olive oil, virgin.....	3414
Nizatidine.....	3379	Olmesartan medoxomil.....	3415
N-Methylpyrrolidone.....	3246	Olsalazine sodium.....	3417
NMR spectrometry (2.2.33.).....	58	Omega-3 acids, composition of fatty acids in oils rich in (2.4.29.).....	161
NMR spectrometry, peptide identification by (2.2.64.).....	118	Omega-3 acids, fish oil rich in.....	2639
N,N-Dimethylaniline (2.4.26.).....	158	Omega-3 acids, total cholesterol in oils rich in (2.4.32.).....	163
Nomegestrol acetate.....	10.1 -4459	Omega-3-acid ethyl esters 60.....	3419
Nonoxinol 9.....	3381	Omega-3-acid ethyl esters 90.....	3421
Non-sterile pharmaceutical preparations and substances for pharmaceutical use, microbiological quality of (5.1.4.).....	627	Omega-3-acid triglycerides.....	3423
Non-sterile products, microbiological examination of (microbial enumeration tests) (2.6.12.).....	201	Omeprazole.....	3425
Non-sterile products, microbiological examination of (test for specified micro-organisms) (2.6.13.).....	205	Omeprazole magnesium.....	3427
Noradrenaline hydrochloride.....	3382	Omeprazole sodium.....	3428
Noradrenaline tartrate.....	3384	Ondansetron hydrochloride dihydrate.....	3430
Norepinephrine hydrochloride.....	3382	Opalescence of liquids, clarity and degree of (2.2.1.).....	21
Norepinephrine tartrate.....	3384	Ophthalmic inserts.....	910
Norethisterone.....	3385	Opium dry extract, standardised.....	1560
Norethisterone acetate.....	3387	Opium, prepared.....	1561
Norfloxacin.....	3388	Opium, raw.....	1562
Norflurane.....	3390	Opium tincture, standardised.....	1564
Norgestimate.....	3396	Optical microscopy (2.9.37.).....	390
Norgestrel.....	3397	Optical rotation (2.2.7.).....	26
Normal immunoglobulin for intramuscular administration, human.....	2860	Oral drops.....	918
Normal immunoglobulin for intravenous administration, human.....	2862	Oral lyophilisates.....	939
Normal immunoglobulin for subcutaneous administration, human.....	2864	Oral powders.....	926
Nortriptyline hydrochloride.....	3397	Oral solutions, emulsions and suspensions.....	917
Noscapine.....	3399	Oral use, liquid preparations for.....	916
Noscapine hydrochloride hydrate.....	3400	Oral use, veterinary semi-solid preparations for.....	942
Notoginseng root.....	1555	Orbifloxacin for veterinary use.....	3431
Nuclear magnetic resonance spectrometry (2.2.33.).....	58	Orciprenaline sulfate.....	3433
Nuclear magnetic resonance spectrometry, peptide identification by (2.2.64.).....	118	Oregano.....	1565
Nucleated cell count and viability (2.7.29.).....	297	Organ preservation, solutions for.....	3852
Nucleic acid amplification techniques (2.6.21.).....	219	Oriental cashew for homoeopathic preparations.....	1702
Nucleic acids in polysaccharide vaccines (2.5.17.).....	172	Orientvine stem.....	1567
Numeration of CD34/CD45+ cells in haematopoietic products (2.7.23.).....	292	Orodispersible films.....	922
Nutmeg oil.....	1556	Orodispersible tablets.....	939
Nux-vomica for homoeopathic preparations.....	1723	Oromucosal capsules.....	922
Nystatin.....	3401	Oromucosal drops, oromucosal sprays and sublingual sprays.....	921
		Oromucosal preparations.....	920
		Oromucosal preparations, semi-solid.....	921
		Oromucosal solutions and oromucosal suspensions.....	921
		Oromucosal sprays, oromucosal drops and sublingual sprays.....	920
		Oromucosal suspensions and oromucosal solutions.....	920
		Orphenadrine citrate.....	3434

Orphenadrine hydrochloride	3436	Parenteral preparations	923
Oseltamivir phosphate	3437	Parenteral preparations, test for extractable volume of (2.9.17.)	347
Osmolality (2.2.35.)	63	Parnaparin sodium	3487
Ouabain	3439	Paroxetine hydrochloride	3488
Oxacillin sodium monohydrate	3440	Paroxetine hydrochloride hemihydrate	3490
Oxaliplatin	3442	Particle size analysis by laser light diffraction (2.9.31.)	373
Oxazepam	3445	Particles, fine, aerodynamic assessment of in preparations for inhalation (2.9.18.)	347
Oxcarbazepine	3446	Particle-size distribution estimation by analytical sieving (2.9.38.)	392
Oxeladin hydrogen citrate	3448	Particulate contamination: sub-visible particles (2.9.19.)	360
Oxfendazole for veterinary use	10.1 -4463	Particulate contamination: visible particles (2.9.20.)	362
Oxidising substances (2.5.30.)	177	Parvovirus vaccine (inactivated), canine	1085
Oxitropium bromide	3450	Parvovirus vaccine (inactivated), porcine	1143
Oxolinic acid	3451	Parvovirus vaccine (live), canine	1086
Oxybuprocaine hydrochloride	3453	Passion flower	1570
Oxybutynin hydrochloride	3454	Passion flower dry extract	1571
Oxycodone hydrochloride	3455	Pastes	936
Oxygen	3456	Pasteurella vaccine (inactivated) for sheep	1138
Oxygen (¹⁵ O)	1222	Pastilles and lozenges	922
Oxygen (93 per cent)	3457	Patches, cutaneous	935
Oxygen in gases (2.5.27.)	176	Patches, transdermal	925
Oxygen-flask method (2.5.10.)	170	Patches, transdermal, dissolution test for (2.9.4.)	333
Oxymetazoline hydrochloride	10.1 -4464	Pea starch	3492
Oxytetracycline dihydrate	3460	Pefloxacin mesilate dihydrate	3493
Oxytetracycline hydrochloride	3462	Pelargonium root	1571
Oxytocin	3464	Pemetrexed disodium heptahydrate	3494
Oxytocin concentrated solution	3465	Penbutolol sulfate	3497
P		Penetrometry, measurement of consistency by (2.9.9.)	337
Paclitaxel	3469	Penicillamine	3498
Pale coneflower root	1568	Penicillin G (benzathine) tetrahydrate	1951
Palmitic acid	3473	Penicillin G potassium	1953
Pamidronate disodium pentahydrate	3474	Penicillin G (procaine) monohydrate	1955
Pancreas powder	3474	Penicillin G sodium	1957
Pancreatic necrosis vaccine (inactivated, oil-adjuvanted, injectable) for salmonids, infectious	1124	Penicillin V	3530
Pancuronium bromide	3477	Penicillin V (benzathine) tetrahydrate	3531
Panleucopenia vaccine (inactivated), feline	1109	Penicillin V potassium	3533
Panleucopenia vaccine (live), feline	1110	Pentaerythrityl tetranitrate, diluted	3499
Pansy, wild (flowering aerial parts)	1668	Pentamidine diisetonate	3501
Pantoprazole sodium sesquihydrate	3478	Pentazocine	3502
Pantothenate, calcium	2063	Pentazocine hydrochloride	3502
Papaverine hydrochloride	3480	Pentazocine lactate	3503
Paper chromatography (2.2.26.)	46	Pentetate sodium calcium for radiopharmaceutical preparations	1223
Papillomavirus vaccine (rDNA), human	989	Pentobarbital	3504
Paraben, butyl	2025	Pentobarbital sodium	3505
Paraben, ethyl	2583	Pentoxifylline	10.1 -4469
Paraben, methyl	3229	Pentoxyverine hydrogen citrate	3509
Paraben, propyl	3660	Peony root, red	1572
Paraben, sodium ethyl	3816	Peony root, white	1573
Paraben, sodium methyl	3830	Pepper	1575
Paraben, sodium propyl	3838	Pepper, long	1510
Paracetamol	3481	Peppermint leaf	1577
Paraffin, hard	3483	Peppermint leaf dry extract	1578
Paraffin, light liquid	3483	Peppermint oil	1579
Paraffin, liquid	3484	Pepsin powder	3509
Paraffin, white soft	3485	Peptide identification by nuclear magnetic resonance spectrometry (2.2.64.)	118
Paraffin, yellow soft	3486	Peptide mapping (2.2.55.)	97
Parahydroxybenzoate, butyl	2025	Peptides, synthetic, acetic acid in (2.5.34.)	181
Parahydroxybenzoate, ethyl	2583	Perborate, hydrated sodium	3833
Parahydroxybenzoate, methyl	3229	Pergolide mesilate	3511
Parahydroxybenzoate, propyl	3660	Perindopril <i>tert</i> -butylamine	10.1 -4470
Parahydroxybenzoate, sodium ethyl	3816	Peritoneal dialysis, solutions for	3515
Parahydroxybenzoate, sodium methyl	3830	Permethrin (25:75)	3517
Parahydroxybenzoate, sodium propyl	3838	Peroxide value (2.5.5.)	168
Parainfluenza virus vaccine (live), bovine	1073	Perphenazine	3519
Parainfluenza virus vaccine (live), canine	1084	Pertussis (acellular, component), diphtheria and tetanus vaccine (adsorbed)	955
Paraldehyde	3486	Pertussis (acellular, component), diphtheria and tetanus vaccine (adsorbed, reduced antigen(s) content)	956
Paramyxovirus 1 (Newcastle disease) vaccine (inactivated), avian	1134		
Paramyxovirus 1 (Newcastle disease) vaccine (live), avian	1136		
Paramyxovirus 3 vaccine (inactivated) for turkeys, avian ..	1068		

Pertussis (acellular, component), diphtheria, tetanus and haemophilus type b conjugate vaccine (adsorbed)	961	Phosphoric acid, concentrated.....	3553
Pertussis (acellular, component), diphtheria, tetanus and hepatitis B (rDNA) vaccine (adsorbed)	963	Phosphoric acid, dilute	3553
Pertussis (acellular, component), diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed).....	964	Phosphorus in polysaccharide vaccines (2.5.18.)	172
Pertussis (acellular, component), diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)	966	Phthalylsulfathiazole	3553
Pertussis (acellular, component), diphtheria, tetanus, hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	968	Physical and physico-chemical methods (2.2.)	21
Pertussis (acellular, component), diphtheria, tetanus, poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	970	Physostigmine salicylate	3554
Pertussis toxin (residual) (2.6.33.)	241	Phytomenadione, racemic	3555
Pertussis vaccine (acellular), assay of (2.7.16.)	286	Phytonadione, racemic.....	3555
Pertussis vaccine (acellular, component, adsorbed).....	1015	Phytosterol.....	3557
Pertussis vaccine (acellular, co-purified, adsorbed)	1016	Picosulfate, sodium	3835
Pertussis vaccine (whole cell, adsorbed).....	1018	Picotamide monohydrate.....	3558
Pertussis vaccine (whole cell), assay of (2.7.7.)	274	Piglet colibacillosis vaccine (inactivated), neonatal	1132
Pertussis (whole cell), diphtheria and tetanus vaccine (adsorbed)	958	Pillules for homoeopathic preparations.....	1696
Pertussis (whole cell), diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed)	973	Pillules, homoeopathic, coated	1697
Pertussis (whole cell), diphtheria, tetanus, poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	974	Pillules, homoeopathic, impregnated.....	1697
Peru balsam	1580	Pilocarpine hydrochloride	3559
Pessaries	940	Pilocarpine nitrate	3560
Pessaries and suppositories, disintegration of (2.9.2.)	325	Pimobendan for veterinary use.....	3561
Pesticide residues (2.8.13.).....	308	Pimozide	3562
Pethidine hydrochloride	3520	Pindolol.....	3563
Petroleum rectificatum for homoeopathic preparations ...	1725	Pine (dwarf) oil.....	1419
pH of solutions, approximate (2.2.4.).....	25	Pine sylvestris oil	1581
pH, potentiometric determination of (2.2.3.)	24	Pioglitazone hydrochloride	3565
Pharmaceutical preparations.....	880	Pipemidic acid trihydrate	3566
Pharmaceutical technical procedures (2.9.)	323	Piperacillin.....	3567
Pharmacognosy, methods in (2.8.).....	305	Piperacillin sodium	3568
Pharmacopoeial harmonisation (5.8.)	755	Piperazine adipate	3570
Phenazone.....	3522	Piperazine citrate	3571
Pheniramine maleate.....	3523	Piperazine hydrate	3572
Phenobarbital.....	3524	Piracetam	3573
Phenobarbital sodium.....	3525	Pirenzepine dihydrochloride monohydrate	3574
Phenol	3527	Piretanide.....	3575
Phenol in immunosera and vaccines (2.5.15.)	172	Pirfenidone.....	3576
Phenolphthalein.....	3527	Piroxicam.....	3577
Phenolsulfonphthalein	3528	Pivampicillin	3579
Phenothiazines, identification by thin-layer chromatography (2.3.3.)	133	Pivmecillinam hydrochloride.....	3581
Phenoxyethanol	3529	Plasma for fractionation, human	2865
Phenoxyethylpenicillin	3530	Plasma (pooled and treated for virus inactivation), human	2867
Phenoxyethylpenicillin (benzathine) tetrahydrate.....	3531	Plasmid vectors for human use, bacterial cells used for the manufacture of.....	781
Phenoxyethylpenicillin potassium	3533	Plasmin inhibitor, assay of human (2.7.25.).....	295
Phentolamine mesilate	3535	Plasters, medicated	935
Phenylalanine.....	3536	Plastic additives (3.1.13.)	441
Phenylbutazone.....	3538	Plastic containers and closures for pharmaceutical use (3.2.2.)	459
Phenylbutyrate, sodium	3833	Plastic containers for aqueous solutions for infusion (3.2.2.1.)	460
Phenylephrine	3539	Plastic containers for human blood and blood components, sterile (3.3.4.).....	471
Phenylephrine hydrochloride.....	3541	Plastic syringes, single-use, sterile (3.3.8.).....	477
Phenylmercuric acetate.....	3542	Platycodon root.....	1582
Phenylmercuric borate	3542	Pneumococcal polysaccharide conjugate vaccine (adsorbed)	1019
Phenylmercuric nitrate	3543	Pneumococcal polysaccharide vaccine	1021
Phenylpropanolamine hydrochloride	3543	Pneumonia vaccine (inactivated), porcine enzootic	1141
Phenytol	3545	Podophylotoxin.....	3582
Phenytol sodium.....	3546	Poliomyelitis (inactivated), diphtheria and tetanus vaccine (adsorbed, reduced antigen(s) content).....	959
Phloroglucinol.....	3548	Poliomyelitis (inactivated), diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed)	964
Phloroglucinol dihydrate	3549	Poliomyelitis (inactivated), diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content)	966
Pholcodine monohydrate	3551	Poliomyelitis (inactivated), diphtheria, tetanus and pertussis (whole cell) vaccine (adsorbed)	973
Phosphates (2.4.11.).....	142	Poliomyelitis (inactivated), diphtheria, tetanus, pertussis (acellular, component) and haemophilus type b conjugate vaccine (adsorbed)	970
Phospholipids for injection, egg	2494	Poliomyelitis (inactivated), diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA) and haemophilus type b conjugate vaccine (adsorbed)	968
Phospholipids for injection, soya.....	3870		

- Poliomyelitis (inactivated), diphtheria, tetanus, pertussis (whole cell) and haemophilus type b conjugate vaccine (adsorbed) 974
- Poliomyelitis vaccine (inactivated) 1023
- Poliomyelitis vaccine (inactivated), *in vivo* assay of (2.7.20.) 289
- Poliomyelitis vaccine (oral) 1026
- Pollens for allergen products 3583
- Poloxamers 3584
- Polyacrylate dispersion 30 per cent 3586
- Polyamide suture, sterile, in distributor for veterinary use 1282
- Poly(ethylene - vinyl acetate) for containers and tubing for total parenteral nutrition preparations (3.1.7.) 434
- Polyethylene oxides, high-molecular-mass 3147
- Polyethylene terephthalate for containers for preparations not for parenteral use (3.1.15.) 448
- Poly(ethylene terephthalate) suture, sterile, in distributor for veterinary use 1283
- Polyethylene with additives for containers for parenteral preparations and for ophthalmic preparations (3.1.5.) 427
- Polyethylene without additives for containers for parenteral preparations and for ophthalmic preparations (3.1.4.) 426
- Polyethyleneglycols 3145
- Polyethyleneglycols, high-molecular-mass 3147
- Polygonum cuspidatum rhizome and root 1583
- Polygonum orientale fruit 1585
- Polymorphism (5.9.) 759
- Polymyxin B sulfate 3587
- Polyolefins (3.1.3.) 423
- Polyoxyl castor oil 3144
- Polyoxyl hydrogenated castor oil 3144
- Polyoxypropylene stearyl ether 3588
- Polypropylene for containers and closures for parenteral preparations and ophthalmic preparations (3.1.6.) 431
- Polysaccharide vaccines for human use, conjugated, carrier proteins for the production of (5.2.11.) 674
- Polysaccharide vaccines, hexosamines in (2.5.20.) 173
- Polysaccharide vaccines, methylpentoses in (2.5.21.) 173
- Polysaccharide vaccines, nucleic acids in (2.5.17.) 172
- Polysaccharide vaccines, O-acetyl in (2.5.19.) 173
- Polysaccharide vaccines, phosphorus in (2.5.18.) 172
- Polysaccharide vaccines, protein in (2.5.16.) 172
- Polysaccharide vaccines, ribose in (2.5.31.) 177
- Polysaccharide vaccines, sialic acid in (2.5.23.) 174
- Polysaccharide vaccines, uronic acids in (2.5.22.) 174
- Polysorbate 20 3589
- Polysorbate 40 3590
- Polysorbate 60 3591
- Polysorbate 80 3591
- Polystyrene sulfonate, sodium 3836
- Poly(vinyl acetate) 3593
- Poly(vinyl acetate) dispersion 30 per cent 3594
- Poly(vinyl alcohol) 3595
- Poly(vinyl alcohol) macrogol grafted copolymer 3140
- Poly(vinyl chloride) (non-plasticised) for containers for solid dosage forms for oral administration, materials based on (3.1.11.) 439
- Poly(vinyl chloride), non-plasticised, materials based on for containers for non-injectable aqueous solutions (3.1.10.) 437
- Poly(vinyl chloride), plasticised, empty sterile containers of, for human blood and blood components (3.3.5.) 473
- Poly(vinyl chloride), plasticised, materials based on, for containers for aqueous solutions for intravenous infusion (3.1.14.) 445
- Poly(vinyl chloride), plasticised, materials based on, for containers for human blood and blood components (3.3.2.) 465
- Poly(vinyl chloride), plasticised, materials based on, for tubing used in sets for the transfusion of blood and blood components (3.3.3.) 468
- Poly(vinyl chloride), plasticised, sterile containers of, for human blood containing anticoagulant solution (3.3.6.) 474
- Poppy petals, red 1595
- Porcine actinobacillosis vaccine (inactivated) 1139
- Porcine enzootic pneumonia vaccine (inactivated) 1141
- Porcine influenza vaccine (inactivated) 1142
- Porcine insulin 2957
- Porcine parvovirus vaccine (inactivated) 1143
- Porcine progressive atrophic rhinitis vaccine (inactivated) 1144
- Pore-size distribution of solids by mercury porosimetry, porosity and (2.9.32.) 377
- Poria 1587
- Porosimetry, mercury, porosity and pore-size distribution of solids by (2.9.32.) 377
- Porosity and pore-size distribution of solids by mercury porosimetry (2.9.32.) 377
- Porosity of sintered-glass filters (2.1.2.) 15
- Porous solids including powders, wettability of (2.9.45.) 406
- Potassium (2.4.12.) 142
- Potassium acetate 3596
- Potassium bromide 3597
- Potassium carbonate 3598
- Potassium chloride 3598
- Potassium citrate 3599
- Potassium clavulanate 3599
- Potassium clavulanate, diluted 3602
- Potassium dichromate for homoeopathic preparations 1721
- Potassium dihydrogen phosphate 3603
- Potassium disulfite 3607
- Potassium hydrogen aspartate hemihydrate 3604
- Potassium hydrogen carbonate 3605
- Potassium hydrogen tartrate 3605
- Potassium hydroxide 3606
- Potassium iodide 3606
- Potassium metabisulfite 3607
- Potassium nitrate 3607
- Potassium perchlorate 3608
- Potassium permanganate 3609
- Potassium sodium tartrate tetrahydrate 3609
- Potassium sorbate 3610
- Potassium sulfate 3610
- Potato starch 3611
- Potentiometric determination of ionic concentration using ion-selective electrodes (2.2.36.) 64
- Potentiometric determination of pH (2.2.3.) 24
- Potentiometric titration (2.2.20.) 35
- Potentiation, methods of preparation of homoeopathic stocks and 1682
- Poultices 936
- Pour-on preparations 942
- Povidone 3612
- Povidone, iodinated 3615
- Powder fineness (2.9.35.) 387
- Powder flow (2.9.36.) 387
- Powder flow properties by shear cell methods (2.9.49.) 411
- Powdered cellulose 2150
- Powders and granules for oral solutions and suspensions 917
- Powders and granules for syrups 918
- Powders and tablets for rectal solutions and suspensions 934
- Powders, bulk density and tapped density of (2.9.34.) 384
- Powders, ear 909
- Powders, effervescent 927
- Powders for cutaneous application 925
- Powders for eye drops and powders for eye lotions 910
- Powders for injections or infusions 924
- Powders for oral drops 918
- Powders, inhalation 931
- Powders, nasal 920
- Powders, oral 926
- Powders, wettability of porous solids including (2.9.45.) 406
- Pramipexole dihydrochloride monohydrate 3615
- Prasugrel hydrochloride 3617
- Pravastatin sodium 3618
- Prazepam 3620

Praziquantel.....	3621	Protein in polysaccharide vaccines (2.5.16.)	172
Prazosin hydrochloride.....	10.1-4473	Protein S, human, assay of (2.7.31.)	300
Precursors for radiopharmaceutical preparations, chemical.....	863	Protein, total (2.5.33.)	178
Prednicarbate.....	10.1-4475	Prothrombin complex, human.....	2870
Prednisolone.....	3625	Protirelin.....	3669
Prednisolone acetate.....	3627	Proxyphylline	3670
Prednisolone pivalate	3629	Pseudoephedrine hydrochloride.....	3671
Prednisolone sodium phosphate.....	3630	Psyllium seed.....	1588
Prednisone.....	3631	Pullulan.....	3672
Pregabalin.....	3633	Pulsed electrochemical detection and direct amperometric detection (2.2.63.)	117
Pregelatinised hydroxypropyl starch.....	3890	Purified water	4207
Pregelatinised starch.....	3891	Purple coneflower herb	1589
Prekallikrein activator (2.6.15.).....	213	Purple coneflower root	1591
Premixes for medicated feeding stuffs for veterinary use ...	927	Pycnometric density of solids, gas (2.9.23.)	364
Preparations for inhalation	927	Pygeum africanum bark	1593
Preparations for inhalation: aerodynamic assessment of fine particles (2.9.18.)	347	Pyrantel embonate.....	10.1-4478
Preparations for irrigation.....	932	Pyrazinamide	3674
Preparations for nebulisation: characterisation (2.9.44.)	404	Pyridostigmine bromide.....	3675
Preservative and anticoagulant solutions for human blood	1856	Pyridoxine hydrochloride.....	3676
Pressurised pharmaceutical preparations.....	933	Pyrimethamine	10.1-4479
Prilocaine.....	3635	Pyrogens (2.6.8.)	199
Prilocaine hydrochloride.....	3636	Pyrophosphate (sodium) decahydrate for radiopharmaceutical preparations	1241
Primaquine diphosphate.....	10.1-4476	Pyrrolidone.....	3678
Primary aromatic amino-nitrogen, determination of (2.5.8.)	169	Q	
Primary standards for volumetric solutions (4.2.1.)	609	Quality control of vaccines, substitution of <i>in vivo</i> method(s) by <i>in vitro</i> method(s) for the (5.2.14.)	679
Primary standards for volumetric solutions (4.2.1.) ..	10.1-4331	Quality of non-sterile pharmaceutical preparations and substances for pharmaceutical use, microbiological (5.1.4.)	627
Primidone.....	3639	Quantification and characterisation of residual host-cell DNA (2.6.35.)	248
Primula root	1588	Quantified hawthorn leaf and flower liquid extract.....	1473
Probenecid.....	3640	Quetiapine fumarate	3683
Procainamide hydrochloride.....	3641	Quillaia bark.....	1593
Procaine benzylpenicillin monohydrate	1955	Quinapril hydrochloride.....	3685
Procaine hydrochloride.....	3642	Quinidine sulfate	3687
Procaine penicillin G monohydrate	1955	Quinine hydrochloride	3689
Process analytical technology (5.25.)	10.1-4339	Quinine sulfate.....	3690
Prochlorperazine maleate	3642	R	
Products of fermentation.....	882	Rabbit haemorrhagic disease vaccine (inactivated)	1147
Products of recombinant DNA technology.....	888	Rabepazole sodium.....	3695
Products with risk of transmitting agents of animal spongiform encephalopathies	884	Rabepazole sodium hydrate.....	10.1-4483
Progenitor cells, human haematopoietic, colony-forming cell assay for (2.7.28.)	296	Rabies immunoglobulin, human	2871
Progesterone.....	3644	Rabies vaccine for human use prepared in cell cultures....	1030
Progressive atrophic rhinitis vaccine (inactivated), porcine	1144	Rabies vaccine (inactivated) for veterinary use	1148
Proguanil hydrochloride.....	3646	Rabies vaccine (live, oral) for foxes and raccoon dogs	1150
Proline.....	3647	Racacadoltril.....	3698
Promazine hydrochloride	3649	Racemethol.....	3197
Promethazine hydrochloride.....	3649	Racemic camphor.....	2069
Propacetamol hydrochloride.....	3651	Racemic ephedrine hydrochloride	2513
Propafenone hydrochloride.....	3652	Racemic menthol	3197
Propanol.....	3654	Racephedrine hydrochloride.....	2513
Propanol and methanol, 2-, test for (2.9.11.)	342	Raclopride ([¹¹ C]methoxy) injection.....	1224
Propantheline bromide	3655	Radioactivity, detection and measurement of (2.2.66.)	119
Propofol	3656	Radiolabelling, fluoride (¹⁸ F) solution for	1194
Propranolol hydrochloride	3658	Radiolabelling, gallium (⁶⁸ Ga) chloride solution for	1206
Propyl gallate.....	3659	Radiolabelling, lutetium (¹⁷⁷ Lu) solution for.....	1218
Propyl parahydroxybenzoate.....	3660	Radiolabelling, sodium iodide (¹²³ I) solution for.....	1228
Propyl parahydroxybenzoate, sodium	3838	Radiolabelling, sodium iodide (¹³¹ I) solution for.....	1232
Propylene glycol.....	3661	Radiolabelling, yttrium (⁹⁰ Y) chloride solution for	1265
Propylene glycol dicaprylocaprate.....	3662	Radionuclides, table of physical characteristics (5.7.)	745
Propylene glycol dilaurate	3662	Radiopharmaceutical preparations	884
Propylene glycol monolaurate.....	3663	Radiopharmaceutical preparations, chemical precursors for	863
Propylene glycol monopalmitostearate.....	3664	Radiopharmaceutical preparations, copper tetramibi tetrafluoroborate for.....	1187
Propylene glycol monostearate	3664	Radiopharmaceutical preparations, iobenguane sulfate for	1216
Propylthiouracil	3665		
Propyphenazone	3666		
Protamine sulfate.....	3667		
Protein assays, host-cell (2.6.34.)	244		
Protein C, human, assay of (2.7.30.).....	299		

- Radiopharmaceutical preparations, medronic acid for 1219
- Radiopharmaceutical preparations, pentetate sodium calcium for 1223
- Radiopharmaceutical preparations, sodium iodohippurate dihydrate for 1234
- Radiopharmaceutical preparations, sodium pyrophosphate decahydrate for 1241
- Radiopharmaceutical preparations, tetra-*O*-acetyl-mannose triflate for 1261
- Radiopharmaceuticals, extemporaneous preparation of (5.19.) 807
- Raloxifene hydrochloride 3699
- Raltegravir chewable tablets 3702
- Raltegravir potassium 3701
- Raltegravir tablets 3704
- Raman spectroscopy (2.2.48.) 92
- Ramipril 3705
- Ramon assay, flocculation value (Lf) of diphtheria and tetanus toxins and toxoids (2.7.27.) 295
- Ranitidine hydrochloride 3708
- Rapeseed oil, refined 3709
- Raspberry leaf **10.1**-4359
- Raw materials of biological origin for the production of cell-based and gene therapy medicinal products (5.2.12.) .. 675
- Reagents (4.) 481
- Reagents (4.1.1.) 481
- Reagents (4.1.1.) **10.1**-4331
- Reagents, standard solutions, buffer solutions (4.1.) 481
- Recombinant DNA technology, products of 888
- Recombinant vectors 779
- Recommendations on dissolution testing (5.17.1.) 801
- Recommendations on methods for dosage forms testing (5.17.) 801
- Rectal capsules 934
- Rectal foams 935
- Rectal preparations 933
- Rectal preparations, semi-solid 935
- Rectal solutions and suspensions, powders and tablets for .. 933
- Rectal solutions, emulsions and suspensions 934
- Rectal tampons 935
- Red peony root 1572
- Red poppy petals 1595
- Reference standards (5.12.) 773
- Refractive index (2.2.6.) 26
- Regorafenib monohydrate 3710
- Rehmannia root **10.1**-4360
- Relative density (2.2.5.) 25
- Remifentanyl hydrochloride 3711
- Repaglinide 3714
- Reserpine 3715
- Residual pertussis toxin (2.6.33.) 241
- Residual solvents (5.4.) 717
- Residual solvents, identification and control of (2.4.24.) **10.1**-4323
- Residue on evaporation of essential oils (2.8.9.) 306
- Residues, pesticide (2.8.13.) 308
- Resistance to crushing of tablets (2.9.8.) 337
- Resorcinol 3716
- Respiratory syncytial virus vaccine (live), bovine 1074
- Restharrow root 1596
- Rhatany root 1597
- Rhatany tincture 1598
- Rhinotracheitis vaccine (inactivated), bovine, infectious .. 1120
- Rhinotracheitis vaccine (inactivated), viral, feline 1113
- Rhinotracheitis vaccine (live), bovine, infectious 1121
- Rhinotracheitis vaccine (live), infectious, turkey 1162
- Rhinotracheitis vaccine (live), viral, feline 1114
- Rhubarb 1598
- Ribavirin 3717
- Riboflavin 3718
- Riboflavin sodium phosphate 3720
- Ribose in polysaccharide vaccines (2.5.31.) 177
- Ribwort plantain 1599
- Rice starch 3721
- Rifabutin 3722
- Rifampicin 3724
- Rifamycin sodium 3725
- Rifaximin 3726
- Rilmenidine dihydrogen phosphate 3728
- Risedronate sodium 2.5-hydrate 3729
- Risperidone 3730
- Ritonavir 3732
- Rivastigmine 3736
- Rivastigmine hydrogen tartrate 3737
- Rizatriptan benzoate 3739
- Rocuronium bromide 3740
- Rolling ball (automatic) and falling ball viscometer methods (2.2.49.) 94
- Roman chamomile flower 1384
- Ropinirole hydrochloride 3742
- Ropivacaine hydrochloride monohydrate 3744
- Roselle 1600
- Rosemary leaf 1601
- Rosemary oil 1603
- Rosuvastatin calcium **10.1**-4484
- Rosuvastatin tablets **10.1**-4487
- Rotating viscometer method - viscosity (2.2.10.) 28
- Rotation, optical (2.2.7.) 26
- Rotavirus diarrhoea vaccine (inactivated), calf 1078
- Rotavirus vaccine (live, oral) 1033
- Rotigotine 3748
- Round amomum fruit 1604
- Roxithromycin 3750
- RRR- α -Tocopherol 4058
- RRR- α -Tocopheryl acetate 4060
- RRR- α -Tocopheryl hydrogen succinate 4064
- Rubber closures for containers for aqueous parenteral preparations, for powders and for freeze-dried powders (3.2.9.) 460
- Rubella immunoglobulin, human 2872
- Rubella, measles and mumps vaccine (live) 1005
- Rubella, measles, mumps and varicella vaccine (live) 1006
- Rubella vaccine (live) 1035
- Ruminant colibacillosis vaccine (inactivated), neonatal ... 1133
- Rupatadine fumarate 3752
- Rutoside trihydrate 3753
- S**
- Saccharin 3759
- Saccharin sodium 3760
- Safety, viral (5.1.7.) 637
- Safflower flower 1606
- Safflower oil, refined 3761
- Saffron for homoeopathic preparations 1710
- Sage leaf (*Salvia officinalis*) 1607
- Sage leaf, three-lobed 1608
- Sage oil, Spanish 1629
- Sage tincture 1609
- Salbutamol 3761
- Salbutamol sulfate 3764
- Salicylic acid 3766
- Salmeterol xinafoate 3767
- Salmon oil, farmed 3769
- Salmonella Enteritidis vaccine (inactivated) for chickens .. 1151
- Salmonella Enteritidis vaccine (live, oral) for chickens 1152
- Salmonella Typhimurium vaccine (inactivated) for chickens 1155
- Salmonella Typhimurium vaccine (live, oral) for chickens 1156
- Salmonids, infectious pancreatic necrosis vaccine (inactivated oil-adjuvanted, injectable) for 1124
- Salvia miltiorrhiza root and rhizome 1610
- Sanguisorba root 1611
- Saponification value (2.5.6.) 169
- Saquinavir mesilate 3771

Saw palmetto extract	1612	Sodium alginate	3799
Saw palmetto fruit	1615	Sodium aluminium silicate	1803
Scanning electron microscopy (2.9.52.)	414	Sodium amidotrizoate	3800
Schisandra fruit	1617	Sodium aminosalicylate dihydrate	3801
Scopolamine	2909	Sodium ascorbate	3802
Scopolamine butylbromide	2910	Sodium aurothiomalate	3804
Scopolamine hydrobromide	2911	Sodium benzoate	3805
Selamectin for veterinary use	3773	Sodium bromide	3806
Selegiline hydrochloride	3775	Sodium calcium edetate	3807
Selenium disulfide	3776	Sodium calcium pentetate for radiopharmaceutical preparations	1223
Selenium for homeopathic preparations	1725	Sodium caprylate	3808
Selfheal fruit-spike, common	1401	Sodium carbonate	3809
Semi-micro determination of water (2.5.12.)	171	Sodium carbonate decahydrate	3809
Semi-solid ear preparations	908	Sodium carbonate monohydrate	3810
Semi-solid eye preparations	910	Sodium carboxymethylcellulose	2093
Semi-solid intrauterine preparations	914	Sodium carboxymethylcellulose, cross-linked	2318
Semi-solid nasal preparations	920	Sodium carboxymethylcellulose, low-substituted	2094
Semi-solid oromucosal preparations	921	Sodium cetostearyl sulfate	3810
Semi-solid preparations for cutaneous application	935	Sodium chloride	3812
Semi-solid preparations for oral use, veterinary	942	Sodium chromate (⁵¹ Cr) sterile solution	1226
Semi-solid rectal preparations	935	Sodium citrate	3813
Semi-solid vaginal preparations	941	Sodium cromoglicate	3813
Senega root	1618	Sodium cyclamate	3814
Senna leaf dry extract, standardised	1621	Sodium dihydrogen phosphate dihydrate	3816
Senna leaflet	10.1 -4361	Sodium disulfite	3829
Senna pods	10.1 -4363	Sodium ethyl parahydroxybenzoate	3816
Separation techniques, chromatographic (2.2.46.)	80	Sodium fluoride	3818
Serine	3777	Sodium fluoride (¹⁸ F) injection	1227
Serratula coronata herb	1624	Sodium fusidate	3818
Sertaconazole nitrate	3778	Sodium glycerophosphate, hydrated	3821
Sertraline hydrochloride	3779	Sodium hyaluronate	3821
Sesame oil, refined	3781	Sodium hydrogen carbonate	3824
Sets for the transfusion of blood and blood components (3.3.7.)	475	Sodium hydroxide	3824
Sevoflurane	3783	Sodium iodide	3825
Shampoos	916	Sodium iodide (¹²³ I) injection	1228
Shear cell methods, powder flow properties by (2.9.49.)	411	Sodium iodide (¹²³ I) solution for radiolabelling	1228
Shellac	3785	Sodium iodide (¹³¹ I) capsules for diagnostic use	1229
Shingles (herpes zoster) vaccine (live)	1036	Sodium iodide (¹³¹ I) capsules for therapeutic use	1230
SI (International System) units (1.)	3	Sodium iodide (¹³¹ I) solution	1231
Sialic acid in polysaccharide vaccines (2.5.23.)	174	Sodium iodide (¹³¹ I) solution for radiolabelling	1232
Siam benzoin	1341	Sodium iodohippurate (¹²³ I) injection	1233
Siam benzoin tincture	1342	Sodium iodohippurate (¹³¹ I) injection	1234
Sieve test (2.9.12.)	343	Sodium iodohippurate dihydrate for radiopharmaceutical preparations	1234
Sieves (2.1.4.)	16	Sodium lactate solution	3825
Sieving, analytical, particle-size distribution estimation by (2.9.38.)	392	Sodium laurilsulfate	3827
Sildenafil citrate	3786	Sodium lauroylsarcosinate for external use	3828
Silica, colloidal anhydrous	3787	Sodium metabisulfite	3829
Silica, colloidal hydrated	3788	Sodium methyl parahydroxybenzoate	3830
Silica, dental type	3788	Sodium molybdate (⁹⁹ Mo) solution (fission)	1235
Silica, hydrophobic colloidal	3789	Sodium molybdate dihydrate	3831
Silicate, aluminium magnesium	1799	Sodium nitrite	3832
Silicate, aluminium sodium	1803	Sodium nitroprusside	3832
Silicone elastomer for closures and tubing (3.1.9.)	436	Sodium perborate, hydrated	3833
Silicone oil used as a lubricant (3.1.8.)	436	Sodium pertechnetate (^{99m} Tc) injection (accelerator-produced)	1237
Silk suture, sterile, braided, in distributor for veterinary use	1283	Sodium pertechnetate (^{99m} Tc) injection (fission)	1238
Silver, colloidal, for external use	3790	Sodium pertechnetate (^{99m} Tc) injection (non-fission)	1240
Silver nitrate	3790	Sodium phenylbutyrate	3833
Simeticone	3791	Sodium phosphate (³² P) injection	1240
Simvastatin	3792	Sodium picosulfate	3835
Single-dose preparations, uniformity of content (2.9.6.)	336	Sodium polystyrene sulfonate	3836
Single-dose preparations, uniformity of mass (2.9.5.)	335	Sodium propionate	3837
Sintered-glass filters (2.1.2.)	15	Sodium propyl parahydroxybenzoate	3838
Sitagliptin phosphate monohydrate	3795	Sodium pyrophosphate decahydrate for radiopharmaceutical preparations	1241
Sitagliptin tablets	3796	Sodium risedronate 2.5-hydrate	3729
Size-exclusion chromatography (2.2.30.)	51	Sodium salicylate	3839
(S)-Lactic acid	3051	Sodium selenite	3840
Smallpox vaccine (live)	1037	Sodium selenite pentahydrate	3840
Sodium acetate ([1- ¹¹ C]) injection	1225	Sodium (S)-lactate solution	3826
Sodium acetate trihydrate	3797	Sodium starch glycolate (type A)	3841
Sodium alendronate trihydrate	3798		

Sodium starch glycolate (type B).....	3842	Spectrometry, X-ray fluorescence (2.2.37.)	65
Sodium starch glycolate (type C).....	3843	Spectrophotometry, infrared absorption (2.2.24.)	39
Sodium stearate.....	3844	Spectrophotometry, ultraviolet and visible absorption (2.2.25.).....	42
Sodium stearyl fumarate.....	3845	Spectroscopy, near-infrared (2.2.40.).....	70
Sodium sulfate, anhydrous.....	3846	Spectroscopy, Raman (2.2.48.).....	92
Sodium sulfate decahydrate.....	10.1 -4493	SPF chicken flocks for the production and quality control of vaccines (5.2.2.).....	647
Sodium sulfite.....	3847	Spheroids and granules, friability of (2.9.41.)	400
Sodium sulfite heptahydrate.....	3848	Spike lavender oil.....	1630
Sodium tetrachloroaurate dihydrate for homoeopathic preparations	1704	Spiramycin.....	3877
Sodium thiosulfate.....	3848	Spirapril hydrochloride monohydrate	3880
Sodium valproate.....	3849	Spirolactone	3881
Soft capsules.....	906	Spot-on preparations.....	942
Soft extracts.....	867	Sprays (liquid nasal) and drops (nasal).....	919
Softening time determination of lipophilic suppositories (2.9.22.)	363	Sprays, veterinary	942
Solid dosage forms, dissolution test for (2.9.3.).....	326	Squalane.....	10.1 -4493
Solid dosage forms, recommendations on dissolution testing of (5.17.1.).....	801	Squalene.....	3886
Solids by mercury porosimetry, porosity and pore-size distribution of (2.9.32.).....	377	St. John's wort.....	1631
Solids, density of (2.2.42.).....	76	St. John's wort dry extract, quantified.....	1633
Solids, gas pycnometric density of (2.9.23.)	364	Standard solutions for limit tests (4.1.2.).....	598
Solids (porous) including powders, wettability of (2.9.45.) ..	406	Standards, reference (5.12.).....	773
Solifenacin succinate	3850	Stannous chloride dihydrate.....	3886
Solubility in alcohol of essential oils (2.8.10.).....	306	Stanozolol	3887
Soluble tablets	939	Staphysagria for homoeopathic preparations	1726
Solution calorimetry and microcalorimetry, characterisation of crystalline solids by (2.2.61.)	115	Star anise.....	1635
Solutions, emulsions and suspensions, oral	917	Star anise oil	1636
Solutions for haemodialysis.....	2798	Starch glycolate (type A), sodium.....	3841
Solutions for haemodialysis, concentrated, water for diluting.....	2797	Starch glycolate (type B), sodium	3842
Solutions for haemofiltration and haemodiafiltration	2803	Starch glycolate (type C), sodium.....	3843
Solutions for organ preservation	3852	Starch, hydroxypropyl	3888
Solutions for peritoneal dialysis.....	3515	Starch, hydroxypropyl, pregelatinised.....	3890
Solutions, suspensions, intrauterine.....	914	Starch, maize	3167
Solvents, residual (5.4.).....	717	Starch, pea	3492
Solvents, residual, identification and control of (2.4.24.)	10.1 -4323	Starch, potato	3611
Somatostatin.....	3853	Starch, pregelatinised	3891
Somatropin	3854	Starch, rice	3721
Somatropin concentrated solution	3856	Starch, wheat	4209
Somatropin for injection	3858	Starches, hydroxyethyl	3892
Somatropin solution for injection	3860	Starflower (borage) oil, refined	1992
Sophora flower	1626	Statistical analysis of results of biological assays and tests (5.3.)	685
Sophora flower-bud.....	1628	Stavudine	3896
Sorbic acid	3861	Steam sterilisation of aqueous preparations, application of the F_0 concept (5.1.5.).....	628
Sorbitan laurate.....	3862	Stearic acid.....	3898
Sorbitan oleate.....	3862	Stearoyl macrogolglycerides	3899
Sorbitan palmitate	3863	Stearyl alcohol.....	3900
Sorbitan sesquioleate.....	3863	Stem cells, human haematopoietic	2857
Sorbitan stearate	3864	Stephania root, fourstamen	1438
Sorbitan trioleate	3865	Sterile braided silk suture in distributor for veterinary use.....	1283
Sorbitol.....	3865	Sterile catgut.....	1269
Sorbitol, liquid (crystallising)	3867	Sterile catgut in distributor for veterinary use.....	1281
Sorbitol, liquid (non-crystallising)	3867	Sterile containers of plasticised poly(vinyl chloride) for human blood containing anticoagulant solution (3.3.6.)	474
Sorbitol, liquid, partially dehydrated	3868	Sterile linen thread in distributor for veterinary use	1282
Sorption-desorption isotherms and water activity, determination of (water-solid interactions) (2.9.39.).....	394	Sterile non-absorbable strands in distributor for veterinary use.....	1283
Sotalol hydrochloride.....	3869	Sterile non-absorbable sutures.....	1270
Soya phospholipids for injection	3870	Sterile plastic containers for human blood and blood components (3.3.4.).....	471
Soya-bean oil, hydrogenated	3872	Sterile polyamide suture in distributor for veterinary use..	1282
Soya-bean oil, refined.....	3873	Sterile poly(ethylene terephthalate) suture in distributor for veterinary use.....	1283
Spanish sage oil.....	1629	Sterile products, biological indicators and related microbial preparations used in the manufacture of (5.1.2.)	622
Specific surface area by air permeability (2.9.14.)	343	Sterile products, methods of preparation of (5.1.1.)	619
Specific surface area by gas adsorption (2.9.26.)	369	Sterile single-use plastic syringes (3.3.8.)	477
Spectinomycin dihydrochloride pentahydrate.....	3873	Sterile synthetic absorbable braided sutures	1274
Spectinomycin sulfate tetrahydrate for veterinary use	3875	Sterile synthetic absorbable monofilament sutures.....	1275
Spectrometry, atomic absorption (2.2.23.).....	37	Sterility (2.6.1.).....	191
Spectrometry, atomic emission (2.2.22.)	36	Sterility, guidelines for using the test for (5.1.9.).....	639
Spectrometry, mass (2.2.43.).....	77		
Spectrometry, nuclear magnetic resonance (2.2.33.)	58		

Sterols in fatty oils (2.4.23.)	150	Suspensions, solutions, intrauterine	914
Sticks	937	Sutures for human use: introduction	10.1 -4349
Sticks, intrauterine	914	Sutures, sterile non-absorbable	1270
Sticks, nasal	920	Sutures, sterile synthetic absorbable braided	1274
Stomata and stomatal index (2.8.3.)	305	Sutures, sterile synthetic absorbable monofilament	1275
Stramonium leaf	1638	Suxamethonium chloride	3948
Stramonium, prepared	1640	Suxibuzone	3949
Strands, sterile non-absorbable, in distributor for veterinary use	1283	Sweet fennel	1434
Streptokinase concentrated solution	3901	Sweet orange oil	1641
Streptomycin sulfate	3902	Swelling index (2.8.4.)	306
Strontium (⁸⁹ Sr) chloride injection	1242	Swine erysipelas vaccine (inactivated)	1158
Strychnos ignatii for homoeopathic preparations	1719	Swine-fever vaccine (live, prepared in cell cultures), classical	1159
Subdivision of tablets	937	Symbols and abbreviations (1.)	3
Sublingual sprays, oromucosal drops and oromucosal sprays	920	Synthetic absorbable braided sutures, sterile	1274
Sublingual tablets and buccal tablets	922	Synthetic absorbable monofilament sutures, sterile	1275
Substances for pharmaceutical use	890	Syringes, plastic, sterile single-use (3.3.8.)	477
Substances for pharmaceutical use, control of impurities in (5.10.)	763	Syrups	918
Substances of animal origin for the production of immunological veterinary medicinal products (5.2.5.)	656	Szechwan lovage rhizome	1642
Substitution of <i>in vivo</i> method(s) by <i>in vitro</i> method(s) for the quality control of vaccines (5.2.14.)	679	T	
Sub-visible particles, particulate contamination (2.9.19.)	360	Table of physical characteristics of radionuclides mentioned in the European Pharmacopoeia (5.7.)	745
Sucralfate	3904	Tablets	937
Sucralose	3905	Tablets and capsules, disintegration of (2.9.1.)	323
Sucrose	3906	Tablets and powders for rectal solutions and suspensions	934
Sucrose, liquid	3908	Tablets, buccal	922
Sucrose monopalmitate	3909	Tablets, chewable	939
Sucrose stearate	3911	Tablets, coated	938
Sufentanil	3912	Tablets, dispersible	939
Sufentanil citrate	3913	Tablets, effervescent	939
Sugar spheres	3915	Tablets for intrauterine solutions and suspensions	914
Sugars, lead in (2.4.10.)	142	Tablets for vaginal solutions and suspensions	941
Sulbactam sodium	3915	Tablets, gastro-resistant	938
Sulfacetamide sodium	3917	Tablets, intrauterine	914
Sulfadiazine	3918	Tablets, modified-release	939
Sulfadimethoxine	3920	Tablets, orodispersible	939
Sulfadimethoxine sodium for veterinary use	3921	Tablets, resistance to crushing (2.9.8.)	337
Sulfadimidine	3922	Tablets, soluble	939
Sulfadoxine	3924	Tablets, subdivision of	937
Sulfafurazole	3925	Tablets, sublingual	922
Sulfaguanidine	3926	Tablets, uncoated	938
Sulfamerazine	3926	Tablets, uncoated, friability of (2.9.7.)	336
Sulfamethizole	10.1 -4494	Tablets, vaginal	941
Sulfamethoxazole	3928	Tacalcitol monohydrate	3953
Sulfamethoxy-pyridazine for veterinary use	3929	Tacrolimus monohydrate	3954
Sulfanilamide	3930	Tadalafil	3957
Sulfasalazine	3931	Talc	3959
Sulfated ash (2.4.14.)	142	Tamoxifen citrate	3961
Sulfates (2.4.13.)	142	Tampons, ear	909
Sulfathiazole	3933	Tampons, medicated	940
Sulfinpyrazone	3934	Tampons, rectal	935
Sulfobutylbetadex sodium	3935	Tampons, vaginal, medicated	941
Sulfur dioxide (2.5.29.)	177	Tamsulosin hydrochloride	3963
Sulfur for external use	3938	Tannic acid	3964
Sulfur for homoeopathic preparations	1727	Tannins in herbal drugs (2.8.14.)	310
Sulfuric acid	3938	Tapentadol hydrochloride	3965
Sulindac	3939	Tapped density and bulk density of powders (2.9.34.)	384
Sulpiride	3940	Tartaric acid	3966
Sultamicillin	3941	Tea tree oil	1643
Sultamicillin tosilate dihydrate	3944	Teat dips	942
Sumatra benzoin	1341	Teat sprays	942
Sumatra benzoin tincture	1343	Technetium (^{99m} Tc) bismuth injection	1243
Sumatriptan succinate	3946	Technetium (^{99m} Tc) colloidal rhenium sulfide injection	1244
Sunflower oil, refined	3948	Technetium (^{99m} Tc) colloidal sulfur injection	1244
Supercritical fluid chromatography (2.2.45.)	80	Technetium (^{99m} Tc) colloidal tin injection	1245
Suppositories	934	Technetium (^{99m} Tc) etifenin injection	1246
Suppositories and pessaries, disintegration of (2.9.2.)	325	Technetium (^{99m} Tc) exametazime injection	1247
Suppositories, lipophilic, softening time determination (2.9.22.)	363	Technetium (^{99m} Tc) gluconate injection	1248
Suspensions, solutions and emulsions, oral	917	Technetium (^{99m} Tc) human albumin injection	1249
		Technetium (^{99m} Tc) macrosal injection	1251
		Technetium (^{99m} Tc) mebrofenin injection	10.1 -4345

Technetium (^{99m} Tc) medronate injection	1253	Tetanus, diphtheria, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	968
Technetium (^{99m} Tc) mertiatide injection	1254	Tetanus, diphtheria, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	970
Technetium (^{99m} Tc) microspheres injection	1255	Tetanus, diphtheria, pertussis (whole cell) and poliomyelitis (inactivated) vaccine (adsorbed)	973
Technetium (^{99m} Tc) oxidronate injection	1256	Tetanus, diphtheria, pertussis (whole cell), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)	974
Technetium (^{99m} Tc) pentetate injection	1257	Tetanus immunoglobulin, human	2873
Technetium (^{99m} Tc) sestamibi injection	1258	Tetanus vaccine (adsorbed)	1042
Technetium (^{99m} Tc) succimer injection	1259	Tetanus vaccine (adsorbed), assay of (2.7.8.)	275
Technetium (^{99m} Tc) tin pyrophosphate injection	1260	Tetanus vaccine for veterinary use	1161
Teicoplanin	3967	Tetracaine	3997
Telmisartan	3970	Tetracaine hydrochloride	3998
Temazepam	3972	Tetracosactide	3999
Temozolomide	3973	Tetracycline	4000
Tenosynovitis vaccine (live), viral, avian	1069	Tetracycline hydrochloride	4001
Tenoxicam	3974	Tetra-O-acetyl-mannose triflate for radiopharmaceutical preparations	1261
Terazosin hydrochloride dihydrate	3976	Tetrazepam	4003
Terbinafine hydrochloride	3978	Tetryzoline hydrochloride	4004
Terbutaline sulfate	3979	Thallous (²⁰¹ Tl) chloride injection	1262
Terconazole	3980	Theobromine	4005
Terfenadine	3982	Theophylline	4005
Teriparatide	3983	Theophylline monohydrate	4007
Terlipressin	3986	Theophylline-ethylenediamine	4008
Terminology used in monographs on biological products (5.2.1.)	647	Theophylline-ethylenediamine hydrate	4009
Terpin monohydrate	3988	Thermal analysis (2.2.34.)	61
Test for anticomplementary activity of immunoglobulin (2.6.17.)	216	Thermogravimetry (2.2.34.)	61
Test for anti-D antibodies in human immunoglobulin (2.6.26.)	230	Thiamazole	4011
Test for aristolochic acids in herbal drugs (2.8.21.)	314	Thiamine hydrochloride	4012
Test for extractable volume of parenteral preparations (2.9.17.)	347	Thiamine nitrate	4014
Test for Fc function of immunoglobulin (2.7.9.)	279	Thiamphenicol	4015
Test for methanol and 2-propanol (2.9.11.)	342	Thin-layer chromatography (2.2.27.)	47
Test for neurovirulence of live virus vaccines (2.6.18.)	218	Thiocolchicoside crystallised from ethanol	4016
Test for specified micro-organisms (microbiological examination of non-sterile products) (2.6.13.)	205	Thiocolchicoside hydrate	10.1-4500
Testosterone	10.1-4499	Thioctic acid	4020
Testosterone decanoate	3991	Thiomersal	4021
Testosterone enantate	3992	Thiopental sodium and sodium carbonate	4022
Testosterone isocaproate	3994	Thioridazine	4024
Testosterone propionate	3995	Thioridazine hydrochloride	4025
Tests for extraneous agents in viral vaccines for human use (2.6.16.)	214	Thomson kudzu vine root	1644
Tests for specified micro-organisms (microbiological examination of live biotherapeutic products) (2.6.38.)	255	Three-lobed sage leaf	1608
Tetanus and diphtheria toxins and toxoids, flocculation value (Lf) of, (Ramon assay) (2.7.27.)	295	Threonine	4027
Tetanus and diphtheria vaccine (adsorbed)	952	Thyme	1646
Tetanus and diphtheria vaccine (adsorbed, reduced antigen(s) content)	953	Thyme oil, thymol type	1648
Tetanus antitoxin for human use	1173	Thyme, wild	1669
Tetanus antitoxin for veterinary use	1177	Thymol	4028
Tetanus, diphtheria and hepatitis B (rDNA) vaccine (adsorbed)	954	Thymol type thyme oil	1648
Tetanus, diphtheria and pertussis (acellular, component) vaccine (adsorbed)	955	Tiabendazole	4029
Tetanus, diphtheria and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content)	956	Tiamulin for veterinary use	4030
Tetanus, diphtheria and pertussis (whole cell) vaccine (adsorbed)	958	Tiamulin hydrogen fumarate for veterinary use	4032
Tetanus, diphtheria and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)	959	Tianeptine sodium	4035
Tetanus, diphtheria, pertussis (acellular, component) and haemophilus type b conjugate vaccine (adsorbed)	961	Tiapride hydrochloride	4036
Tetanus, diphtheria, pertussis (acellular, component) and hepatitis B (rDNA) vaccine (adsorbed)	963	Tiaprofenic acid	10.1-4503
Tetanus, diphtheria, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)	964	Tibolone	4039
Tetanus, diphtheria, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)	966	Ticarcillin sodium	4040
		Tick-borne encephalitis vaccine (inactivated)	1043
		Ticlopidine hydrochloride	4041
		Tigecycline	4043
		Tilidine hydrochloride hemihydrate	4045
		Timolol maleate	4046
		Tinctures	867
		Tinidazole	4048
		Tinnevely senna pods	10.1-4363
		Tinzaparin sodium	4049
		Tioconazole	4050
		Tiotropium bromide monohydrate	4051
		Titanium dioxide	4052
		Titration, amperometric (2.2.19.)	35

Titration, potentiometric (2.2.20.).....	35	Tryptophan.....	4115
Titration, voltametric (2.2.65.).....	119	TSE, animal, minimising the risk of transmitting via human and veterinary medicinal products (5.2.8.)	661
Titration, complexometric (2.5.11.).....	170	TSE, animal, products with risk of transmitting agents of..	884
Tizanidine hydrochloride	4053	Tuberculin for human use, old.....	4117
Tobramycin.....	4055	Tuberculin purified protein derivative, avian	4119
Tocopherol, all- <i>rac</i> - α	4057	Tuberculin purified protein derivative, bovine.....	4120
Tocopherol, <i>RRR</i> - α	4058	Tuberculin purified protein derivative for human use.....	4120
Tocopheryl acetate, all- <i>rac</i> - α	4059	Tuberculosis (BCG) vaccine, freeze-dried.....	949
α -Tocopheryl acetate concentrate (powder form)	4062	Tubes for comparative tests (2.1.5.).....	17
Tocopheryl acetate, <i>RRR</i> - α	4060	Tubing and closures, silicone elastomer for (3.1.9.).....	436
Tocopheryl hydrogen succinate, DL- α -	4062	Tubing and containers for total parenteral nutrition preparations, poly(ethylene - vinyl acetate) for (3.1.7.)....	43
Tocopheryl hydrogen succinate, <i>RRR</i> - α -	4064	Tubing used in sets for the transfusion of blood and blood components, materials based on plasticised poly(vinyl chloride) for (3.3.3.)	468
Tolbutamide.....	4066	Turkey infectious rhinotracheitis vaccine (live)	1162
Tolfenamic acid.....	4067	Turmeric, Javanese.....	1652
Tolnaftate	4068	Turmeric rhizome.....	1653
Tolterodine tartrate.....	4070	Turpentine oil.....	1655
Tolu balsam	1649	Tylosin for veterinary use.....	4122
Toluenesulfonate (methyl, ethyl and isopropyl) in active substances (2.5.40.).....	185	Tylosin phosphate bulk solution for veterinary use.....	4127
Topiramate.....	4071	Tylosin phosphate for veterinary use	4131
Torsemide	4073	Tylosin tartrate for veterinary use.....	4136
Tormentil	1650	Typhae pollen.....	1656
Tormentil tincture	1650	Typhoid polysaccharide and hepatitis A (inactivated, adsorbed) vaccine.....	982
Tosylchloramide sodium	4074	Typhoid polysaccharide vaccine	1044
Total ash (2.4.16.).....	143	Typhoid vaccine.....	1046
Total cholesterol in oils rich in omega-3 acids (2.4.32.).....	163	Typhoid vaccine (live, oral, strain Ty 21a)	1046
Total organic carbon in water for pharmaceutical use (2.2.44.)	79	Tyrosine	4140
Total protein (2.5.33.).....	178	Tyrosine	4140
Traditional Chinese medicine, names of herbal drugs used in (5.22.)	10.1-4335	Tyrosine	4140
Tragacanth	1651	Tyrosine	4140
Tramadol hydrochloride	4074	Tyrosine	4140
Tramazoline hydrochloride monohydrate.....	4076	Tyrosine	4140
Trandolapril.....	4077	Tyrosine	4140
Tranexamic acid.....	10.1-4504	Tyrosine	4140
Transdermal patches	925	Tyrosine	4140
Transdermal patches, dissolution test for (2.9.4.).....	333	Tyrosine	4140
Trapidil.....	4079	Tyrosine	4140
Trehalose dihydrate	4080	Tyrosine	4140
Tretinoin	4082	Tyrosine	4140
Triacetin.....	4083	Tyrosine	4140
Triamcinolone	4083	Tyrosine	4140
Triamcinolone acetonide	4085	Tyrosine	4140
Triamcinolone hexacetonide	4086	Tyrosine	4140
Triamterene	4088	Tyrosine	4140
Tribenoside.....	4089	Tyrosine	4140
Tributyl acetylcitrate.....	4090	Tyrosine	4140
Trichloroacetic acid.....	4092	Tyrosine	4140
Triclabendazole for veterinary use	4093	Tyrosine	4140
Triethanolamine.....	4106	Tyrosine	4140
Triethyl citrate.....	4094	Tyrosine	4140
Trifluoperazine hydrochloride	4095	Tyrosine	4140
Triflusal	4095	Tyrosine	4140
Triglycerides, medium-chain	4096	Tyrosine	4140
Triglycerides, omega-3-acid	3423	Tyrosine	4140
Triglycerol diisostearate	4097	Tyrosine	4140
Trihexyphenidyl hydrochloride	4098	Tyrosine	4140
Trimebutine maleate	4099	Tyrosine	4140
Trimeprazine hemitartrate	1782	Tyrosine	4140
Trimetazidine dihydrochloride.....	4100	Tyrosine	4140
Trimethadione.....	4101	Tyrosine	4140
Trimethoprim.....	4102	Tyrosine	4140
Trimipramine maleate.....	4104	Tyrosine	4140
Tri- <i>n</i> -butyl phosphate	4091	Tyrosine	4140
Tritiated (³ H) water injection	1263	Tyrosine	4140
Trolamine.....	4106	Tyrosine	4140
Trometamol.....	4107	Tyrosine	4140
Tropicamide.....	4108	Tyrosine	4140
Tropisetron hydrochloride.....	4110	Tyrosine	4140
Trospium chloride	4111	Tyrosine	4140
Troxerutin.....	4112	Tyrosine	4140
Trypsin.....	4114	Tyrosine	4140

- Vaccines for human use, conjugated polysaccharide, carrier proteins for the production of (5.2.11.) 674
- Vaccines for human use, viral, tests for extraneous agents in (2.6.16.) 214
- Vaccines for veterinary use 896
- Vaccines for veterinary use, inactivated, healthy chicken flocks for the production of (5.2.13.) 679
- Vaccines, polysaccharide, hexosamines in (2.5.20.) 173
- Vaccines, polysaccharide, methylpentoses in (2.5.21.) 173
- Vaccines, polysaccharide, nucleic acids in (2.5.17.) 172
- Vaccines, polysaccharide, *O*-acetyl in (2.5.19.) 173
- Vaccines, polysaccharide, phosphorus in (2.5.18.) 172
- Vaccines, polysaccharide, protein in (2.5.16.) 172
- Vaccines, polysaccharide, ribose in (2.5.31.) 177
- Vaccines, polysaccharide, sialic acid in (2.5.23.) 174
- Vaccines, polysaccharide, uronic acids in (2.5.22.) 174
- Vaccines, SPF chicken flocks for the production and quality control of (5.2.2.) 647
- Vaccines, substitution of *in vivo* method(s) by *in vitro* method(s) for the quality control of (5.2.14.) 679
- Vaccines, veterinary, cell cultures for the production of (5.2.4.) 654
- Vaccines, viral live, test for neurovirulence (2.6.18.) 218
- Vaginal capsules 941
- Vaginal foams 941
- Vaginal preparations 940
- Vaginal preparations, semi-solid 941
- Vaginal solutions and suspensions, tablets for 941
- Vaginal solutions, emulsions and suspensions 941
- Vaginal tablets 941
- Vaginal tampons, medicated 941
- Valaciclovir hydrochloride 4157
- Valaciclovir hydrochloride hydrate 4160
- Valerian dry aqueous extract 1659
- Valerian dry hydroalcoholic extract 1660
- Valerian root 1660
- Valerian root, cut 1662
- Valerian tincture 1664
- Validation of nucleic acid amplification techniques for the detection of B19 virus (B19V) DNA in plasma pools: guidelines 219
- Validation of nucleic acid amplification techniques for the detection of hepatitis C virus (HCV) RNA in plasma pools: guidelines 219
- Valine 4162
- Valnemulin hydrochloride for veterinary use 4164
- Valproate, sodium 3849
- Valproic acid 4165
- Valsartan 4167
- Vancomycin hydrochloride 4168
- Vanillin 4172
- Vapour, preparations to be converted into 928
- Vardenafil hydrochloride trihydrate 4172
- Varicella immunoglobulin for intravenous administration, human 2875
- Varicella immunoglobulin, human 2875
- Varicella, measles, mumps and rubella vaccine (live) 1006
- Varicella vaccine (live) 1048
- Vectors for human use, adeno-associated-virus 788
- Vectors for human use, adenovirus 782
- Vectors for human use, plasmid 780
- Vectors for human use, plasmid, bacterial cells used for the manufacture of 781
- Vectors for human use, poxvirus 784
- Vectors for human use, retroviridae-derived 786
- Vecuronium bromide 4173
- Vedaprofen for veterinary use 4175
- Vegetable fatty oils 901
- Venlafaxine hydrochloride 4176
- Verapamil hydrochloride 4178
- Verbena herb 1665
- Veterinary liquid preparations for cutaneous application... 941
- Veterinary medicinal products, immunological, substances of animal origin for the production of (5.2.5.) 656
- Veterinary semi-solid preparations for oral use 942
- Veterinary vaccines and immunosera, evaluation of efficacy of (5.2.7.) 661
- Viability, nucleated cell count and (2.7.29.) 297
- Vibriosis (cold-water) vaccine (inactivated) for salmonids 1163
- Vibriosis vaccine (inactivated) for salmonids 1164
- VICH (5.8.) 755
- Vigabatrin 4180
- Vinblastine sulfate 4181
- Vincamine 4182
- Vincristine sulfate 4183
- Vindesine sulfate 4185
- Vinorelbine tartrate 4186
- Vinpocetine 4188
- Viper venom antiserum, European 1174
- Viral diarrhoea vaccine (inactivated), bovine 1075
- Viral hepatitis type I vaccine (live), duck 1099
- Viral rhinotracheitis vaccine (inactivated), feline 1113
- Viral rhinotracheitis vaccine (live), feline 1114
- Viral safety (5.1.7.) 637
- Viral tenosynovitis vaccine (live), avian 1069
- Viral vaccines for human use, tests for extraneous agents in (2.6.16.) 214
- Viscometer method, capillary (2.2.9.) 27
- Viscometer methods, falling ball and automatic rolling ball (2.2.49.) 94
- Viscose wadding, absorbent 4189
- Viscosity - rotating viscometer method (2.2.10.) 28
- Viscosity (2.2.8.) 27
- Visible and ultraviolet absorption spectrophotometry (2.2.25.) 42
- Visible particles, particulate contamination (2.9.20.) 362
- Vitamin A 4191
- Vitamin A concentrate (oily form), synthetic 4192
- Vitamin A concentrate (powder form), synthetic 4193
- Vitamin A concentrate (solubilisate/emulsion), synthetic.. 4194
- Voltametric titration (2.2.65.) 119
- Volumetric analysis (4.2.) 609
- Volumetric solutions (4.2.2.) 609
- Volumetric solutions, primary standards for (4.2.1.) 609
- Volumetric solutions, primary standards for (4.2.1.) 10.1-4331
- von Willebrand factor, human 2875
- von Willebrand factor, human, assay of (2.7.21.) 290
- Voriconazole 4196
- ## W
- Warfarin sodium 4201
- Warfarin sodium clathrate 4202
- Washes, nasal 920
- Water (¹⁵O) injection 1264
- Water activity and sorption-desorption isotherms, determination of (water-solid interactions) (2.9.39.) 394
- Water, determination by distillation (2.2.13.) 31
- Water for diluting concentrated haemodialysis solutions.. 2797
- Water for injections 4203
- Water for pharmaceutical use, total organic carbon in (2.2.44.) 79
- Water for preparation of extracts 4206
- Water in essential oils (2.8.5.) 306
- Water in gases (2.5.28.) 176
- Water: micro determination (2.5.32.) 178
- Water, purified 4207
- Water: semi-micro determination (2.5.12.) 171
- Water-solid interactions: determination of sorption-desorption isotherms and of water activity (2.9.39.) 394
- Wettability of porous solids including powders (2.9.45.) 406
- Wheat starch 4209
- Wheat-germ oil, refined 4210

Wheat-germ oil, virgin.....	4210	Yellow beeswax.....	1932
White beeswax	1931	Yellow fever vaccine (live)	1049
White horehound	1667	Yellow soft paraffin.....	3486
White peony root.....	1573	Yersiniosis vaccine (inactivated) for salmonids	1102
White soft paraffin.....	3485	Yohimbine hydrochloride.....	4231
Wild pansy (flowering aerial parts).....	1668	Yttrium (⁹⁰ Y) chloride solution for radiolabelling.....	1265
Wild thyme	1669		
Willow bark	1671	Z	
Willow bark dry extract.....	1672	Zanamivir hydrate	10.1 -4513
Wool alcohols.....	4210	Zanthoxylum bungeanum pericarp.....	1675
Wool fat.....	4211	Zidovudine	4236
Wool fat, hydrogenated.....	4215	Zinc acetate dihydrate.....	4238
Wool fat, hydrous.....	4216	Zinc acexamate	4239
Wormwood.....	1673	Zinc chloride	4241
		Zinc gluconate.....	4241
X		Zinc oxide	4242
Xanthan gum.....	4221	Zinc stearate	4242
Xenon (¹³³ Xe) injection	1264	Zinc sulfate heptahydrate	4243
X-ray fluorescence spectrometry (2.2.37.).....	65	Zinc sulfate hexahydrate.....	4244
X-ray powder diffraction (XRPD), characterisation of crystalline and partially crystalline solids by (2.9.33.).....	379	Zinc sulfate monohydrate.....	4244
Xylazine hydrochloride for veterinary use	4222	Zinc undecylenate	4244
Xylitol.....	4223	Ziprasidone hydrochloride monohydrate.....	4245
Xylometazoline hydrochloride	10.1 -4509	Ziprasidone mesilate trihydrate	4247
Xylose.....	4226	Zoledronic acid monohydrate.....	10.1 -4514
		Zolmitriptan	4251
Y		Zolpidem tartrate.....	10.1 -4516
Yarrow	1674	Zopiclone.....	4254
Yeasticidal, bactericidal or fungicidal activity of antiseptic medicinal products, determination of (5.1.11.)	643	Zoster (shingles) vaccine (live), herpes.....	1036
		Zuclopenthixol decanoate.....	4255

<i>α-1-Proteinase inhibitor humanum</i>	2869	<i>Acidum pipemidicum trihydricum</i>	3566
A		<i>Acidum salicylicum</i>	3766
<i>Abacaviri sulfas</i>	1733	<i>Acidum (S)-lacticum</i>	3051
<i>Abelmoschi corolla</i>	1289	<i>Acidum sorbicum</i>	3861
<i>Absinthii herba</i>	1673	<i>Acidum stearicum</i>	3898
<i>Acaciae gummi</i>	1290	<i>Acidum succinicum ad praeparationes homoeopathicas</i>	1698
<i>Acaciae gummi dispersione desiccatum</i>	1734	<i>Acidum sulfuricum</i>	3938
<i>Acamprosatum calcicum</i>	1736	<i>Acidum tartaricum</i>	3966
<i>Acanthopanax gracilistylis cortex</i>	1292	<i>Acidum thiocticum</i>	4020
<i>Acarbosum</i>	1736	<i>Acidum tiaprofenicum</i>	10.1-4503
<i>Acari ad producta allergenica</i>	3281	<i>Acidum tolafenamicum</i>	4067
<i>Acebutololi hydrochloridum</i>	1738	<i>Acidum tranexamicum</i>	10.1-4504
<i>Aceclofenacum</i>	1740	<i>Acidum trichloroaceticum</i>	4092
<i>Acemetacinum</i>	1742	<i>Acidum undecylenicum</i>	4148
<i>Acesulfamum kalicum</i>	1744	<i>Acidum ursodeoxycholicum</i>	4152
<i>Acetazolamidum</i>	1745	<i>Acidum valproicum</i>	4165
<i>Acetonum</i>	1747	<i>Acidum zoledronicum monohydricum</i>	10.1-4514
<i>Acetylcholini chloridum</i>	1748	<i>Acitretinum</i>	1760
<i>Acetylcysteinum</i>	1749	<i>Adapalenum</i>	1761
<i>β-Acetyldigoxinum</i>	1750	<i>Adeninum</i>	1762
<i>Acetylenum (1 per centum) in nitrogenio intermixtum</i>	1752	<i>Adenosinum</i>	1763
<i>Achyranthis bidentatae radix</i>	1293	<i>Adeps A 3-O-desacyl-4'-monophosphorylatus</i>	2355
<i>Aciclovirum</i>	1758	<i>Adeps lanae</i>	4211
<i>Acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum</i>	3216	<i>Adeps lanae cum aqua</i>	4216
<i>Acidi methacrylici et ethylis acrylatis polymerisatum 1:1</i>	3214	<i>Adeps lanae hydrogenatus</i>	4215
<i>Acidi methacrylici et methylis methacrylatis polymerisatum 1:1</i>	3217	<i>Adeps solidus</i>	2811
<i>Acidi methacrylici et methylis methacrylatis polymerisatum 1:2</i>	3218	<i>Adeps solidus cum additamentis</i>	2812
<i>Acidum 4-aminobenzoicum</i>	1819	<i>Adonis vernalis ad praeparationes homoeopathicas</i>	10.1-4369
<i>Acidum aceticum glaciale</i>	1746	<i>Adrenalini tartras</i>	1767
<i>Acidum acetylsalicylicum</i>	1753	<i>Adrenalinum</i>	1766
<i>Acidum adipicum</i>	1765	<i>Aer medicinalis</i>	1768
<i>Acidum alginicum</i>	1781	<i>Aer medicinalis artificiosus</i>	1770
<i>Acidum amidotrizoicum dihydricum</i>	1812	<i>Aether</i>	2577
<i>Acidum aminocaproicum</i>	1821	<i>Aether anaestheticus</i>	2577
<i>Acidum ascorbicum</i>	1877	<i>Aetherolea</i>	864
<i>Acidum asparticum</i>	1883	<i>Agar</i>	1295
<i>Acidum benzoicum</i>	1945	<i>Agni casti fructus</i>	1295
<i>Acidum boricum</i>	1993	<i>Agni casti fructus extractum siccum</i>	1296
<i>Acidum caprylicum</i>	2073	<i>Agrimoniae herba</i>	1297
<i>Acidum chenodeoxycholicum</i>	2163	<i>Akebiae caulis</i>	1298
<i>Acidum citricum</i>	2235	<i>Alaninum</i>	1771
<i>Acidum citricum monohydricum</i>	2236	<i>Albendazolum</i>	1773
<i>Acidum edeticum</i>	2492	<i>Albumini humani solutio</i>	2832
<i>Acidum etacrynicum</i>	2563	<i>Alchemillae herba</i>	1300
<i>Acidum folicum hydricum</i>	2690	<i>Alcohol 2,4-dichlorobenzylis</i>	2390
<i>Acidum formicum</i>	2703	<i>Alcohol benzylis</i>	1949
<i>Acidum fusidicum</i>	2719	<i>Alcohol cetylicus</i>	2160
<i>Acidum glutamicum</i>	2762	<i>Alcohol cetylicus et stearylicus</i>	2155
<i>Acidum hydrochloridum concentratum</i>	2879	<i>Alcohol cetylicus et stearylicus emulsificans A</i>	2156
<i>Acidum hydrochloridum dilutum</i>	2879	<i>Alcohol cetylicus et stearylicus emulsificans B</i>	2157
<i>Acidum iopanoicum</i>	2980	<i>Alcohol isopropylis</i>	3003
<i>Acidum ioxaglicum</i>	2986	<i>Alcohol oleicus</i>	3412
<i>Acidum lacticum</i>	3050	<i>Alcohol stearylicus</i>	3900
<i>Acidum lactobionicum</i>	3053	<i>Alcoholes adipis lanae</i>	4210
<i>Acidum maleicum</i>	3168	<i>Alcuronii chloridum</i>	1774
<i>Acidum malicum</i>	3169	<i>Alfacalcidolum</i>	1776
<i>Acidum medronicum ad radiopharmaceutica</i>	1219	<i>Alfadexum</i>	1777
<i>Acidum mefenamicum</i>	3186	<i>Alfentanili hydrochloridum hydricum</i>	1778
<i>Acidum nalidixicum</i>	3323	<i>Alfuzosini hydrochloridum</i>	1780
<i>Acidum nicotinicum</i>	3359	<i>Alimemazini hemitartras</i>	1782
<i>Acidum niflumicum</i>	3362	<i>Allantoinum</i>	1783
<i>Acidum nitricum</i>	3373	<i>Allii sativi bulbi pulvis</i>	1446
<i>Acidum oleicum</i>	3411	<i>Allium sativum ad praeparationes homoeopathicas</i>	1701
<i>Acidum oxolinicum</i>	3451	<i>Allopurinolum</i>	1784
<i>Acidum palmiticum</i>	3473	<i>Almagatum</i>	1786
<i>Acidum phosphoricum concentratum</i>	3553	<i>Almotriptani malas</i>	10.1-4373
<i>Acidum phosphoricum dilutum</i>	3553	<i>Aloe barbadensis</i>	1301
<i>Acidum picricum ad praeparationes homoeopathicas</i>	1698	<i>Aloe capensis</i>	1302
		<i>Aloes extractum siccum normatum</i>	1303
		<i>Alovudini (¹⁸F) solutio iniectionis</i>	1181
		<i>Alprazolamum</i>	1788
		<i>Alprenololi hydrochloridum</i>	1790
		<i>Alprostadilum</i>	1791

<i>Alteplasm ad iniectabile</i>	1793	<i>Aprotininum</i>	1864
<i>Althaeae folium</i>	1525	<i>Aqua ad dilutionem solutionum concentratarum ad haemodialysim</i>	2797
<i>Althaeae radix</i>	1526	<i>Aqua ad extracta praeparanda</i>	4206
<i>Altizidum</i>	10.1 -4374	<i>Aqua ad iniectabile</i>	4203
<i>Alumen</i>	1798	<i>Aqua purificata</i>	4207
<i>Aluminii chloridum hexahydricum</i>	1798	<i>Aquae (¹⁵O) solutio iniectabilis</i>	1264
<i>Aluminii hydroxidum hydricum ad adsorptionem</i>	1798	<i>Aquae trititae (³H) solutio iniectabilis</i>	1263
<i>Aluminii magnesi silicas</i>	1799	<i>Arachidis oleum hydrogenatum</i>	1869
<i>Aluminii natrri silicas</i>	1803	<i>Arachidis oleum raffinatum</i>	1870
<i>Aluminii oxidum hydricum</i>	1801	<i>Argenti nitras</i>	3790
<i>Aluminii phosphas hydricus</i>	1803	<i>Argentum colloidal ad usum externum</i>	3790
<i>Aluminii phosphatis liquamen</i>	1802	<i>Arginini aspartas</i>	1871
<i>Aluminii stearas</i>	1804	<i>Arginini hydrochloridum</i>	1872
<i>Aluminii sulfas</i>	1806	<i>Argininum</i>	1870
<i>Alverini citras</i>	1807	<i>Argon</i>	1873
<i>Amanita phalloides ad praeparationes homoeopathicas</i>	1699	<i>Aripiprazolum</i>	1874
<i>Amantadini hydrochloridum</i>	1808	<i>Arnicae flos</i>	1318
<i>Ambroxoli hydrochloridum</i>	1809	<i>Arnicae tinctura</i>	1320
<i>Amfetamini sulfas</i>	1810	<i>Arsenii trioxidum ad praeparationes homoeopathicas</i>	1704
<i>Amikacini sulfas</i>	1815	<i>Articaini hydrochloridum</i>	1876
<i>Amikacinum</i>	1813	<i>Ascorbylis palmitas</i>	1879
<i>Amiloridi hydrochloridum dihydricum</i>	10.1 -4375	<i>Asparaginum monohydricum</i>	10.1 -4376
<i>Aminoglutethimidum</i>	1821	<i>Aspartamum</i>	1881
<i>Amiodaroni hydrochloridum</i>	1823	<i>Astragali mongholici radix</i>	1325
<i>Amisulpridum</i>	1825	<i>Atazanaviri sulfas</i>	10.1 -4378
<i>Amitriptylini hydrochloridum</i>	1826	<i>Atenololum</i>	10.1 -4380
<i>Amlodipini besilas</i>	1827	<i>Atomoxetini hydrochloridum</i>	1889
<i>Ammoniae (¹³N) solutio iniectabilis</i>	1183	<i>Atorvastatinum calcicum trihydricum</i>	1890
<i>Ammoniae solutio concentrata</i>	1829	<i>Atovaquonum</i>	1892
<i>Ammonii bromidum</i>	1832	<i>Atractylodis lanceae rhizoma</i>	1327
<i>Ammonii carbonas ad praeparationes homoeopathicas</i>	1701	<i>Atractylodis macrocephalae rhizoma</i>	1328
<i>Ammonii chloridum</i>	1832	<i>Atracurii besilas</i>	1894
<i>Ammonii glycyrrhizas</i>	1833	<i>Atropa belladonna ad praeparationes homoeopathicas</i>	1705
<i>Ammonii hydrogenocarbonas</i>	1834	<i>Atropini sulfas</i>	1898
<i>Ammonio methacrylatis copolymerum A</i>	1830	<i>Atropinum</i>	1897
<i>Ammonio methacrylatis copolymerum B</i>	1831	<i>Aucklandiae radix</i>	1329
<i>Amobarbitalum</i>	1834	<i>Aurantii amari epicarpri et mesocarpri tinctura</i>	1353
<i>Amobarbitalum natricum</i>	1835	<i>Aurantii amari epicarpium et mesocarpium</i>	1352
<i>Amomi fructus</i>	1304	<i>Aurantii amari flos</i>	1353
<i>Amomi fructus rotundus</i>	1604	<i>Aurantii dulcis aetheroleum</i>	1641
<i>Amorolfini hydrochloridum</i>	1836	<i>Auricularia</i>	908
<i>Amoxicillinum natricum</i>	1838	<i>Azaperonum ad usum veterinarium</i>	1900
<i>Amoxicillinum trihydricum</i>	1840	<i>Azathioprinum</i>	1901
<i>Amphotericinum B</i>	1842	<i>Azelastini hydrochloridum</i>	1902
<i>Ampicillinum</i>	1844	<i>Azithromycinum</i>	1904
<i>Ampicillinum natricum</i>	1846		
<i>Ampicillinum trihydricum</i>	1849	B	
<i>Amygdalae oleum raffinatum</i>	1787	<i>Bacampicillini hydrochloridum</i>	1911
<i>Amygdalae oleum virginale</i>	1787	<i>Bacitracinum</i>	1913
<i>Amyla hydroxyethyla</i>	3892	<i>Bacitracinum zincum</i>	1917
<i>Amylmetacresolum</i>	1851	<i>Baclofenum</i>	1921
<i>Amylum hydroxypropylum</i>	3888	<i>Ballotae nigrae herba</i>	1358
<i>Amylum hydroxypropylum pregelificatum</i>	3890	<i>Balsamum peruvianum</i>	1580
<i>Amylum pregelificatum</i>	3891	<i>Balsamum toltanum</i>	1649
<i>Anamirta cocculus ad praeparationes homoeopathicas</i>	1708	<i>Bambuteroli hydrochloridum</i>	1922
<i>Anastrozolum</i>	1852	<i>Barbitalum</i>	1923
<i>Andrographidis herba</i>	1305	<i>Barii chloridum dihydricum ad praeparationes homoeopathicas</i>	1705
<i>Anemarrhenae asphodeloides rhizoma</i>	1307	<i>Barii sulfas</i>	1924
<i>Angelicae archangelicae radix</i>	1309	<i>BCG ad immunocurationem</i>	948
<i>Angelicae dahuricae radix</i>	1310	<i>Beclometasoni dipropionas</i>	1926
<i>Angelicae pubescentis radix</i>	1312	<i>Beclometasoni dipropionas monohydricus</i>	1929
<i>Angelicae sinensis radix</i>	1314	<i>Belamcandae chinensis rhizoma</i>	1334
<i>Anisi aetheroleum</i>	1315	<i>Belladonnae folii extractum siccum normatum</i>	1337
<i>Anisi fructus</i>	1317	<i>Belladonnae folii tinctura normata</i>	1338
<i>Anisi stellati aetheroleum</i>	1636	<i>Belladonnae folium</i>	1336
<i>Anisi stellati fructus</i>	1635	<i>Belladonnae pulvis normatus</i>	1339
<i>Antazolini hydrochloridum</i>	1855	<i>Benazeprili hydrochloridum</i>	1932
<i>Anticorpora monoclonalia ad usum humanum</i>	878	<i>Bendroflumethiazidum</i>	1934
<i>Antithrombinum III humanum densatum</i>	2835	<i>Benperidolum</i>	1935
<i>Apis mellifera ad praeparationes homoeopathicas</i>	1703	<i>Benserazidi hydrochloridum</i>	1936
<i>Apomorphini hydrochloridum hemihydricum</i>	1862		
<i>Aprepitantum</i>	1863		
<i>Aprotinini solutio concentrata</i>	1867		

Bentonitum	1938	Cabergolinum	2031
Benzalkonii chloridi solutio.....	1940	Cadmii sulfas hydricus ad praeparationes homoeopathicas	1707
Benzalkonii chloridum	1938	Calcifediolum monohydricum	2035
Benzathini benzylpenicillinum tetrahydricum	1951	Calcii acetas	2044
Benzathini phenoxymethylpenicillinum tetrahydricum	3531	Calcii ascorbas	2045
Benzbromaronum	1942	Calcii carbonas	2046
Benzethonii chloridum.....	1943	Calcii chloridum dihydricum	2047
Benzocainum	10.1-4385	Calcii chloridum hexahydricum	2047
Benzoe sumatranus	1341	Calcii dobesilas monohydricus	2048
Benzoe tonkinensis	1341	Calcii fluoridum ad praeparationes homoeopathicas	1707
Benzois sumatranii tinctura	1343	Calcii folinas hydricus	2049
Benzois tonkinensis tinctura	1342	Calcii glucoheptonas	2051
Benzoylis peroxidum cum aqua	1946	Calcii gluconas	2052
Benzydamini hydrochloridum	1947	Calcii gluconas ad iniectabile	2053
Benzylis benzoas	1950	Calcii gluconas anhydricus	2052
Benzylpenicillinum kalicum	1953	Calcii glycerophosphas	2054
Benzylpenicillinum natricum	1957	Calcii hydrogenophosphas	2055
Benzylpenicillinum procainum monohydricum	1955	Calcii hydrogenophosphas dihydricus	2056
Betacarotenum	1959	Calcii hydroxidum	2057
Betadexum	1960	Calcii iodidum tetrahydricum ad praeparationes homoeopathicas	1708
Betahistini dihydrochloridum	1962	Calcii lactas	2058
Betahistini mesilas	1963	Calcii lactas monohydricus	2058
Betamethasoni acetas	1966	Calcii lactas pentahydricus	2059
Betamethasoni dipropionas	1968	Calcii lactas trihydricus	2059
Betamethasoni natrii phosphas	1970	Calcii laevulinas dihydricus	2062
Betamethasoni valeras	1971	Calcii levofolinas hydricus	2060
Betamethasonum	1964	Calcii pantothenas	2063
Betaxololi hydrochloridum	1973	Calcii stearas	2065
Betulae folium	1345	Calcii sulfas dihydricus	2067
Bezafibratum	1975	Calcipotriolum	2036
Bicalutamidum	1976	Calcipotriolum monohydricum	2038
Bifonazolum	1977	Calcitoninum salmonis	2040
Biotinum	1979	Calcitriolum	2043
Biperideni hydrochloridum	1980	Calendulae flos	10.1-4353
Bisacodylum	1982	Camelliae sinensis non fermentata folia	1464
Bismuthi subcarbonas	1983	Camphora racemica	2069
Bismuthi subgallas	1984	Candesartanum cilexetili	2070
Bismuthi subnitras ponderosus	1985	Capecitabinum	2072
Bismuthi subsalicylas	1986	Capsici extractum spissum normatum	1374
Bisoprololi fumaras	1986	Capsici fructus	1371
Bistortae rhizoma	1347	Capsici oleoresina raffinata et normata	1373
Bleomycini sulfas	1989	Capsici tinctura normata	1375
Boldi folii extractum siccum	1363	Capsulae	906
Boldi folium	1361	Captoprilum	2075
Boldinum	1990	Carbacholum	2078
Boraginis officinalis oleum raffinatum	1992	Carbamazepinum	2078
Borax	1992	Carbasalatum calcicum	2080
Brimonidini tartras	1998	Carbidopum	2081
Bromazepamum	1999	Carbimazolum	2083
Bromhexini hydrochloridum	2000	Carbo activatus	2162
Bromocriptini mesilas	2001	Carbocisteinum	2084
Bromperidoli decanoas	2005	Carbomera	2085
Bromperidolum	2003	Carbonei dioxidum	2086
Brompheniraminii maleas	2007	Carbonei monoxidum	2088
Brotizolamum	2008	Carbonei monoxidum (¹⁵ O)	1184
Budesonidum	2009	Carbonei monoxidum (5 per centum) in nitrogenio intermixtum	2089
Bufexamacum	2011	Carboplatinum	2089
Bufloxedili hydrochloridum	2012	Carboprostum trometamolium	2090
Bumetanidum	2014	Carboxymethylamylum natricum A	3841
Bupivacaini hydrochloridum	2015	Carboxymethylamylum natricum B	3842
Bupleuri radix	1365	Carboxymethylamylum natricum C	3843
Buprenorphini hydrochloridum	2019	Carisoprodolum	2091
Buprenorphinum	2017	Carmellosum	2092
Buserelinum	2020	Carmellosum calcicum	2093
Buspironi hydrochloridum	2022	Carmellosum natricum	2093
Busulfanum	2024	Carmellosum natricum conexum	2318
Butylhydroxyanisolum	2026	Carmellosum natricum substitutum humile	2094
Butylhydroxytoluenum	2027	Carmustinum	2095
Butylis parahydroxybenzoas	2025	Carprofenum ad usum veterinarium	2097
C		Carrageenanum	2098
C1-esterasi inhibitor humanus	2837		

<i>Carteololi hydrochloridum</i>	2099	<i>Chlorphenamini maleas</i>	2187
<i>Carthami flos</i>	1606	<i>Chlorpromazini hydrochloridum</i>	2188
<i>Carthami oleum raffinatum</i>	3761	<i>Chlorprothixeni hydrochloridum</i>	2189
<i>Carvedilolum</i>	2101	<i>Chlortalidonum</i>	2191
<i>Carvi aetheroleum</i>	1377	<i>Chlortetracyclini hydrochloridum</i>	10.1 -4390
<i>Carvi fructus</i>	1376	<i>Cholecalciferoli pulvis</i>	2198
<i>Caryophylli floris aetheroleum</i>	1396	<i>Cholecalciferolum</i>	2195
<i>Caryophylli flos</i>	1396	<i>Cholecalciferolum densatum oleosum</i>	2197
<i>Cefaclorum</i>	2105	<i>Cholecalciferolum in aqua dispergibile</i>	2199
<i>Cefadroxilum monohydricum</i>	2106	<i>Cholesterolum</i>	2201
<i>Cefalexinum monohydricum</i>	2108	<i>Cholesterolum ad usum parenteralem</i>	2202
<i>Cefalotinum natricum</i>	2109	<i>Cholini (¹⁴C)methyl solutio iniectionis</i>	1185
<i>Cefamandoli naffas</i>	2111	<i>Chondroitini natrii sulfas</i>	2203
<i>Cefapirinum natricum</i>	2112	<i>Chorda resorbilis sterilis</i>	1269
<i>Cefatrizinum propylen glycolum</i>	2113	<i>Chorda resorbilis sterilis in fuso ad usum veterinarium</i>	1281
<i>Cefazolinum natricum</i>	2114	<i>Chromii (⁵¹Cr) edetatis solutio iniectionis</i>	1186
<i>Cefepimi dihydrochloridum monohydricum</i>	2117	<i>Chymotrypsinum</i>	2205
<i>Cefiximum</i>	2119	<i>Ciclesonidum</i>	2206
<i>Cefoperazonum natricum</i>	2120	<i>Ciclopirox olaminum</i>	2209
<i>Cefotaximum natricum</i>	2122	<i>Ciclopiroxum</i>	2208
<i>Cefoxitinum natricum</i>	2124	<i>Ciclosporinum</i>	2210
<i>Cefpodoximum proxetili</i>	2126	<i>Cilastatinum natricum</i>	2212
<i>Cefprozilum monohydricum</i>	2128	<i>Cilazaprilum</i>	2214
<i>Cefradinum</i>	2130	<i>Cimetidini hydrochloridum</i>	2217
<i>Ceftazidimum pentahydricum</i>	2132	<i>Cimetidinum</i>	2215
<i>Ceftazidimum pentahydricum et natrii carbonas ad iniectionem</i>	2134	<i>Cimicifugae rhizoma</i>	1355
<i>Ceftriaxonum natricum</i>	2136	<i>Cinchocaini hydrochloridum</i>	2218
<i>Cefuroximum axetili</i>	2138	<i>Cinchonae cortex</i>	1387
<i>Cefuroximum natricum</i>	2139	<i>Cinchonae extractum fluidum normatum</i>	1389
<i>Celecoxibum</i>	2141	<i>Cineolum</i>	2220
<i>Celiprololi hydrochloridum</i>	2142	<i>Cinnamomi cassiae aetheroleum</i>	1381
<i>Cellulae stirpes haematopoieticae humanae</i>	2857	<i>Cinnamomi cortex</i>	1390
<i>Cellulosi acetas</i>	2143	<i>Cinnamomi zeylanici corticis aetheroleum</i>	1391
<i>Cellulosi acetas butyras</i>	2144	<i>Cinnamomi zeylanici folii aetheroleum</i>	1391
<i>Cellulosi acetas phthalas</i>	2145	<i>Cinnarizinum</i>	2221
<i>Cellulosi pulvis</i>	2150	<i>Ciprofibratum</i>	2222
<i>Cellulosum microcristallinum</i>	2146	<i>Ciprofloxacinum hydrochloridum</i>	2225
<i>Cellulosum microcristallinum et carmellosum natricum</i>	3269	<i>Ciprofloxacinum</i>	2223
<i>Centaurii herba</i>	1382	<i>Cisatracurii besilas</i>	2226
<i>Centellae asiaticae herba</i>	1383	<i>Cisplatinum</i>	2231
<i>Cera alba</i>	1931	<i>Citaloprami hydrobromidum</i>	2232
<i>Cera carnauba</i>	2096	<i>Citaloprami hydrochloridum</i>	2234
<i>Cera flava</i>	1932	<i>Citri reticulatae aetheroleum</i>	1524
<i>Cetirizini dihydrochloridum</i>	2153	<i>Citri reticulatae epicarpium et mesocarpium</i>	1522
<i>Cetobemidoni hydrochloridum</i>	3032	<i>Citronellae aetheroleum</i>	1392
<i>Cetostearyl isononanoas</i>	2159	<i>Cladribinum</i>	2237
<i>Cetrimidum</i>	2159	<i>Clarithromycinum</i>	2238
<i>Cetyl palmitas</i>	2160	<i>Clazurilum ad usum veterinarium</i>	2241
<i>Cetylpyridinii chloridum</i>	2161	<i>Cleopridi malas</i>	2243
<i>Chamomillae romanae flos</i>	1384	<i>Clemastini fumaras</i>	2244
<i>Chelidonii herba</i>	1463	<i>Clematidis armandii caulis</i>	1394
<i>Chinidini sulfas</i>	3687	<i>Clenbuteroli hydrochloridum</i>	2246
<i>Chinini hydrochloridum</i>	3689	<i>Clindamycinum hydrochloridum</i>	2247
<i>Chinini sulfas</i>	3690	<i>Clindamycinum phosphas</i>	2248
<i>Chitosani hydrochloridum</i>	2164	<i>Clioquinolum</i>	2251
<i>Chlorali hydras</i>	2165	<i>Clobazamum</i>	2252
<i>Chlorambucilum</i>	2166	<i>Clobetasoli propionas</i>	10.1 -4392
<i>Chloramphenicoli natrii succinas</i>	2170	<i>Clobetasoni butyras</i>	2255
<i>Chloramphenicoli palmitas</i>	2168	<i>Clofaziminum</i>	2258
<i>Chloramphenicolum</i>	2167	<i>Clofibratum</i>	2259
<i>Chlorcyclizini hydrochloridum</i>	2171	<i>Clomifeni citras</i>	2260
<i>Chlordiazepoxidi hydrochloridum</i>	2173	<i>Clomipramini hydrochloridum</i>	2261
<i>Chlordiazepoxidum</i>	2172	<i>Clonazepamum</i>	2263
<i>Chlorhexidini diacetat</i>	2174	<i>Clonidini hydrochloridum</i>	2264
<i>Chlorhexidini digluconatis solutio</i>	2176	<i>Clopamidum</i>	2265
<i>Chlorhexidini dihydrochloridum</i>	2178	<i>Clopidogregli besilas</i>	2267
<i>Chlormadinoni acetat</i>	2180	<i>Clopidogregli hydrochloridum</i>	2268
<i>Chlorobutanolum</i>	2182	<i>Clopidogregli hydrogenosulfas</i>	2270
<i>Chlorobutanolum hemihydricum</i>	2183	<i>Closantelum natricum dihydricum ad usum veterinarium</i>	2272
<i>Chlorocresolum</i>	2184	<i>Clotrimazolum</i>	2273
<i>Chloroquini phosphas</i>	2185	<i>Cloxacillinum natricum</i>	2275
<i>Chloroquini sulfas</i>	2186	<i>Clozapinum</i>	2276

<i>Cocaini hydrochloridum</i>	2278	<i>Deferipronum</i>	2344
<i>Cocois oleum raffinatum</i>	2279	<i>Deferoxamini mesilas</i>	2347
<i>Cocoylis caprylocapras</i>	2280	<i>Delphinium staphisagria ad praeparationes</i> <i>homoeopathicas</i>	1726
<i>Codeini hydrochloridum dihydricum</i>	2281	<i>Dembrexini hydrochloridum monohydricum ad usum</i> <i>veterinarium</i>	2350
<i>Codeini phosphas hemihydricus</i>	2285	<i>Demeclocyclini hydrochloridum</i>	10.1 -4397
<i>Codeini phosphas sesquihydricus</i>	2288	<i>Deptropini citras</i>	2353
<i>Codeinum monohydricum</i>	2283	<i>Dequalinii chloridum</i>	2354
<i>Codergocrini mesilas</i>	2290	<i>Desfluranum</i>	2357
<i>Codonopsis radix</i>	1397	<i>Desipramini hydrochloridum</i>	2358
<i>Coffeinum</i>	2032	<i>Deslanosidum</i>	2359
<i>Coffeinum monohydricum</i>	2033	<i>Desloratadinum</i>	2360
<i>Coicis semen</i>	1398	<i>Desmopressinum</i>	2361
<i>Colae semen</i>	1400	<i>Desogestrelum</i>	2363
<i>Colchicinum</i>	2303	<i>Detomidini hydrochloridum ad usum veterinarium</i>	2364
<i>Colestyraminum</i>	2305	<i>Dexamethasoni acetas</i>	2367
<i>Colistimethatum natricum</i>	2306	<i>Dexamethasoni isonicotinas</i>	2369
<i>Colistini sulfas</i>	2309	<i>Dexamethasoni natrii phosphas</i>	2370
<i>Colophonium</i>	1401	<i>Dexamethasonum</i>	2365
<i>Compressi</i>	937	<i>Dexamfetamini sulfas</i>	2373
<i>Copolymerum macrogolo et alcoholi poly(vinylco)</i> <i>constatum</i>	3140	<i>Dexchlorphenirami maleas</i>	2374
<i>Copolymerum methacrylatis butylati basicum</i>	1925	<i>Dexpanthenolum</i>	2375
<i>Copovidonum</i>	2311	<i>Dextranomerum</i>	2380
<i>Coptidis rhizoma</i>	1386	<i>Dextranum 1 ad iniectionabile</i>	2376
<i>Coriandri aetheroleum</i>	1404	<i>Dextranum 40 ad iniectionabile</i>	2377
<i>Coriandri fructus</i>	1403	<i>Dextranum 60 ad iniectionabile</i>	2378
<i>Corpora ad usum pharmaceuticum</i>	890	<i>Dextranum 70 ad iniectionabile</i>	2379
<i>Cortisoni acetas</i>	2315	<i>Dextrinum</i>	2380
<i>Corydalis rhizoma</i>	1405	<i>Dextromethorphan hydrobromidum</i>	2381
<i>Crataegi folii cum flore extractum fluidum quantificatum</i>	1473	<i>Dextromoramide tartras</i>	2382
<i>Crataegi folii cum flore extractum siccum</i>	1472	<i>Dextropropoxypheni hydrochloridum</i>	2383
<i>Crataegi folium cum flore</i>	1471	<i>Diacereinum</i>	2384
<i>Crataegi fructus</i>	10.1 -4357	<i>Diazepamum</i>	2386
<i>Cresolum crudum</i>	2318	<i>Diazoxidum</i>	2388
<i>Croci sativi stigma ad praeparationes homoeopathicas</i>	1710	<i>Dibrompropamidini diisetonas</i>	2388
<i>Crospovidonum</i>	2319	<i>Dibutylis phthalas</i>	2389
<i>Crotamitonum</i>	2321	<i>Diclazurilum ad usum veterinarium</i>	2391
<i>Cupri acetas monohydricus ad praeparationes</i> <i>homoeopathicas</i>	1711	<i>Diclofenacum kalicum</i>	2393
<i>Cupri sulfas</i>	2313	<i>Diclofenacum natricum</i>	2394
<i>Cupri sulfas pentahydricus</i>	2314	<i>Dicloxacillinum natricum</i>	2396
<i>Cupri tetramibi tetrafluoroboras ad radiopharmaceutica</i>	1187	<i>Dicycloverini hydrochloridum</i>	2397
<i>Cuprum ad praeparationes homoeopathicas</i>	1712	<i>Didanosinum</i>	2398
<i>Curcumae longae rhizoma</i>	1653	<i>Dienogestum</i>	2400
<i>Curcumae zanthorrhizae rhizoma</i>	1652	<i>Diethylcarbamazini citras</i>	2403
<i>Cyamopsidis seminis pulvis</i>	1466	<i>Diethylenglycoli aether monoethylicus</i>	2404
<i>Cyanocobalamini (⁵⁷Co) capsulae</i>	1188	<i>Diethylenglycoli palmitostearas</i>	2405
<i>Cyanocobalamini (⁵⁷Co) solutio</i>	1188	<i>Diethylis phthalas</i>	2402
<i>Cyanocobalamini (⁵⁸Co) capsulae</i>	1189	<i>Diethylstilbestrolum</i>	2406
<i>Cyanocobalamini (⁵⁸Co) solutio</i>	1189	<i>Difloxacin hydrochloridum trihydricum ad usum</i> <i>veterinarium</i>	2407
<i>Cyanocobalaminum</i>	2322	<i>Digitalis purpurea ad praeparationes homoeopathicas</i>	1712
<i>Cyclizini hydrochloridum</i>	2323	<i>Digitalis purpureae folium</i>	1412
<i>Cyclopentolati hydrochloridum</i>	2324	<i>Digitoxinum</i>	2409
<i>Cyclophosphamidum</i>	2326	<i>Digoxinum</i>	2410
<i>Cynarae folii extractum siccum</i>	1323	<i>Dihydralazini sulfas hydricus</i>	2413
<i>Cynarae folium</i>	1321	<i>Dihydrocodeini hydrogenotartras</i>	2414
<i>Cyproheptadini hydrochloridum</i>	2326	<i>Dihydrogocristini mesilas</i>	2415
<i>Cyproteroni acetas</i>	2327	<i>Dihydroergotamini mesilas</i>	2418
<i>Cysteini hydrochloridum monohydricum</i>	2329	<i>Dihydrostreptomycini sulfas ad usum veterinarium</i>	2420
<i>Cystinum</i>	2331	<i>Dihydrotachysterolum</i>	2422
<i>Cytarabinum</i>	2332	<i>Dikalii clorazepas monohydricus</i>	2439
D		<i>Dikalii phosphas</i>	2440
<i>Dacarbazinum</i>	2337	<i>Diltiazemi hydrochloridum</i>	2423
<i>Dalteparinum natricum</i>	2338	<i>Dimenhydrinatum</i>	2425
<i>Danaparoidum natricum</i>	2340	<i>Dimercaprolum</i>	2426
<i>Dapsonum</i>	2342	<i>Dimethylacetamidum</i>	2428
<i>Daunorubicini hydrochloridum</i>	2343	<i>Dimethylis sulfoxidum</i>	10.1 -4398
<i>D-Camphora</i>	2067	<i>Dimeticonum</i>	2429
<i>Decylis oleas</i>	2344	<i>Dimetinden maleas</i>	2429
<i>Deferiproni compressi</i>	2346	<i>Dinatrii clodronas tetrahydricus</i>	2257
<i>Deferiproni solutio peroralis</i>	2345	<i>Dinatrii edetas</i>	2445
		<i>Dinatrii etidronas</i>	2589

<i>Dinatrii pamidronas pentahydricus</i>	3474	<i>Ephedri racemici hydrochloridum</i>	2513
<i>Dinatrii phosphas</i>	2446	<i>Ephedrinum</i>	2510
<i>Dinatrii phosphas dihydricus</i>	2447	<i>Ephedrinum hemihydricum</i>	2511
<i>Dinatrii phosphas dodecahydricus</i>	2447	<i>Epinastini hydrochloridum</i>	2513
<i>Dinitrogenii oxidum</i>	3377	<i>Epirubicini hydrochloridum</i>	2514
<i>Dinoprostomum</i>	2432	<i>Eplerenonum</i>	2516
<i>Dinoprostum trometamolom</i>	2431	<i>Equiseti herba</i>	1426
<i>Dioscoreae nipponicae rhizoma</i>	1413	<i>Ergocalciferolum</i>	2518
<i>Dioscoreae oppositifoliae rhizoma</i>	1414	<i>Ergometrini maleas</i>	10.1 -4407
<i>Diosminum</i>	2433	<i>Ergotamini tartras</i>	2521
<i>Diphenhydramini hydrochloridum</i>	2435	<i>Erythritolum</i>	2522
<i>Diphenoxylati hydrochloridum</i>	2436	<i>Erythromycini estolas</i>	2527
<i>Dipivefrini hydrochloridum</i>	2437	<i>Erythromycini ethylsuccinas</i>	2531
<i>Diprophyllinum</i>	10.1 -4399	<i>Erythromycini lactobionas</i>	2533
<i>Dipyridamolum</i>	2442	<i>Erythromycini stearas</i>	2537
<i>Dirithromycinum</i>	2444	<i>Erythromycinum</i>	2524
<i>Disopyramidi phosphas</i>	2449	<i>Erythropoietini solutio concentrata</i>	2540
<i>Disopyramidum</i>	2448	<i>Escitaloprami oxalas</i>	10.1 -4408
<i>Disulfiramum</i>	2450	<i>Escitalopramum</i>	2544
<i>Dithranolum</i>	2451	<i>Eserini salicylas</i>	3554
<i>DL-Methioninum</i>	3225	<i>Esketamini hydrochloridum</i>	2548
<i>DL-α-Tocopherylis hydrogenosuccinas</i>	4062	<i>Esomeprazolum magnesium dihydricum</i>	2549
<i>Dobutamini hydrochloridum</i>	2452	<i>Esomeprazolum magnesium trihydricum</i>	2551
<i>Docetaxelum</i>	2453	<i>Esomeprazolum natricum</i>	2553
<i>Docetaxelum trihydricum</i>	2455	<i>Estradioli benzoas</i>	2555
<i>Dodecylis gallas</i>	2457	<i>Estradioli valeras</i>	2557
<i>Domperidoni maleas</i>	2460	<i>Estradiolum hemihydricum</i>	2556
<i>Domperidonum</i>	2458	<i>Estrilolum</i>	2559
<i>Donepezili hydrochloridum</i>	10.1 -4400	<i>Estrogeni coniuncti</i>	2561
<i>Donepezili hydrochloridum monohydricum</i>	10.1 -4401	<i>Etamsylatum</i>	2565
<i>Dopamini hydrochloridum</i>	2461	<i>Etanerceptum</i>	2566
<i>Dopexamini dihydrochloridum</i>	2463	<i>Ethacridini lactas monohydricus</i>	2570
<i>Dorzolamidi hydrochloridum</i>	2464	<i>Ethambutoli hydrochloridum</i>	2571
<i>Dosulepini hydrochloridum</i>	2466	<i>Ethanolum (96 per centum)</i>	2573
<i>Doxaprami hydrochloridum</i>	2467	<i>Ethanolum anhydricum</i>	2575
<i>Doxazosini mesilas</i>	2468	<i>Ethinylestradiolum</i>	2578
<i>Doxepini hydrochloridum</i>	2470	<i>Ethionamidum</i>	2580
<i>Doxorubicini hydrochloridum</i>	2471	<i>Ethosuximidum</i>	2581
<i>Doxycyclini hyclas</i>	2472	<i>Ethylcellulosum</i>	2585
<i>Doxycyclinum monohydricum</i>	2474	<i>Ethylendiaminum</i>	2587
<i>Doxylamini hydrogenosuccinas</i>	2476	<i>Ethylenglycoli monopalmitostearas</i>	2586
<i>Dronedaroni hydrochloridum</i>	2477	<i>Ethylis acetas</i>	2582
<i>Droperidolum</i>	2478	<i>Ethylis oleas</i>	2583
<i>Drospirenonum</i>	2480	<i>Ethylis parahydroxybenzoas</i>	2583
<i>Drynariae rhizoma</i>	1416	<i>Ethylis parahydroxybenzoas natricus</i>	3816
<i>Duloxetine hydrochloridum</i>	2481	<i>Ethylmorphini hydrochloridum</i>	2587
<i>Dutasteridum</i>	2483	<i>Etilefrini hydrochloridum</i>	2589
<i>Dydrogesteronum</i>	2485	<i>Etodolacum</i>	2591
E		<i>Etofenamatum</i>	2593
<i>Ebastinum</i>	2489	<i>Etomidatum</i>	2595
<i>Echinaceae angustifoliae radix</i>	1548	<i>Etoposidum</i>	2596
<i>Echinaceae pallidae radix</i>	1568	<i>Eucalypti aetheroleum</i>	1429
<i>Echinaceae purpureae herba</i>	1589	<i>Eucalypti folium</i>	1428
<i>Echinaceae purpureae radix</i>	1591	<i>Eucommiae cortex</i>	1430
<i>Ecliptae herba</i>	1420	<i>Eugenolum</i>	2599
<i>Econazoli nitras</i>	2491	<i>Everolimusum</i>	2601
<i>Econazolum</i>	2490	<i>Evodiae fructus</i>	1431
<i>Edrophonii chloridum</i>	2493	<i>Exemestatum</i>	10.1 -4410
<i>Eleutherococci radix</i>	1423	F	
<i>Emedastini difumaras</i>	2496	<i>Factor humanus von Willebrandi</i>	2875
<i>Emplastra transcutanea</i>	925	<i>Factor IX coagulationis humanus</i>	2846
<i>Enalaprilatum dihydricum</i>	2499	<i>Factor VII coagulationis humanus</i>	2838
<i>Enalapрили maleas</i>	2497	<i>Factor VIII coagulationis humanus</i>	2844
<i>Enilconazolum ad usum veterinarium</i>	2500	<i>Factor VIII coagulationis humanus (ADNr)</i>	2845
<i>Enoxaparinum natricum</i>	2502	<i>Factor XI coagulationis humanus</i>	2855
<i>Enoxololum</i>	2504	<i>Factoris IX coagulationis humani (ADNr) pulvis ad solutionem iniectionabilem</i>	2853
<i>Enrofloxacinum ad usum veterinarium</i>	2505	<i>Factoris IX coagulationis humani (ADNr) solutio concentrata</i>	2848
<i>Entacaponum</i>	2507	<i>Factoris VIIa coagulationis humani (ADNr) solutio concentrata</i>	2840
<i>Entecavirum monohydricum</i>	2508		
<i>Ephedrae herba</i>	1425		
<i>Ephedri hydrochloridum</i>	2511		

<i>Fagopyri herba</i>	1364	<i>Flurazepamum monohydrochloridum</i>	2679
<i>Famotidinum</i>	2609	<i>Flurbiprofenum</i>	2680
<i>Febantelum ad usum veterinarium</i>	2610	<i>Fluspirilenum</i>	2681
<i>Felbinacum</i>	2611	<i>Flutamidum</i>	2682
<i>Felodipinum</i>	2612	<i>Fluticasoni propionas</i>	2683
<i>Felypressinum</i>	2614	<i>Flutrimazolum</i>	2685
<i>Fenbendazolum ad usum veterinarium</i>	2615	<i>Fluvastatinum natricum</i>	2686
<i>Fenbufenum</i>	2616	<i>Fluvoxamini maleas</i>	2688
<i>Fenofibratum</i>	2617	<i>Foeniculi amari fructus</i>	1433
<i>Fenoteroli hydrobromidum</i>	2618	<i>Foeniculi amari fructus aetheroleum</i>	1348
<i>Fentanyl citras</i>	2621	<i>Foeniculi amari herbae aetheroleum</i>	1350
<i>Fentanylum</i>	2619	<i>Foeniculi dulcis fructus</i>	1434
<i>Fenticonazoli nitras</i>	2622	<i>Follitropini solutio concentrata</i>	2697
<i>Ferri chloridum hexahydricum</i>	2624	<i>Follitropinum</i>	2691
<i>Ferrosi fumaras</i>	2624	<i>Formaldehydi solutio (35 per centum)</i>	2703
<i>Ferrosi gluconas</i>	2625	<i>Formoteroli fumaras dihydricus</i>	2704
<i>Ferrosi sulfas desiccatus</i>	2626	<i>Foscarnetum natricum hexahydricum</i>	2706
<i>Ferrosi sulfas heptahydricus</i>	2627	<i>Fosfomycinum calcicum</i>	2708
<i>Ferrum ad praeparationes homoeopathicas</i>	1714	<i>Fosfomycinum natricum</i>	2709
<i>Fexofenadini hydrochloridum</i>	2628	<i>Fosfomycinum trometamolom</i>	2710
<i>Fibrini glutinum</i>	2630	<i>Fosinoprilum natricum</i>	2711
<i>Fibrinogenum humanum</i>	2856	<i>Fragmenta epithelii phaneraeque bestiarum ad producta allergenica</i>	1854
<i>Fila non resorbilia sterilia</i>	1270	<i>Framycetini sulfas</i>	2714
<i>Fila non resorbilia sterilia in fuso ad usum veterinarium</i> ..	1283	<i>Frangulae cortex</i>	1439
<i>Fila resorbilia synthetica monofilamenta sterilia</i>	1275	<i>Frangulae corticis extractum siccum normatum</i>	1441
<i>Fila resorbilia synthetica torta sterilia</i>	1274	<i>Fraxini chinensis cortex</i>	10.1 -4356
<i>Filgrastimi solutio concentrata</i>	2631	<i>Fraxini folium</i>	1324
<i>Filgrastimi solutio iniectionis</i>	2634	<i>Fructosum</i>	2715
<i>Filipendulae ulmariae herba</i>	1533	<i>Fucus vel Ascophyllum</i>	1494
<i>Filum bombycis tortum sterile in fuso ad usum veterinarium</i>	1283	<i>Fulvestrantum</i>	2716
<i>Filum ethyleni polyterephthalici sterile in fuso ad usum veterinarium</i>	1283	<i>Fumariae herba</i>	1444
<i>Filum lini sterile in fuso ad usum veterinarium</i>	1282	<i>Furosemidum</i>	2718
<i>Filum polyamidi sterile in fuso ad usum veterinarium</i>	1282	G	
<i>Finasteridum</i>	2636	<i>Gabapentinum</i>	2725
<i>Fingolimodi hydrochloridum</i>	2637	<i>Gadobutrolum monohydricum</i>	2726
<i>Fipronilum ad usum veterinarium</i>	2639	<i>Gadodiamidum hydricum</i>	2728
<i>Flavoxati hydrochloridum</i>	2642	<i>Galactosum</i>	2730
<i>Flecainidi acetat</i>	2643	<i>Galantamini hydrobromidum</i>	2731
<i>Flubendazolum</i>	2644	<i>Gallii (⁶⁷Ga) citratis solutio iniectionis</i>	1206
<i>Flucloxacillinum magnesicum octahydricum</i>	2645	<i>Gallii (⁶⁸Ga) chloridi solutio ad radio-signandum</i>	1206
<i>Flucloxacillinum natricum</i>	2647	<i>Gallii (⁶⁸Ga) edotreotidi solutio iniectionis</i>	1208
<i>Fluconazolum</i>	2649	<i>Gammadexum</i>	10.1 -4423
<i>Flucytosinum</i>	2650	<i>Ganciclovirum</i>	2735
<i>Fludarabini phosphas</i>	2652	<i>Gardeniae fructus</i>	1369
<i>Fludeoxyglucosi (¹⁸F) solutio iniectionis</i>	1190	<i>Gastrodiae rhizoma</i>	1447
<i>Fludrocortisoni acetat</i>	2654	<i>Gefitinibum</i>	2737
<i>Flumazenili (N-[¹¹C]methyl) solutio iniectionis</i>	1192	<i>Gelatina</i>	2738
<i>Flumazenilum</i>	2655	<i>Gemcitabini hydrochloridum</i>	2739
<i>Flumequinum</i>	2657	<i>Gemfibrozilum</i>	2740
<i>Flumetasoni pivalas</i>	2658	<i>Gentamicini sulfas</i>	2742
<i>Flunarizini dihydrochloridum</i>	2659	<i>Gentianae radix</i>	1448
<i>Flunitrazepamum</i>	2660	<i>Gentianae tinctura</i>	1449
<i>Flunixin megluminum ad usum veterinarium</i>	2661	<i>Gestodenum</i>	2744
<i>Fluocinoloni acetamidum</i>	2662	<i>Ginkgonis extractum siccum raffinatum et quantificatum</i> ..	1451
<i>Fluocortoloni pivalas</i>	10.1 -4415	<i>Ginkgonis folium</i>	1454
<i>Fluoresceinum</i>	2666	<i>Ginseng extractum siccum</i>	1457
<i>Fluoresceinum natricum</i>	2667	<i>Ginseng radix</i>	1455
<i>Fluoridi (¹⁸F) solutio ad radio-signandum</i>	1194	<i>Glibenclamidum</i>	2746
<i>Fluorocholini (¹⁸F) solutio iniectionis</i>	1195	<i>Gliclazidum</i>	2747
<i>Fluorodopae (¹⁸F) ab electrophila substitutione solutio iniectionis</i>	1197	<i>Glimepiridum</i>	2749
<i>Fluorodopae (¹⁸F) ab nucleophila substitutione solutio iniectionis</i>	1198	<i>Glipizidum</i>	2751
<i>Fluoroethyl-L-tyrosini (¹⁸F) solutio iniectionis</i>	1201	<i>Glossa</i>	905
<i>Fluoromisonidazoli (¹⁸F) solutio iniectionis</i>	1204	<i>Glucagonum humanum</i>	2753
<i>Fluorouracilum</i>	2669	<i>Glucosamini hydrochloridum</i>	2754
<i>Fluoxetini hydrochloridum</i>	2670	<i>Glucosamini sulfas kalii chloridum</i>	2755
<i>Flupentixoli dihydrochloridum</i>	2672	<i>Glucosamini sulfas natrii chloridum</i>	2757
<i>Fluphenazini decanoas</i>	10.1 -4416	<i>Glucosum</i>	2758
<i>Fluphenazini dihydrochloridum</i>	2675	<i>Glucosum liquidum</i>	2759
<i>Fluphenazini enantas</i>	10.1 -4418	<i>Glucosum liquidum dispersione desiccatum</i>	2760
		<i>Glucosum monohydricum</i>	2761

Glutathionum	2763	Hydrocortisoni hydrogenosuccinas.....	2888
Glycerol-formalum	2769	Hydrocortisonum	2883
Glyceroli dibehenas	2767	Hydrogenii peroxidum 3 per centum	2889
Glyceroli distearas	2768	Hydrogenii peroxidum 30 per centum	2890
Glyceroli monocaprylas	2770	Hydromorphoni hydrochloridum	2890
Glyceroli monocaprylocapras	2771	Hydroxocobalamini acetate	2892
Glyceroli monolinoleas	2772	Hydroxocobalamini chloridum.....	2893
Glyceroli mono-oleas.....	2773	Hydroxocobalamini sulfas.....	2894
Glyceroli monostearas 40-55.....	2774	Hydroxycarbamidum.....	2895
Glyceroli trinitratis solutio	2775	Hydroxychloroquini sulfas	2896
Glycerolum.....	2765	Hydroxyethylcellulosum	2898
Glycerolum (85 per centum)	2766	Hydroxyethylis salicylas.....	2897
Glycinum.....	2777	Hydroxypropylbetadexum	2901
Glycopyrronii bromidum.....	2779	Hydroxypropylcellulosum.....	2903
Gonadorelini acetate	2781	Hydroxypropylcellulosum substitutum humile	2904
Gonadotrophinum chorionicum.....	2782	Hydroxyzini hydrochloridum	2906
Gonadotropinum sericum equinum ad usum veterinarium.....	2783	Hymecromonum.....	2907
Goserelinum.....	2783	Hymenopteri venena ad producta allergenica	2908
Gossypii oleum hydrogenatum.....	2317	Hyoscini butylbromidum.....	2910
Gramicidinum	2785	Hyoscini hydrobromidum	2911
Graminis rhizoma	1407	Hyoscinum	2909
Granisetroni hydrochloridum	2787	Hyoscyamini sulfas	2913
Granula ad praeparationes homoeopathicas.....	1696	Hyoscyamus niger ad praeparationes homoeopathicas	1717
Granula homoeopathica imbuta.....	1697	Hyperici herba	1631
Granula homoeopathica velata	1697	Hyperici herbae extractum siccum quantificatum.....	1633
Granulata	912	Hypericum perforatum ad praeparationes homoeopathicas.....	1718
Griseofulvinum.....	2788	Hypromellosi phthalas	2916
Guaiacolum	2789	Hypromellosum	2914
Guaiifenesinum.....	2791		
Guanethidini monosulfas	2792	I	
Guar galactomannanum	2793	Ibuprofenum	2921
Guaranae semen.....	1467	Ichthammolum	2923
		Idoxuridinum	2924
H		Iecoris aselli domestici oleum.....	2291
Halofantrini hydrochloridum	2805	Iecoris aselli oleum A	2295
Haloperidoli decanoas	2808	Iecoris aselli oleum B	2299
Haloperidolum	2806	Ifosfamidum.....	2925
Halothanum.....	2809	Imatinibi mesilas	2926
Hamamelidis cortex.....	1468	Imidaclopridum ad usum veterinarium	2929
Hamamelidis folium	1469	Imipenemum monohydricum	2930
Harpagophyti extractum siccum.....	1410	Imipramini hydrochloridum	2931
Harpagophyti radix.....	1411	Immunoglobulinum anti-T lymphocytorum ex animali ad usum humanum.....	1858
Hedera helix ad praeparationes homoeopathicas	1715	Immunoglobulinum humanum anti-D	2834
Hederae folium	1489	Immunoglobulinum humanum anti-D ad usum intravenosum.....	2835
Helianthi annui oleum raffinatum.....	3948	Immunoglobulinum humanum hepatitis A	2858
Helium.....	2814	Immunoglobulinum humanum hepatitis B	2858
Heparina massae molecularis minoris.....	2818	Immunoglobulinum humanum hepatitis B ad usum intravenosum.....	2859
Heparinum calcicum	2814	Immunoglobulinum humanum morbillicum	2859
Heparinum natricum.....	2816	Immunoglobulinum humanum normale ad usum intramusculum.....	2860
Heptaminoli hydrochloridum	2821	Immunoglobulinum humanum normale ad usum intravenosum.....	2862
Hexamidini diisetionas.....	2822	Immunoglobulinum humanum normale ad usum subdermicum	2864
Hexetidinum	2823	Immunoglobulinum humanum rabicum.....	2871
Hexylresorcinolum	2824	Immunoglobulinum humanum rubellae	2872
Hibisci sabdariffae flos.....	1600	Immunoglobulinum humanum tetanicum.....	2873
Hippocastani semen	1475	Immunoglobulinum humanum varicellae.....	2875
Hippocastani seminis extractum siccum normatum.....	1477	Immunoglobulinum humanum varicellae ad usum intravenosum.....	2875
Histamini dihydrochloridum	2825	Immunosera ad usum veterinarium	873
Histaminum ad praeparationes homoeopathicas.....	1716	Immunosera ex animale ad usum humanum	871
Histidini hydrochloridum monohydricum.....	2827	Immunoserum botulinicum	1169
Histidinum	2826	Immunoserum contra venena viperarum europaearum.....	1174
Homatropini hydrobromidum	2829	Immunoserum diphthericum	1170
Homatropini methylbromidum	2830	Immunoserum gangraenicum (Clostridium novyi).....	1171
Houttuyniae herba	1478	Immunoserum gangraenicum (Clostridium perfringens) ...	1171
Hyaluronidasum	2877	Immunoserum gangraenicum (Clostridium septicum).....	1172
Hydralazini hydrochloridum	2878		
Hydrargyri dichloridum	3202		
Hydrastis canadensis ad praeparationes homoeopathicas ..	1716		
Hydrastis rhizoma	1461		
Hydrochlorothiazidum	2879		
Hydrocodoni hydrogenotartras 2.5-hydricus	2881		
Hydrocortisoni acetate	2886		

<i>Immunoserum gangraenicum mixtum</i>	1170	<i>Juniperi aetheroleum</i>	1493
<i>Immunoserum tetanicum ad usum humanum</i>	1173	<i>Juniperi galbulus</i>	1492
<i>Immunoserum tetanicum ad usum veterinarium</i>	1177		
<i>Indapamidum</i>	2932	K	
<i>Indii (¹¹¹In) chloridi solutio</i>	1211	<i>Kalii acetas</i>	3596
<i>Indii (¹¹¹In) oxini solutio</i>	1212	<i>Kalii bichromas ad praeparationes homoeopathicas</i>	1721
<i>Indii (¹¹¹In) pentetatis solutio iniectionabilis</i>	1213	<i>Kalii bromidum</i>	3597
<i>Indinaviri sulfas</i>	2934	<i>Kalii carbonas</i>	3598
<i>Indometacinum</i>	2936	<i>Kalii chloridum</i>	3598
<i>Infliximabum solutio concentrata</i>	2938	<i>Kalii citras</i>	3599
<i>Inhalanda</i>	927	<i>Kalii clavulanas</i>	3599
<i>Insulini zinci amorphi suspensio iniectionabilis</i>	2962	<i>Kalii clavulanas dilutus</i>	3602
<i>Insulini zinci cristallini suspensio iniectionabilis</i>	2962	<i>Kalii dihydrogenophosphas</i>	3603
<i>Insulini zinci suspensio iniectionabilis</i>	2961	<i>Kalii hydrogenoaspartas hemihydricus</i>	3604
<i>Insulinum aspartum</i>	2945	<i>Kalii hydrogenocarbonas</i>	3605
<i>Insulinum biphasicum iniectionabile</i>	2953	<i>Kalii hydrogenotartras</i>	3605
<i>Insulinum glarginum</i>	2949	<i>Kalii hydroxidum</i>	3606
<i>Insulinum humanum</i>	2951	<i>Kalii iodidum</i>	3606
<i>Insulinum isophanum biphasicum iniectionabile</i>	2953	<i>Kalii metabisulfis</i>	3607
<i>Insulinum isophanum iniectionabile</i>	2954	<i>Kalii natrii tartras tetrahydricus</i>	3609
<i>Insulinum lisprum</i>	2954	<i>Kalii nitras</i>	3607
<i>Insulinum porcinum</i>	2957	<i>Kalii perchloras</i>	3608
<i>Insulinum solubile iniectionabile</i>	2954	<i>Kalii permanganas</i>	3609
<i>Interferoni alfa-2 solutio concentrata</i>	2963	<i>Kalii sorbas</i>	3610
<i>Interferoni beta-1a solutio concentrata</i>	2965	<i>Kalii sulfas</i>	3610
<i>Interferoni gamma-1b solutio concentrata</i>	2968	<i>Kanamycini monosulfas</i>	3030
<i>int-rac-α-Tocopherolum</i>	4057	<i>Kanamycini sulfas acidus</i>	3029
<i>int-rac-α-Tocopherylis acetas</i>	4059	<i>Kaolinum ponderosum</i>	3031
<i>Iobenguani (¹²³I) solutio iniectionabilis</i>	1213	<i>Ketamini hydrochloridum</i>	3031
<i>Iobenguani (¹³¹I) solutio iniectionabilis ad usum diagnosticum</i>	1214	<i>Ketoconazolum</i>	3033
<i>Iobenguani (¹³¹I) solutio iniectionabilis ad usum therapeuticum</i>	1215	<i>Ketoprofenum</i>	3035
<i>Iobenguani sulfas ad radiopharmaceutica</i>	1216	<i>Ketorolacum trometamolum</i>	3037
<i>Iodinati (¹²⁵I) humani albumini solutio iniectionabilis</i>	1210	<i>Ketotifeni hydrogenofumaras</i>	3038
<i>Iodixanolum</i>	2971	<i>Kryptonum (^{81m}Kr) ad inhalationem</i>	1217
<i>Iodomethylnorcholesteroli (¹³¹I) solutio iniectionabilis</i>	1217		
<i>Iodum</i>	2971	L	
<i>Iohexolum</i>	2974	<i>Labetaloli hydrochloridum</i>	3043
<i>Iopamidolum</i>	2978	<i>Lacca</i>	3785
<i>Iopromidum</i>	2981	<i>Lacosamidi compressi</i>	3049
<i>Iotrolanum</i>	2984	<i>Lacosamidi praeparatio ad infusionem</i>	3046
<i>Ipecacuanhae extractum fluidum normatum</i>	1483	<i>Lacosamidi solutio peroralis</i>	3047
<i>Ipecacuanhae pulvis normatus</i>	1483	<i>Lacosamidum</i>	3045
<i>Ipecacuanhae radix</i>	1485	<i>Lactitolum monohydricum</i>	3051
<i>Ipecacuanhae tinctura normata</i>	1486	<i>Lactosum</i>	3054
<i>Ipratropii bromidum</i>	2988	<i>Lactosum monohydricum</i>	3055
<i>Irbesartanum</i>	2990	<i>Lactulosum</i>	3056
<i>Irinotecani hydrochloridum trihydricum</i>	10.1-4429	<i>Lactulosum liquidum</i>	3058
<i>Isatidis radix</i>	1487	<i>Lamivudinum</i>	3060
<i>Isoconazoli nitras</i>	2994	<i>Lamotriginum</i>	3063
<i>Isoconazolum</i>	2993	<i>Lansoprazolum</i>	3064
<i>Isofluranum</i>	2996	<i>Lanugo cellulosi absorbens</i>	4189
<i>Isoleucinum</i>	2997	<i>Lanugo gossypii absorbens</i>	2316
<i>Isomaltum</i>	2998	<i>Lauromacrogolum 400</i>	3065
<i>Isoniazidum</i>	3000	<i>Lavandulae aetheroleum</i>	1499
<i>Isoprenalini hydrochloridum</i>	10.1-4431	<i>Lavandulae flos</i>	1497
<i>Isoprenalini sulfas</i>	3002	<i>Leflunomidum</i>	3069
<i>Isopropylis isostearas</i>	3004	<i>Leonuri cardiaca herba</i>	1542
<i>Isopropylis myristas</i>	3004	<i>Letrozolum</i>	3070
<i>Isopropylis palmitas</i>	3005	<i>Leucinum</i>	3071
<i>Isosorbidi dinitras dilutus</i>	10.1-4432	<i>Leuprorelinum</i>	3073
<i>Isosorbidi mononitras dilutus</i>	10.1-4434	<i>Levamisoli hydrochloridum</i>	3075
<i>Isotretinoinum</i>	3009	<i>Levamisolum ad usum veterinarium</i>	3074
<i>Isoxsuprini hydrochloridum</i>	3010	<i>Levetiracetamum</i>	3077
<i>Isradipinum</i>	3012	<i>Levistici radix</i>	1512
<i>Itraconazolum</i>	3013	<i>Levocabastini hydrochloridum</i>	3078
<i>Ivermectinum</i>	3015	<i>Levocarnitinum</i>	10.1-4439
		<i>Levodopum</i>	3082
J		<i>Levodropropizinium</i>	3083
<i>Josamycini propionas</i>	3023	<i>Levofloxacinum hemihydricum</i>	3085
<i>Josamycinum</i>	3021	<i>Levomentholum</i>	3086
		<i>Levomepromazini hydrochloridum</i>	3087
		<i>Levomepromazini maleas</i>	3088

<i>Levomethadoni hydrochloridum</i>	3089	<i>Magnesii glycerophosphas</i>	3158
<i>Levonorgestrelum</i>	10.1-4440	<i>Magnesii hydrogenophosphas trihydricus ad praeparationes</i>	
<i>Levothyroxinum natricum</i>	3094	<i>homoeopathicas</i>	1722
<i>Lichen islandicus</i>	1480	<i>Magnesii hydroxidum</i>	3158
<i>Lidocaini hydrochloridum monohydricum</i>	3097	<i>Magnesii lactas dihydricus</i>	3159
<i>Lidocainum</i>	3095	<i>Magnesii oxidum leve</i>	3160
<i>Ligustici chuanxiong rhizoma</i>	1642	<i>Magnesii oxidum ponderosum</i>	3159
<i>Ligustici radix et rhizoma</i>	1505	<i>Magnesii peroxidum</i>	3161
<i>Limonis aetheroleum</i>	1500	<i>Magnesii pidolas</i>	3161
<i>Lincomycini hydrochloridum</i>	3098	<i>Magnesii stearas</i>	3163
<i>Lini oleum virginale</i>	3101	<i>Magnesii subcarbonas levis</i>	3153
<i>Lini semen</i>	1507	<i>Magnesii subcarbonas ponderosus</i>	3153
<i>Liothyroninum natricum</i>	3101	<i>Magnesii sulfas heptahydricus</i>	3165
<i>Liquiritiae extractum siccum ad saporandum</i>	1508	<i>Magnesii trisilicas</i>	3165
<i>Liquiritiae radix</i>	1509	<i>Magnesium fluoratum ad praeparationes</i>	
<i>Lisinoprilum dihydricum</i>	10.1-4443	<i>homoeopathicas</i>	10.1-4370
<i>Lithii carbonas</i>	3104	<i>Magnoliae biondii flos immaturus</i>	1515
<i>Lithii citras</i>	3105	<i>Magnoliae officinalis cortex</i>	1517
<i>L-Methionini</i> (¹⁴ C)methyl solutio iniectabilis	1220	<i>Magnoliae officinalis flos</i>	1519
<i>Lobelini hydrochloridum</i>	3105	<i>Malathionum</i>	3167
<i>Lomustinum</i>	3107	<i>Maltitolum</i>	3170
<i>Loperamidi hydrochloridum</i>	3108	<i>Maltitolum liquidum</i>	3171
<i>Loperamidi oxidum monohydricum</i>	3109	<i>Maltodextrinum</i>	3172
<i>Lopinavirum</i>	3111	<i>Malvae folium</i>	1521
<i>Loratadinum</i>	3114	<i>Malvae sylvestris flos</i>	1520
<i>Lorazepamum</i>	3116	<i>Mangani gluconas</i>	3173
<i>Losartanum kalicum</i>	3117	<i>Mangani glycerophosphas hydricus</i>	3174
<i>Lovastatinum</i>	3120	<i>Mangani sulfas monohydricus</i>	3174
<i>Lufenuronum ad usum veterinarium</i>	3121	<i>Mannitolum</i>	3175
<i>Lupuli flos</i>	1474	<i>Maprotilini hydrochloridum</i>	3177
<i>Lutetii</i> (¹⁷⁷ Lu) solutio ad radio-signandum	1218	<i>Marbofloxacinum ad usum veterinarium</i>	3178
<i>Lycii fructus</i>	1332	<i>Marrubii herba</i>	1667
<i>Lycopi herba</i>	1514	<i>Masticabilia gummis medicata</i>	907
<i>Lymecyclinum</i>	3123	<i>Mastix</i>	1526
<i>Lynestrenolum</i>	3125	<i>Mate folium</i>	1527
<i>Lysini acetat</i>	3126	<i>Matricariae aetheroleum</i>	1531
<i>Lysini hydrochloridum</i>	3127	<i>Matricariae extractum fluidum</i>	1530
<i>Lythri herba</i>	1511	<i>Matricariae flos</i>	1529
M			
<i>Macrogol 20 glyceroli monostearas</i>	3134	<i>Maydis amyllum</i>	3167
<i>Macrogol 40 sorbitoli heptaoleas</i>	3135	<i>Maydis oleum raffinatum</i>	10.1-4447
<i>Macrogol 6 glyceroli caprylocapras</i>	3133	<i>Mebendazolum</i>	3180
<i>Macrogola</i>	3145	<i>Mebeverini hydrochloridum</i>	3181
<i>Macrogola massae molecularis magnae</i>	3147	<i>Meclozini dihydrochloridum</i>	3183
<i>Macrogolglyceridorum caprylocaprates</i>	2074	<i>Medroxyprogesteroni acetat</i>	3184
<i>Macrogolglyceridorum laurates</i>	3068	<i>Mefloquini hydrochloridum</i>	3187
<i>Macrogolglyceridorum linoleates</i>	3100	<i>Megestrol acetat</i>	3189
<i>Macrogolglyceridorum oleates</i>	3411	<i>Megluminum</i>	3191
<i>Macrogolglyceridorum stearates</i>	3899	<i>Mel</i>	2831
<i>Macrogolglyceroli cocoates</i>	3143	<i>Melaleucaae aetheroleum</i>	1643
<i>Macrogolglyceroli hydroxystearas</i>	3144	<i>Meldonium dihydricum</i>	3192
<i>Macrogolglyceroli ricinoleas</i>	3144	<i>Meliloti herba</i>	1534
<i>Macrogoli 15 hydroxystearas</i>	3133	<i>Melissae folii extractum siccum</i>	1537
<i>Macrogoli 30 dipolyhydroxystearas</i>	3135	<i>Melissae folium</i>	1536
<i>Macrogoli aether cetostearylicus</i>	3136	<i>Meloxicamum</i>	3193
<i>Macrogoli aether isotridecylicus</i>	3137	<i>Melphalanum</i>	3194
<i>Macrogoli aether laurilicus</i>	3137	<i>Menadionum</i>	3196
<i>Macrogoli aether oleicus</i>	3140	<i>Menthae arvensis aetheroleum partim mentholum</i>	
<i>Macrogoli aether stearylicus</i>	3142	<i>depletum</i>	1541
<i>Macrogoli oleas</i>	3139	<i>Menthae piperitae aetheroleum</i>	1579
<i>Macrogoli stearas</i>	3142	<i>Menthae piperitae folii extractum siccum</i>	1578
<i>Magaldratum</i>	3148	<i>Menthae piperitae folium</i>	1577
<i>Magnesii acetat tetrahydricus</i>	3149	<i>Mentholum racemicum</i>	3197
<i>Magnesii aluminometasilicas</i>	3150	<i>Menyanthis trifoliatae folium</i>	1360
<i>Magnesii aspartas dihydricus</i>	3151	<i>Mepivacaini hydrochloridum</i>	3198
<i>Magnesii chloridum 4.5-hydricum</i>	3154	<i>Meprobamatum</i>	3200
<i>Magnesii chloridum hexahydricum</i>	3155	<i>Mepyramini maleas</i>	3200
<i>Magnesii citras</i>	3155	<i>Mercaptopurinum monohydricum</i>	10.1-4447
<i>Magnesii citras dodecahydricus</i>	3156	<i>Meropenemum trihydricum</i>	3203
<i>Magnesii citras nonahydricus</i>	3157	<i>Mesalazinum</i>	3204
<i>Magnesii gluconas</i>	3157	<i>Mesnum</i>	3207
		<i>Mesterololum</i>	3208
		<i>Mestranolum</i>	3209
		<i>Metacresolum</i>	3210

<i>Metamizolum natricum monohydricum</i>	3211	<i>Myrtilli fructus recentis extractum siccum raffinatum et normatum</i>	1442
<i>Metformini hydrochloridum</i>	10.1 -4448	<i>Myrtilli fructus siccus</i>	1343
<i>Methadoni hydrochloridum</i>	3219	N	
<i>Methanolum</i>	3222	<i>Nabumetonom</i>	3317
<i>Methanum</i>	3220	<i>N-Acetyltryptophanum</i>	1755
<i>Methanum (2 per centum) in nitrogenio intermixtum</i>	3221	<i>N-Acetyltyrosinum</i>	1757
<i>Methenaminum</i>	3223	<i>Nadololum</i>	3318
<i>Methioninum</i>	3223	<i>Nadroparinum calcicum</i>	3319
<i>Methotrexatum</i>	3225	<i>Naftidrofuryli hydrogenooxalas</i>	3322
<i>Methylcellulosum</i>	3231	<i>Naloxoni hydrochloridum dihydricum</i>	3325
<i>Methyldopum</i>	3233	<i>Naltrexoni hydrochloridum</i>	3327
<i>Methyleni chloridum</i>	3235	<i>Nandroloni decanoas</i>	10.1 -4457
<i>Methylergometrini maleas</i>	3236	<i>Naphazolini hydrochloridum</i>	3330
<i>Methylhydroxyethylcellulosum</i>	3237	<i>Naphazolini nitras</i>	3331
<i>Methylis nicotinas</i>	3228	<i>Naproxenum</i>	3333
<i>Methylis parahydroxybenzoas</i>	3229	<i>Naproxenum natricum</i>	3335
<i>Methylis parahydroxybenzoas natricus</i>	3830	<i>Nasalia</i>	918
<i>Methylis salicylas</i>	3230	<i>Nateglinidum</i>	3337
<i>Methylphenidati hydrochloridum</i>	3238	<i>Natrii acetas trihydricus</i>	3797
<i>Methylphenobarbitalum</i>	3239	<i>Natrii acetatis ([¹¹C]) solutio iniectionis</i>	1225
<i>Methylprednisoloni acetat</i>	3243	<i>Natrii alendronas trihydricus</i>	3798
<i>Methylprednisoloni hydrogenosuccinas</i>	3245	<i>Natrii alginas</i>	3799
<i>Methylprednisolonum</i>	3240	<i>Natrii amidotrizoas</i>	3800
<i>Methylrosanilinii chloridum</i>	3247	<i>Natrii aminosalicylas dihydricus</i>	3801
<i>Methyltestosteronum</i>	3249	<i>Natrii ascorbas</i>	3802
<i>Methylthioninii chloridum hydricum</i>	3250	<i>Natrii aurothiomalas</i>	3804
<i>Metixeni hydrochloridum</i>	3251	<i>Natrii benzoas</i>	3805
<i>Metoclopramidi hydrochloridum monohydricum</i>	3253	<i>Natrii bromidum</i>	3806
<i>Metoclopramidum</i>	3252	<i>Natrii calcii edetas</i>	3807
<i>Metolazonum</i>	3255	<i>Natrii calcii pentetas ad radiopharmaceutica</i>	1223
<i>Metoprololi succinas</i>	3256	<i>Natrii caprylas</i>	3808
<i>Metoprololi tartras</i>	3258	<i>Natrii carbonas</i>	3809
<i>Metrifonatum</i>	3259	<i>Natrii carbonas decahydricus</i>	3809
<i>Metronidazoli benzoas</i>	3262	<i>Natrii carbonas monohydricus</i>	3810
<i>Metronidazolum</i>	3261	<i>Natrii cetylo- et stearylosulfas</i>	3810
<i>Mexiletini hydrochloridum</i>	3263	<i>Natrii chloridum</i>	3812
<i>Mianserini hydrochloridum</i>	3264	<i>Natrii chromatis (⁵¹Cr) solutio sterilis</i>	1226
<i>Miconazoli nitras</i>	3267	<i>Natrii citras</i>	3813
<i>Miconazolum</i>	3266	<i>Natrii cromoglicas</i>	3813
<i>Midazolamum</i>	3270	<i>Natrii cyclamas</i>	3814
<i>Milbemycinum oximum ad usum veterinarium</i>	3272	<i>Natrii dihydrogenophosphas dihydricus</i>	3816
<i>Millefolii herba</i>	1674	<i>Natrii docusas</i>	2457
<i>Minocyclini hydrochloridum dihydricum</i>	3275	<i>Natrii fluoridi (¹⁸F) solutio iniectionis</i>	1227
<i>Minoxidilum</i>	3277	<i>Natrii fluoridum</i>	3818
<i>Mirtazapinum</i>	3278	<i>Natrii fusidas</i>	3818
<i>Misoprostolum</i>	3279	<i>Natrii glycerophosphas hydricus</i>	3821
<i>Mitomycinum</i>	3282	<i>Natrii hyaluronas</i>	3821
<i>Mitoxantroni hydrochloridum</i>	3283	<i>Natrii hydrogenocarbonas</i>	3824
<i>Modafinilum</i>	3285	<i>Natrii hydroxidum</i>	3824
<i>Molgramostimi solutio concentrata</i>	3286	<i>Natrii iodidi (¹²³I) solutio iniectionis</i>	1228
<i>Molsidominum</i>	3288	<i>Natrii iodidi (¹²³I) solutio ad radio-signandum</i>	1228
<i>Mometasoni furoas</i>	10.1 -4450	<i>Natrii iodidi (¹³¹I) capsulae ad usum diagnosticum</i>	1229
<i>Mometasoni furoas monohydricus</i>	3293	<i>Natrii iodidi (¹³¹I) capsulae ad usum therapeuticum</i>	1230
<i>Montelukastum natricum</i>	3295	<i>Natrii iodidi (¹³¹I) solutio</i>	1231
<i>Moranteli hydrogenotartras ad usum veterinarium</i>	3298	<i>Natrii iodidi (¹³¹I) solutio ad radio-signandum</i>	1232
<i>Morphini hydrochloridum</i>	3299	<i>Natrii iodidum</i>	3825
<i>Morphini sulfas</i>	3300	<i>Natrii iodohippuras dihydricus ad radiopharmaceutica</i>	1234
<i>Moutan cortex</i>	1543	<i>Natrii iodohippurati (¹²³I) solutio iniectionis</i>	1233
<i>Moxidectinum ad usum veterinarium</i>	3303	<i>Natrii iodohippurati (¹³¹I) solutio iniectionis</i>	1234
<i>Moxifloxacini hydrochloridum</i>	3306	<i>Natrii lactatis solutio</i>	3825
<i>Moxonidinum</i>	3308	<i>Natrii laurilsulfas</i>	3827
<i>Mucres ad producta allergenica</i>	3302	<i>Natrii lauroylsarcosinas ad usum externum</i>	3828
<i>Mupirocinum</i>	3309	<i>Natrii metabisulfis</i>	3829
<i>Mupirocinum calcicum</i>	3310	<i>Natrii molybdas dihydricus</i>	3831
<i>Musci medicati</i>	911	<i>Natrii molybdatis (⁹⁹Mo) fissione formati solutio</i>	1235
<i>Mycophenolas mofetil</i>	3312	<i>Natrii nitris</i>	3832
<i>Mycophenolatum natricum</i>	3314	<i>Natrii nitroprussias</i>	3832
<i>myo-Inositolum</i>	2944	<i>Natrii perboras hydricus</i>	3833
<i>Myristicae fragrantis aetheroleum</i>	1556	<i>Natrii pertechnetatis (^{99m}Tc) acceleratore formati solutio iniectionis</i>	1237
<i>Myrrha</i>	1546		
<i>Myrrhae tinctura</i>	1547		
<i>Myrtilli fructus recens</i>	1344		

<i>Natrii pertechnetatis (^{99m}Tc) fissionis formati solutio iniectionabilis</i>	1238	<i>Notoginseng radix</i>	1555
<i>Natrii pertechnetatis (^{99m}Tc) sine fissionis formati solutio iniectionabilis</i>	1240	<i>Nystatinum</i>	3401
<i>Natrii phenylbutyras</i>	3833	O	
<i>Natrii phosphatis (³²P) solutio iniectionabilis</i>	1240	<i>Octoxinolum 10</i>	3405
<i>Natrii picosulfas</i>	3835	<i>Octreotidum</i>	3405
<i>Natrii polystyrenesulfonas</i>	3836	<i>Octyldodecanolum</i>	3407
<i>Natrii propionas</i>	3837	<i>Octylis gallas</i>	3407
<i>Natrii pyrophosphas decahydricus ad radiopharmaceutica</i>	1241	<i>Oenotherae oleum raffinatum</i>	2601
<i>Natrii risedronas 2.5-hydricus</i>	3729	<i>Ofloxacinum</i>	3408
<i>Natrii salicylas</i>	3839	<i>Olanzapinum</i>	3410
<i>Natrii selenis</i>	3840	<i>Olea herbaria</i>	901
<i>Natrii selenis pentahydricus</i>	3840	<i>Oleae folii extractum siccum</i>	1559
<i>Natrii (S)-lactatis solutio</i>	3826	<i>Oleae folium</i>	1557
<i>Natrii stearas</i>	3844	<i>Olibanum indicum</i>	1480
<i>Natrii stearylism fumaras</i>	3845	<i>Olivae oleum raffinatum</i>	3413
<i>Natrii sulfas anhydricus</i>	3846	<i>Olivae oleum virginale</i>	3414
<i>Natrii sulfas decahydricus</i>	10.1 -4493	<i>Olmesartanum medoxomilum</i>	3415
<i>Natrii sulfis</i>	3847	<i>Olsalazinum natricum</i>	3417
<i>Natrii sulfis heptahydricus</i>	3848	<i>Omega-3 acidorum esteri ethylici 60</i>	3419
<i>Natrii tetrachloroauras dihydricus ad praeparationes homoeopathicas</i>	1704	<i>Omega-3 acidorum esteri ethylici 90</i>	3421
<i>Natrii thiosulfas</i>	3848	<i>Omega-3 acidorum triglycerida</i>	3423
<i>Natrii valproas</i>	3849	<i>Omeprazololum</i>	3425
<i>Neohesperidin-dihydrochalconum</i>	3339	<i>Omeprazololum magnesianum</i>	3427
<i>Neomycini sulfas</i>	3340	<i>Omeprazololum natricum</i>	3428
<i>Neostigmini bromidum</i>	3342	<i>Ondansetroni hydrochloridum dihydricum</i>	3430
<i>Neostigmini metilsulfas</i>	3343	<i>Ononidis radix</i>	1596
<i>Neroli aetheroleum</i>	1550	<i>Ophiopogonis radix</i>	10.1 -4354
<i>Netilmicini sulfas</i>	3344	<i>Ophthalmica</i>	909
<i>Nevirapinum</i>	3346	<i>Opii extractum siccum normatum</i>	1560
<i>Nevirapinum hemihydricum</i>	3347	<i>Opii pulvis normatus</i>	1561
<i>Niaouli typo cineolo aetheroleum</i>	1554	<i>Opii tinctura normata</i>	1564
<i>Nicardipini hydrochloridum</i>	3348	<i>Opium crudum</i>	1562
<i>Nicergolinum</i>	3349	<i>Orbifloxacinum ad usum veterinarium</i>	3431
<i>Nicethamidum</i>	3364	<i>Orciprenalini sulfas</i>	3433
<i>Niclosamidum</i>	3351	<i>Origani herba</i>	1565
<i>Niclosamidum monohydricum</i>	3352	<i>Orphenadrini citras</i>	3434
<i>Nicorandilum</i>	3353	<i>Orphenadrini hydrochloridum</i>	3436
<i>Nicotinamidum</i>	3354	<i>Orthosiphonis folium</i>	1491
<i>Nicotini ditartras dihydricus</i>	3356	<i>Oryzae amyllum</i>	3721
<i>Nicotini resinas</i>	3357	<i>Oseltamiviri phosphas</i>	3437
<i>Nicotinum</i>	3355	<i>Ouabainum</i>	3439
<i>Nifedipinum</i>	3360	<i>Oxacillinum natricum monohydricum</i>	3440
<i>Nifuroxazidum</i>	3363	<i>Oxaliplatinum</i>	3442
<i>Nilotinibi hydrochloridum monohydricum</i>	3365	<i>Oxazepamum</i>	3445
<i>Nilutamidum</i>	3367	<i>Oxcarbazepinum</i>	3446
<i>Nimesulidum</i>	3368	<i>Oxeladini hydrogenocitras</i>	3448
<i>Nimodipinum</i>	3369	<i>Oxfendazolum ad usum veterinarium</i>	10.1 -4463
<i>Nitrazepamum</i>	3371	<i>Oxitropii bromidum</i>	3450
<i>Nitrendipinum</i>	3372	<i>Oxybuprocaini hydrochloridum</i>	3453
<i>Nitrofuralem</i>	3374	<i>Oxybutynini hydrochloridum</i>	3454
<i>Nitrofurantoinum</i>	3375	<i>Oxycodoni hydrochloridum</i>	3455
<i>Nitrogenii oxidum</i>	3373	<i>Oxygenium</i>	3456
<i>Nitrogenium</i>	3376	<i>Oxygenium (¹⁵O)</i>	1222
<i>Nitrogenium oxygenio depletum</i>	3377	<i>Oxygenium 93 per centum</i>	3457
<i>Nizatidinum</i>	3379	<i>Oxymetazolini hydrochloridum</i>	10.1 -4464
<i>N-Methylpyrrolidonum</i>	3246	<i>Oxytetracyclini hydrochloridum</i>	3462
<i>Nomegestroli acetat</i>	10.1 -4459	<i>Oxytetracyclinum dihydricum</i>	3460
<i>Nonoxinolum 9</i>	3381	<i>Oxytocini solutio concentrata</i>	3465
<i>Noradrenalinii hydrochloridum</i>	3382	<i>Oxytocinum</i>	3464
<i>Noradrenalinii tartras</i>	3384	P	
<i>Norethisteroni acetat</i>	3387	<i>Paclitaxelum</i>	3469
<i>Norethisteronum</i>	3385	<i>Paeoniae radix alba</i>	1573
<i>Norfloxacinum</i>	3388	<i>Paeoniae radix rubra</i>	1572
<i>Norfluranum</i>	3390	<i>Pancreatis pulvis</i>	3474
<i>Norgestimatum</i>	3396	<i>Pancuronii bromidum</i>	3477
<i>Norgestrelum</i>	3397	<i>Pantoprazolum natricum sesquihydricum</i>	3478
<i>Nortriptylini hydrochloridum</i>	3397	<i>Papaverini hydrochloridum</i>	3480
<i>Noscapini hydrochloridum hydricum</i>	3400	<i>Papaveris rhoeados flos</i>	1595
<i>Noscapinum</i>	3399	<i>Paracetamololum</i>	3481
		<i>Paraffinum liquidum</i>	3484

<i>Paraffinum perliquidum</i>	3483	<i>Piperazini citras</i>	3571
<i>Paraffinum solidum</i>	3483	<i>Piperazinum hydricum</i>	3572
<i>Paraldehydum</i>	3486	<i>Piperis fructus</i>	1575
<i>Parenteralia</i>	923	<i>Piperis longi fructus</i>	1510
<i>Parnaparinum natricum</i>	3487	<i>Piracetamum</i>	3573
<i>Paroxetini hydrochloridum</i>	3488	<i>Pirenzepini dihydrochloridum monohydricum</i>	3574
<i>Paroxetini hydrochloridum hemihydricum</i>	3490	<i>Piretanidum</i>	3575
<i>Passiflorae herba</i>	1570	<i>Pirfenidonum</i>	3576
<i>Passiflorae herbae extractum siccum</i>	1571	<i>Piroxicamum</i>	3577
<i>Pefloxacini mesilas dihydricus</i>	3493	<i>Piscis oleum omega-3 acidis abundans</i>	2639
<i>Pelargonii radix</i>	1571	<i>Pisi amyllum</i>	3492
<i>Pemetrexedum dinatricum heptahydricum</i>	3494	<i>Pivampicillinum</i>	3579
<i>Penbutololi sulfas</i>	3497	<i>Pivmecillinami hydrochloridum</i>	3581
<i>Penicillaminum</i>	3498	<i>Plantae ad ptisanam</i>	870
<i>Pentaerythrityli tetranitras dilutus</i>	3499	<i>Plantae medicinales</i>	869
<i>Pentamidini diisetonas</i>	3501	<i>Plantae medicinales ad praeparationes homoeopathicas</i> ...	1680
<i>Pentazocini hydrochloridum</i>	3502	<i>Plantae medicinales praeparatae</i>	869
<i>Pentazocini lactas</i>	3503	<i>Plantaginis lanceolatae folium</i>	1599
<i>Pentazocinum</i>	3502	<i>Plantaginis ovatae semen</i>	1489
<i>Pentobarbitalum</i>	3504	<i>Plantaginis ovatae seminis tegumentum</i>	1488
<i>Pentobarbitalum natricum</i>	3505	<i>Plantarum medicinalium extracta</i>	865
<i>Pentoxifyllinum</i>	10.1 -4469	<i>Plasma humanum ad separationem</i>	2865
<i>Pentoxiverini hydrogenocitras</i>	3509	<i>Plasma humanum coagmentatum conditumque ad</i> <i>extinguendum virum</i>	2867
<i>Pepsini pulvis</i>	3509	<i>Platycodonis radix</i>	1582
<i>Pergolidi mesilas</i>	3511	<i>Podophyllotoxinum</i>	3582
<i>Permethrinum 25:75</i>	3517	<i>Pollines ad producta allergenica</i>	3583
<i>Perphenazinum</i>	3519	<i>Poloxamera</i>	3584
<i>Persicariae tinctoriae folium</i>	1481	<i>Polyacrylatis dispersio 30 per centum</i>	3586
<i>Pethidini hydrochloridum</i>	3520	<i>Poly(alcohol vinylicus)</i>	3595
<i>Petroleum ad praeparationes homoeopathicas</i>	1725	<i>Polygalae radix</i>	1618
<i>Pharmaceutica</i>	880	<i>Polygoni avicularis herba</i>	1495
<i>Phenazonum</i>	3522	<i>Polygoni cuspidati rhizoma et radix</i>	1583
<i>Pheniraminum maleas</i>	3523	<i>Polygoni multiflori radix</i>	1437
<i>Phenobarbitalum</i>	3524	<i>Polygoni orientalis fructus</i>	1585
<i>Phenobarbitalum natricum</i>	3525	<i>Polymyxini B sulfas</i>	3587
<i>Phenolphthaleinum</i>	3527	<i>Polyoxypropyleni aether stearylicus</i>	3588
<i>Phenolsulfonphthaleinum</i>	3528	<i>Polysorbatum 20</i>	3589
<i>Phenolum</i>	3527	<i>Polysorbatum 40</i>	3590
<i>Phenoxyethanolum</i>	3529	<i>Polysorbatum 60</i>	3591
<i>Phenoxyethylpenicillinum</i>	3530	<i>Polysorbatum 80</i>	3591
<i>Phenoxyethylpenicillinum kalicum</i>	3533	<i>Poly(vinylis acetate)</i>	3593
<i>Phentolamini mesilas</i>	3535	<i>Poly(vinylis acetate) dispersio 30 per centum</i>	3594
<i>Phenylalaninum</i>	3536	<i>Poria</i>	1587
<i>Phenylbutazonum</i>	3538	<i>Povidonum</i>	3612
<i>Phenylephrini hydrochloridum</i>	3541	<i>Povidonum iodatum</i>	3615
<i>Phenylephrinum</i>	3539	<i>Praeadmixta ad alimenta medicata ad usum veterinarium</i> ..	927
<i>Phenylhydrargyri acetate</i>	3542	<i>Praecursores chimici ad radiopharmaceutica</i>	863
<i>Phenylhydrargyri boras</i>	3542	<i>Praeparationes ad irrigationem</i>	932
<i>Phenylhydrargyri nitras</i>	3543	<i>Praeparationes buccales</i>	920
<i>Phenylpropanolamini hydrochloridum</i>	3543	<i>Praeparationes celeres ad ptisanam</i>	871
<i>Phenytinum</i>	3545	<i>Praeparationes homoeopathicae</i>	1679
<i>Phenytinum natricum</i>	3546	<i>Praeparationes insulini iniectiones</i>	10.1 -4427
<i>Phloroglucinolum</i>	3548	<i>Praeparationes intramammariae ad usum veterinarium</i>	913
<i>Phloroglucinolum dihydricum</i>	3549	<i>Praeparationes intraruminales</i>	913
<i>Pholcodinum monohydricum</i>	3551	<i>Praeparationes intra-uterinae ad usum veterinarium</i>	914
<i>Phospholipida ex ovo ad iniectionem</i>	2494	<i>Praeparationes liquidae ad usum dermicum</i>	916
<i>Phospholipida ex soia ad iniectionem</i>	3870	<i>Praeparationes liquidae peroraliae</i>	916
<i>Phthalylsulfathiazolum</i>	3553	<i>Praeparationes liquidae veterinariae ad usum dermicum</i> ...	941
<i>Physostigmini salicylas</i>	3554	<i>Praeparationes molles ad usum dermicum</i>	935
<i>Phytomenadionum racemicum</i>	3555	<i>Praeparationes molles veterinariae peroraliae</i>	942
<i>Phytosterolum</i>	3557	<i>Praeparationes pharmaceuticae in vasis cum pressu</i>	933
<i>Picotamidum monohydricum</i>	3558	<i>Pramipexoli dihydrochloridum monohydricum</i>	3615
<i>Pilocarpini hydrochloridum</i>	3559	<i>Prasugreli hydrochloridum</i>	3617
<i>Pilocarpini nitras</i>	3560	<i>Pravastatinum natricum</i>	3618
<i>Pimobendanum ad usum veterinarium</i>	3561	<i>Prazepamum</i>	3620
<i>Pimozidum</i>	3562	<i>Praziquantelum</i>	3621
<i>Pindololum</i>	3563	<i>Prazosini hydrochloridum</i>	10.1 -4473
<i>Pini pumilionis aetheroleum</i>	1419	<i>Prednicarbatum</i>	10.1 -4475
<i>Pini sylvestris aetheroleum</i>	1581	<i>Prednisoloni acetate</i>	3627
<i>Pioglitazoni hydrochloridum</i>	3565	<i>Prednisoloni natrii phosphas</i>	3630
<i>Piperacillinum</i>	3567	<i>Prednisoloni pivalas</i>	3629
<i>Piperacillinum natricum</i>	3568	<i>Prednisolonum</i>	3625
<i>Piperazini adipas</i>	3570		

<i>Prednisonum</i>	3631	<i>Raltegraviri compressi masticabiles</i>	3702
<i>Pregabalinum</i>	3633	<i>Raltegravirum kalicum</i>	3701
<i>Prilocaini hydrochloridum</i>	3636	<i>Ramiprilum</i>	3705
<i>Prilocainum</i>	3635	<i>Ranitidini hydrochloridum</i>	3708
<i>Primaquini diphosphas</i>	10.1 -4476	<i>Rapae oleum raffinatum</i>	3709
<i>Primidonum</i>	3639	<i>Ratanhiae radix</i>	1597
<i>Primulae radix</i>	1588	<i>Ratanhiae tinctura</i>	1598
<i>Probenecidum</i>	3640	<i>Rectalia</i>	933
<i>Procainamidi hydrochloridum</i>	3641	<i>Regorafenibum monohydricum</i>	3710
<i>Procaini hydrochloridum</i>	3642	<i>Rehmanniae radix</i>	10.1 -4360
<i>Prochlorperazini maleas</i>	3642	<i>Remifentanili hydrochloridum</i>	3711
<i>Producta ab arte ADN recombinandorum</i>	888	<i>Repaglinidum</i>	3714
<i>Producta ab fermentatione</i>	882	<i>Reserpinum</i>	3715
<i>Producta allergenica</i>	861	<i>Resorcinolum</i>	3716
<i>Producta biotherapeutica viva ad usum humanum</i>	876	<i>Rhamni purshianae cortex</i>	1378
<i>Producta cum possibili transmissione vectorium</i> <i>enkephalopathiarum spongiformium animalium</i>	884	<i>Rhamni purshianae extractum siccum normatum</i>	1380
<i>Progesteronum</i>	3644	<i>Rhei radix</i>	1598
<i>Proguanili hydrochloridum</i>	3646	<i>Rhenii sulfidi colloidalis et technetii (^{99m}Tc) solutio</i> <i>iniectionabilis</i>	1244
<i>Prolinum</i>	3647	<i>Ribavirinum</i>	3717
<i>Promazini hydrochloridum</i>	3649	<i>Ribis nigri folium</i>	1359
<i>Promethazini hydrochloridum</i>	3649	<i>Riboflavini natrii phosphas</i>	3720
<i>Propacetamoli hydrochloridum</i>	3651	<i>Riboflavinum</i>	3718
<i>Propafenoni hydrochloridum</i>	3652	<i>Ricini oleum hydrogenatum</i>	10.1 -4389
<i>Propanolum</i>	3654	<i>Ricini oleum raffinatum</i>	2103
<i>Propanthelini bromidum</i>	3655	<i>Ricini oleum virginale</i>	2104
<i>Propofolum</i>	3656	<i>Rifabutinum</i>	3722
<i>Propranololi hydrochloridum</i>	3658	<i>Rifampicinum</i>	3724
<i>Propylenglycoli dicaprylocapras</i>	3662	<i>Rifamycinum natricum</i>	3725
<i>Propylenglycoli dilauras</i>	3662	<i>Rifaximinum</i>	3726
<i>Propylenglycoli monolauras</i>	3663	<i>Rilménidini dihydrogenophosphas</i>	3728
<i>Propylenglycoli monopalmitostearas</i>	3664	<i>Risperidonum</i>	3730
<i>Propylenglycolum</i>	3661	<i>Ritonavirum</i>	3732
<i>Propylis gallas</i>	3659	<i>Rivastigmini hydrogenotartras</i>	3737
<i>Propylis parahydroxybenzoas</i>	3660	<i>Rivastigminum</i>	3736
<i>Propylis parahydroxybenzoas natricus</i>	3838	<i>Rizatriptani benzoas</i>	3739
<i>Propylthiouracilum</i>	3665	<i>Rocuronii bromidum</i>	3740
<i>Propyphenazonum</i>	3666	<i>Ropiniroli hydrochloridum</i>	3742
<i>Protamini sulfas</i>	3667	<i>Ropivacaini hydrochloridum monohydricum</i>	3744
<i>Prothrombinum multiplex humanum</i>	2870	<i>Rosae pseudo-fructus</i>	1415
<i>Protirelinum</i>	3669	<i>Rosmarini aetheroleum</i>	1603
<i>Proxiphyllinum</i>	3670	<i>Rosmarini folium</i>	1601
<i>Prunellae spica</i>	1401	<i>Rosuvastatini compressi</i>	10.1 -4487
<i>Pruni africanae cortex</i>	1593	<i>Rosuvastatinum calcicum</i>	10.1 -4484
<i>Pseudoephedrini hydrochloridum</i>	3671	<i>Rotigotinum</i>	3748
<i>Psyllii semen</i>	1588	<i>Roxithromycinum</i>	3750
<i>Puerariae lobatae radix</i>	1496	<i>RRR-α-Tocopherolum</i>	4058
<i>Puerariae thomsonii radix</i>	1644	<i>RRR-α-Tocopherylis acetas</i>	4060
<i>Pullulanum</i>	3672	<i>RRR-α-Tocopherylis hydrogenosuccinas</i>	4064
<i>Pulveres ad usum dermicum</i>	925	<i>Rubi idaei folium</i>	10.1 -4359
<i>Pulveres perorales</i>	926	<i>Rupatadini fumaras</i>	3752
<i>Pyranteli embonas</i>	10.1 -4478	<i>Rusci rhizoma</i>	1367
<i>Pyrazinamidum</i>	3674	<i>Rutosidum trihydricum</i>	3753
<i>Pyridostigmini bromidum</i>	3675		
<i>Pyridoxini hydrochloridum</i>	3676	S	
<i>Pyrimethaminum</i>	10.1 -4479	<i>Sabalis serrulatae extractum</i>	1612
<i>Pyrrolidonum</i>	3678	<i>Sabalis serrulatae fructus</i>	1615
		<i>Sacchari monopalmitas</i>	3909
Q		<i>Sacchari sphaerae</i>	3915
<i>Quercus cortex</i>	1557	<i>Sacchari stearas</i>	3911
<i>Quetiapini fumaras</i>	3683	<i>Saccharinum</i>	3759
<i>Quillajae cortex</i>	1593	<i>Saccharinum natricum</i>	3760
<i>Quinapрили hydrochloridum</i>	3685	<i>Saccharum</i>	3906
		<i>Saccharum liquidum</i>	3908
R		<i>Salbutamoli sulfas</i>	3764
<i>Rabeprazolum natricum</i>	3695	<i>Salbutamololum</i>	3761
<i>Rabeprazolum natricum hydricum</i>	10.1 -4483	<i>Salicis cortex</i>	1671
<i>Racecadotrilum</i>	3698	<i>Salicis corticis extractum siccum</i>	1672
<i>Raclopridi (¹⁴C)methoxy) solutio iniectionabilis</i>	1224	<i>Salmeteroli xinafoas</i>	3767
<i>Radiopharmaceutica</i>	884	<i>Salmonis domestici oleum</i>	3769
<i>Raloxifeni hydrochloridum</i>	3699	<i>Salviae lavandulifoliae aetheroleum</i>	1629
<i>Raltegraviri compressi</i>	3704	<i>Salviae miltiorrhizae radix et rhizoma</i>	1610

<i>Salviae officinalis folium</i>	1607	<i>Sotaloli hydrochloridum</i>	3869
<i>Salviae sclareae aetheroleum</i>	1393	<i>Spectinomycini dihydrochloridum pentahydricum</i>	3873
<i>Salviae tinctura</i>	1609	<i>Spectinomycini sulfas tetrahydricus ad usum</i>	
<i>Salviae trilobae folium</i>	1608	<i>veterinarium</i>	3875
<i>Sambuci flos</i>	1421	<i>Spicae aetheroleum</i>	1630
<i>Sanguisorbae radix</i>	1611	<i>Spiramycinum</i>	3877
<i>Saquinaviri mesilas</i>	3771	<i>Spirapili hydrochloridum monohydricum</i>	3880
<i>Schisandrae chinensis fructus</i>	1617	<i>Spironolactonum</i>	3881
<i>Scopolamini butylbromidum</i>	2910	<i>Squalanum</i>	10.1 -4493
<i>Scopolamini hydrobromidum</i>	2911	<i>Squalenum</i>	3886
<i>Scopolaminum</i>	2909	<i>Stanni colloidalis et technetii (^{99m}Tc) solutio iniectionabilis</i>	1245
<i>Scutellariae baicalensis radix</i>	1331	<i>Stanni pyrophosphatis et technetii (^{99m}Tc) solutio</i>	
<i>Selamectinum ad usum veterinarium</i>	3773	<i>iniectionabilis</i>	1260
<i>Selegilini hydrochloridum</i>	3775	<i>Stannosi chloridum dihydricum</i>	3886
<i>Selenii disulfidum</i>	3776	<i>Stanozololum</i>	3887
<i>Selenium ad praeparationes homoeopathicas</i>	1725	<i>Stavudinum</i>	3896
<i>Semecarpus anacardium ad praeparationes</i>		<i>Stephaniae tetrandrae radix</i>	1438
<i>homoeopathicas</i>	1702	<i>Stramonii folium</i>	1638
<i>Sennae folii extractum siccum normatum</i>	1621	<i>Stramonii pulvis normatus</i>	1640
<i>Sennae foliolum</i>	10.1 -4361	<i>Streptokinasi solutio concentrata</i>	3901
<i>Sennae fructus</i>	10.1 -4363	<i>Streptomycini sulfas</i>	3902
<i>Serinum</i>	3777	<i>Strontii (⁸⁹Sr) chloridi solutio iniectionabilis</i>	1242
<i>Serpylli herba</i>	1669	<i>Strychnos ignatii ad praeparationes homoeopathicas</i>	1719
<i>Serratulae coronatae herba</i>	1624	<i>Strychnos nux-vomica ad praeparationes homoeopathicas</i> ..	1723
<i>Sertaconazoli nitras</i>	3778	<i>Styli</i>	937
<i>Sertralini hydrochloridum</i>	3779	<i>Sucralfatum</i>	3904
<i>Serum bovinum</i>	1996	<i>Sucralosum</i>	3905
<i>Sesami oleum raffinatum</i>	3781	<i>Sufentanili citras</i>	3913
<i>Sevofluranum</i>	3783	<i>Sufentanilum</i>	3912
<i>Sildenafil citras</i>	3786	<i>Sulbactamum natricum</i>	3915
<i>Silica ad usum dentalem</i>	3788	<i>Sulfacetamidum natricum</i>	3917
<i>Silica colloidalis anhydrica</i>	3787	<i>Sulfadiazinum</i>	3918
<i>Silica colloidalis hydrica</i>	3788	<i>Sulfadimethoxinum</i>	3920
<i>Silica hydrophobica colloidalis</i>	3789	<i>Sulfadimethoxinum natricum ad usum veterinarium</i>	3921
<i>Silybi mariani extractum siccum raffinatum et normatum</i> ..	1538	<i>Sulfadimidinum</i>	3922
<i>Silybi mariani fructus</i>	1539	<i>Sulfadoxinum</i>	3924
<i>Simeticonum</i>	3791	<i>Sulfafurazolum</i>	3925
<i>Simvastatinum</i>	3792	<i>Sulfaguanidinum</i>	3926
<i>Sinomenii caulis</i>	1567	<i>Sulfamerazinum</i>	3926
<i>Sitagliptini compressi</i>	3796	<i>Sulfamethizolum</i>	10.1 -4494
<i>Sitagliptini phosphas monohydricus</i>	3795	<i>Sulfamethoxazolum</i>	3928
<i>Soiae oleum hydrogenatum</i>	3872	<i>Sulfamethoxy-pyridazinum ad usum veterinarium</i>	3929
<i>Soiae oleum raffinatum</i>	3873	<i>Sulfanilamidum</i>	3930
<i>Solani amylum</i>	3611	<i>Sulfasalazinum</i>	3931
<i>Solidaginis herba</i>	1458	<i>Sulfathiazolum</i>	3933
<i>Solidaginis virgaureae herba</i>	1460	<i>Sulfapyrazonum</i>	3934
<i>Solifenacin succinas</i>	3850	<i>Sulfobutylbetadexum natricum</i>	3935
<i>Solutiones ad conservationem partium corporis</i>	3852	<i>Sulfur ad praeparationes homoeopathicas</i>	1727
<i>Solutiones ad haemocolaturam haemodiolaturamque</i>	2803	<i>Sulfur ad usum externum</i>	3938
<i>Solutiones ad haemodialyse</i>	2798	<i>Sulfuris colloidalis et technetii (^{99m}Tc) solutio iniectionabilis</i> ..	1244
<i>Solutiones ad peritonealem dialyse</i>	3515	<i>Sulindacum</i>	3939
<i>Solutiones anticoagulantes et sanguinem humanum</i>		<i>Sulpiridum</i>	3940
<i>conservantes</i>	1856	<i>Sultamicillini tosilas dihydricus</i>	3944
<i>Solutiones concentratae ad haemocolaturam</i>		<i>Sultamicillinum</i>	3941
<i>haemodiolaturamque</i>	2801	<i>Sumatriptani succinas</i>	3946
<i>Somatostatinum</i>	3853	<i>Suxamethonii chloridum</i>	3948
<i>Somatropini solutio concentrata</i>	3856	<i>Suxibuzonum</i>	3949
<i>Somatropini solutio iniectionabilis</i>	3860		
<i>Somatropinum</i>	3854		
<i>Somatropinum iniectionabile</i>	3858		
<i>Sophorae flavescentis radix</i>	1503		
<i>Sophorae japonicae flos</i>	1626		
<i>Sophorae japonicae flos immaturus</i>	1628		
<i>Sorbitani lauras</i>	3862		
<i>Sorbitani oleas</i>	3862		
<i>Sorbitani palmitas</i>	3863		
<i>Sorbitani sesquioleas</i>	3863		
<i>Sorbitani stearas</i>	3864		
<i>Sorbitani trioleas</i>	3865		
<i>Sorbitolum</i>	3865		
<i>Sorbitolum liquidum cristallisable</i>	3867		
<i>Sorbitolum liquidum non cristallisable</i>	3867		
<i>Sorbitolum liquidum partim deshydricum</i>	3868		
		T	
		<i>Tacalcitolum monohydricum</i>	3953
		<i>Tacrolimus monohydricum</i>	3954
		<i>Tadalafilum</i>	3957
		<i>Talcum</i>	3959
		<i>Tamoxifeni citras</i>	3961
		<i>Tamponae medicatae</i>	940
		<i>Tamsulosini hydrochloridum</i>	3963
		<i>Tanacetii parthenii herba</i>	1436
		<i>Tanninum</i>	3964
		<i>Tapentadolii hydrochloridum</i>	3965
		<i>Taraxaci officinalis herba cum radice</i>	1408
		<i>Taraxaci officinalis radix</i>	1409
		<i>Technetii (^{99m}Tc) bisisati solutio iniectionabilis</i>	1243

<i>Technetii</i> (^{99m} Tc) et etifenini solutio iniectionabilis.....	1246	<i>Timololi maleas</i>	4046
<i>Technetii</i> (^{99m} Tc) exametazimi solutio iniectionabilis.....	1247	<i>Tincturae maternae ad praeparationes homoeopathicas</i>	1681
<i>Technetii</i> (^{99m} Tc) gluconatis solutio iniectionabilis.....	1248	<i>Tinidazolum</i>	4048
<i>Technetii</i> (^{99m} Tc) humani albumini solutio iniectionabilis.....	1249	<i>Tinzaparinum natricum</i>	4049
<i>Technetii</i> (^{99m} Tc) macrosalbi suspensio iniectionabilis.....	1251	<i>Tioconazolum</i>	4050
<i>Technetii</i> (^{99m} Tc) mebrofenini solutio iniectionabilis	10.1 -4345	<i>Tiotropii bromidum monohydricum</i>	4051
<i>Technetii</i> (^{99m} Tc) medronati solutio iniectionabilis	1253	<i>Titanii dioxidum</i>	4052
<i>Technetii</i> (^{99m} Tc) mertiatidi solutio iniectionabilis.....	1254	<i>Tizanidini hydrochloridum</i>	4053
<i>Technetii</i> (^{99m} Tc) microsphaerarum suspensio iniectionabilis ..	1255	<i>Tobramycinum</i>	4055
<i>Technetii</i> (^{99m} Tc) oxidronati solutio iniectionabilis	1256	<i>α-Tocopherylis acetatis pulvis</i>	4062
<i>Technetii</i> (^{99m} Tc) pentetatis solutio iniectionabilis	1257	<i>Tolbutamidum</i>	4066
<i>Technetii</i> (^{99m} Tc) sestamibi solutio iniectionabilis	1258	<i>Tolnaftatum</i>	4068
<i>Technetii</i> (^{99m} Tc) succimeri solutio iniectionabilis.....	1259	<i>Tolterodini tartras</i>	4070
<i>Teicoplaninum</i>	3967	<i>Topiramatum</i>	4071
<i>Telmisartanum</i>	3970	<i>Torasemidum</i>	4073
<i>Temazepamum</i>	3972	<i>Tormentillae rhizoma</i>	1650
<i>Temozolomidum</i>	3973	<i>Tormentillae tinctura</i>	1650
<i>Tenoxicamum</i>	3974	<i>Tosylchloramidum natricum</i>	4074
<i>Terazosini hydrochloridum dihydricum</i>	3976	<i>Toxinum botulinicum A ad iniectionabile</i>	1993
<i>Terbinafini hydrochloridum</i>	3978	<i>Toxinum botulinicum B ad iniectionabile</i>	1995
<i>Terbutalini sulfas</i>	3979	<i>Tragacantha</i>	1651
<i>Terconazolum</i>	3980	<i>Tramadoli hydrochloridum</i>	4074
<i>Terebinthinae aetheroleum</i>	1655	<i>Tramazolini hydrochloridum monohydricum</i>	4076
<i>Terfenadinum</i>	3982	<i>Trandolaprilum</i>	4077
<i>Teriparatidum</i>	3983	<i>Trapidilum</i>	4079
<i>Terlipressinum</i>	3986	<i>Trehalosum dihydricum</i>	4080
<i>Terpinum monohydricum</i>	3988	<i>Tretinoinum</i>	4082
<i>tert-Butylamini perindoprilum</i>	10.1 -4470	<i>Triacetinum</i>	4083
<i>Testosteroni decanoas</i>	3991	<i>Triamcinoloni acetonidum</i>	4085
<i>Testosteroni enantas</i>	3992	<i>Triamcinoloni hexacetonidum</i>	4086
<i>Testosteroni isocaproas</i>	3994	<i>Triamcinolonum</i>	4083
<i>Testosteroni propionas</i>	3995	<i>Triamterenum</i>	4088
<i>Testosteronum</i>	10.1 -4499	<i>Tribenosidum</i>	4089
<i>Tetracaini hydrochloridum</i>	3998	<i>Tributylis acetylcitras</i>	4090
<i>Tetracainum</i>	3997	<i>Tricalcii phosphas</i>	2065
<i>Tetracosactidum</i>	3999	<i>Triclabendazolum ad usum veterinarium</i>	4093
<i>Tetracyclini hydrochloridum</i>	4001	<i>Triethylis citras</i>	4094
<i>Tetracyclinum</i>	4000	<i>Trifluoperazini hydrochloridum</i>	4095
<i>Tetra-O-acetylmannosi triflas ad radiopharmaceutica</i>	1261	<i>Triflusalum</i>	4095
<i>Tetrazepamum</i>	4003	<i>Triglycerida media</i>	4096
<i>Tetryzolini hydrochloridum</i>	4004	<i>Triglyceroli diisostearas</i>	4097
<i>Thallosi</i> (²⁰¹ Tl) chloridi solutio iniectionabilis	1262	<i>Trigonellae foenugraeci semen</i>	1435
<i>Theobromatis oleum</i>	2279	<i>Trihexyphenidyli hydrochloridum</i>	4098
<i>Theobrominum</i>	4005	<i>Trimebutini maleas</i>	4099
<i>Theophyllinum</i>	4005	<i>Trimetazidini dihydrochloridum</i>	4100
<i>Theophyllinum et ethylenediaminum</i>	4008	<i>Trimethadionum</i>	4101
<i>Theophyllinum et ethylenediaminum hydricum</i>	4009	<i>Trimethoprimum</i>	4102
<i>Theophyllinum monohydricum</i>	4007	<i>Trimipramini maleas</i>	4104
<i>Thiamazolum</i>	4011	<i>Tri-n-butylis phosphas</i>	4091
<i>Thiamini hydrochloridum</i>	4012	<i>Tritici aestivi oleum raffinatum</i>	4210
<i>Thiamini nitras</i>	4014	<i>Tritici aestivi oleum virginale</i>	4210
<i>Thiamphenicolum</i>	4015	<i>Tritici amyllum</i>	4209
<i>Thiocolchicosidum ex ethanolo cristallisatum</i>	4016	<i>Trolaminum</i>	4106
<i>Thiocolchicosidum hydricum</i>	10.1 -4500	<i>Trometamolium</i>	4107
<i>Thiomersalum</i>	4021	<i>Tropicamidum</i>	4108
<i>Thiopentalum natricum et natrii carbonas</i>	4022	<i>Tropisetroni hydrochloridum</i>	4110
<i>Thioridazini hydrochloridum</i>	4025	<i>Trospii chloridum</i>	4111
<i>Thioridazinum</i>	4024	<i>Troxerutinum</i>	4112
<i>Threoninum</i>	4027	<i>Trypsinum</i>	4114
<i>Thymi herba</i>	1646	<i>Tryptophanum</i>	4115
<i>Thymi typo thymolo aetheroleum</i>	1648	<i>Tuberculi aviarii derivatum proteinosum purificatum</i> ...	4119
<i>Thymolum</i>	4028	<i>Tuberculi bovini derivatum proteinosum purificatum</i>	4120
<i>Tiabendazolum</i>	4029	<i>Tuberculi derivatum proteinosum purificatum ad usum humanum</i>	4120
<i>Tiamulini hydrogenofumaras ad usum veterinarium</i>	4032	<i>Tuberculinum pristinum ad usum humanum</i>	4117
<i>Tiamulinum ad usum veterinarium</i>	4030	<i>Tylosini phosphas ad usum veterinarium</i>	4131
<i>Tianeptinum natricum</i>	4035	<i>Tylosini phosphatis solutio ad usum veterinarium</i>	4127
<i>Tiapridi hydrochloridum</i>	4036	<i>Tylosini tartras ad usum veterinarium</i>	4136
<i>Tibolonum</i>	4039	<i>Tylosinum ad usum veterinarium</i>	4122
<i>Ticarcillinum natricum</i>	4040	<i>Typhae pollis</i>	1656
<i>Ticlopidini hydrochloridum</i>	4041	<i>Tyrosinum</i>	4140
<i>Tigecyclinum</i>	4043	<i>Tyrothricinum</i>	4142
<i>Tiliae flos</i>	1506		
<i>Tilidini hydrochloridum hemihydricum</i>	4045		

U

Ubidecarenonum	4147
Uncariae rhynchophyllae ramulus cum uncis	1657
Ureum	4149
Urofollitropinum	4149
Urokinasum	4151
Urtica dioica ad praeparationes homoeopathicas	1728
Urticae folium	1551
Urticae radix	1553
Uvae ursi folium	1333

V

Vaccina ad usum humanum	893
Vaccina ad usum veterinarium	896
Vaccinum actinobacillosidis inactivatum ad suem	1139
Vaccinum adenovirosidis caninae vivum	1080
Vaccinum adenovirus caninae inactivatum	1079
Vaccinum anaemiae infectivae pulli vivum	1122
Vaccinum anthracis adsorbatum ab colato culturarum ad usum humanum	947
Vaccinum anthracis vivum ad usum veterinarium	1055
Vaccinum aphtharum epizooticarum inactivatum ad ruminantes	1115
Vaccinum Bordetellae bronchisepticae vivum ad canem	1070
Vaccinum bronchitidis infectivae aviariae inactivatum	1059
Vaccinum bronchitidis infectivae aviariae vivum	1060
Vaccinum brucellosis (<i>Brucella melitensis</i> stirps Rev. 1) vivum ad usum veterinarium	1076
Vaccinum bursitidis infectivae aviariae inactivatum	1062
Vaccinum bursitidis infectivae aviariae vivum	1063
Vaccinum calicivirosis felinae inactivatum	1106
Vaccinum calicivirosis felinae vivum	1107
Vaccinum chlamydiosis felinae inactivatum	1108
Vaccinum cholerae aviariae inactivatum	1117
Vaccinum cholerae perorale inactivatum	951
Vaccinum Clostridii botulini ad usum veterinarium	1087
Vaccinum Clostridii chauvoei ad usum veterinarium	1088
Vaccinum Clostridii novyi B ad usum veterinarium	1088
Vaccinum Clostridii perfringentis ad usum veterinarium	1090
Vaccinum Clostridii septici ad usum veterinarium	1092
Vaccinum coccidiosidis vivum ad pullum	1094
Vaccinum colibacillosis fetus a partu recentis inactivatum ad ruminantes	1133
Vaccinum colibacillosis fetus a partu recentis inactivatum ad suem	1132
Vaccinum diarrhoeae viralis bovinae inactivatum	1075
Vaccinum diphtheriae adsorbatum	977
Vaccinum diphtheriae, antigeni minutum, adsorbatum	978
Vaccinum diphtheriae et tetani adsorbatum	952
Vaccinum diphtheriae et tetani, antigeni-o(-is) minutum, adsorbatum	953
Vaccinum diphtheriae, tetani et hepatitis B (ADNr) adsorbatum	954
Vaccinum diphtheriae, tetani et pertussis ex cellulis integris adsorbatum	958
Vaccinum diphtheriae, tetani et pertussis sine cellulis ex elementis praeparatum adsorbatum	955
Vaccinum diphtheriae, tetani et pertussis sine cellulis ex elementis praeparatum, antigeni-o(-is) minutum, adsorbatum	956
Vaccinum diphtheriae, tetani et poliomyelitis inactivatum, antigeni-o(-is) minutum, adsorbatum	959
Vaccinum diphtheriae, tetani, pertussis ex cellulis integris et poliomyelitis inactivatum adsorbatum	973
Vaccinum diphtheriae, tetani, pertussis ex cellulis integris, poliomyelitis inactivatum et haemophili stirpis b coniugatum adsorbatum	974
Vaccinum diphtheriae, tetani, pertussis sine cellulis ex elementis praeparatum et haemophili stirpis b coniugatum adsorbatum	961
Vaccinum diphtheriae, tetani, pertussis sine cellulis ex elementis praeparatum et hepatitis B (ADNr) adsorbatum	963

Vaccinum diphtheriae, tetani, pertussis sine cellulis ex elementis praeparatum et poliomyelitis inactivatum adsorbatum ..	964
Vaccinum diphtheriae, tetani, pertussis sine cellulis ex elementis praeparatum et poliomyelitis inactivatum, antigeni-o(-is) minutum, adsorbatum	966
Vaccinum diphtheriae, tetani, pertussis sine cellulis ex elementis praeparatum, hepatitis B (ADNr), poliomyelitis inactivatum et haemophili stirpis b coniugatum adsorbatum	968
Vaccinum diphtheriae, tetani, pertussis sine cellulis ex elementis praeparatum, poliomyelitis inactivatum et haemophili stirpis b coniugatum adsorbatum	970
Vaccinum encephalitis ixodibus adiectae inactivatum ..	1043
Vaccinum encephalomyelitis infectivae aviariae vivum ..	1065
Vaccinum erysipelas suillae inactivatum	1158
Vaccinum febris flavae vivum	1049
Vaccinum febris typhoidis	1046
Vaccinum febris typhoidis polysaccharidicum	1044
Vaccinum febris typhoidis vivum perorale (stirpis Ty 21a) ..	1046
Vaccinum furunculosis inactivatum ad salmonidas cum adiuvatione oleosa ad iniectionem	1119
Vaccinum haemophili stirpis b et meningococcale classis C coniugatum	979
Vaccinum haemophili stirpis b coniugatum	980
Vaccinum hepatitis A inactivatum adsorbatum	984
Vaccinum hepatitis A inactivatum adsorbatum et febris typhoidis polysaccharidicum	982
Vaccinum hepatitis A inactivatum et hepatitis B (ADNr) adsorbatum	983
Vaccinum hepatitis A inactivatum virosomale	985
Vaccinum hepatitis B (ADNr)	988
Vaccinum hepatitis viralis anatis stirpis I vivum	1099
Vaccinum herpesvirus equini inactivatum	1103
Vaccinum inactivatum diarrhoeae vituli coronavirio illatae	1077
Vaccinum inactivatum diarrhoeae vituli rotavirio illatae ..	1078
Vaccinum influenzae equinae inactivatum	1104
Vaccinum influenzae inactivatum ad suem	1142
Vaccinum influenzae inactivatum ex cellulis corticisque antigeniis praeparatum	998
Vaccinum influenzae inactivatum ex cellulis virisque integris praeparatum	1003
Vaccinum influenzae inactivatum ex corticis antigeniis praeparatum	996
Vaccinum influenzae inactivatum ex corticis antigeniis praeparatum virosomale	1000
Vaccinum influenzae inactivatum ex viris integris praeparatum	1002
Vaccinum influenzae inactivatum ex virorum fragmentis praeparatum	995
Vaccinum influenzae vivum pernasale	992
Vaccinum laryngotracheitis infectivae aviariae vivum	1066
Vaccinum leptospirosis bovinae inactivatum	1071
Vaccinum leptospirosis caninae inactivatum	1082
Vaccinum leucosis felinae inactivatum	1112
Vaccinum mannheimiae bovinae inactivatum	1125
Vaccinum mannheimiae inactivatum ad ovem	1126
Vaccinum meningococcale classis C coniugatum	1010
Vaccinum meningococcale classium A, C, W135 et Y coniugatum	1009
Vaccinum meningococcale polysaccharidicum	1012
Vaccinum morbi Aujeszkyi ad suem inactivatum	1055
Vaccinum morbi Aujeszkyi vivum ad suem ad usum parenteralem	1057
Vaccinum morbi Carrei vivum ad canem	1081
Vaccinum morbi Carrei vivum ad mustelidas	1097
Vaccinum morbi haemorrhagici cuniculi inactivatum	1147
Vaccinum morbi Marek vivum	1128
Vaccinum morbi oris rubri inactivatum ad Onchorhynchum mykiss	1102
Vaccinum morbi partus diminutionis MCMLXXXVI inactivatum ad pullum	1100
Vaccinum morbillorum, parotitis et rubellae vivum	1005

<i>Vaccinum morbillorum, parotitidis, rubellae et varicellae vivum</i>	1006	<i>Valerianae extractum hydroalcoholicum siccum</i>	1660
<i>Vaccinum morbillorum vivum</i>	1007	<i>Valerianae radix</i>	1660
<i>Vaccinum Mycoplasmae galliseptici inactivatum</i>	1129	<i>Valerianae radix minutata</i>	1662
<i>Vaccinum myxomatosis vivum ad cuniculum</i>	1131	<i>Valerianae tinctura</i>	1664
<i>Vaccinum necrosis pancreatica infectivae inactivatum ad salmonidas cum adjuvante oleosa ad iniectionem</i>	1124	<i>Valinum</i>	4162
<i>Vaccinum panleucopeniae felinae infectivae inactivatum</i>	1109	<i>Valnemulini hydrochloridum ad usum veterinarium</i>	4164
<i>Vaccinum panleucopeniae felinae infectivae vivum</i>	1110	<i>Valsartanum</i>	4167
<i>Vaccinum papillomaviri humani (ADNr)</i>	989	<i>Vancomycini hydrochloridum</i>	4168
<i>Vaccinum parainfluenzae viri canini vivum</i>	1084	<i>Vanillinum</i>	4172
<i>Vaccinum paramyxovirus 3 aviarii inactivatum ad meleagrem</i>	1068	<i>Vardenafili hydrochloridum trihydricum</i>	4172
<i>Vaccinum parotitidis vivum</i>	1014	<i>Vaselinum album</i>	3485
<i>Vaccinum parvovirus caninae inactivatum</i>	1085	<i>Vaselinum flavum</i>	3486
<i>Vaccinum parvovirus caninae vivum</i>	1086	<i>Vecuronii bromidum</i>	4173
<i>Vaccinum parvovirus inactivatum ad suem</i>	1143	<i>Vedaprofenum ad usum veterinarium</i>	4175
<i>Vaccinum pasteurellae inactivatum ad ovem</i>	1138	<i>Venlafaxini hydrochloridum</i>	4176
<i>Vaccinum pertussis ex cellulis integris adsorbatum</i>	1018	<i>Verapamili hydrochloridum</i>	4178
<i>Vaccinum pertussis sine cellulis copurificatum adsorbatum</i>	1016	<i>Verbasci flos</i>	1545
<i>Vaccinum pertussis sine cellulis ex elementis praeparatum adsorbatum</i>	1015	<i>Verbenae citriodora folium</i>	1502
<i>Vaccinum pestis anatis vivum</i>	1098	<i>Verbenae herba</i>	1665
<i>Vaccinum pestis classicae suillae vivum ex cellulis</i>	1159	<i>Via praeparandi stirpes homoeopathicas et potentificandi</i>	1682
<i>Vaccinum pneumococcale polysaccharidicum</i>	1021	<i>Vigabatrinum</i>	4180
<i>Vaccinum pneumococcale polysaccharidicum coniugatum adsorbatum</i>	1019	<i>Vinblastini sulfas</i>	4181
<i>Vaccinum pneumoniae enzooticae suillae inactivatum</i>	1141	<i>Vincaminum</i>	4182
<i>Vaccinum poliomyelitis inactivatum</i>	1023	<i>Vincristini sulfas</i>	4183
<i>Vaccinum poliomyelitis perorale</i>	1026	<i>Vindesini sulfas</i>	4185
<i>Vaccinum pseudopestis aviariae inactivatum</i>	1134	<i>Vinorelbini tartras</i>	4186
<i>Vaccinum pseudopestis aviariae vivum</i>	1136	<i>Vinopocetinum</i>	4188
<i>Vaccinum rabiei ex cellulis ad usum humanum</i>	1030	<i>Violae herba cum flore</i>	1668
<i>Vaccinum rabiei inactivatum ad usum veterinarium</i>	1148	<i>Vitamine A synthetici densati pulvis</i>	4193
<i>Vaccinum rabiei perorale vivum ad vulpem et nyctereutem</i>	1150	<i>Vitaminum A</i>	4191
<i>Vaccinum rhinitidis atrophicantis ingravescentis suillae inactivatum</i>	1144	<i>Vitaminum A syntheticum densatum oleosum</i>	4192
<i>Vaccinum rhinotracheitidis infectivae bovinae inactivatum</i>	1120	<i>Vitaminum A syntheticum, solubilisatum densatum in aqua dispergibile</i>	4194
<i>Vaccinum rhinotracheitidis infectivae bovinae vivum</i>	1121	<i>Voriconazolum</i>	4196
<i>Vaccinum rhinotracheitidis infectivae vivum ad meleagrem</i>	1162	W	
<i>Vaccinum rhinotracheitidis viralis felinae inactivatum</i>	1113	<i>Warfarinum natricum</i>	4201
<i>Vaccinum rhinotracheitidis viralis felinae vivum</i>	1114	<i>Warfarinum natricum clathratum</i>	4202
<i>Vaccinum rotaviri vivum perorale</i>	1033	X	
<i>Vaccinum rubellae vivum</i>	1035	<i>Xanthani gummi</i>	4221
<i>Vaccinum Salmonellae Enteritidis inactivatum ad pullum</i>	1151	<i>Xenoni (¹³³Xe) solutio iniectabilis</i>	1264
<i>Vaccinum Salmonellae Enteritidis vivum perorale ad pullum</i>	1152	<i>Xylazini hydrochloridum ad usum veterinarium</i>	4222
<i>Vaccinum Salmonellae Typhimurium inactivatum ad pullum</i>	1155	<i>Xylitolum</i>	4223
<i>Vaccinum Salmonellae Typhimurium vivum perorale ad pullum</i>	1156	<i>Xylometazolini hydrochloridum</i>	10.1-4509
<i>Vaccinum tenosynovitis viralis aviariae vivum</i>	1069	<i>Xylosum</i>	4226
<i>Vaccinum tetani ad usum veterinarium</i>	1161	Y	
<i>Vaccinum tetani adsorbatum</i>	1042	<i>Yohimbini hydrochloridum</i>	4231
<i>Vaccinum tuberculosis (BCG) cryodesiccatum</i>	949	<i>Yttrii (⁹⁰Y) chloridi solutio ad radio-signandum</i>	1265
<i>Vaccinum varicellae vivum</i>	1048	Z	
<i>Vaccinum variolae gallinae vivum</i>	1118	<i>Zanamivirum hydricum</i>	10.1-4513
<i>Vaccinum variolae vivum</i>	1037	<i>Zanthoxyli bungeani pericarpium</i>	1675
<i>Vaccinum vibriosidis aquae frigidae inactivatum ad salmonidas</i>	1163	<i>Zidovudinum</i>	4236
<i>Vaccinum vibriosidis inactivatum ad salmonidas</i>	1164	<i>Zinci acetate dihydricus</i>	4238
<i>Vaccinum viri parainfluenzae bovini vivum</i>	1073	<i>Zinci acexamas</i>	4239
<i>Vaccinum viri syncytialis meatus spiritus bovini vivum</i>	1074	<i>Zinci chloridum</i>	4241
<i>Vaccinum zonae vivum</i>	1036	<i>Zinci gluconas</i>	4241
<i>Vaginalia</i>	940	<i>Zinci oxidum</i>	4242
<i>Valacicloviri hydrochloridum</i>	4157	<i>Zinci stearas</i>	4242
<i>Valacicloviri hydrochloridum hydricum</i>	4160	<i>Zinci sulfas heptahydricus</i>	4243
<i>Valerianae extractum aquosum siccum</i>	1659	<i>Zinci sulfas hexahydricus</i>	4244
		<i>Zinci sulfas monohydricus</i>	4244
		<i>Zinci undecylenas</i>	4244
		<i>Zingiberis rhizoma</i>	1450
		<i>Ziprasidoni hydrochloridum monohydricum</i>	4245
		<i>Ziprasidoni mesilas trihydricus</i>	4247
		<i>Zolmitriptanum</i>	4251
		<i>Zolpidemi tartras</i>	10.1-4516
		<i>Zopiclonum</i>	4254

Zuclopenthixoli decanoas 4255

